

AUTOTAXIN INHIBITOR COMPOUNDS

1. CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 63/088,219, filed October 6, 2020, which is hereby incorporated in its entirety by reference.


2. BACKGROUND

[0002] Autotaxin (ATX), also known as ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP-2) or lysophospholipase D, is a protein that belongs to the ENPP family of enzymes. As the only member of the ENPP family of enzymes with lysophospholipase D (lysoPLD) activity, ATX is responsible for the hydrolysis of lysophosphatidyl choline (LPC) into lysophosphatidic acid (LPA). LPA is a family of bioactive lipids of varying fatty acyl chain length that signals LPA receptors to modulate various cellular events. LPA and LPA receptor activities are attributed to a broad range of physiological actions, such as blood pressure regulation, platelet activation, cell growth, and smooth muscle contraction. LPA and LPA receptor activities have also been associated with various other physiological conditions, disorders, and diseases, such as proliferative diseases, cancer, inflammation, autoimmune disease, and fibrosis.

3. SUMMARY OF THE INVENTION

[0003] The present disclosure provides autotaxin (ATX) inhibitor compounds and compositions including said compounds. The present disclosure also provides methods of using said compounds and compositions for inhibiting ATX. Also provided are methods of preparing said compounds and compositions, and synthetic precursors of said compounds.

[0004] In a first aspect, the ATX inhibitor compound is of formula (I):



or a pharmaceutically acceptable salt thereof,

wherein:

X^1 , X^2 , and X^3 are independently selected from C- R^1 and N;

Z^1 , Z^2 , and Z^3 are independently selected from C- R^1 and N;

each R^1 is independently selected from -H, -halogen, optionally substituted -(C₁-C₆)alkyl and optionally substituted -(C₁-C₆)alkoxy;

Y is selected from S, O, and N- R^2 , wherein R^2 is selected from -H, and optionally substituted -(C₁-C₆)alkyl;

R^3 is selected from optionally substituted R^4 -C(O)-(C₁-C₃)alkyl-, R^4 C(O)-, optionally substituted monocyclic or bicyclic carbocycle, optionally substituted monocyclic or bicyclic heterocycle, R^5R^6 HC-, and R^5R^6 N-;

R^4 is selected from H₂N-, HO-, R^5R^6 N-, optionally substituted (C₁-C₁₀)alkyl-, optionally substituted (C₁-C₁₀)alkoxy-, optionally substituted monocyclic or bicyclic carbocycle, optionally substituted monocyclic or bicyclic heterocycle, optionally substituted cycloalkyl-(C₁-C₆)alkylene-, and optionally substituted heterocycle-(C₁-C₆)alkylene-;

R^5 and R^6 are independently selected from H-, H₂N-, HO-, optionally substituted (C₁-C₁₀)alkyl-, optionally substituted monocyclic or bicyclic carbocycle (e.g., saturated monocyclic carbocycle, e.g., cycloalkyl), optionally substituted monocyclic or bicyclic heterocycle (e.g., saturated monocyclic heterocycle, e.g., azetidine, pyrrolidine or piperidine), optionally substituted R^4 C(O)-(C₁-C₁₀)alkyl-, R^4 C(O)-, R^4 -, and substituted amino;

or R^5 and R^6 together with the nitrogen or carbon atom to which they are attached are cyclically linked to form an optionally substituted carbocycle or an optionally substituted heterocycle (e.g., azetidine, morpholine, piperidine or piperazine);


R^7 is selected from H-, and optionally substituted (C₁-C₆)alkyl-;

R^8 is selected from -H, -halogen, and optionally substituted -(C₁-C₆)alkyl-;

R^9 and each R^{10} are independently selected from -H, -halogen, -CN, -OH, optionally substituted -(C₁-C₆)alkoxy, -NH₂, substituted amino, optionally substituted -(C₁-C₆)alkyl-NH₂ (e.g., -CH₂NH₂) and optionally substituted -(C₁-C₆)alkyl-; and

n is 0, 1, 2, 3, 4, or 5.

[0005] In some embodiments, the compound of formula (I) is a compound of formula (Ia):



(Ia)

wherein:


R¹ is selected from -H, -halogen, optionally substituted -(C₁-C₆)alkyl and optionally substituted -(C₁-C₆)alkoxy;

R³ is selected from R⁴C(O)-, R⁴C(O)CH₂-, R⁵R⁶N-, and R⁵R⁶HC-;

R¹¹ is -H, -halogen, -CN, -OH, optionally substituted -(C₁-C₆)alkoxy, -NH₂, -NR⁵R⁶, -CH₂NH₂ and optionally substituted -(C₁-C₆)alkyl; and

n is 0, 1, 2, or 3.

[0006] In some embodiments, the compound of formula (I) is a compound of formula (Ib):





(Ib)


wherein:


X¹ is C-H or N; and


R¹ is selected from -H, -halogen, optionally substituted -(C₁-C₆)alkyl and optionally substituted -(C₁-C₆)alkoxy.

[0007] In some embodiments of formula (I)-(Ib),





d) R³ is  that is an optionally substituted monocyclic or bicyclic (C₂-C₉)heterocycle- (e.g., (C₂-C₅)heterocycloalkyl-); or

e) R³ is  that is an optionally substituted monocyclic or bicyclic (C₃-C₈)carbocycle- (e.g., (C₃-C₆)cycloalkyl-), or an optionally substituted monocyclic or bicyclic (C₂-C₉)heterocycle- (e.g., (C₂-C₅)heterocycloalkyl-);

wherein:

R⁴ is selected from HO-, H₂N-, R¹⁵R¹⁶N-, optionally substituted (C₁-C₅)alkyl-, optionally substituted monocyclic or bicyclic carbocycle, and optionally substituted monocyclic or bicyclic heterocycle;


R¹² is selected from -H, -NH₂, -OH, -CH₂C(O)R⁴, -C(O)R⁴, -CHR¹⁵R¹⁶, -NR¹⁵R¹⁶, optionally substituted -(C₁-C₅)alkyl, optionally substituted monocyclic or bicyclic -(C₃-C₈)carbocycle (e.g., -(C₃-C₆)cycloalkyl), and an optionally substituted monocyclic or bicyclic -(C₂-C₉)heterocycle (e.g., -(C₂-C₅)heterocycloalkyl);

R¹³ and R¹⁴ are independently selected from -H, -CH₂C(O)R¹⁷, -CH₂R¹⁷, -C(O)R¹⁷, -R¹⁸C(O)R¹⁷, -CH₂R¹⁸C(O)R¹⁷, optionally substituted -(C₁-C₅)alkyl, optionally substituted monocyclic or bicyclic -(C₃-C₈)carbocycle (e.g., -(C₃-C₆)cycloalkyl), and an optionally substituted monocyclic or bicyclic -(C₂-C₉)heterocycle (e.g., -(C₂-C₅)heterocycloalkyl), wherein R¹⁷ and R¹⁸ are independently selected from optionally substituted -(C₁-C₅)alkyl, optionally substituted monocyclic or bicyclic -(C₃-C₈)carbocycle (e.g., -(C₃-C₆)cycloalkyl), and an optionally substituted monocyclic or bicyclic -(C₂-C₉)heterocycle (e.g., -(C₂-C₅)heterocycloalkyl); and

R¹⁵ and R¹⁶ are independently selected from H-, optionally substituted (C₂-C₅)heterocycloalkyl-C(O)-, optionally substituted (C₃-C₆)cycloalkyl-C(O)-, optionally substituted (C₁-C₅)alkyl-, optionally substituted 3- to 10-membered saturated monocyclic heterocycle or carbocycle, and optionally substituted 3- to 10-membered saturated bicyclic heterocycle or carbocycle, wherein the optional substituents are selected from hydroxy, HOCH₂-, cyano, halogen, substituted amino (e.g., (C₁-C₅)alkyl-substituted amino), and (C₁-C₅)alkyl; or R¹⁵ and R¹⁶ are cyclically linked to form a 3- to 6-membered monocyclic

saturated heterocycle, optionally substituted with hydroxy, HOCH₂-, cyano, halogen, substituted amino (e.g., (C₁-C₅)alkyl-substituted amino), or (C₁-C₅)alkyl.

[0008] In some embodiments of formula (I)-(Ib),




R^4 is selected from R^{32} -, $R^{32}\text{HN}$ -, $R^{32}\text{N}(R^{33})$ -, and $R^{32}\text{HN}-R^{36}$;

R^{32} and R^{33} are independently selected from H-, optionally substituted -(C₁-C₃)alkyl, optionally substituted cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), and optionally substituted saturated heterocycle (e.g., azetidine, pyrrolidine, piperidine, morpholine, piperazine, morpholine-3-one, or piperidine-2-one);

R^{36} is selected from optionally substituted (C₁-C₃)alkyl, optionally substituted cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), and optionally substituted saturated heterocycle (e.g., azetidine, pyrrolidine, piperidine); and

the optional substituents of the R^{32} , R^{33} and R^{36} groups are independently selected from -CN, -OH, -CH₂OH, -(C₁-C₃)alkyl (e.g., -CH₃), -(C₁-C₃)alkoxy, -(C₃-C₆)cycloalkyl, (C₂-C₅)heterocycloalkyl (e.g., azetidine), and -N(R^{37}) R^{38} , wherein R^{37} and R^{38} are independently selected from H, (C₁-C₃)alkyl, (C₃-C₆)cycloalkyl (e.g., cyclopropyl or cyclobutyl), and (C₂-C₅)heterocycloalkyl (e.g., azetidine).

[0009] In some embodiments of formula (I)-(Ib),







R^{14} is selected from R^{34} -, $R^{34}\text{CH}_2$ -, $R^{34}\text{C}(\text{O})R^{35}$ -, and $R^{34}\text{C}(\text{O})R^{35}\text{CH}_2$;

each R^{34} and R^{35} are independently selected from optionally substituted -(C₁-C₃)alkyl, optionally substituted cycloalkyl, and optionally substituted saturated heterocycle (e.g., azetidine, pyrrolidine, piperidine, morpholine, piperazine); and

the optional substituents of the R^{34} and R^{35} groups are independently selected from -CN, -OH, -CH₂OH, -(C₁-C₃)alkyl (e.g., -CH₃), -(C₁-C₃)alkoxy, and -(C₁-C₃)alkyl; and

R^{13} is -H.

[0010] In some embodiments of formula (I)-(Ib), R^3 is . In some embodiments,


R^3 is selected from: , , and .


[0011] In certain embodiments,

R^{12} is selected from H-, H_2N -, $R^{31}-C(O)$ -, $R^{31}-C(O)CH_2$ -, $R^{31}-NHC(O)$ -, $R^{31}-C(O)NH$ -, $R^{31}-NH$ -, $R^{31}-N(CH_3)C(O)$ -, $R^{31}-C(O)N(CH_3)$ -, $R^{31}-N(CH_3)$ -, and $R^{31}-O$ -;

R^{31} is selected from optionally substituted cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), and optionally substituted saturated heterocycle (e.g., azetidine, pyrrolidine, piperidine, morpholine, piperazine, morpholine-3-one, or piperidine-2-one); and

the optional substituents of the R^{31} group are selected from NC-, HO-, $HOCH_2$ -, $(C_1-C_3)alkyl$ - (e.g., H_3C -), $(C_1-C_3)alkoxy$ -, substituted $(C_1-C_3)alkyl$ -, and $(C_3-C_6)cycloalkyl$ - (e.g., cyclopropyl), and $(C_2-C_5)heterocycloalkyl$ - (e.g., azetidine, pyrrolidine, piperidine, morpholine, piperazine, morpholine-3-one, or piperidine-2-one).

[0012] In some embodiments of formula (I)-(Ib), R^3 is . In another


embodiments, R^3 is . In another embodiments,

R^{12} is selected from H-, $R^{31}-C(O)$ -, $R^{31}-C(O)CH_2$ -, $R^{31}-NHC(O)$ -, $R^{31}-C(O)NH$ -, $R^{31}-N(CH_3)C(O)$ -, and $R^{31}-C(O)N(CH_3)$ -;

R^{31} is selected from optionally substituted $(C_1-C_3)alkyl$ -, optionally substituted cycloalkyl- (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl-), and optionally substituted saturated heterocycle (e.g., azetidine, pyrrolidine, piperidine); and

the optional substituents of the R^{31} group are selected from NC-, HO-, $HOCH_2$ -, $(C_1-C_3)alkyl$ - (e.g., H_3C -), $(C_1-C_3)alkoxy$ - and substituted $(C_1-C_3)alkyl$.

[0013] In some embodiments of formula (I), the compound is of formula (Ic):




wherein:

X^1 and X^4 are independently N or C- R^1 ;

R^1 is selected from H, halogen, optionally substituted $-(C_1-C_6)$ alkyl, and optionally substituted $-(C_1-C_6)$ alkoxy; and

R^{31} is selected from optionally substituted (C_2-C_5) heterocycloalkyl-, and optionally substituted (C_3-C_7) cycloalkyl-. In some embodiments of formula (Ic), R^{31} is optionally substituted (C_3-C_5) heterocycloalkyl.

[0014] In some embodiments of formula (Ic), the compound is of formula (Id):



wherein:

X^1 and X^4 are independently N or CH; and


R^{41} is H-, or HO-; and

q is 0, 1 or 2; wherein

when q is 0 or 1, X^5 is CH_2 ; and

when q is 2, X^5 is NH, O, or CH(OH).

[0015] In some embodiments of formula (I), the compound is of formula (Ie):



wherein:

X^1 and X^4 are independently N or C- R^1 ;


R^1 is selected from H, halogen, optionally substituted $-(C_1-C_6)$ alkyl, and optionally substituted $-(C_1-C_6)$ alkoxy;

R^{31} is selected from optionally substituted (C_2-C_5) heterocycloalkyl, and optionally substituted (C_3-C_7) cycloalkyl-;

R^{11} is -H, -halogen, -CN, -OH, optionally substituted $-(C_1-C_6)$ alkoxy, - NH_2 , $-NR^5R^6$, $-CH_2NH_2$ and optionally substituted $-(C_1-C_6)$ alkyl; and

n is 0, 1, 2, or 3.

[0016] In some embodiments of formula (Ie), the compound is of formula (If):



wherein:

X^1 and X^4 are independently N or CH;

R^{41} is H-, or HO-; and

q is 0, 1 or 2; wherein

when q is 0 or 1, X^5 is CH_2 ; and

when q is 2, X^5 is NH, O, or CH(OH).

[0017] In a second aspect, the present disclosure provides for a pharmaceutical composition comprising an ATX inhibitor compound, or a pharmaceutically acceptable salt thereof, as

described herein (e.g., a compound of formula (I)-(If)), and a pharmaceutically acceptable excipient.

[0018] In a third aspect, the present disclosure provides a method of inhibiting ATX using said compounds and compositions. In some embodiments, the method includes contacting a sample comprising ATX with an effective amount of an ATX inhibitor compound, or a pharmaceutically acceptable salt thereof, as described herein (e.g., a compound of formula (I)-(If)) to inhibit the ATX.


4. DETAILED DESCRIPTION OF THE INVENTION

4.1. ATX Inhibitor Compounds

[0019] As summarized above, the present disclosure provides compounds and compositions for use in inhibiting autotaxin (ATX). The compounds can include a fused bicyclic structure including a five membered imidazole ring fused (e.g., a imidazole ring fused at 1,2 positions) to a six membered heterocycle ring such as a pyridine (e.g., where the imidazo N1 atom is part of the pyridine ring), pyridiazine, pyrazine or pyrimidine ring. In some embodiments the fused bicyclic structure is an imidazo[1,2-a]pyridine, imidazo[1,2-b]pyridazine, imidazo[1,2-a]pyrimidine, or imidazo[1,2-a]pyrazine. The fused bicyclic structure is substituted at the 3-position with an amino group substituted with a five membered heterocycle such as a 2-substituted thiazole, oxazole or imidazole ring that itself is further substituted at the 4-position with an optionally substituted phenyl ring.

[0020] In the ATX inhibitor compounds of this disclosure, the fused bicyclic structure can be substituted at the 6 position with a six membered heterocycle such as a pyridin-3-yl, pyrimidin-5-yl, pyridazin-3-yl or pyrazin-2-yl that is itself further substituted at the para position with various para substituents (e.g., as described herein).

[0021] More specifically, in a first aspect, the present disclosure provides a compound of formula (I):



or a pharmaceutically acceptable salt thereof,

wherein:

X^1 , X^2 , and X^3 are independently selected from C- R^1 and N;

Z^1 , Z^2 , and Z^3 are independently selected from C- R^1 and N;

each R^1 is independently selected from -H, -halogen, optionally substituted -(C₁-C₆)alkyl and optionally substituted -(C₁-C₆)alkoxy;

Y is selected from S, O, and N- R^2 , wherein R^2 is selected from -H, and optionally substituted -(C₁-C₆)alkyl;

R^3 is selected from optionally substituted R^4 -C(O)-(C₁-C₃)alkyl-, R^4 C(O)-, optionally substituted monocyclic or bicyclic carbocycle, optionally substituted monocyclic or bicyclic heterocycle, R^5R^6 HC-, and R^5R^6 N-;

R^4 is selected from H₂N-, HO-, R^5R^6 N-, optionally substituted (C₁-C₁₀)alkyl-, optionally substituted (C₁-C₁₀)alkoxy-, optionally substituted monocyclic or bicyclic carbocycle, optionally substituted monocyclic or bicyclic heterocycle, optionally substituted cycloalkyl-(C₁-C₆)alkylene-, and optionally substituted heterocycle-(C₁-C₆)alkylene-;

R^5 and R^6 are independently selected from H-, H₂N-, HO-, optionally substituted (C₁-C₁₀)alkyl-, optionally substituted monocyclic or bicyclic carbocycle (e.g., saturated monocyclic carbocycle, e.g., cycloalkyl), optionally substituted monocyclic or bicyclic heterocycle (e.g., saturated monocyclic heterocycle, e.g., azetidine, pyrrolidine or piperidine), optionally substituted R^4 C(O)-(C₁-C₁₀)alkyl-, R^4 C(O)-, R^4 -, and substituted amino;

or R^5 and R^6 together with the nitrogen or carbon atom to which they are attached are cyclically linked to form an optionally substituted carbocycle or an optionally substituted heterocycle (e.g., azetidine, morpholine, piperidine or piperazine);

R^7 is selected from H-, and optionally substituted (C₁-C₆)alkyl-;

R^8 is selected from -H, -halogen, and optionally substituted -(C₁-C₆)alkyl-;

R^9 and each R^{10} are independently selected from -H, -halogen, -CN, -OH, optionally substituted -(C₁-C₆)alkoxy, -NH₂, substituted amino, optionally substituted -(C₁-C₆)alkyl-NH₂ (e.g., -CH₂NH₂) and optionally substituted -(C₁-C₆)alkyl-; and

n is 0, 1, 2, 3, 4, or 5.

[0022] In some embodiments of formula (I), X^1 is N. In some embodiments of formula (I), X^2 is N. In some embodiments of formula (I), X^3 is N.

[0023] In some embodiments of formula (I), X^1 is N, X^2 is C-H, and X^3 is C-H.

[0024] In some embodiments of formula (I), X^1 is C-H, X^2 is C-H, and X^3 is C-H.


[0025] In some embodiments of formula (I), Y is S. In some embodiments, Y is O. In some embodiments, Y is NH.

[0026] In some embodiments of formula (I), Z^1 is N. In some embodiments of formula (I), Z^2 is N. In some embodiments of formula (I), Z^3 is N. In some embodiments of formula (I), one and only one of Z^1 to Z^3 is N.

[0027] In some embodiments of formula (I), Z^1 is C-H, Z^2 is C-H, and Z^3 is C-H.

[0028] In some embodiments of formula (I), n is 0. In some embodiments of formula (I), n is 1. In some embodiments of formula (I), n is 1 and the R^{10} substituent is located at the para position. In some embodiments of formula (I), n is 2.

[0029] In some embodiments, the compound of formula (I) is a compound of formula (Ia):



wherein:

R^1 is selected from -H, -halogen, optionally substituted $-(C_1-C_6)$ alkyl and optionally substituted $-(C_1-C_6)$ alkoxy;

R^3 is selected from $R^4C(O)-$, $R^4C(O)CH_2-$, R^5R^6N- , and R^5R^6HC- ;

R^{11} is -H, -halogen, -CN, -OH, optionally substituted $-(C_1-C_6)$ alkoxy, - NH_2 , $-NR^5R^6$, $-CH_2NH_2$ and optionally substituted $-(C_1-C_6)$ alkyl; and

n is 0, 1, 2, or 3.

[0030] In some embodiments of formula (I)-(Ia), X^1 is N. In some other embodiment of formula (I)-(Ia), X^1 is C-H.

[0031] In some embodiments of formula (I)-(Ia), R^1 is H. In some embodiments of formula (I)-(Ia), R^1 is substituted $-(C_1-C_3)$ alkyl. In some embodiments of formula (I)-(Ia), R^1 is methyl. In some embodiments of formula (I)-(Ia), R^1 is a halogen. In certain embodiments of formula (I)-(Ia), R^1 is F. In some embodiments of formula (I)-(Ia), R^1 is substituted $-(C_1-C_3)$ alkoxy. In some embodiments of formula (I)-(Ia), R^1 is methoxy.


[0032] In some embodiments of formula (I)-(Ia), R^7 is optionally substituted (C_1-C_6) alkyl-. In some embodiments of formula (I)-(Ia), R^7 is (C_1-C_3) alkyl-. In some embodiments of formula (I)-(Ia), R^7 is H_3CH_2C- . In some embodiments of formula (I)-(Ia), R^7 is H_3C- .

[0033] In some embodiments of formula (I)-(Ia), R⁸ is optionally substituted -(C₁-C₆)alkyl. In some embodiments of formula (I)-(Ia), R⁸ is (C₁-C₃)alkyl-. In another embodiment of formula (I)-(Ia), R⁸ is -CH₂CH₃. In another embodiment of formula (I)-(Ia), R⁸ is -CH₃.

[0034] In some embodiments of formula (I)-(Ia), R⁹ is selected from -halogen, -CN, -OH, -(C₁-C₆)alkoxy, -NH₂, substituted amino, -(C₁-C₆)alkyl-NH₂ (e.g., -CH₂NH₂) and -(C₁-C₆)alkyl. In some embodiments of formula (I)-(Ia), R⁹ is halogen. In certain cases, the halogen is F or Cl. In some embodiments of formula (I)-(Ia), R⁹ is -OH. In some embodiments of formula (I)-(Ia), R⁹ is -OCH₃. In some embodiments of formula (I)-(Ia), R⁹ is amino or substituted amino. In some embodiments of formula (I)-(Ia), R⁹ is -(C₁-C₆)alkyl-NH₂. In certain cases of formula (I)-(Ia), R⁹ is -CH₂NH₂. In some embodiments of formula (I)-(Ia), R⁹ is -(C₁-C₆)alkyl. In some embodiments of formula (I)-(Ia), R⁹ is CH₃. In some embodiments of formula (I)-(Ia), R⁹ is -CH₂CH₃. In some embodiments of formula (I)-(Ia), R⁹ is H. In some embodiments of formula (I)-(Ia), R⁹ is -CN.

[0035] In some embodiments of formula (Ia), R¹¹ is -halogen. In another embodiment of formula (Ia), R¹¹ is -F. In some embodiments of formula (Ia), R¹¹ is -CN. In some embodiments of formula (Ia), R¹¹ is -OH. In some embodiments of formula (Ia), R¹¹ is -(C₁-C₆)alkoxy. In some embodiments of formula (Ia), R¹¹ is -NH₂ or -NR⁵R⁶. In some embodiments of formula (Ia), R¹¹ is -CH₂NH₂. In some embodiments of formula (Ia), R¹¹ is -(C₁-C₆)alkyl. In some embodiments of formula (Ia), R¹¹ is -CH₃. In some embodiments of formula (Ia), R¹¹ is -CH₂CH₃.

[0036] In some embodiments, the compound of formula (I) is a compound of formula (Ib):



wherein:






X¹ is C-H or N; and

R¹ is selected from -H, -halogen, optionally substituted -(C₁-C₆)alkyl, and optionally substituted -(C₁-C₆)alkoxy.

[0037] In some embodiments of formula (Ib), X^1 is N. In some other embodiment of formula (Ib), X^1 is C-H.

[0038] In some embodiments of formula (Ib), R^1 is H. In some embodiments of formula (Ib), R^1 is substituted $-(C_1-C_3)$ alkyl. In some embodiments of formula (Ib), R^1 is methyl. In some embodiments of formula (Ib), R^1 is a halogen. In certain embodiments of formula (Ib), R^1 is F. In some embodiments of formula (Ib), R^1 is substituted $-(C_1-C_3)$ alkoxy. In some embodiments of formula (Ib), R^1 is methoxy.

[0039] In some embodiments of the compound of formula (I)-(Ib),



wherein:

R^4 is selected from HO-, H_2N -, $R^{15}R^{16}N$ -, optionally substituted (C_1-C_5)alkyl-, optionally substituted monocyclic or bicyclic carbocycle, and optionally substituted monocyclic or bicyclic heterocycle;


R^{12} is selected from -H, - NH_2 , -OH, - $CH_2C(O)R^4$, - $C(O)R^4$, - $CHR^{15}R^{16}$, - $NR^{15}R^{16}$, optionally substituted $-(C_1-C_5)$ alkyl, optionally substituted monocyclic or bicyclic $-(C_3-C_8)$ carbocycle (e.g., $-(C_3-C_6)$ cycloalkyl), and an optionally substituted monocyclic or bicyclic $-(C_2-C_9)$ heterocycle (e.g., $-(C_2-C_5)$ heterocycloalkyl);

R^{13} and R^{14} are independently selected from -H, - $CH_2C(O)R^{17}$, - CH_2R^{17} , - $C(O)R^{17}$, - $R^{18}C(O)R^{17}$, - $CH_2R^{18}C(O)R^{17}$, optionally substituted $-(C_1-C_5)$ alkyl, optionally substituted

monocyclic or bicyclic $-(C_3-C_8)$ carbocycle (e.g., $-(C_3-C_6)$ cycloalkyl), and an optionally substituted monocyclic or bicyclic $-(C_2-C_9)$ heterocycle (e.g., $-(C_2-C_5)$ heterocycloalkyl), wherein R^{17} and R^{18} are independently selected from optionally substituted $-(C_1-C_5)$ alkyl, optionally substituted monocyclic or bicyclic $-(C_3-C_8)$ carbocycle (e.g., $-(C_3-C_6)$ cycloalkyl), and an optionally substituted monocyclic or bicyclic $-(C_2-C_9)$ heterocycle (e.g., $-(C_2-C_5)$ heterocycloalkyl); and

R^{15} and R^{16} are independently selected from H-, optionally substituted (C_2-C_5) heterocycloalkyl- $C(O)-$, optionally substituted (C_3-C_6) cycloalkyl- $C(O)-$, optionally substituted (C_1-C_5) alkyl-, optionally substituted 3- to 10-membered saturated monocyclic heterocycle or carbocycle, and optionally substituted 3- to 10-membered saturated bicyclic heterocycle or carbocycle, wherein the optional substituents are selected from hydroxy, $HOCH_2-$, cyano, halogen, substituted amino (e.g., (C_1-C_5) alkyl-substituted amino), and (C_1-C_5) alkyl; or R^{15} and R^{16} are cyclically linked to form a 3- to 6-membered monocyclic saturated heterocycle, optionally substituted with hydroxy, $HOCH_2-$, cyano, halogen, substituted amino (e.g., (C_1-C_5) alkyl-substituted amino), or (C_1-C_5) alkyl.

[0040] In some embodiments of the compound of formula (I)-(Ib),



R^4 is selected from R^{32} , $R^{32}HN-$, $R^{32}N(R^{33})-$, and $R^{32}HN-R^{36}-$;

R^{32} and R^{33} are independently selected from H-, optionally substituted $-(C_1-C_3)$ alkyl, optionally substituted cycloalkyl, and optionally substituted saturated heterocycle; and

R^{36} is selected from optionally substituted (C_1-C_3) alkyl, optionally substituted cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), and optionally substituted saturated heterocycle (e.g., azetidine, pyrrolidine, piperidine); and


the optional substituents of the R^{32} , R^{33} and R^{36} groups are independently selected from $-CN$, $-OH$, $-CH_2OH$, $-(C_1-C_3)$ alkyl (e.g., $-CH_3$), $-(C_1-C_3)$ alkoxy, $-(C_3-C_6)$ cycloalkyl, $-(C_2-C_5)$ heterocycloalkyl (e.g., azetidine), and $-N(R^{37})R^{38}$, wherein R^{37} and R^{38} are independently selected from H, (C_1-C_3) alkyl, (C_3-C_6) cycloalkyl (e.g., cyclopropyl or cyclobutyl), and (C_2-C_5) heterocycloalkyl (e.g., azetidine).

[0041] In some embodiments, R^{33} is $-(C_1-C_3)$ alkyl and R^{32} is optionally substituted cycloalkyl, or optionally substituted saturated heterocycle. In some embodiments, R^{32} is optionally substituted cycloalkyl that is optionally substituted cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, R^{32} is optionally substituted heterocycle

that is optionally substituted azetidine, pyrrolidine, piperidine, morpholine, piperazine, morpholine-3-one, or piperidine-2-one.


[0042] In some embodiments, R^4 is an azetidine, pyrrolidine or piperidine ring that is substituted (e.g., at the 3-position) with -OH. In some embodiments, R^4 is $R^{32}HN-R^{36}$ - where R^{36} is azetidine and R^{32} is selected from azetidine, cyclobutyl, cyclopropyl, ethyl and methyl. In some embodiments, R^4 is $R^{32}HN$ -, where R^{32} is selected from H, -(C₁-C₃)alkyl (e.g., methyl), azetidine, pyrrolidine, piperidine, cyclopentyl, cyclobutyl, and cyclopropyl, and R^{32} is optionally substituted, e.g., with -CN or -OH.

[0043] In some embodiments, R^4 is selected from:



[0044] In some embodiments of formula (Ib), the compound is selected from compounds 11-16, 47-65 and 87 of Table 1.

[0045] In some embodiments of the compound of formula (I)-(Ib),




R^{14} is selected from R^{34} -, $R^{34}CH_2$ -, $R^{34}C(O)R^{35}$ -, and $R^{34}C(O)R^{35}CH_2$;

each R^{34} and R^{35} are independently selected from optionally substituted -(C₁-C₃)alkyl, optionally substituted cycloalkyl, and optionally substituted saturated heterocycle;

the optional substituents of the R^{34} and R^{35} groups are independently selected from -CN, -OH, -CH₂OH, -(C₁-C₃)alkyl (e.g., -CH₃), -(C₁-C₃)alkoxy, and -(C₁-C₃)alkyl; and


R¹³ is -H. In some embodiments, the optionally substituted cycloalkyl is optionally substituted cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, the optionally substituted heterocycle is optionally substituted azetidine, pyrrolidine, piperidine, morpholine, piperazine, morpholine-3-one, or piperidine-2-one.

[0046] In some embodiments, R^{14} is selected from:



[0047] In some embodiments of formula (Ib), the compound is selected from compounds 21, 22, and 34-41 of Table 1.

[0048] In some embodiments of the compound of formula (I)-(Ib),




R¹² is selected from H-, H₂N-, R³¹-C(O)-, R³¹-C(O)CH₂-, R³¹-NHC(O)-, R³¹-C(O)NH-, R³¹-NH-, R³¹-N(CH₃)C(O)-, R³¹-C(O)N(CH₃)-, R³¹-N(CH₃)-, and R³¹-O-;

R³¹ is selected from optionally substituted cycloalkyl, optionally substituted saturated heterocycle; and

the optional substituents of the R³¹ group are selected from NC-, HO-, HOCH₂-, (C₁-C₃)alkyl- (e.g., H₃C-), (C₁-C₃)alkoxy-, substituted (C₁-C₃)alkyl-, and (C₃-C₆)cycloalkyl- (e.g., cyclopropyl), and (C₂-C₅)heterocycloalkyl- (e.g., azetidine, pyrrolidine, piperidine, morpholine, piperazine, morpholine-3-one, or piperidine-2-one). In some embodiments, the optionally substituted cycloalkyl is optionally substituted cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, the optionally substituted saturated

heterocycle is optionally substituted azetidine, pyrrolidine, piperidine, morpholine, piperazine, morpholine-3-one, or piperidine-2-one.


[0049] In some embodiments, R^{12} is selected from:




[0050] In some embodiments of formula (Ib), the compound is selected from compounds 1-10, 17-20, 23-33, 42-46, 66-80 and of Table 1.

[0051] In some embodiments of formula (Ib), the compound is selected from compounds 81-86, 88-98, 105-115, and 118-127 of Table 1.

[0052] In some embodiments of the compound of formula (I)-(Ib), R³ is



another embodiment, R³ is




. In another embodiment,

R¹² is selected from H-, R³¹-C(O)-, R³¹-C(O)CH₂-, R³¹-NHC(O)-, R³¹-C(O)NH-, R³¹-N(CH₃)C(O)-, and R³¹-C(O)N(CH₃)-

R³¹ is selected from optionally substituted (C₁-C₃)alkyl-, optionally substituted cycloalkyl-, and optionally substituted saturated heterocycle; and


the optional substituents of the R³¹ group are selected from NC-, HO-, HOCH₂-, (C₁-C₃)alkyl- (e.g., H₃C-), (C₁-C₃)alkoxy- and substituted (C₁-C₃)alkyl-. In some embodiments, the optionally substituted cycloalkyl is optionally substituted cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, the optionally substituted heterocycle is optionally substituted azetidine, optionally substituted pyrrolidine, or optionally substituted piperidine.

[0053] In another embodiment, R¹² is selected from:



[0054] In some embodiments of formula (Ib), the compound is selected from compounds 99-104 of Table 1.

[0055] In some embodiments of formula (I)-(Ia), the compound is of formula (Ie):



wherein:

X¹ and X⁴ are independently N or C-R¹;


R¹ is selected from H, halogen, optionally substituted -(C₁-C₆)alkyl, and optionally substituted -(C₁-C₆)alkoxy; and

R^{31} is selected from optionally substituted (C_2-C_5) heterocycloalkyl, and optionally substituted (C_3-C_7) cycloalkyl-;

R^{11} is -H, -halogen, -CN, -OH, optionally substituted $-(C_1-C_6)$ alkoxy, - NH_2 , $-NR^5R^6$, $-CH_2NH_2$ and optionally substituted $-(C_1-C_6)$ alkyl; and
 n is 0, 1, 2, or 3.

[0056] In some embodiments of the compound of formula (Ie), the optional substituents of the R^{31} group are selected from NC-, HO-, $HOCH_2$ -, (C_1-C_3) alkyl- (e.g., H_3C -), (C_1-C_3) alkoxy-, substituted (C_1-C_3) alkyl-, and (C_3-C_6) cycloalkyl- (e.g., cyclopropyl).

[0057] In some embodiments of formula (Ie), the compound is of formula (If):



wherein:

X^1 and X^4 are independently N or CH;

R^{41} is H-, or HO-; and

q is 0, 1 or 2; wherein

when q is 0 or 1, X^5 is CH_2 ; and

when q is 2, X^5 is NH, O, or CH(OH).

[0058] In some embodiments of formula (Ie)-(If), R^7 is optionally substituted (C_1-C_6) alkyl-.

In some embodiments of formula (Ie)-(If), R^7 is (C_1-C_3) alkyl-. In some embodiments of formula (Ie)-(If), R^7 is H_3CH_2C -. In some embodiments of formula (Ie)-(If), R^7 is H_3C -.

[0059] In some embodiments of formula (Ie)-(If), R^8 is optionally substituted $-(C_1-C_6)$ alkyl.


In some embodiments of formula (Ie)-(If), R^8 is (C_1-C_3) alkyl-. In some embodiments of formula (Ie)-(If), R^8 is $-CH_2CH_3$. In some embodiments of formula (Ie)-(If), R^8 is $-CH_3$.

[0060] In some embodiments of formula (Ie)-(If), R^9 is selected from -halogen, -CN, -OH, $-(C_1-C_6)$ alkoxy, $-NH_2$, substituted amino, $-(C_1-C_6)$ alkyl- NH_2 (e.g., $-CH_2NH_2$) and $-(C_1-C_6)$ alkyl. In some embodiments of formula (Ie)-(If), R^9 is halogen. In certain cases, the halogen is F or Cl. In some embodiments of formula (Ie)-(If), R^9 is -OH. In some embodiments of formula (Ie)-(If), R^9 is $-OCH_3$. In some embodiments of formula (Ie)-(If), R^9

is amino or substituted amino. In some embodiments of formula (Ie)-(If), R^9 is $-(C_1-C_6)alkyl-NH_2$. In certain cases, R^9 is $-CH_2NH_2$. In some embodiments of formula (Ie)-(If), R^9 is $-(C_1-C_6)alkyl$. In some embodiments of formula (Ie)-(If), R^9 is CH_3 . In some embodiments of formula (Ie)-(If), R^9 is $-CH_2CH_3$. In some embodiments of formula (Ie)-(If), R^9 is H. In some embodiments of formula (Ie)-(If), R^9 is $-CN$.

[0061] In some embodiments of formula (Ie)-(If), R^{11} is -halogen. In another embodiment of formula (Ie)-(If), R^{11} is -F. In some embodiments of formula (Ie)-(If), R^{11} is $-CN$. In some embodiments of formula (Ie)-(If), R^{11} is $-OH$. In some embodiments of formula (Ie)-(If), R^{11} is $-(C_1-C_6)alkoxy$. In some embodiments of formula (Ie)-(If), R^{11} is $-NH_2$ or $-NR^5R^6$. In some embodiments of formula (Ie)-(If), R^{11} is $-CH_2NH_2$. In some embodiments of formula (Ie)-(If), R^{11} is $-(C_1-C_6)alkyl$. In some embodiments of formula (Ie)-(If), R^{11} is $-CH_3$. In some embodiments of formula (Ie)-(If), R^{11} is $-CH_2CH_3$.

[0062] In some embodiments of formula (I)-(Ib), the compound is of formula (Ic):




wherein:

X^1 and X^4 are independently N or C- R^1 ;

R^1 is selected from H, halogen, optionally substituted $-(C_1-C_6)alkyl$, and optionally substituted $-(C_1-C_6)alkoxy$; and

R^{31} is optionally substituted $(C_2-C_5)heterocycloalkyl$ -, or optionally substituted $(C_3-C_7)cycloalkyl$. In some embodiments of formula (Ic), the optional substituents of the R^{31} group are selected from NC-, HO-, $HOCH_2$ -, $(C_1-C_3)alkyl$ - (e.g., H_3C -), $(C_1-C_3)alkoxy$ -, substituted $(C_1-C_3)alkyl$ -, $(C_3-C_6)cycloalkyl$ - (e.g., cyclopropyl), and $(C_2-C_5)heterocycloalkyl$ - (e.g., azetidine, pyrrolidine, piperidine, morpholine, piperazine, morpholine-3-one, or piperidine-2-one).

[0063] In some embodiments of formula (Ic), the compound is of formula (Id):



wherein:

X^1 and X^4 are independently N or CH;

R^{41} is H-, or HO-; and

q is 0, 1 or 2; wherein


when q is 0 or 1, X^5 is CH_2 ; and

when q is 2, X^5 is NH, O, or CH(OH).

[0064] In some embodiments of formula (Ic)-(If), X^1 is N. In some other embodiment of formula (Ic)-(If), X^1 is C-H.


[0065] In some embodiments of formula (Ic)-(If), R^1 is H. In some embodiments of formula (Ic)-(If), R^1 is substituted $-(C_1-C_3)$ alkyl. In some embodiments of formula (Ic)-(If), R^1 is methyl. In some embodiments of formula (Ic)-(If), R^1 is a halogen. In certain embodiments of formula (Ic)-(If), R^1 is F. In some embodiments of formula (Ic)-(If), R^1 is substituted $-(C_1-C_3)$ alkoxy. In some embodiments of formula (Ic)-(If), R^1 is methoxy.

[0066] In some embodiments, the compound of formula (Id) is of the structure:




or a salt thereof.

[0067] In some embodiments, the compound of formula (Id) is of the structure:




or a salt thereof.

[0068] In some embodiments, the compound of formula (Id) is of the structure:




or a salt thereof.

[0069] In some embodiments, the compound of formula (Id) is of the structure:




or a salt thereof.

[0070] In some embodiments, the compound of formula (Id) is of the structure:




or a salt thereof.

[0071] In some embodiments, the compound of formula (Id) is of the structure:




or a salt thereof.

[0072] In some embodiments, the compound of formula (Id) is of the structure:




or a salt thereof.

[0073] In some embodiments, the compound of formula (Id) is of the structure:




or a salt thereof.

[0074] In some embodiments, the compound of formula (Id) is of the structure:




or a salt thereof.

[0075] In some embodiments, the compound of formula (Id) is of the structure:




or a salt thereof.

[0076] In some embodiments, the compound of formula (Id) is of the structure:



or a salt thereof.


[0077] In some embodiments, the compound of formula (Id) is of the structure:



or a salt thereof.

[0078] ATX inhibitor compounds of the present disclosure (e.g., of any one of formula (I)-(If)) may have a structure selected from any of those listed in Table 1 or a pharmaceutically acceptable salt thereof.

[0079] Also disclosed herein are compounds of formula (II):



or a pharmaceutically acceptable salt or isomer thereof,

wherein:

Z^1 , Z^2 , and Z^3 are independently selected from C- R^1 and N;

R^{20} and R^{21} are each independently selected from H, and optionally substituted -(C₁-C₆)alkyl;

or R^{20} and R^{21} together with the boron atom to which they are attached from an optionally substituted heterocycle;

each R^1 is independently selected from -H, -halogen, optionally substituted -(C₁-C₆)alkyl and optionally substituted -(C₁-C₆)alkoxy;

Y is selected from S, O, and N- R^2 , wherein R^2 is selected from -H, and optionally substituted -(C₁-C₆)alkyl;


R^7 is selected from H-, and optionally substituted (C₁-C₆)alkyl-;

R^8 is selected from -H, -halogen, and optionally substituted -(C₁-C₆)alkyl;


R^9 and each R^{10} are independently selected from -H, -halogen, -CN, -OH, optionally substituted -(C₁-C₆)alkoxy, -NH₂, substituted amino, optionally substituted -(C₁-C₆)alkyl-NH₂ and optionally substituted -(C₁-C₆)alkyl; and

n is 0, 1, 2, 3, 4, or 5.

[0080] In certain embodiments, the compound of formula (II) is:



[0081] Also disclosed herein are compound of formula (III):



or a pharmaceutically acceptable salt or isomer thereof,

wherein:

X^1 , X^2 , and X^3 are independently selected from C- R^1 and N;

Z^1 , Z^2 , and Z^3 are independently selected from C- R^1 and N;

each R^1 is independently selected from -H, -halogen, optionally substituted $-(C_1-C_6)$ alkyl and optionally substituted $-(C_1-C_6)$ alkoxy;

Y is selected from S, O, and N- R^2 , wherein R^2 is selected from -H, and optionally substituted $-(C_1-C_6)$ alkyl;

R^{3a} is selected from optionally substituted $R^4-C(O)-(C_1-C_3)$ alkyl-, $R^4C(O)-$, halogen, optionally substituted monocyclic or bicyclic carbocycle, optionally substituted monocyclic or bicyclic heterocycle, R^5R^6HC- , and R^5R^6N- ;

R^4 is selected from H_2N- , $HO-$, R^5R^6N- , optionally substituted (C_1-C_{10}) alkyl-, optionally substituted (C_1-C_{10}) alkoxy-, optionally substituted monocyclic or bicyclic carbocycle, optionally substituted monocyclic or bicyclic heterocycle, optionally substituted cycloalkyl- (C_1-C_6) alkylene-, and optionally substituted heterocycle- (C_1-C_6) alkylene-;

R^5 and R^6 are independently selected from H-, H_2N- , $HO-$, optionally substituted (C_1-C_{10}) alkyl-, optionally substituted monocyclic or bicyclic carbocycle, optionally substituted monocyclic or bicyclic heterocycle, optionally substituted $R^4C(O)-(C_1-C_{10})$ alkyl-, $R^4C(O)-$, R^4- , and substituted amino;

or R^5 and R^6 together with the nitrogen or carbon atom to which they are attached are cyclically linked to form an optionally substituted carbocycle or an optionally substituted heterocycle;


R^7 is selected from H-, and optionally substituted (C_1-C_6) alkyl-;

R^8 is selected from -H, -halogen, and optionally substituted $-(C_1-C_6)$ alkyl-;










R^9 and each R^{10} are independently selected from -H, -halogen, -CN, -OH, optionally substituted $-(C_1-C_6)$ alkoxy, $-NH_2$, substituted amino, optionally substituted $-(C_1-C_6)$ alkyl- NH_2 and optionally substituted $-(C_1-C_6)$ alkyl; and












n is 0, 1, 2, 3, 4, or 5.

[0082] In certain embodiments, the compound of formula (III) is one of the following compounds:



(129),





[0083] In certain embodiments, compounds of the present disclosure (e.g., of any one of formula (II)-(III)) may have a structure selected from any of those listed in Table 1A or a pharmaceutically acceptable salt thereof.

4.1.1. Isotopically Labelled Analogs

[0084] The present disclosure also encompasses isotopically-labeled compounds which are identical to those compounds as described herein, except that one or more atoms are replaced

by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature ("isotopologues"). The compounds of the present disclosure may also contain unnatural proportions of atomic isotopes at one or more atoms that constituted such compounds. Examples of isotopes that can be incorporated into compounds described herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as ^2H ("D"), ^3H , ^{13}C , ^{14}C , ^{15}N , ^{18}O , ^{17}O , ^{31}P , ^{32}P , ^{35}S , ^{18}F , and ^{36}Cl , respectively. For example, a compound described herein can have one or more H atoms replaced with deuterium.


[0085] Generally, reference to or depiction of a certain element such as hydrogen or H is meant to include all isotopes of that element. For example, if an R group is defined to include hydrogen or H, it also includes deuterium and tritium. Compounds comprising radioisotopes such as tritium, ^{14}C , ^{32}P and ^{35}S are thus within the scope of the present technology. Procedures for inserting such labels into the compounds of the present technology will be readily apparent to those skilled in the art based on the disclosure herein.

[0086] Unless otherwise stated, compounds described herein are intended to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by ^{13}C - or ^{14}C - enriched carbon are within the scope of the present disclosure.


[0087] In some embodiments, certain isotopically-labeled compounds, such as those labeled with ^3H and ^{14}C , can be useful in compound and/or substrate tissue distribution assays. Tritiated (^3H) and carbon-14 (^{14}C) isotopes can be particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium can afford certain therapeutic advantages resulting from greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements, and hence can be preferred in some circumstances. Isotopically-labeled compounds can generally be prepared by following procedures analogous to those disclosed herein, for example, in the Examples section, by substituting an isotopically-labeled reagent for a non-isotopically-labeled reagent.

[0088] In some embodiments, the compounds disclosed in the present disclosure are deuterated analogs of any of the compounds, or a salt thereof, as described herein. A deuterated analog of a compound of formula (I)-(If) is a compound where one or more hydrogen atoms are substituted with a deuterium. In some embodiments, the deuterated analog is a compound of formula (I) that includes a deuterated R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , or R^{10} group. In certain embodiments of a deuterated analog of a compound of formula

(I), R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , and R^{10} are independently selected from optionally substituted (C₁-C₆)alkyl, optionally substituted (C₁-C₆)alkoxy, optionally substituted (C₁-C₆)alkylene-heterocycloalkyl, optionally substituted monocyclic or bicyclic carbocycle, and optionally substituted monocyclic or bicyclic heterocycle including at least one deuterium atom. In certain embodiments of the deuterated analog of a compound of formula (I), R^1 , R^7 , R^8 , R^9 , and R^{10} are independently selected from an optionally substituted (C₁-C₃) alkyl, an optionally substituted (C₁-C₃)alkoxy, and an optionally substituted (C₁-C₃)-alkylene-heterocycle (e.g. -(CH₂)_m-morpholine, -(CH₂)_m-piperazine, and -(CH₂)_m-piperidine). In some embodiments of a deuterated analog of formula (I), R^1 , R^7 , R^8 , R^9 and R^{10} are independently -CD₃. In some embodiments of a deuterated analog of formula (I), R^1 , R^7 , R^8 , R^9 and R^{10} are independently -CD₂-CD₃. In some embodiments of a deuterated analog of a compound of formula (I), wherein the optional substituent is an optionally substituted heterocycloalkyl



including at least one deuterium atom (e.g. , , , and



[0089] Deuterium substituted compounds are synthesized using various methods such as described in: Dean, Dennis C.; Editor. Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development. [In: Curr., Pharm. Des., 2000; 6(10)] 2000, 110 pp; George W.; Varma, Rajender S. The Synthesis of Radiolabeled Compounds via Organometallic Intermediates, Tetrahedron, 1989, 45(21), 6601-21; and Evans, E. Anthony. Synthesis of radiolabeled compounds, J. Radioanal. Chem., 1981, 64(1-2), 9-32.

[0090] Deuterated starting materials are readily available and are subjected to the synthetic methods described herein to provide for the synthesis of deuterium-containing compounds. Large numbers of deuterium-containing reagents and building blocks are available commercially from chemical vendors, such as Aldrich Chemical Co.

4.1.2. Fluorinated Analogs

[0091] In some embodiments, the compounds disclosed in the present disclosure are fluorinated analogs of any of the compounds, or a salt thereof, as described herein. A

fluorinated analog of a compound of formula (I)-(If) is a compound where one or more hydrogen atoms or substituents are substituted with a fluorine atom. In some embodiments, the fluorinated analog is a compound of formula (I) that includes a fluorinated R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , or R^{10} group. In some embodiments of a fluorinated analog of a compound of formula (I), R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , and R^{10} are independently selected from optionally substituted (C₁-C₆)alkyl, optionally substituted (C₁-C₆)alkoxy, optionally substituted (C₁-C₆)alkylene-heterocycloalkyl, optionally substituted monocyclic or bicyclic carbocycle, optionally substituted monocyclic or bicyclic heterocycle, optionally substituted aryl, and optionally substituted heteroaryl including at least one fluorine atom. In some embodiments of a fluorinated analog of a compound of formula (I), the hydrogen atom of an aliphatic or an aromatic C-H bond is replaced by a fluorine atom. In some embodiments of a fluorinated analog of a compound of formula (I), at least one hydrogen of an optionally substituted aryl or an optionally substituted heteroaryl is replaced by a fluorine atom. In some embodiments of a fluorinated analog of a compound of formula (I), a hydroxyl substituent (-OH) or an amino substituent (-NH₂) is replaced by a fluorine atom. In some embodiments of a fluorinated analog of a compound of formula (I), R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , and R^{10} are independently selected from F, CF₃, CF₂CF₃, CHF₂, OCF₃, OCHF₂, and OCF₂CF₃.

4.1.3. Isomers

[0092] The term “compound”, as used herein, is meant to include all stereoisomers, geometric isomers, tautomers, and isotopes of the structures depicted.

[0093] The compounds herein described may have asymmetric centers, geometric centers (e.g., double bond), or both. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. In some embodiments, the compounds described herein have one or more chiral centers. It is understood that if an absolute stereochemistry is not expressly indicated, then each chiral center may independently be of the R-configuration or the S-configuration or a mixture thereof. Thus, compounds described herein include enriched or resolved optical isomers at any or all asymmetric atoms as are apparent from the depictions. Racemic mixtures of R-enantiomer and S-enantiomer, and enantio-enriched stereomeric mixtures comprising of R- and S-enantiomers, as well as the individual optical isomers can be isolated or synthesized so as to be substantially free of their enantiomeric or

diastereomeric partners, and these stereoisomers are all within the scope of the present technology.

[0094] Compounds of the present disclosure containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms, by synthesis from optically active starting materials, or through use of chiral auxiliaries.

[0095] Geometric isomers, resulting from the arrangement of substituents around a carbon-carbon double bond or arrangement of substituents around a cycloalkyl or heterocyclic ring, can also exist in the compounds of the present disclosure. Geometric isomers of olefins, C=N double bonds, or other types of double bonds may be present in the compounds described herein, and all such stable isomers are included in the present disclosure. Specifically, *cis* and *trans* geometric isomers of the compounds of the present disclosure may also exist and may be isolated as a mixture of isomers or as separated isomeric forms.

[0096] Compounds of the present disclosure also include tautomeric forms. Tautomeric forms result from the swapping of a single bond with an adjacent double bond and the concomitant migration of a proton. Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge. Examples prototropic tautomers include ketone – enol pairs, amide – imidic acid pairs, lactam – lactim pairs, amide – imidic acid pairs, enamine – imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, such as, 1H- and 3H-imidazole, 1H-, 2H- and 4H- 1,2,4-triazole, 1H- and 2H- isoindole, and 1H- and 2H-pyrazole. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.

4.1.4. Salts and other forms

[0097] In some embodiments, the compounds described herein are present in a salt form. In some embodiments, the compounds are provided in the form of pharmaceutically acceptable salts.

[0098] Compounds included in the present compositions that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that can be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, *i.e.*, salts containing pharmacologically acceptable anions, including but not limited to, malate, oxalate, chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate,

citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (*i.e.*, 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)) salts.

[0099] Compounds containing an amine functional group or a nitrogen-containing heteroaryl group may be basic in nature and may react with any number of inorganic and organic acids to form the corresponding pharmaceutically acceptable salts. Inorganic acids commonly employed to form such salts include hydrochloric, hydrobromic, hydroiodic, sulfuric, and phosphoric acids, and related inorganic acids. Organic acids commonly employed to form such salts include para-toluenesulfonic, methanesulfonic, oxalic, para-bromophenylsulfonic, fumaric, maleic, carbonic, succinic, citric, benzoic and acetic acid, and related organic acids. Such pharmaceutically acceptable salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, β -hydroxybutyrate, glycollate, maleate, tartrate, methanesulfonate, propanesulfonates, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate, hippurate, gluconate, lactobionate, and the related salts.

[0100] Examples of salts include, but are not limited to: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, flucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, undecanoate, and the like.

[0101] Other examples of salts include anions of the compounds of the present disclosure compounded with a suitable cation such as N^+ , NH_4^+ , and NW_4^+ (where W can be a C_1 - C_8 alkyl group), and the like. For therapeutic use, salts of the compounds of the present disclosure can be pharmaceutically acceptable. However, salts of acids and bases that are

non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.

[0102] Compounds included in the present compositions that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include alkali metal or alkaline earth metal salts and, particularly, calcium, magnesium, sodium, lithium, zinc, potassium, and iron salts.

[0103] Compounds that include a basic or acidic moiety can also form pharmaceutically acceptable salts with various amino acids. The compounds of the disclosure can contain both acidic and basic groups; for example, one amino and one carboxylic acid group. In such a case, the compound can exist as an acid addition salt, a zwitterion, or a base salt.

[0104] The compounds described herein can be present in various forms including crystalline, powder and amorphous forms of those compounds, pharmaceutically acceptable salts, including, for example, polymorphs, pseudopolymorphs, solvates, hydrates, unsolvated polymorphs (including anhydrides), conformational polymorphs, and amorphous forms of the compounds, as well as mixtures thereof.

[0105] The compounds described herein may exist as solvates, especially hydrates, and unless otherwise specified, all such solvates and hydrates are intended. Hydrates may form during manufacture of the compounds or compositions comprising the compounds, or hydrates may form over time due to the hygroscopic nature of the compounds. Compounds of the present technology may exist as organic solvates as well, including DMF, ether, and alcohol solvates, among others. The identification and preparation of any particular solvate is within the skill of the ordinary artisan of synthetic organic or medicinal chemistry.

[0106] In some embodiments, the compounds described herein are present in a solvate form. In some embodiments, the compounds described herein are present in a hydrate form when the solvent component of the solvate is water.

4.1.5. Prodrugs

[0107] Aspects of this disclosure include prodrug derivatives of any of the ATX inhibitor compounds. In some embodiments, the compounds described herein are present in a prodrug form. Any convenient prodrug forms of the subject compounds can be prepared, for example, according to the strategies and methods described by Rautio *et al.* ("Prodrugs: design and clinical applications", *Nature Reviews Drug Discovery* 7, 255-270 (February 2008)).

[0108] It is understood that all variations of salts, solvates, hydrates, prodrugs and/or stereoisomers of the compounds described herein and shown in Table 1 are meant to be encompassed by the present disclosure.

[0109] In some embodiments, the compound is represented by the structure of one of the compounds in Table 1. The present disclosure is meant to encompass, a compound of Table 1, or a salt, a single stereoisomer, a mixture of stereoisomers and/or an isotopically labelled form thereof.











Table 1			
Compounds			
Cmpd	Structure	Cmpd	Structure
1		2	
3		4	
5		6	
7		8	
9		10	

Table 1			
Compounds			
Cmpd	Structure	Cmpd	Structure
11		12	
13		14	
15		16	
17		18	
19		20	
21		22	
23		24	

Table 1			
Compounds			
Cmpd	Structure	Cmpd	Structure
25		26	
27		28	
29		30	
31		32	
33		34	
35		36	
37		38	

Table 1			
Compounds			
Cmpd	Structure	Cmpd	Structure
39		40	

Table 1			
Compounds			
Cmpd	Structure	Cmpd	Structure
41		42	
43		44	
45		46	
47		48	
49		50	

Table 1			
Compounds			
Cmpd	Structure	Cmpd	Structure
51		52	
53		54	
55		56	
57		58	
59		60	
61		62	
63		64	

Table 1			
Compounds			
Cmpd	Structure	Cmpd	Structure
65		66	
67		68	
69		70	
71		72	
73		74	
75		76	
77		78	







Table 1 Compounds			
Cmpd	Structure	Cmpd	Structure
79		80	
81		82	
83		84	







Table 1 Compounds			
Cmpd	Structure	Cmpd	Structure
85		86	
87		88	
89		90	

Table 1
Compounds

Cmpd	Structure	Cmpd	Structure
91		92	
93		94	
95		96	
97		98	
99		100	
101		102	
103		104	

Table 1			
Compounds			
Cmpd	Structure	Cmpd	Structure
105		106	
107		108	
109		110	
111		112	
113		114	
115		118	
119		120	

Table 1 Compounds			
Cmpd	Structure	Cmpd	Structure
121		122	
123		124	
125		126	
127			

4.1.6. Compound synthesis

[0110] Compounds of the present disclosure may be synthesized according to standard methods known in the art [see, e.g. Morrison and Boyd in “Organic Chemistry”, 6th edition, Prentice Hall (1992)]. Some compounds and/or intermediates of the present disclosure may be commercially available, known in the literature, or readily obtainable by those skilled in the art using standard procedures. Some compounds of the present disclosure may be synthesized using schemes, examples, or intermediates described herein. Where the synthesis of a compound, intermediate or variant thereof is not fully described, those skilled in the art can recognize that the reaction time, number of equivalents of reagents and/or temperature may be modified from reactions described herein to prepare compounds presented or intermediates or variants thereof and that different work-up and/or purification techniques may be necessary or desirable to prepare such compounds, intermediates, or variants.

[0111] Synthesized compounds may be validated for proper structure by methods known to those skilled in the art, for example by nuclear magnetic resonance (NMR) spectroscopy and/or mass spectrometry. Thus, also provided by this disclosure are synthetic precursor or intermediate compounds. In some embodiments, the compound or precursor intermediate compound (e.g., a precursor in the synthesis of a compound listed in Table 1) is represented by the structure of one of the compounds in Table 1A, or a protected version thereof. The present disclosure is meant to encompass, a compound of Table 1A, or a salt, a single stereoisomer, a mixture of stereoisomers and/or an isotopically labelled form thereof.























Table 1A			
Additional compounds and/or precursor intermediates			
Cmpd	Structure	Cmpd	Structure
128		129	
130		131	
132		133	
134		135	

Table 1A			
Additional compounds and/or precursor intermediates			
Cmpd	Structure	Cmpd	Structure
136		137	
138		139	
140		141	
142		143	
144		145	
146		147	
148		149	

4.2. Compositions

[0112] Compounds of the present disclosure may be included in a composition that includes one or more compounds and at least one excipient (e.g., a pharmaceutically acceptable excipient). Such compositions may include an ATX inhibitor.

[0113] The compounds described herein can find use in pharmaceutical compositions for administration to a subject in need thereof in a variety of therapeutic applications where inhibition of ATX is desirable. In some embodiments, compounds of the present disclosure may be formulated as pharmaceutical compositions.

[0114] Accordingly, in a second aspect, the present disclosure provides pharmaceutical compositions comprising at least one compound described herein, a pharmaceutically acceptable salt thereof, or a prodrug thereof, and at least one pharmaceutically acceptable excipient. The phrase “pharmaceutically acceptable excipient,” refers any ingredient other than the inventive compounds described herein (for example, a vehicle capable of suspending or dissolving the active compound) and having the properties of being substantially nontoxic and non-inflammatory in a patient. Excipients may include, for example: antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colors), emollients, emulsifiers, fillers (diluent), film formers or coatings, flavors, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, sorbents, dispensing, or dispersing agents, sweeteners, and waters of hydration. In some embodiments, the pharmaceutical composition comprises a compound as described herein, a pharmaceutically acceptable salt thereof, or a prodrug thereof in a therapeutically effective amount.

[0115] In some embodiments, the pharmaceutical compositions are formulated for oral delivery. In some embodiments, the pharmaceutical compositions are formulated for parenteral administration to a subject in need thereof. In some parenteral embodiments, the pharmaceutical compositions are formulated for intravenous administration to a subject in need thereof. In some parenteral embodiments, the pharmaceutical compositions are formulated for subcutaneous administration to a subject in need thereof.

4.3. Methods of Inhibiting ATX

[0116] Aspects of the present disclosure include methods of inhibiting ATX using ATX inhibitor compounds described herein. Such methods may include methods of modulating (e.g., inhibiting) ATX in biological systems by contacting such systems with ATX inhibiting

compounds (e.g., ATX inhibitor compounds having structures according to any of those of Table 1 or Table 1A, or a pharmaceutically acceptable salt thereof). Biological systems may include, but are not limited to, cells, tissues, organs, bodily fluids, organisms, non-mammalian subjects, and mammalian subjects (e.g., humans).

[0117] In some embodiments, the method of inhibiting ATX comprises contacting a biological system or sample comprising ATX with an effective amount of any of the compounds or a pharmaceutically acceptable salt thereof as described herein, or a pharmaceutical composition as described herein to inhibit ATX. In certain embodiments, the biological system or sample is *in vitro*. In another embodiment, the biological system or sample is *in vivo*.

[0118] The ATX inhibitors may inhibit the enzymatic activity of ATX in a sample, e.g., as assessed by a hATX/ENPP2 inhibition assay described in Example 12. ATX inhibitors according to such methods may have IC₅₀ values for ATX inhibition (e.g., as assessed by the assay of Example 12) of less than 1000 nM, such as 200 nM or less, or 20 nM or less. Biological systems may include subjects (e.g., human subjects).

[0119] In some embodiments, the present disclosure provides methods of inhibiting ATX activity in a subject in need thereof. In some cases, the percentage of ATX activity inhibited in a subject may be at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9%. In some cases, this level of inhibition and/or maximum inhibition of ATX activity may be achieved by from about 1 hour after administration to about 3 hours after administration, from about 2 hours after administration to about 4 hours after administration, from about 3 hours after administration to about 10 hours after administration, from about 5 hours after administration to about 20 hours after administration, or from about 12 hours after administration to about 24 hours after administration. Inhibition of ATX activity may continue throughout a period of at least 1 day, of at least 2 days, of at least 3 days, of at least 4 days, of at least 5 days, of at least 6 days, of at least 7 days, of at least 2 weeks, of at least 3 weeks, of at least 4 weeks, of at least 8 weeks, of at least 3 months, of at least 6 months, or at least 1 year. In some cases, this level of inhibition may be achieved through daily administration. Such daily administration may include administration for at least 2 days, for at least 3 days, for at least 4 days, for at least 5 days, for at least 6 days, for at least 7 days, for at least 2 weeks, for at least 3 weeks, for at least 4 weeks, for at least 2 months, for at least 4 months, for at least 6 months, for at least 1 year, or for at least 5 years. In some cases, subjects may be

administered compounds or compositions of the present disclosure for the life of such subjects.

[0120] In some embodiments, the present disclosure provides methods of modulating LPA or a LPA-associated activity in a subject. In some cases, the percentage of LPA or a LPA-associated activity modulated in a subject may be at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9%.

[0121] In some embodiments, compounds of the present disclosure may be used in assays used to assess ATX inhibition and/or modulation of LPA or LPA-associated biological activity. Some assays may include diagnostic assays. In some cases, compounds may be included in methods of drug discovery. In some embodiments, methods of the present disclosure include use of ATX-inhibiting compounds of the present disclosure to assess ATX inhibition by other compounds. Such methods may include conjugating ATX inhibiting compounds with one or more detectable labels (e.g., fluorescent dyes) and measuring ATX dissociation (via detectable label detection) in the presence of the other compounds. The detectable labels may include fluorescent compounds.

4.3.1. Therapeutic indications

[0122] In some embodiments, methods of the present disclosure include methods of treating therapeutic indications using compounds and/or compositions disclosed herein. The term “therapeutic indication” refers to any symptom, condition, disorder, or disease that may be alleviated, stabilized, improved, cured, or otherwise addressed by some form of treatment or other therapeutic intervention (e.g., through ATX inhibitor administration). Therapeutic indications of interest may include, but are not limited to, inflammatory indications, autoimmune indications, proliferative diseases, cancer, and fibrosis. In certain embodiments, the fibrosis occurs in the liver, e.g., liver fibrosis. Therapeutic indications associated with ATX and/or LPA biological activity and/or dysfunction are referred to herein as “ATX-related indications.” In some embodiments, methods of the present disclosure may include treating ATX-related indications by administering compounds and/or compositions disclosed herein (e.g., ATX inhibitor compounds).

[0123] The terms “treat,” “treatment,” and the like, refer to relief from or alleviation of pathological processes. In the context of the present disclosure insofar as it relates to any of

the other conditions recited herein below, the terms “treat,” “treatment,” and the like mean to relieve or alleviate at least one symptom associated with such condition, or to slow or reverse the progression or anticipated progression of such condition.

4.4. Definitions

[0124] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains.

[0125] It is understood that the definitions provided herein are not intended to be mutually exclusive. Accordingly, some chemical moieties may fall within the definition of more than one term.

[0126] The symbol “” refers to a covalent bond that is a single or a double bond.

[0127] The term “C_x-C_y” when used in conjunction with a chemical moiety, such as alkyl, alkenyl, or alkynyl is meant to include groups that contain from x to y carbons in the chain. For example, the term “C₁-C₆ alkyl” refers to substituted or unsubstituted saturated hydrocarbon groups, including straight-chain alkyl and branched-chain alkyl groups that contain from 1 to 6 carbons. In some embodiments, the term “(C_x-C_y)alkylene” refers to a substituted or unsubstituted alkylene chain with from x to y carbons in the alkylene chain. For example “(C_x-C_y)alkylene may be selected from methylene, ethylene, propylene, butylene, pentylene, and hexylene, any one of which is optionally substituted.

[0128] The term “**alkyl**” refers to an unbranched or branched saturated hydrocarbon chain. In some embodiments, alkyl as used herein has 1 to 20 carbon atoms ((C₁-C₂₀)alkyl), 1 to 10 carbon atoms ((C₁-C₁₀)alkyl), 1 to 8 carbon atoms ((C₁-C₈)alkyl), 1 to 6 carbon atoms ((C₁-C₆)alkyl), 1 to 5 carbon atoms ((C₁-C₅)alkyl) or 1 to 3 carbon atoms ((C₁-C₃)alkyl). Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, isopentyl, neopentyl, n-hexyl, 2-hexyl, 3-hexyl, and 3-methyl pentyl. When an alkyl residue having a specific number of carbons is named, all geometric isomers having that number of carbons may be encompassed. For example, “butyl” can include n-butyl, sec-butyl, isobutyl and t-butyl, and “propyl” can include n-propyl and isopropyl. Unless stated otherwise specifically in the specification, an alkyl chain is optionally substituted by one or more substituents such as those substituents described herein.

[0129] The term “**alkylene**” refers to a straight divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing no

unsaturation, and preferably having from 1 to 20 carbon atoms ((C₁-C₂₀)alkylene), 1 to 10 carbon atoms ((C₁-C₁₀)alkylene), 1 to 6 carbon atoms ((C₁-C₆)alkylene), or 1 to 5 carbon atoms ((C₁-C₅)alkylene). Examples include, but are not limited to, methylene, ethylene, propylene, butylene, and the like. The alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. The points of attachment of the alkylene chain to the rest of the molecule and to the radical group are through the terminal carbons respectively. Unless stated otherwise specifically in the specification, an alkylene chain is optionally substituted by one or more substituents such as those substituents described herein. Examples include, methylene (–CH₂–), ethylene (–CH₂CH₂–), propylene (–CH₂CH₂CH₂–), 2-methylpropylene (–CH₂–CH(CH₃)–CH₂–), hexylene (–(CH₂)₆–) and the like.

[0130] The term “**alkenyl**” refers to an aliphatic hydrocarbon group containing at least one carbon-carbon double bond including straight-chain, branched-chain and cyclic alkenyl groups. In some embodiments, the alkenyl group has 2-10 carbon atoms (a C₂₋₁₀ alkenyl). In another embodiment, the alkenyl group has 2-4 carbon atoms in the chain (a C₂₋₄ alkenyl). Exemplary alkenyl groups include, but are not limited to, ethenyl, propenyl, n-butenyl, i-butenyl, 3-methylbut-2-enyl, n-pentenyl, heptenyl, octenyl, cyclohexyl-butenyl and decenyl. An alkylalkenyl is an alkyl group as defined herein bonded to an alkenyl group as defined herein. The alkenyl group can be unsubstituted or substituted through available carbon atoms with one or more groups defined hereinabove for alkyl

[0131] The term “**alkynyl**” refers to straight or branched monovalent hydrocarbyl groups having from 2 to 6 carbon atoms and preferably 2 to 3 carbon atoms and having at least 1 and preferably from 1 to 2 sites of acetylenic (C≡C–) unsaturation. Examples of such alkynyl groups include, but are not limited to, acetylenyl (C≡CH), and propargyl (CH₂C≡CH).

[0132] The term “**aryl**” refers to a monocyclic or polycyclic group having at least one hydrocarbon aromatic ring, wherein all of the ring atoms of the at least one hydrocarbon aromatic ring are carbon. Aryl may include groups with a single aromatic ring (e.g., phenyl) and multiple fused aromatic rings (e.g., naphthyl, anthryl). Aryl may further include groups with one or more aromatic hydrocarbon rings fused to one or more non-aromatic hydrocarbon rings (e.g., fluorenyl; 2,3-dihydro-1H-indene; 1,2,3,4-tetrahydronaphthalene). In certain embodiments, aryl includes groups with an aromatic hydrocarbon ring fused to a non-aromatic ring, wherein the non-aromatic ring comprises at least one ring heteroatom independently selected from the group consisting of N, O, and S. For example, in some embodiments, aryl includes groups with a phenyl ring fused to a non-aromatic ring, wherein

the non-aromatic ring comprises at least one ring heteroatom independently selected from the group consisting of N, O, and S (e.g., chromane; thiochromane; 2,3-dihydrobenzofuran; indoline). In some embodiments, aryl as used herein has from 6 to 14 carbon atoms ((C₆-C₁₄)aryl), or 6 to 10 carbon atoms ((C₆-C₁₀)aryl). Where the aryl includes fused rings, the aryl may connect to one or more substituents or moieties of the formulae described herein through any atom of the fused ring for which valency permits.

[0133] The term “**cycloalkyl**” refers to a monocyclic or polycyclic saturated hydrocarbon. In some embodiments, cycloalkyl has 3 to 20 carbon atoms ((C₃-C₂₀)cycloalkyl), 3 to 8 carbon atoms ((C₃-C₈)cycloalkyl), 3 to 6 carbon atoms ((C₃-C₆)cycloalkyl), or 3 to 5 carbon atoms ((C₃-C₅)cycloalkyl). In some embodiments, cycloalkyl has 3 to 8 carbon atoms having single or multiple cyclic rings including fused, bridged, and spiro ring systems. Examples of suitable cycloalkyl groups include, but are not limited to, adamantyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, octahydropentalenyl, octahydro-1*H*-indene, decahydronaphthalene, cubane, bicyclo[3.1.0]hexane, and bicyclo[1.1.1]pentane, and the like.

[0134] The term “**carbocycle**” refers to a saturated, unsaturated or aromatic ring system in which each atom of the ring system is carbon. Carbocycle includes 3- to 10-membered monocyclic rings, 6- to 12-membered bicyclic rings, and 6- to 12-membered bridged rings. Each ring of a bicyclic carbocycle may be selected from saturated, unsaturated, and aromatic rings. In an exemplary embodiment, an aromatic ring, e.g., phenyl, may be fused to a saturated or unsaturated ring, e.g., cyclohexane, cyclopentane, or cyclohexene. A bicyclic carbocycle includes any combination of saturated, unsaturated and aromatic bicyclic rings, as valence permits. A bicyclic carbocycle includes any combination of ring sizes such as 4-5 fused ring systems, 5-5 fused ring systems, 5-6 fused ring systems, 6-6 fused ring systems, 5-7 fused ring systems, 6-7 fused ring systems, 5-8 fused ring systems, and 6-8 fused ring systems. Exemplary carbocycles include cyclopentyl, cyclohexyl, cyclohexenyl, adamantyl, phenyl, indanyl, and naphthyl.

[0135] The term “**heterocycle**” refers to a saturated, unsaturated or aromatic ring comprising one or more heteroatoms. Exemplary heteroatoms include N, O, Si, P, B, and S atoms. Heterocycles include 3- to 10-membered monocyclic rings, 6- to 12-membered bicyclic rings, and 6- to 12-membered bridged rings. A bicyclic heterocycle includes any combination of saturated, unsaturated and aromatic bicyclic rings, as valence permits. In an exemplary embodiment, an aromatic ring, e.g., pyridyl, may be fused to a saturated or unsaturated ring, e.g., cyclohexane, cyclopentane, morpholine, piperidine or cyclohexene. A bicyclic heterocycle includes any combination of ring sizes such as 4-5 fused ring systems, 5-5 fused

ring systems, 5-6 fused ring systems, 6-6 fused ring systems, 5-7 fused ring systems, 6-7 fused ring systems, 5-8 fused ring systems, and 6-8 fused ring systems.

[0136] The term “**heteroaryl**” refers to an aromatic group of from 4 to 10 carbon atoms and 1 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur within the ring. Such heteroaryl groups can have a single ring (i.e., pyridinyl or furyl) or multiple condensed rings (i.e., indolizinyl or benzothienyl) wherein the condensed rings may or may not be aromatic and/or contain a heteroatom provided that the point of attachment is through an atom of the aromatic heteroaryl group. In one embodiment, the nitrogen and/or the sulfur ring atom(s) of the heteroaryl group are optionally oxidized to provide for the N oxide (N→O), sulfinyl, or sulfonyl moieties. Preferred heteroaryls include 5 or 6 membered heteroaryls such as pyridinyl, pyrrolyl, indolyl, thiophenyl, and furanyl.

[0137] The term “**heteroalkyl**” refers to an alkyl substituent in which one or more of the carbon atoms and any attached hydrogen atoms are independently replaced with the same or different heteroatomic group. For example, 1, 2, or 3 carbon atoms may be independently replaced with the same or different heteroatomic substituent.

[0138] The term “**substituted**” refers to moieties having substituents replacing a hydrogen on one or more carbons or substitutable heteroatoms, e.g., NH or NH₂, of a compound. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound. For example, stable compounds include, but is not limited to, compounds which do not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. In certain embodiments, substituted refers to moieties having substituents replacing two hydrogen atoms on the same carbon atom, such as substituting the two hydrogen atoms on a single carbon with an oxo, imino or thioxo group. The term “substituted” is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. The permissible substituents can be one or more and the same or different for appropriate organic compounds.

[0139] It will be understood by those skilled in the art that substituents can themselves be substituted, if appropriate. Unless specifically stated as “unsubstituted,” references to chemical moieties herein are understood to include substituted variants. For example, reference to a “heteroaryl” group or moiety implicitly includes both substituted and unsubstituted variants, unless specified otherwise.

[0140] When referring to compound features, the phrase "**optionally substituted**" may be used interchangeably with the phrase "unsubstituted or substituted" and refers to when a non-hydrogen substituent may or may not be present on a given atom or group, and, thus, the description includes structures where a non-hydrogen substituent is present and structures where a non-hydrogen substituent is not present. For example, "optionally substituted alkyl" encompasses both "alkyl" and "substituted alkyl" as defined herein. It will be understood by those skilled in the art, with respect to any group containing one or more substituents, that such groups are not intended to introduce any substitution or substitution patterns that are sterically impractical, synthetically non-feasible and/or inherently unstable.

[0141] In some embodiments, substituents may include any substituents described herein, for example: halogen, hydroxy, oxo (=O), thioxo (=S), cyano (-CN), nitro (-NO₂), imino (=N-H), oximo (=N-OH), hydrazino (=N-NH₂), -R^b-OR^a, -R^b-OC(O)-R^a, -R^b-OC(O)-OR^a, -R^b-OC(O)-N(R^a)₂, -R^b-N(R^a)₂, -R^b-C(O)R^a, -R^b-C(O)OR^a, -R^b-C(O)N(R^a)₂, -R^b-O-R^c-C(O)N(R^a)₂, -R^b-N(R^a)C(O)OR^a, -R^b-N(R^a)C(O)R^a, -R^b-N(R^a)S(O)_tR^a (where t is 1 or 2), -R^b-S(O)_tR^a (where t is 1 or 2), -R^b-S(O)_tOR^a (where t is 1 or 2), and -R^b-S(O)_tN(R^a)₂ (where t is 1 or 2). In another exemplary embodiment, substituents include alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, and heteroarylalkyl, any of which may be optionally substituted by alkyl, alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, imino, oximo, hydrazine, -R^bOR^a, -R^b-OC(O)-R^a, -R^b-OC(O)-OR^a, -R^b-OC(O)-N(R^a)₂, -R^b-N(R^a)₂, -R^b-C(O)R^a, -R^b-C(O)OR^a, -R^b-C(O)N(R^a)₂, -R^b-O-R^c-C(O)N(R^a)₂, -R^b-N(R^a)C(O)OR^a, -R^b-N(R^a)C(O)R^a, -R^b-N(R^a)S(O)_tR^a (where t is 1 or 2), -R^b-S(O)_tR^a (where t is 1 or 2), -R^b-S(O)_tOR^a (where t is 1 or 2) and -R^b-S(O)_tN(R^a)₂ (where t is 1 or 2); and wherein each R^a, R^b, and R^c are independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, and heteroarylalkyl; and wherein each R^a, R^b, and R^c, valence permitting, may be optionally substituted with alkyl, alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, imino, oximo, hydrazine, -R^bOR^a, -R^b-OC(O)-R^a, -R^b-OC(O)-OR^a, -R^b-OC(O)-N(R^a)₂, -R^b-N(R^a)₂, -R^b-C(O)R^a, -R^b-C(O)OR^a, -R^b-C(O)N(R^a)₂, -R^b-O-R^c-C(O)N(R^a)₂, -R^b-N(R^a)C(O)OR^a, -R^b-N(R^a)C(O)R^a, -R^b-N(R^a)S(O)_tR^a (where t is 1 or 2), -R^b-S(O)_tR^a (where t is 1 or 2), -R^b-S(O)_tOR^a (where t is 1 or 2) and -R^b-S(O)_tN(R^a)₂ (where t is 1 or 2).

[0142] The term “**isomers**” refers to two or more compounds comprising the same numbers and types of atoms, groups or components, but with different structural arrangement and connectivity of the atoms.

[0143] The term “**tautomer**” refers to one of two or more structural isomers which readily convert from one isomeric form to another and which exist in equilibrium.

[0144] A “**stereoisomer**” refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable. The present invention contemplates various stereoisomers and mixtures thereof and includes “**enantiomers**”, which refers to two stereoisomers whose molecules are non-superimposeable mirror images of one another.

[0145] Individual enantiomers and diastereomers of compounds of the present disclosure can be prepared synthetically from commercially available starting materials that contain asymmetric or stereogenic centers, or by preparation of racemic mixtures followed by resolution methods well known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary, (2) salt formation employing an optically active resolving agent, (3) direct separation of the mixture of optical enantiomers on chiral liquid chromatographic columns, or (4) kinetic resolution using stereoselective chemical or enzymatic reagents. Racemic mixtures also can be resolved into their respective enantiomers by well-known methods, such as chiral-phase gas chromatography or crystallizing the compound in a chiral solvent. Stereoselective syntheses, a chemical or enzymatic reaction in which a single reactant forms an unequal mixture of stereoisomers during the creation of a new stereocenter or during the transformation of a pre-existing one, are well known in the art. Stereoselective syntheses encompass both enantio- and diastereoselective transformations. See, for example, Carreira and Kvaerno, *Classics in Stereoselective Synthesis*, Wiley-VCH: Weinheim, 2009.

[0146] The symbol = denotes a bond that may be a single, double or triple bond as described herein. Substituents around a carbon-carbon double bond are designated as being in the “**Z**” or “**E**” configuration, where the terms “**Z**” and “**E**” are used in accordance with IUPAC standards. Unless otherwise specified, structures depicting double bonds encompass both the “**E**” and “**Z**” isomers.

[0147] Substituents around a carbon-carbon double bond alternatively can be referred to as “**cis**” or “**trans**,” where “**cis**” represents substituents on the same side of the double bond and

“trans” represents substituent on opposite sides of the double bond. The arrangement of substituents around a carbocyclic ring can also be designated as “cis” or “trans.” The term “cis” represents substituents on the same side of the plane of the ring and the term “trans” represents substituents on opposite sides of the plane of the ring. Mixtures of compound wherein the substituents are disposed on both the same and opposite sides of the plane of the ring are designated “cis/trans.”

[0148] Singular articles such as “a,” “an” and “the” and similar referents in the context of describing the elements are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, including the upper and lower bounds of the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (*i.e.*, “such as”) provided herein, is intended merely to better illuminate the embodiments and does not pose a limitation on the scope of the claims unless otherwise stated.

[0149] In some embodiments, where the use of the term “**about**” is before a quantitative value, the present disclosure also includes the specific quantitative value itself, unless specifically stated otherwise. As used herein, the term “about” refers to a $\pm 10\%$ variation from the nominal value unless otherwise indicated or inferred. Where a percentage is provided with respect to an amount of a component or material in a composition, the percentage should be understood to be a percentage based on weight, unless otherwise stated or understood from the context.

[0150] Where a molecular weight is provided and not an absolute value, for example, of a polymer, then the molecular weight should be understood to be an average molecule weight, unless otherwise stated or understood from the context.

[0151] It should be understood that the order of steps or order for performing certain actions is immaterial so long as the present disclosure remain operable. Moreover, two or more steps or actions can be conducted simultaneously.

[0152] A dash (“—”) symbol that is not between two letters or symbols refers to a point of bonding or attachment for a substituent. For example, -NH_2 is attached through the nitrogen atom.

[0153] The term “**pharmaceutically acceptable salt**” refers to a salt which is acceptable for administration to a subject. It is understood that such salts, with counter ions, will have acceptable mammalian safety for a given dosage regime. Such salts can also be derived from pharmaceutically acceptable inorganic or organic bases and from pharmaceutically acceptable inorganic or organic acids, and may comprise organic and inorganic counter ions. The neutral forms of the compounds described herein may be converted to the corresponding salt forms by contacting the compound with a base or acid and isolating the resulting salts.


[0154] The terms “**pharmaceutically acceptable excipient**,” “**pharmaceutically acceptable diluent**,” “**pharmaceutically acceptable carrier**,” and “**pharmaceutically acceptable adjuvant**” are used interchangeably and refer to an excipient, diluent, carrier, or adjuvant that is useful in preparing a pharmaceutical composition that are generally safe, non-toxic and neither biologically nor otherwise undesirable, and include an excipient, diluent, carrier, and adjuvant that are acceptable for veterinary use as well as human pharmaceutical use. The phrase “pharmaceutically acceptable excipient” includes both one and more than one such excipient, diluent, carrier, and/or adjuvant.

[0155] The term “**pharmaceutical composition**” is meant to encompass a composition suitable for administration to a subject, such as a mammal, especially a human. In general a “pharmaceutical composition” is sterile, and preferably free of contaminants that are capable of eliciting an undesirable response within the subject (*i.e.*, the compound(s) in the pharmaceutical composition is pharmaceutical grade). Pharmaceutical compositions can be designed for administration to subjects or patients in need thereof *via* a number of different routes of administration including oral, buccal, rectal, parenteral, intraperitoneal, intradermal, intracheal, intramuscular, subcutaneous, and the like.

4.5. Additional Embodiments

[0156] Aspects of this disclosure are further described in the following numbered clauses:

[0157] Clause 1. A compound of formula (I):



or a pharmaceutically acceptable salt or isomer thereof, wherein:

X^1 , X^2 , and X^3 are independently selected from C-R¹ and N;

Z^1 , Z^2 , and Z^3 are independently selected from C-R¹ and N;

each R¹ is independently selected from -H, -halogen, optionally substituted -(C₁-C₆)alkyl and optionally substituted -(C₁-C₆)alkoxy;

Y is selected from S, O, and N-R², wherein R² is selected from -H, and optionally substituted -(C₁-C₆)alkyl;

R³ is selected from optionally substituted R⁴-C(O)-(C₁-C₃)alkyl-, R⁴C(O)-, optionally substituted monocyclic or bicyclic carbocycle, optionally substituted monocyclic or bicyclic heterocycle, R⁵R⁶HC-, and R⁵R⁶N-;

R⁴ is selected from H₂N-, HO-, R⁵R⁶N-, optionally substituted (C₁-C₁₀)alkyl-, optionally substituted (C₁-C₁₀)alkoxy-, optionally substituted monocyclic or bicyclic carbocycle, optionally substituted monocyclic or bicyclic heterocycle, optionally substituted cycloalkyl-(C₁-C₆)alkylene-, and optionally substituted heterocycle-(C₁-C₆)alkylene-;

R⁵ and R⁶ are independently selected from H-, H₂N-, HO-, optionally substituted (C₁-C₁₀)alkyl-, optionally substituted monocyclic or bicyclic carbocycle, optionally substituted monocyclic or bicyclic heterocycle, optionally substituted R⁴C(O)-(C₁-C₁₀)alkyl-, R⁴C(O)-, R⁴-, and substituted amino;

or R⁵ and R⁶ together with the nitrogen or carbon atom to which they are attached are cyclically linked to form an optionally substituted carbocycle or an optionally substituted heterocycle;

R⁷ is selected from H-, and optionally substituted (C₁-C₆)alkyl-;

R⁸ is selected from -H, -halogen, and optionally substituted -(C₁-C₆)alkyl-;

R⁹ and each R¹⁰ are independently selected from -H, -halogen, -CN, -OH, optionally substituted -(C₁-C₆)alkoxy, -NH₂, substituted amino, optionally substituted -(C₁-C₆)alkyl-NH₂ and optionally substituted -(C₁-C₆)alkyl; and

n is 0, 1, 2, 3, 4, or 5.


[0158] Clause 2. The compound of clause 1, wherein X^1 is N, X^2 is C-H, and X^3 is C-H.

[0159] Clause 3. The compound of clause 1, wherein X^1 is C-H, X^2 is C-H, and X^3 is C-H.

[0160] Clause 4. The compound of any one of clauses 1 to 3, wherein Y is S.

[0161] Clause 5. The compound of any one of clauses 1 to 4, wherein Z^1 is C-H, Z^2 is C-H, and Z^3 is C-H.

[0162] Clause 6. The compound of any one of clauses 1 to 5, wherein the compound is of formula (Ia):



wherein:

R^1 is selected from -H, -halogen, optionally substituted $-(C_1-C_6)$ alkyl and optionally substituted $-(C_1-C_6)$ alkoxy;

R^3 is selected from $R^4C(O)-$, $R^4C(O)CH_2-$, R^5R^6N- , and R^5R^6HC- ;

R^{11} is -H, -halogen, -CN, -OH, optionally substituted $-(C_1-C_6)$ alkoxy, - NH_2 , $-NR^5R^6$, $-CH_2NH_2$ and optionally substituted $-(C_1-C_6)$ alkyl; and
 n is 0, 1, 2, or 3.

[0163] Clause 7. The compound of clause 6, wherein X^1 is N.

[0164] Clause 8. The compound of clause 6, wherein X^1 is C-H.

[0165] Clause 9. The compound of any one of clauses 1 to 8, wherein R^7 is optionally substituted (C_1-C_6) alkyl-.

[0166] Clause 10. The compound of clause 9, wherein R^7 is H_3C- .

[0167] Clause 11. The compound of any one of clauses 1 to 10, wherein R^8 is optionally substituted $-(C_1-C_6)$ alkyl.


[0168] Clause 12. The compound of clause 11, wherein R^8 is $-CH_2CH_3$.

[0169] Clause 13. The compound of any one of clauses 1 to 12, wherein R^9 is -CN.

[0170] Clause 14. The compound of any one of clauses 1 to 13, wherein R^{11} is -halogen.

[0171] Clause 15. The compound of clause 14, wherein R^{11} is -F.






[0172] Clause 16. The compound of any one of clauses 1 to 15, wherein the compound is of formula (Ib):



(Ib)

wherein: X^1 is C-H or N; and R^1 is -H, -halogen, or optionally substituted -(C₁-C₆)alkyl and optionally substituted -(C₁-C₆)alkoxy.

[0173] Clause 17. The compound of any one of clauses 1 to 16, wherein:



R^4 is selected from HO-, H₂N-, R¹⁵R¹⁶N-, optionally substituted (C₁-C₅)alkyl-, optionally substituted monocyclic or bicyclic carbocycle, and optionally substituted monocyclic or bicyclic heterocycle;


R^{12} is selected from -H, -NH₂, -OH, -CH₂C(O)R⁴, -C(O)R⁴, -CHR¹⁵R¹⁶, -NR¹⁵R¹⁶, optionally substituted -(C₁-C₅)alkyl, optionally substituted monocyclic or bicyclic -(C₃-C₈)carbocycle, and an optionally substituted monocyclic or bicyclic -(C₂-C₉)heterocycle; and

R^{13} and R^{14} are independently selected from -H, -CH₂C(O)R¹⁷, -CH₂R¹⁷, -C(O)R¹⁷, -R¹⁸C(O)R¹⁷, -CH₂R¹⁸C(O)R¹⁷, optionally substituted -(C₁-C₅)alkyl, optionally substituted monocyclic or bicyclic -(C₃-C₈)carbocycle, and an optionally substituted monocyclic or bicyclic -(C₂-C₉)heterocycle, wherein R^{17} and R^{18} are independently selected from optionally substituted -(C₁-C₅)alkyl, optionally substituted monocyclic or bicyclic -(C₃-C₈)carbocycle, and an optionally substituted monocyclic or bicyclic -(C₂-C₉)heterocycle; and

R^{15} and R^{16} are independently selected from H-, optionally substituted (C₂-C₅)heterocycloalkyl-C(O)-, optionally substituted (C₃-C₆) cycloalkyl-C(O)-, optionally

substituted (C₁-C₅)alkyl-, optionally substituted 3- to 10-membered saturated monocyclic heterocycle or carbocycle, and optionally substituted 3- to 10-membered saturated bicyclic heterocycle or carbocycle, wherein the optional substituents are selected from hydroxy, HOCH₂-, cyano, halogen, substituted amino, and (C₁-C₅)alkyl; or R¹⁵ and R¹⁶ are cyclically linked to form a 3- to 6-membered monocyclic saturated heterocycle, optionally substituted with hydroxy, HOCH₂-, cyano, halogen, substituted amino, or (C₁-C₅)alkyl.

[0174] Clause 18. The compound of any one of clauses 1 to 17, wherein:




R⁴ is selected from R³², R³²HN-, R³²N(R³³)-, and R³²HN-R³⁶-;

R³² and R³³ are independently selected from H-, optionally substituted (C₁-C₃)alkyl, optionally substituted cycloalkyl, and optionally substituted saturated heterocycle;

R³⁶ is selected from optionally substituted (C₁-C₃)alkyl, optionally substituted cycloalkyl, and optionally substituted saturated heterocycle; and


the optional substituents of the R³², R³³ and R³⁶ groups are independently selected from -CN, -OH, -CH₂OH, -(C₁-C₃)alkyl, -(C₁-C₃)alkoxy, -(C₃-C₆)cycloalkyl, (C₂-C₅)heterocycloalkyl, and -N(R³⁷)R³⁸, wherein R³⁷ and R³⁸ are independently selected from H, (C₁-C₃)alkyl, (C₃-C₆)cycloalkyl, and (C₂-C₅)heterocycloalkyl.

[0175] Clause 19. The compound of clause 18, wherein R⁴ is selected from:



[0176] Clause 20. The compound of clause 19, wherein the compound is selected from compounds 11-16, 47-65 and 87 of Table 1.

[0177] Clause 21. The compound of any one of clauses 1 to 17, wherein:




R^{14} is selected from R^{34} -, $R^{34}CH_2$ -, $R^{34}C(O)R^{35}$ -, and $R^{34}C(O)R^{35}CH_2$ -;

each R^{34} and R^{35} are independently selected from optionally substituted $-(C_1-C_3)alkyl$, optionally substituted cycloalkyl, and optionally substituted saturated heterocycle;

the optional substituents of the R^{34} and R^{35} groups are independently selected from -CN, -OH, $-CH_2OH$, $-(C_1-C_3)alkyl$, $-(C_1-C_3)alkoxy$, and $-(C_1-C_3)alkyl$; and


R^{13} is -H.

[0178] Clause 22. The compound of clause 21, wherein R^{14} is selected from:




[0179] Clause 23. The compound of clause 22, wherein the compound is selected from compounds 21, 22, and 34-41 of Table 1.

[0180] Clause 24. The compound of any one of clauses 1 to 17, wherein R^3 is



[0181] Clause 25. The compound of clause 24, wherein R^3 is selected from:




[0182] Clause 26. The compound of clause 24 or 25, wherein:


R^{12} is selected from H-, H_2N -, $R^{31}-C(O)$ -, $R^{31}-C(O)CH_2$ -, $R^{31}-NHC(O)$ -, $R^{31}-C(O)NH$ -, $R^{31}-NH$ -, $R^{31}-N(CH_3)C(O)$ -, $R^{31}-C(O)N(CH_3)$ -, $R^{31}-N(CH_3)$ -, and $R^{31}-O$ - ;

R^{31} is selected from optionally substituted cycloalkyl, and optionally substituted saturated heterocycle; and

the optional substituents of the R^{31} group are selected from NC-, HO-, HOCH₂-, (C₁-C₃)alkyl-, (C₁-C₃)alkoxy-, substituted (C₁-C₃)alkyl-, (C₃-C₆)cycloalkyl-, and (C₂-C₅)heterocycloalkyl-.


[0183] Clause 27. The compound of any one of clauses 24 to 26, wherein R^{12} is selected from:





[0184] Clause 28. The compound of any one of clauses 24 to 27, wherein the compound is selected from compounds 1-10, 17-20, 23-33, 42-46, 66-86, 88-98, 105-115, and 118-127 of Table 1.

[0185] Clause 29. The compound of any one of clauses 1 to 5, wherein the compound is of formula (Ie):



wherein:

X^1 and X^4 are independently N or C- R^1 ;

R^1 is selected from H, halogen, optionally substituted $-(C_1-C_6)alkyl$, and optionally substituted $-(C_1-C_6)alkoxy$; and


R^{31} is selected from optionally substituted $(C_2-C_5)heterocycloalkyl$, and optionally substituted $(C_3-C_7)cycloalkyl$;

R^{11} is -H, -halogen, -CN, -OH, optionally substituted $-(C_1-C_6)alkoxy$, - NH_2 , $-NR^5R^6$, $-CH_2NH_2$ and optionally substituted $-(C_1-C_6)alkyl$; and

n is 0, 1, 2, or 3.

[0186] Clause 30. The compound of clause 29, wherein the optional substituents of the R^{31} group are selected from NC-, HO-, $HOCH_2$ -, $(C_1-C_3)alkyl$ - (e.g., H_3C -), $(C_1-C_3)alkoxy$ -, substituted $(C_1-C_3)alkyl$ -, and $(C_3-C_6)cycloalkyl$ - (e.g., cyclopropyl).

[0187] Clause 31. The compound of clause 29 or 30, wherein the compound is of formula (If):



wherein:

X^1 and X^4 are independently N or CH;

R^{41} is H-, or HO-; and

q is 0, 1 or 2; wherein

when q is 0 or 1, X^5 is CH_2 ; and

when q is 2, X^5 is NH, O, or $CH(OH)$.

[0188] Clause 32. The compound of any one of clauses 29 to 31, wherein R^7 is optionally substituted $(C_1-C_6)alkyl$ -.

[0189] Clause 33. The compound of clause 32, wherein R^7 is H_3C -.

[0190] Clause 34. The compound of any one of clauses 29 to 33, wherein R^8 is optionally substituted $-(C_1-C_6)alkyl$ -.


[0191] Clause 35. The compound of clause 34, wherein R^8 is $-CH_2CH_3$.

[0192] Clause 36. The compound of any one of clauses 29 to 35, wherein R^9 is -CN.

[0193] Clause 37. The compound of any one of clauses 29 to 36, wherein R^{11} is -halogen.

[0194] Clause 38. The compound of clause 37, wherein R^{11} is -F.

[0195] Clause 39. The compound of clause 24 or 29, wherein the compound is of formula (Ic):



wherein:


X^1 and X^4 are independently N or C- R^1 ;

R^1 is selected from H, halogen, optionally substituted $-(C_1-C_6)$ alkyl, and optionally substituted $-(C_1-C_6)$ alkoxy; and

R^{31} is selected from optionally substituted (C_2-C_5) heterocycloalkyl, and optionally substituted (C_3-C_7) cycloalkyl-.

[0196] Clause 40. The compound of clause 39, wherein the optional substituents of the R^{31} group are selected from NC-, HO-, $HOCH_2$ -, (C_1-C_3) alkyl- (e.g., H_3C -), (C_1-C_3) alkoxy-, substituted (C_1-C_3) alkyl-, and (C_3-C_6) cycloalkyl- (e.g., cyclopropyl).

[0197] Clause 41. The compound of clause 39 or 40, wherein the compound is of formula (Id):



wherein:

X^1 and X^4 are independently N or CH;

R^{41} is H-, or HO-; and

q is 0, 1 or 2; wherein


when q is 0 or 1, X^5 is CH_2 ; and


when q is 2, X^5 is NH, O, or CH(OH).

[0198] Clause 42. The compound of any one of clauses 29 to 41, wherein X¹ is N.


[0199] Clause 43. The compound of any one of clauses 29 to 41, wherein X¹ is C-H.

[0200] Clause 44. The compound of any one of clauses 41 to 43, wherein the compound is selected from.:






[0201] Clause 45. The compound of any one of clauses 1 to 17, wherein R^3 is



[0202] Clause 46. The compound of clause 45, wherein R^3 is




[0203] Clause 47. The compound of clause 45 or 46, wherein:

R^{12} is selected from H-, R^{31} -C(O)-, R^{31} -C(O)CH₂-, R^{31} -NHC(O)-, R^{31} -C(O)NH-, R^{31} -N(CH₃)C(O)-, and R^{31} -C(O)N(CH₃) -;

R^{31} is selected from optionally substituted (C₁-C₃)alkyl-, optionally substituted cycloalkyl-, and optionally substituted saturated heterocycle; and

the optional substituents of the R^{31} group are selected from NC-, HO-, HOCH₂-, (C₁-C₃)alkyl-, (C₁-C₃)alkoxy- and substituted (C₁-C₃)alkyl-.

[0204] Clause 48. The compound of any one of clauses 46 to 47, wherein R^{12} is selected from:



[0205] Clause 49. The compound of any one of clauses 45 to 48, wherein the compound is selected from compounds 99-104 of Table 1.

[0206] Clause 50. A pharmaceutical composition comprising: a compound or a pharmaceutically acceptable salt thereof according to any one of clauses 1 to 49; and a pharmaceutically acceptable excipient.

[0207] Clause 51. A compound for use in inhibiting autotaxin (ATX), wherein the compound is a compound or a pharmaceutically acceptable salt thereof according to any one of clauses 1 to 49.

[0208] Clause 52. A pharmaceutical composition for use in inhibiting autotaxin (ATX), wherein the pharmaceutical composition is according to clause 50.

[0209] Clause 53. Use of a compound for the manufacture of a medicament for inhibiting autotaxin (ATX), wherein the compound is a compound or a pharmaceutically acceptable salt thereof according to any one of clauses 1 to 49.

[0210] Clause 54. Use of a pharmaceutical composition for the manufacture of a medicament for inhibiting autotaxin (ATX), wherein the pharmaceutical composition is according to clause 50.

[0211] Clause 55. A method of inhibiting autotaxin, the method comprising contacting a biological system comprising autotaxin with an effective amount of a compound or a pharmaceutically acceptable salt thereof according to any one of clauses 1 to 49 to inhibit autotaxin.

[0212] Clause 56. The method of clause 55, wherein the biological system is comprised in an *in vitro* sample.

[0213] Clause 57. The method of clause 55, wherein the biological system is *in vivo*.

[0214] Clause 58. A method of inhibiting autotaxin in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof according to any one of clauses 1 to 49, or a pharmaceutical composition according to clause 50.

[0215] Clause 59. A method of treating an ATX-related indication in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof according to any one of clauses 1 to 49, or a pharmaceutical composition according to clause 50.

[0216] Clause 60. The method of clause 59, wherein the ATX-related indication is selected from an inflammatory disease, autoimmune disease, proliferative disease, cancer, and fibrosis.

[0217] Clause 61. The method of clause 60, wherein the fibrosis occurs in the liver, e.g., the fibrosis is liver fibrosis.

[0218] Clause 62. A compound for use in inhibiting autotaxin (ATX), wherein the compound is a compound or a pharmaceutically acceptable salt thereof according to any one of clauses 1 to 49.

[0219] Clause 63. A pharmaceutical composition for use in inhibiting autotaxin (ATX), wherein the pharmaceutical composition is according to clause 50.


[0220] Clause 64. Use of a compound for the manufacture of a medicament for treating an ATX-related indication, wherein the compound is a compound or a pharmaceutically acceptable salt thereof according to any one of clauses 1 to 49.

[0221] Clause 65. Use of a pharmaceutical composition for the manufacture of a medicament treating an ATX-related indication, wherein the pharmaceutical composition is according to clause 50.

[0222] Clause 66. The use of clause 64 or 65, wherein the ATX-related indication is selected from an inflammatory disease, autoimmune disease, proliferative disease, cancer, and fibrosis.

[0223] Clause 67. The use of clause 66, wherein the fibrosis occurs in the liver, e.g., the fibrosis is liver fibrosis.

[0224] Clause 68. A compound of formula (II):



or a pharmaceutically acceptable salt or isomer thereof,
wherein:

Z^1 , Z^2 , and Z^3 are independently selected from C- R^1 and N;

R^{20} and R^{21} are each independently selected from H, and optionally substituted -(C₁-C₆)alkyl; or R^{20} and R^{21} together with the boron atom to which they are attached from an optionally substituted heterocycle;

each R^1 is independently selected from -H, -halogen, optionally substituted -(C₁-C₆)alkyl and optionally substituted -(C₁-C₆)alkoxy;

Y is selected from S, O, and N- R^2 , wherein R^2 is selected from -H, and optionally substituted -(C₁-C₆)alkyl;


R^7 is selected from H-, and optionally substituted (C₁-C₆)alkyl-;

R^8 is selected from -H, -halogen, and optionally substituted -(C₁-C₆)alkyl;


R^9 and each R^{10} are independently selected from -H, -halogen, -CN, -OH, optionally substituted $-(C_1-C_6)$ alkoxy, $-NH_2$, substituted amino, optionally substituted $-(C_1-C_6)$ alkyl- NH_2 and optionally substituted $-(C_1-C_6)$ alkyl; and

n is 0, 1, 2, 3, 4, or 5.

[0225] Clause 69. The compound of clause 68, wherein the compound is:



[0226] Clause 70. A compound of formula (III):



(III)

or a pharmaceutically acceptable salt or isomer thereof, wherein:

X^1 , X^2 , and X^3 are independently selected from $C-R^1$ and N;

Z^1 , Z^2 , and Z^3 are independently selected from $C-R^1$ and N;

each R^1 is independently selected from -H, -halogen, optionally substituted $-(C_1-C_6)$ alkyl and optionally substituted $-(C_1-C_6)$ alkoxy;

Y is selected from S, O, and $N-R^2$, wherein R^2 is selected from -H, and optionally substituted $-(C_1-C_6)$ alkyl;

R^{3a} is selected from optionally substituted $R^4-C(O)-(C_1-C_3)$ alkyl-, $R^4C(O)-$, halogen, optionally substituted monocyclic or bicyclic carbocycle, optionally substituted monocyclic or bicyclic heterocycle, R^5R^6HC- , and R^5R^6N- ;

R^4 is selected from H_2N- , $HO-$, R^5R^6N- , optionally substituted (C_1-C_{10}) alkyl-, optionally substituted (C_1-C_{10}) alkoxy-, optionally substituted monocyclic or bicyclic carbocycle, optionally substituted monocyclic or bicyclic heterocycle, optionally substituted cycloalkyl- (C_1-C_6) alkylene-, and optionally substituted heterocycle- (C_1-C_6) alkylene-;

R^5 and R^6 are independently selected from H-, H_2N- , $HO-$, optionally substituted (C_1-C_{10}) alkyl-, optionally substituted monocyclic or bicyclic carbocycle, optionally substituted

monocyclic or bicyclic heterocycle, optionally substituted $R^4C(O)-(C_1-C_{10})alkyl-$, $R^4C(O)-$, R^4- , and substituted amino;

or R^5 and R^6 together with the nitrogen or carbon atom to which they are attached are cyclically linked to form an optionally substituted carbocycle or an optionally substituted heterocycle;

R^7 is selected from H-, and optionally substituted $(C_1-C_6)alkyl-$;

R^8 is selected from -H, -halogen, and optionally substituted $-(C_1-C_6)alkyl$;

R^9 and each R^{10} are independently selected from -H, -halogen, -CN, -OH, optionally substituted $-(C_1-C_6)alkoxy$, $-NH_2$, substituted amino, optionally substituted $-(C_1-C_6)alkyl-NH_2$ and optionally substituted $-(C_1-C_6)alkyl$; and

n is 0, 1, 2, 3, 4, or 5.

[0227] Clause 71. The compound of clause 70, wherein the compound is selected from compounds 128-132, and 134-149 of Table 1A.

[0228] As described herein, the text refers to various embodiments of the present compounds, compositions, and methods. The various embodiments described are meant to provide a variety of illustrative examples and should not be construed as descriptions of alternative species. Rather, it should be noted that the descriptions of various embodiments provided herein may be of overlapping scope. The embodiments discussed herein are merely illustrative and are not meant to limit the scope of the present technology.

5. EXAMPLES

[0229] The following examples are offered to illustrate the present disclosure and are not to be construed in any way as limiting the scope of the present technology. Any methods that are functionally equivalent are within the scope of the present technology. Various modifications of the present technology in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications fall within the scope of the appended claims.

[0230] Unless otherwise stated, all temperatures are in degrees Celsius. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental errors and deviation should be allowed for.

[0231] All experiments conformed to the ethical guidelines for investigation in conscious animals and in full compliance with the central Israeli animal care commission.

[0232] In the examples below, if an abbreviation is not defined, it has its generally accepted meaning.

aq.	=	aqueous
LC-MS	=	liquid chromatography-mass spectrometry
MS	=	mass spectrometry
THF	=	tetrahydrofuran
NaHCO ₃	=	sodium bicarbonate
Cs ₂ CO ₃	=	cesium carbonate
NaH	=	sodium hydride
o/n	=	overnight
HATU	=	1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate
r.t.	=	room temperature
LAH	=	lithium aluminum hydride
DCM	=	dichloromethane
DMF	=	dimethylformamide
DMSO	=	dimethyl sulfoxide
DIEA	=	diisopropylethylamine
equiv.	=	equivalent
EtOAc or EA	=	ethyl acetate
EtOH	=	ethanol
EDCI	=	1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
g	=	gram
h	=	hours
HCl	=	hydrochloric acid
HPLC	=	high-performance liquid chromatography
HOAc	=	acetic acid
HOBT	=	hydroxybenzotriazole
M	=	molar
MeOH	=	methanol
mg	=	milligrams
mL	=	milliliters
mmol	=	millimols
mp	=	melting point

m/z	=	mass to charge ratio
NaCl	=	sodium chloride
Na ₂ CO ₃	=	sodium carbonate
NMR	=	nuclear magnetic resonance
NaOH	=	sodium hydroxide
Na ₂ SO ₄	=	sodium sulfate
ppm	=	parts per million
TFA	=	trifluoroacetic acid
TLC	=	thin layer chromatography
TsOH	=	p-Toluenesulfonic acid
UV	=	ultraviolet
wt %	=	weight percent
μM	=	micromolar

5.1. General Synthetic Methods


Compound characterization

[0233] Final compounds were confirmed by HPLC/MS analysis and determined to be >90% pure by weight. ¹H and ¹³C NMR spectra were recorded in CDCl₃ (residual internal standard CHCl₃ = δ 7.26), DMSO-d₆ (residual internal standard CD₃SOCD₂H = δ 2.50), methanol-d₄ (residual internal standard CD₂HOD = δ 3.20), or acetone-d₆ (residual internal standard CD₃COCD₂H = δ 2.05). The chemical shifts (δ) reported are given in parts per million (ppm) and the coupling constants (J) are in Hertz (Hz). The spin multiplicities are reported as s = singlet, bs = broad singlet, bm = broad multiplet, d = doublet, t = triplet, q = quartet, p = pentuplet, dd = doublet of doublet, ddd = doublet of doublet of doublet, dt = doublet of triplet, td = triplet of doublet, tt = triplet of triplet, and m = multiplet.


[0234] HPLC-MS analysis was carried out with gradient elution. Medium pressure liquid chromatography (MPLC) was performed with silica gel columns in both the normal phase and reverse phase.

5.2. Example 1 – Synthesis of Amino-linked Pyrimidine-type Compounds

General Scheme 1




5.2.1. Synthesis of Compound 128




[0235] A mixture of 2-((6-bromo-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (2 g, 4.38 mmol), 2-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (1.16 g, 4.82 mmol), $\text{Pd(PPh}_3\text{)}_4$ (1.01 g, 876.55 μmol), Na_2CO_3 (1.86 g, 17.53 mmol) was dissolved in dioxane (40 mL) and water (10 mL) and stirred at 80 °C under N_2 for 6 h. The mixture was cooled to room temperature, then diluted with water (100 mL), extracted with EA (50 mL $\times$ 2). The organic layer was dried over Na_2SO_4 and evaporated, the residue was purified by silica gel (PE: EA= 1: 1) to afford **compound 128**, 2-((6-(2-chloropyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (2 g, 88.29% yield) as a brown solid. MS: $m/z = 490.2$ ($\text{M}+1$, ESI $^+$).

5.2.2. Synthesis of Compound 21



[0236] To a solution of 2-((2-ethyl-6-(2-(piperidin-4-ylamino)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (150 mg, 270.93 μmol) and 1-hydroxy cyclopropane-1-carboxylic acid (33.19 mg, 325.11 μmol) in DMF (5 mL) was added HATU (153.32 mg, 406.39 μmol) and DIEA (140.06 mg, 1.08 mmol), the reaction mixture was stirred at 25 °C for 6 h. The reaction mixture was poured into water (50 mL) and extracted with EA (10 mLx3). The combined organic layers were dried over Na_2SO_4 and concentrated under reduced pressure and purified by Prep-HPLC to afford **compound 21** 2-((2-ethyl-6-(2-((1-(1-hydroxycyclopropane-1-carbonyl)piperidin-4-yl)amino)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl) thiazole-5-carbonitrile (51 mg, 29.53% yield) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.70 (s, 2H), 8.63 (s, 1H), 8.11-8.07 (t, 2H), 7.68 (s, 2H), 7.45-7.40 (m, 3H), 6.30 (s, 1H), 4.32 (s, 2H), 4.03-4.00 (m, 1H), 3.63 (s, 3H), 2.70-2.64 (dd, 2H), 1.91-1.88 (d, 2H), 1.42 (s, 2H), 1.28-1.17 (m, 5H), 0.90-0.87 (m, 2H), 0.76-0.73 (m, 2H); MS: m/z = 638.2($M+1$, ESI+).

5.2.3. Synthesis of Compound 22

*Step one:*


[0237] To a solution of **compound 128**, 2-((6-(2-chloropyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (500 mg, 1.02 mmol) and tert-butyl 4-aminopiperidine-1-carboxylate (245.26 mg, 1.22 mmol) in MeCN (20 mL) was added Cs_2CO_3 (997.50 mg, 3.06 mmol), the reaction mixture was stirred at 90 °C for 16 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by column chromatography to afford tert-butyl 4-((5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridine-6-yl)pyrimidin-2-

yl)amino)piperidine-1-carboxylate (550 mg, 82.44% yield) as a brown solid. MS: m/z = 654.2(M+1, ESI+).

Step two:

[0238] To a solution of tert-butyl 4-((5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethyl imidazo[1,2-a] pyridin-6-yl)pyrimidin-2-yl)amino)piperidine-1-carboxylate (300 mg, 458.88 μ mol) in MeOH (3 mL) was added 3M HCl in EA (3 M, 5 mL). The reaction mixture was stirred at 25 °C for 1 h. The excess of solvent was removed under reduced pressure. The residue was purified by Prep-HPLC to afford **compound 22**, 2-((2-ethyl-6-(2-(piperidin-4-ylamino) pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (20 mg, 7.87% yield) as a yellow solid. ^1H NMR (400 MHz, DMSO- d_6) δ 8.67 (s, 2H), 8.59 (s, 1H), 8.10-8.07 (m, 2H), 7.67 (s, 2H), 7.43-7.39 (t, 2H), 7.32-7.30 (d, 1H), 3.81-3.79 (m, 1H), 3.63 (s, 3H), 2.98-2.95 (d, 2H), 2.70-2.64 (dd, 2H), 2.55 (s, 1H), 1.86-1.80 (m, 4H), 1.39-1.36 (dd, 2H), 1.28-1.25 (t, 3H); MS: m/z = 554.2(M+1, ESI+).

5.2.4. Synthesis of Compound 34




Step one:

[0239] To a solution of 2-((6-(2-chloropyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (800 mg, 1.63 mmol) and tert-butyl 3-aminoazetidine-1-carboxylate (562.42 mg, 3.27 mmol) in DMF (5 mL) was added DIEA (633.09 mg, 4.9 mmol), the resulting mixture was stirred at 80 °C for 5 h. The reaction mixture was poured into water (50 mL) and extracted with DCM (10 mLx3). The combined organic layers were washed with water (50 mLx3) and brine (50 mL), dried over Na_2SO_4 and concentrated under reduced pressure and purified by column chromatography to afford tert-butyl 3-((5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)amino)azetidine-1-carboxylate (680 mg, 66.65% yield) as a yellow solid. MS: m/z = 626.1 (M+1, ESI+).


Step two:

[0240] To a solution of tert-butyl 3-((5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethyl imidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)amino)azetidine-1-carboxylate (680 mg, 1.09 mmol) in DCM (8 mL) was added TFA (3 g, 26.31 mmol). The reaction mixture was stirred at 25 °C for 3 h. The excess of solvent was removed under reduced pressure, the residue was purified by Prep-HPLC to afford **compound 34**, 2-((6-(2-(azetidin-3-ylamino) pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (400 mg, 70.03% yield) as a yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.77 (s, 2H), 8.67 (s, 1H), 8.15-8.08 (m, 3H), 7.70 (s, 2H), 7.44-7.40 (t, 2H), 4.81-4.74 (m, 1H), 4.15-4.10 (t, 2H), 3.98-3.94 (t, 2H), 3.63 (s, 3H), 2.70-2.64 (dd, 2H), 1.28-1.25 (t, 3H); MS: m/z = 526.1(M+1, ESI+).

5.2.5. Synthesis of Compound 35

[0241] To a solution of **compound 34**, 2-((6-(2-(azetidin-3-ylamino)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl) (methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (120 mg, 228.31 μmol) and 1-hydroxy cyclopropane-1-carboxylic acid (46.62 mg, 456.62 μmol) in DCM (5 mL) was added HOBT (61.70 mg, 456.62 μmol), EDCI (87.53 mg, 456.62 μmol) and DIEA (118.03 mg, 913.24 μmol), the resulting mixture was stirred at 25°C for 1 h. The reaction mixture was poured into water (50 mL) and extracted with DCM (10 mLx3). The combined organic layers were dried over Na₂SO₄ and concentrated under reduced pressure and purified by Prep-HPLC to afford **compound 35**, 2-((2-ethyl-6-(2-((1-(1-hydroxycyclopropane-1-carbonyl)azetidin-3-yl)amino)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl) (methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (70 mg, 50.29% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.74 (s, 2H), 8.66 (s, 1H), 8.11-8.07 (m, 3H), 7.69 (s, 2H), 7.44-7.40 (t, 2H), 5.98 (s, 1H), 4.74-4.70 (t, 1H), 4.58-4.52 (m, 1H), 4.30 (s, 1H), 4.17-4.13 (t, 1H), 3.82 (s, 1H), 3.63 (s, 3H), 2.70-2.64 (dd, 2H), 1.28-1.25 (t, 3H), 1.03-1.00 (dd, 2H), 0.78-0.75 (dd, 2H); MS: m/z = 610.1(M+1, ESI+).

5.2.6. Synthesis of Compound 36


*Step one:*

[0242] To a solution of **compound 34**, 2-((6-(2-(azetidin-3-ylamino)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (160 mg, 304.41 μmol) and 1-(tert-butoxycarbonyl)azetidine-3-carboxylic acid (122.51 mg, 608.83 μmol) in DCM (5 mL) was added HOBt (82.27 mg, 608.83 μmol), EDCI (116.71 mg, 608.83 μmol) and DIEA (157.37 mg, 1.22 mmol), the resulting mixture was stirred at 25°C for 1 h. The reaction mixture was poured into water (50 mL) and extracted with DCM (10 mL $\times$ 3). The combined organic layers were dried over Na₂SO₄ and concentrated under reduced pressure and purified by column chromatography to afford tert-butyl 3-((5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)amino)azetidine-1-carboxylate (180 mg, 83.42% yield) as a yellow solid. MS: m/z = 709.2(M+1, ESI+).

Step two:


[0243] To a solution of tert-butyl 3-((5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)amino)azetidine-1-carboxylate (150 mg, 211.62 μmol) in DCM (4 mL) was added TFA (1.5 g, 13.15 mmol). The reaction mixture was stirred at 25 °C for 1 h. The excess of solvent was removed under reduced pressure, the residue was purified by Prep-HPLC to afford **compound 36**, 2-((6-(2-((1-(azetidine-3-carboxyl)azetidin-3-yl)amino)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (68 mg, 52.79% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.75 (s, 2H), 8.66 (s, 1H), 8.34 (s, 1H), 8.11-8.07 (m, 3H), 7.69 (s, 2H), 7.44-7.40 (t, 2H), 4.60-4.56 (m, 1H), 4.35-4.31 (t, 1H), 4.18-4.14 (t, 1H), 3.93-3.73 (m, 6H), 3.63 (s, 3H), 3.56-3.50 (m, 1H), 2.70-2.64 (dd, 2H), 1.28-1.25 (t, 3H); MS: m/z = 609.1(M+1, ESI+).

5.2.7. Synthesis of Compound 37



[0244] To a solution of **compound 34**, 2-((6-(2-(azetidin-3-ylamino)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (200 mg, 380.52 μmol) in DCM (5 mL) was added triphosgene (56.46 mg, 190.26 μmol) and stirred at 0 °C for 0.5 h, then DIEA (147.54 mg, 1.14 mmol) was added and stirred at 0 °C for another 0.5 h. After that, azetidin-3-ol hydrochloride (55.63 mg, 761.03 μmol) was added to the above reaction mixture and stirred at 25 °C for 0.5 h. Added water (50 mL) to the reaction mixture, then extracted with DCM (50 mL $\times$ 2). The organic layer was washed with water (50 mL $\times$ 2) and brine (50 mL), dried over Na_2SO_4 and concentrated. The residue was purified by Prep-HPLC to afford **compound 37**, 2-((2-ethyl-6-(2-((1-(3-hydroxyazetidine-1-carbonyl)azetidin-3-yl)amino)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (105 mg, 44.17% yield) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.73 (s, 2H), 8.66 (s, 1H), 8.09-8.03 (m, 3H), 7.69 (s, 2H), 7.44-7.40 (t, 2H), 5.60-5.58 (d, 1H), 4.56-4.53 (m, 1H), 4.39-4.35 (m, 1H), 4.10-4.07 (t, 2H), 3.99-3.95 (t, 2H), 3.76 (s, 2H), 3.63 (s, 3H), 3.59-3.55 (m, 2H), 2.69-2.64 (dd, 2H), 1.28-1.23 (t, 3H); MS: m/z = 625.1 ($\text{M}+1$, ESI^+).

5.2.8. Synthesis of Compound 38 Formate

*Step one:*


[0245] To a solution of **compound 128**, 2-((6-(2-chloropyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (900 mg, 1.84 mmol) and tert-butyl 3-(aminomethyl)azetidine-1-carboxylate (411.24 mg, 2.21 mmol) in dioxane (15 mL) was added DIEA (951.23 mg, 7.36 mmol), the resulting mixture was stirred

at 100 °C for 16 h. After cooled to room temperature, the reaction mixture was poured into water (150 mL) and extracted with EA (50 mLx3). The combined organic layers were dried over Na₂SO₄ and concentrated under reduce pressure and purified by column chromatography to afford tert-butyl 3-(((5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)amino)methyl)azetidine-1-carboxylate (820 mg, 69.66% yield) as a yellow solid. MS: m/z = 640.3 (M+1, ESI+).

Step two:

[0246] To a solution of tert-butyl 3-(((5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)amino)methyl)azetidine-1-carboxylate (800 mg, 1.25 mmol) in DCM (15 mL) was added TFA (142.59 mg, 1.25 mmol). The reaction mixture was stirred at 25 °C for 1 h. The excess of solvent was removed under reduced pressure, the residue was purified by Prep-HPLC to afford **compound 38 formate**, 2-((6-(2-((azetidin-3-ylmethyl) amino)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile formate (400 mg, 59.28% yield) as a yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.70 (s, 2H), 8.63 (s, 1H), 8.38 (s, 1H), 8.11-8.07 (t, 2H), 7.69 (s, 2H), 7.63-7.60 (t, 1H), 7.44-7.40 (t, 2H), 3.87-3.82 (t, 2H), 3.67-3.63 (m, 5H), 3.53-3.50 (t, 2H), 3.02-2.97 (m, 1H), 2.69-2.64 (dd, 3H), 1.28-1.25 (t, 3H); MS: m/z = 540.2(M+1, ESI+).


5.2.9. Synthesis of Compound 39



[0247] To a solution of **compound 38**, 2-((6-(2-((azetidin-3-ylmethyl)amino)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (160 mg, 296.50 μmol) in DCM (5 mL) was added triphosgene (54.99 mg, 185.31 μmol) and stirred at 0 °C for 0.5 h, then DIEA (191.28 mg, 1.48 mmol) was added and stirred at 0 °C for another 0.5 h. After that, azetidin-3-ol hydrochloride (43.86 mg, 0.6 mmol) was added to the above reaction mixture and stirred at 25 °C for 0.5 h. Added water (50 mL) to the reaction mixture, then extracted with DCM (50 mLx2). The organic layer was washed with water (50 mLx2) and brine (50 mL), dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC to afford **compound 39**, 2-((2-ethyl-6-(2-(((1-(3-

hydroxyazetidine-1-carbonyl)azetidin-3-yl)methyl)amino)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (24 mg, 12.69% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.69 (s, 2H), 8.63 (s, 1H), 8.11-8.07 (t, 2H), 7.68 (s, 2H), 7.62-7.59 (t, 1H), 7.44-7.40 (t, 2H), 5.57 (s, 1H), 4.36 (s, 1H), 3.96-3.93 (t, 2H), 3.85-3.81 (t, 2H), 3.63 (s, 3H), 3.58-3.53 (m, 4H), 3.50-3.47 (t, 2H), 2.79-2.75 (m, 1H), 2.69-2.64 (dd, 2H), 1.28-1.24 (t, 3H); MS: m/z = 639.2(M+1, ESI+).

5.2.10. Synthesis of Compound 40



Step one:


[0248] To a solution of **compound 34**, 2-((6-(2-((azetidin-3-ylmethyl)amino)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (300 mg, 555.94 μmol) and 1-(tert-butoxycarbonyl)azetidine-3-carboxylic acid (123.05 mg, 611.53 μmol) in DMF (6 mL) was added HOBt (90.14 mg, 667.13 μmol), EDCI (127.89 mg, 667.13 μmol) and DIEA (287.40 mg, 2.22 mmol), the resulting mixture was stirred at 25°C for 3 h. The reaction mixture was poured into water (50 mL) and extracted with EA (10 mLx3). The combined organic layers were washed with water (50 mLx2) and brine (50 mL), dried over Na₂SO₄ and concentrated under reduced pressure and purified by column chromatography to afford tert-butyl 3-(3-(((5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)amino)methyl)azetidine-1-carbonyl)azetidine-1-carboxylate (350 mg, 87.28% yield) as a brown solid. MS: m/z = 723.3 (M+1, ESI+).

Step two:

[0249] To a solution of tert-butyl 3-(3-(((5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)amino)methyl)azetidine-1-carbonyl)azetidine-1-carboxylate (350 mg, 484.21 μmol) in DCM (4 mL) was added TFA (2 mL). The reaction mixture was stirred at 25 °C for 16 h. The excess of solvent was removed under reduced pressure, the residue was purified by Prep-HPLC to afford **compound 40**, 2-((6-(2-(((1-(azetidine-3-carbonyl)azetidin-3-yl)methyl)amino)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (30 mg, 9.95% yield) as a white solid. ¹H NMR (400


MHz, DMSO- d_6) δ 8.69 (s, 2H), 8.63 (s, 1H), 8.09 (s, 2H), 7.68 (s, 2H), 7.64-7.62 (t, 1H), 7.44-7.40 (t, 2H), 4.06-4.02 (t, 1H), 3.89-3.74 (m, 3H), 3.69-3.54 (m, 6H), 3.50-3.41 (m, 5H), 2.81 (s, 1H), 2.69-2.64 (dd, 2H), 1.28-1.24 (t, 3H); MS: m/z = 623.1(M+1, ESI+).

5.2.11. Synthesis of Compound 41




[0250] To a solution of **compound 34**, 2-((6-(2-((azetidin-3-ylmethyl)amino)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (41.62 mg, 407.69 μ mol) in DMF (4 mL) was added HOBT (60.09 mg, 444.75 μ mol), EDCI (85.26 mg, 444.75 μ mol) and DIEA (191.60 mg, 1.48 mmol), the resulting mixture was stirred at 25°C for 3 h. The reaction mixture was poured into water (50 mL) and extracted with EA (10 mLx3). The combined organic layers were washed with water (50 mLx2) and brine (50 mL), dried over Na_2SO_4 and concentrated under reduced pressure and purified by column chromatography to afford **compound 41**, 2-((2-ethyl-6-(2-(((1-(1-hydroxy cyclopropane-1-carbonyl)azetidin-3-yl)methyl)amino)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluoro phenyl)thiazole-5-carbonitrile (70 mg, 30.28% yield) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 8.70 (s, 2H), 8.64 (s, 1H), 8.11-8.07 (t, 2H), 7.68 (s, 2H), 7.66-7.64 (t, 1H), 7.44-7.40 (t, 2H), 5.94 (s, 1H), 4.48-4.44 (t, 1H), 4.18-4.15 (m, 1H), 3.90-3.86 (t, 1H), 3.63-3.60 (m, 4H), 3.54-3.51 (t, 2H), 2.85-2.78 (m, 1H), 2.69-2.64 (dd, 2H), 1.28-1.25 (t, 3H), 0.99-0.98 (d, 2H), 0.74-0.73 (d, 2H); MS: m/z = 624.2 (M+1, ESI+).

5.3. Example 2 – Synthesis of Azetidine-linked Pyrimidine-type Compounds

General Scheme 2


5.3.1. Synthesis of Compound 129 Hydrochloride

*Step one:*

[0251] A mixture of **compound 128**, 2-((6-(2-chloropyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (1 g, 2.04 mmol) and tert-butyl azetidin-3-ylcarbamate (386.66 mg, 2.25 mmol) in DMF (20 mL) was added Cs_2CO_3 (1.99 g, 6.12 mmol) and stirred at 25 °C for 3 h. The reaction mixture was diluted with water (100mL), extracted with DCM (30 mL $\times$ 3) and dried over Na_2SO_4 . The organic layer was evaporated to afford tert-butyl (1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidin-3-yl)carbamate (1.1 g, 86.13% yield) as a brown solid. MS: $m/z = 626.3$ ($M+1$, ESI⁺).


[0252] To a solution of tert-butyl (1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidin-3-yl)carbamate (1.2 g, 1.92 mmol) in DCM (20 mL) was added HCl (3 M in EA, 12.79 mL), the mixture was stirred at 25 °C for 3h. Then concentrated, the residue was washed with EA (30 mL), the solid was collected to afford **compound 129 hydrochloride**, 2-((6-(2-(3-aminoazetidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (1 g, 99.00% yield) as a white solid. MS: $m/z = 526.3$ ($M+1$, ESI+).

5.3.2. Synthesis of Compound 130



[0253] To a solution of **compound 128**, 2-((6-(2-chloropyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (1.2 g, 2.45 mmol) and azetidin-3-ol hydrochloride (321.99 mg, 2.94 mmol) in MeCN (30 mL) was added Cs_2CO_3 (2.39 g, 7.35 mmol). The reaction mixture was stirred at 70 °C for 3 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by column chromatography to afford **compound 130**, 2-((2-ethyl-6-(2-(3-hydroxyazetidin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (850 mg, 65.91% yield) as a yellow solid. MS: $m/z = 527.1$ ($M+1$, ESI+).


5.3.3. Synthesis of Compound 131



[0254] To a solution of **compound 130**, 2-((2-ethyl-6-(2-(3-hydroxyazetidin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (800.00 mg, 1.52 mmol) in DCM (20 mL) was added Dess-Martin (1.29 g, 3.04 mmol). The

reaction mixture was stirred at 25 °C for 3 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by column chromatography to afford **compound 131**, 2-((2-ethyl-6-(2-(3-oxoazetidin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (680 mg, 85.33% yield) as a yellow solid. MS: $m/z = 525.4$ ($M+1$, ESI+).

5.3.4. Synthesis of Compound 132




Step one:

[0255] To a solution of **compound 128** 2-((6-(2-chloropyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (800 mg, 1.63 mmol) and methyl azetidine-3-carboxylate hydrochloride (369.79 mg, 2.45 mmol) in DMF (10 mL) was added Cs_2CO_3 (2.13 g, 6.53 mmol), the resulting mixture was stirred at 100°C for 2 h. The reaction mixture was poured into water (100 mL) and extracted with EA (30 mLx3). The combined organic layers were washed with water (100 mLx3) and brine (100 mL), dried over Na_2SO_4 and concentrated under reduce pressure, the residue was purified by column chromatography to afford methyl 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidine-3-carboxylate (800 mg, 86.16% yield) as a brown solid. MS: $m/z = 569.1$ ($M+1$, ESI+).

Step two:

[0256] To a solution of methyl 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidine-3-carboxylate (800 mg, 1.41 mmol) in THF (10 mL) and H_2O (5 mL) was added NaOH (112.55 mg, 2.81 mmol) and stirred at 25 °C for 16 h. The reaction mixture was acidified to pH to 7 with 2 N HCl, extracted with EA (10 mLx3). The combined organic layers were washed with water (10 mLx3) and brine (10 mL), dried over Na_2SO_4 and concentrated under reduce pressure, the residue was purified by column chromatography to afford **compound 132**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidine-3-carboxylic acid (440 mg, 56.41% yield) as a brown solid MS: $m/z = 555.2$ ($M+1$, ESI+).

5.3.5. Synthesis of Compound 3


*Step one:*

[0257] To a solution of **compound 128**, 2-((6-(2-chloropyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (300 mg, 612.3 μmol) and tert-butyl azetidin-3-ylcarbamate (158.18 mg, 918.5 μmol) in MeCN (20 mL) was added Cs_2CO_3 (598.49 mg, 183.7 μmol), the reaction mixture was stirred at 80 °C for 2 h. Filtered and concentrated, the residue was purified by Prep-HPLC to afford tert-butyl (1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidin-3-yl)carbamate (210 mg, 54.81% yield) as a yellow solid. MS: m/z = 626.2 ($M+1$, ESI+).

Step two:

[0258] To a solution of tert-butyl (1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidin-3-yl)carbamate (210 mg, 335.6 μmol) in DCM (20 mL) was added TFA (328.98 mg, 3.36 mmol), the reaction mixture was stirred at 25 °C for 4 h. Concentrated and the residue was purified by Prep-HPLC to afford **compound 3**, 2-((6-(2-(3-aminoazetidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (80 mg, 45.35% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6) δ 8.72 (s, 2H), 8.64 (s, 1H), 8.11-8.07 (t, 2H), 7.68 (s, 2H), 7.44-7.39 (t, 2H), 4.23-4.19 (t, 2H), 3.82-3.78 (m, 1H), 3.68-3.63 (m, 5H), 2.70-2.64 (dd, 2H), 2.17 (t, 2H), 1.29-1.25 (t, 3H); MS: m/z = 526.1 ($M+1$, ESI+).

5.3.6. Synthesis of Compound 23




Step one:

[0259] A mixture of **compound 129 hydrochloride**, 2-((6-(2-(3-aminoazetidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methylamino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (150 mg, 285.39 μmol), (2R,4S)-1-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (72.59 mg, 313.93 μmol), HOBT (46.27 mg, 342.46 μmol) and EDCI (65.65 mg, 342.46 μmol) dissolved in DMF (3 mL) was added DIEA (147.53 mg, 1.14 mmol) and stirred at 25°C for 2 h. The mixture was diluted with water (30 mL), extracted with EA (10 mL $\times$ 3) and dried over Na_2SO_4 . Then the organic layer was evaporated to afford tert-butyl (2R,4S)-2-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methylamino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidin-3-yl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylate (160 mg, 81.21% yield) as a brown oil. MS: m/z = 739.2 ($M+1$, ESI+).

Step two:

[0260] To a solution of tert-butyl (2R,4S)-2-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methylamino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidin-3-yl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylate (160 mg, 216.56 μmol) in DCM (3 mL) was added HCl (3 M in EA, 1.08 mL), the mixture was stirred at 25°C for 2 h. After that, the reaction mixture was evaporated and the residue was purified by Prep-HPLC to afford **compound 23**, (2R,4S)-N-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methylamino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidin-3-yl)-4-hydroxypyrrolidine-2-carboxamide (10 mg, 7.24% yield) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.76 (s, 2H), 8.65 (s, 1H), 8.62 (s, 1H), 8.10-8.07 (t, 2H), 7.69 (s, 2H), 7.44-7.40 (t, 2H), 4.70-4.58 (m, 2H), 4.30-4.26 (t, 2H), 4.16 (s, 1H), 3.97-3.95 (m, 2H), 3.75-3.68 (m, 1H), 3.63 (s, 3H), 2.88-2.84 (m, 1H), 2.74-2.64 (m, 3H), 2.02-1.90 (m, 2H), 1.71-1.64 (m, 1H), 1.28-1.24 (t, 3H); MS: m/z = 639.4 ($M+1$, ESI+).


5.3.7. Synthesis of Compound 24

Step one:

[0261] A mixture of **compound 129 hydrochloride**, 2-((6-(2-(3-aminoazetidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (150 mg, 285.39 μmol), (2S,4S)-1-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (72.59 mg, 313.93 μmol), HOBT (46.27 mg, 342.46 μmol) and EDCI (65.65 mg, 342.46 μmol) dissolved in DMF (3 mL) was added DIEA (147.53 mg, 1.14 mmol) and stirred at 25°C for 6 h. The mixture was diluted with water (30 mL), extracted with EA (10 mL $\times$ 3) and dried over Na₂SO₄. Then the organic layer was evaporated to afford tert-butyl (2S,4S)-2-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidin-3-yl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylate (150 mg, 71.14% yield) as a brown oil. MS: m/z = 739.2 (M+1, ESI+).

Step two:

[0262] To a solution of tert-butyl (2S,4S)-2-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidin-3-yl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylate (150 mg, 203.02 μmol) in DCM (3 mL) was added HCl (3 M in EA, 1.02 mL), the mixture was stirred at 25°C for 2 h. The resulting mixture was evaporated and the residue was purified by Prep-HPLC to afford **compound 24**, (2S,4S)-N-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidin-3-yl)-4-hydroxypyrrolidine-2-carboxamide (70 mg, 54.26% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.76 (s, 2H), 8.65 (s, 1H), 8.58-8.56 (d, 1H), 8.10-8.07 (t, 2H), 7.69 (s, 2H), 7.44-7.40 (t, 2H), 4.62-4.59 (m, 2H), 4.32-4.27 (m, 2H), 4.12-4.08 (m, 1H), 3.98-3.93 (m, 2H), 3.63 (s, 3H), 3.50-3.47 (dd, 1H), 2.88-2.84 (dd, 1H), 2.70-2.64 (m, 3H), 2.15-1.97 (m, 2H), 1.65-1.59 (m, 1H), 1.28-1.25 (t, 3H); MS: m/z = 639.4 (M+1, ESI+).


5.3.8. Synthesis of Compound 25

Step one:

[0263] A mixture of **compound 129 hydrochloride**, 2-((6-(2-(3-aminoazetidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (150 mg, 285.39 μmol), (2R,4R)-1-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (72.59 mg, 313.93 μmol), HOBT (46.27 mg, 342.46 μmol) and EDCI (65.65 mg, 342.46 μmol) dissolved in DMF (3 mL) was added DIEA (147.53 mg, 1.14 mmol) and stirred at 25 °C for 4 h. The mixture was diluted with water (30 mL), extracted with EA (10 mL $\times$ 3) and dried over Na_2SO_4 . Then the organic layer was evaporated to afford tert-butyl (2R,4R)-2-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidin-3-yl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylate (155 mg, 73.51% yield) as a brown oil. MS: m/z = 739.2 ($M+1$, ESI+).

Step two:

[0264] To a solution of tert-butyl (2R,4R)-2-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidin-3-yl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylate (155 mg, 209.79 μmol) in DCM (3 mL) was added HCl (3 M in EA, 1.05 mL), the reaction mixture was stirred at 25°C for 2 h. The result mixture was evaporated and the residue was purified by Prep-HPLC to afford **compound 25**, (2R,4R)-N-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidin-3-yl)-4-hydroxypyrrolidine-2-carboxamide (24 mg, 17.91% yield) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.76 (s, 2H), 8.66 (s, 1H), 8.59-8.57 (d, 1H), 8.10-8.07 (t, 2H), 7.69 (s, 2H), 7.44-7.40 (t, 2H), 4.63-4.58 (m, 2H), 4.32-4.27 (m, 2H), 4.12-4.08 (m, 1H), 3.98-3.93 (m, 2H), 3.63 (s, 3H), 3.52-3.48 (dd, 1H), 2.89-2.85 (dd, 1H), 2.70-2.64 (m, 3H), 2.15-1.95 (m, 2H), 1.66-1.60 (m, 1H), 1.28-1.24 (t, 3H); MS: m/z = 639.4 ($M+1$, ESI+).


5.3.9. Synthesis of Compound 26

Step one:

[0265] A mixture of **compound 129 hydrochloride**, 2-((6-(2-(3-aminoazetidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methylamino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (150 mg, 285.39 μmol), (2S,4R)-1-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (72.59 mg, 313.93 μmol), HOBT (46.27 mg, 342.46 μmol) and EDCI (65.65 mg, 342.46 μmol) dissolved in DMF (3 mL) was added DIEA (147.53 mg, 1.14 mmol) and stirred at 25°C for 2 h. The mixture was diluted with water (30 mL), extracted with EA (10 mL $\times$ 3) and dried over Na_2SO_4 . Then the organic layer was evaporated to afford tert-butyl (2S,4R)-2-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methylamino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidin-3-yl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylate (166 mg, 78.73% yield) as a brown oil. MS: $m/z = 739.2$ ($M+1$, ESI+).

Step two:

[0266] To a solution of tert-butyl (2S,4R)-2-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methylamino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidin-3-yl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylate (166 mg, 224.68 μmol) in DCM (3 mL) was added HCl (3 M in EA, 1.12 mL), the reaction mixture was stirred at 25°C for 2 h. The result mixture was evaporated and the residue was purified by Prep-HPLC to afford **compound 26**, (2S,4R)-N-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methylamino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidin-3-yl)-4-hydroxypyrrolidine-2-carboxamide (70 mg, 46.14% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6) δ 8.75 (s, 2H), 8.65 (s, 1H), 8.57-8.55 (d, 1H), 8.10-8.07 (t, 2H), 7.69 (s, 2H), 7.44-7.40 (t, 2H), 4.63-4.60 (m, 2H), 4.29-4.26 (m, 2H), 4.15 (s, 1H), 3.98-3.93 (m, 2H), 3.70-3.63 (m, 4H), 2.84-2.80 (dd, 1H), 2.72-2.64 (m, 3H), 1.92-1.87 (m, 2H), 1.69-1.63 (m, 1H), 1.28-1.25 (t, 3H); MS: $m/z = 639.4$ ($M+1$, ESI+).


5.3.10. Synthesis of Compound 27 Formate

Step one:

[0267] To a solution of **compound 131**, 2-((2-ethyl-6-(2-(3-oxoazetidin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (400 mg, 762.53 μmol) and tert-butyl 3-aminoazetidine-1-carboxylate (157.59 mg, 915.03 μmol) in DCM (10 mL) was added $\text{NaBH}(\text{OAc})_3$ (323.22 mg, 1.53 mmol). The mixture was stirred at 25 °C for 24 h. The resulting solution was quenched by saturated NH_4Cl (30 mL) and extracted with DCM (30 mL x 3), the combined organic layers were washed with water (30 mL) and brine (30 mL), dried over Na_2SO_4 and concentrated under reduced pressure. The residue was purified by column chromatography to afford tert-butyl 3-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidin-3-yl)amino)azetidine-1-carboxylate (260 mg, 50.08% yield) as a yellow solid. MS: $m/z = 681.6$ ($M+1$, ESI+).

Step two:


[0268] To a solution of tert-butyl 3-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidin-3-yl)amino)azetidine-1-carboxylate (260.00 mg, 381.91 μmol) in DCM (10 mL) was added TFA (435.45 mg, 3.82 mmol). The reaction mixture was stirred at 25 °C for 3 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by Prep-HPLC to afford **compound 27 Formate**, 2-((6-(2-(3-(azetidin-3-ylamino)azetidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile formate (70 mg, 29.28% yield) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.74 (s, 2H), 8.64 (s, 1H), 8.11-8.07 (t, 2H), 7.69 (s, 2H), 7.44-7.40 (t, 2H), 4.19-4.17 (m, 2H), 3.93 (s, 2H), 3.72-3.63 (m, 10H), 2.70-2.64 (dd, 2H), 1.28-1.25 (t, 3H); MS: $m/z = 581.2$ ($M+1$, ESI+).

5.3.11. Synthesis of Compound 27

[0269] **Compound 27 formate**, 2-((6-(2-(3-(azetidin-3-ylamino)azetidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-


carbonitrile formate (34 mg, 0.054 mmol) was purified by Prep-HPLC to afford **compound 27**, 2-((6-(2-(3-(azetidin-3-ylamino)azetidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (13 mg, 41.26% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.73 (s, 2H), 8.64 (s, 1H), 8.11-8.07 (t, 2H), 7.68 (s, 2H), 7.44-7.40 (t, 2H), 4.18-4.14 (t, 2H), 3.72-3.38 (m, 13H), 2.69-2.64 (dd, 2H), 1.28-1.24 (t, 3H); MS: m/z= 581.3 (M+1, ESI+).

5.3.12. Synthesis of Compound 28




[0270] A mixture of **compound 131**, 2-((2-ethyl-6-(2-(3-oxoazetidin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (159.39 mg, 303.84 μmol) and 1-amino cyclopropane-1-carbonitrile hydrochloride (72.05 mg, 607.69 μmol) in DCM (10 mL) was stirred at 25 °C for 1 h. Then NaBH(OAc)₃ (193.19 mg, 911.53 μmol) was added to the above solution in portions. The reaction mixture was stirred at 25 °C for 16 h. The resulting solution was quenched by saturated NH₄Cl (30 mL) and extracted with DCM (30 mL x 3), the combined organic layers were washed with water (30 mL) and brine (30 mL), dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by Prep-HPLC to afford **compound 28**, 2-((2-ethyl-6-(2-(3-(1-cyanocyclopropylamino)azetidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (72 mg, 40.12% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.75 (s, 2H), 8.66 (s, 1H), 8.11-8.07 (t, 2H), 7.69 (s, 2H), 7.44-7.40 (t, 2H), 4.30-4.27 (m, 2H), 4.21-4.18 (d, 1H), 3.91-3.88 (m, 3H), 3.63 (s, 3H), 2.70-2.64 (dd, 2H), 1.28-1.25 (t, 3H), 1.20-1.17 (dd, 2H), 1.01-0.98 (dd, 2H); MS: m/z= 591.2 (M+1, ESI+).

5.3.13. Synthesis of Compound 29



[0271] To a solution of **compound 129 hydrochloride**, 2-((6-(2-(3-aminoazetidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (80 mg, 142.33 μmol) and 1-cyanocyclopropane-1-carboxylic acid (23.72 mg, 213.50 μmol) in DCM (5 mL) was added HOBT (29.06 mg, 213.50 μmol), EDCI (40.93 mg, 213.50 μmol) and DIEA (73.58 mg, 569.33 μmol). The resulting mixture was stirred at 25°C for 10 h. The reaction mixture was poured into water (20 mL) and extracted with DCM (10 mLx3). The combined organic layers were dried over Na_2SO_4 and concentrated under reduced pressure and purified by Prep-HPLC to afford **compound 29**, 1-cyano-N-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidin-3-yl)cyclopropane-1-carboxamide (13 mg, 14.77% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6) δ 8.77-8.73 (m, 3H), 8.66 (s, 1H), 8.09 (s, 2H), 7.70 (s, 2H), 7.44-7.40 (t, 2H), 4.65 (s, 1H), 4.28 (s, 2H), 4.06 (s, 2H), 3.63 (s, 3H), 2.71-2.67 (m, 2H), 1.57-1.53 (m, 4H), 1.29-1.26 (t, 3H); MS: m/z = 619.1 (M+1, ESI+).


5.3.14. Synthesis of Compound 30



[0272] To a solution of **compound 131**, 2-((2-ethyl-6-(2-(3-oxoazetidin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (180 mg, 343.14 μmol) and (1-aminocyclopropyl)methanol hydrochloride (50.89 mg, 411.76 μmol) in DCM (10 mL) was added $\text{NaBH}(\text{OAc})_3$ (145.45 mg, 686.27 μmol). The reaction mixture was stirred at 25 °C for 24 h. The resulting mixture was quenched by saturated NH_4Cl (30 mL) and extracted with DCM (10 mLx3), the combined organic layers were washed with brine (30 mL), dried over Na_2SO_4 and evaporated under reduce pressure. The residue was purified by Prep-HPLC to afford **compound 30**, 2-((2-ethyl-6-(2-(3-((1-(hydroxymethyl)cyclopropyl)amino)azetidin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (62 mg, 30.33% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6) δ 8.72 (s, 2H), 8.64 (s, 1H), 8.10-8.07 (t, 2H), 7.68 (s, 2H), 7.44-7.40 (t, 2H), 4.55-4.52 (t, 1H), 4.24-4.21 (t, 2H), 3.82-3.75 (m, 3H), 3.63


(s, 3H), 3.27-3.25 (d, 2H), 2.93 (bs, 1H), 2.69-2.64 (dd, 2H), 1.28-1.24 (t, 3H), 0.43-0.41 (d, 4H); MS: m/z = 596.3 (M+1, ESI+).

5.3.15. Synthesis of Compound 31



[0273] To a solution of **compound 129 hydrochloride**, 2-((6-(2-(3-aminoazetidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methylamino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (80 mg, 142.33 μ mol) and 1-hydroxycyclopropane-1-carboxylic acid (21.80 mg, 213.50 μ mol) in DCM (5 mL) was added HOBT (29.06 mg, 213.50 μ mol), EDCI (40.93 mg, 213.50 μ mol) and DIEA (73.58 mg, 569.33 μ mol). The resulting mixture was stirred at 25°C for 1 h. The reaction mixture was poured into water (20 mL) and extracted with DCM (10 mLx3). The combined organic layers were dried over Na₂SO₄ and concentrated under reduced pressure and purified by Prep-HPLC to afford **compound 31**, N-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methylamino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidin-3-yl)-1-hydroxycyclopropane-1-carboxamide (15 mg, 17.24% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.75-8.73 (d, 2H), 8.63 (s, 2H), 8.07 (s, 2H), 7.67 (s, 2H), 7.42-7.38 (t, 2H), 6.19 (s, 1H), 4.70 (s, 1H), 4.28-4.24 (m, 2H), 4.07-4.06 (m, 2H), 3.63 (s, 3H), 2.68-2.62 (m, 2H), 1.27-1.23 (t, 3H), 1.00 (s, 2H), 0.82 (s, 2H); MS: m/z = 610.1 (M+1, ESI+).


5.3.16. Synthesis of Compound 32



[0274] To a solution of **compound 132**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methylamino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidine-3-carboxylic acid (200 mg, 360.62 μ mol) and 1-aminocyclopropane-1-carbonitrile hydrochloride (42.60 mg, 361.01 μ mol) in DMF (10 mL) was added HATU (204.08 mg, 540.93 μ mol) and DIEA


(186.43 mg, 1.44 mmol) and stirred at 25 °C for 2 h. The reaction mixture was poured into water (100 mL), extracted with EA (30 mLx3). The combined organic layers were washed with water (100 mLx3) and brine (100 mL), dried over Na₂SO₄ and concentrated under reduce pressure, the residue was purified by Prep-HPLC to afford **compound 32**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)-N-(1-cyanocyclopropyl)azetidine-3-carboxamide (46 mg, 20.62% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.97 (s, 1H), 8.76 (s, 2H), 8.66 (s, 1H), 8.10-8.07 (t, 2H), 7.69 (s, 2H), 7.44-7.40 (t, 2H), 4.20-4.16 (t, 2H), 4.08-4.05 (t, 2H), 3.63 (s, 3H), 3.45-3.40 (m, 1H), 2.70-2.64 (dd, 2H), 1.49-1.45 (dd, 2H), 1.28-1.25 (t, 3H), 1.17-1.14 (dd, 2H); MS: m/z =619.2 (M+1, ESI+).

5.3.17. Synthesis of Compound 33



[0275] To a solution of **compound 132**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidine-3-carboxylic acid (200 mg, 360.62 μmol) and (1-amino cyclopropyl)methanol (31.42 mg, 360.62 μmol) in DMF (10 mL) was added HATU (204.08 mg, 540.93 μmol) and DIEA (186.43 mg, 1.44 mmol) and stirred at 25 °C for 16 h. The reaction mixture was poured into water (100 mL), extracted with EA (30 mLx3). The combined organic layers were washed with water (100 mLx3) and brine (100 mL), dried over Na₂SO₄ and concentrated under reduce pressure, the residue was purified by Prep-HPLC to afford **compound 33**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)-N-(1-(hydroxymethyl)cyclopropyl)azetidine-3-carboxamide (114 mg, 50.68% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.75 (s, 2H), 8.65 (s, 1H), 8.29 (s, 1H), 8.10-8.07 (t, 2H), 7.69 (s, 2H), 7.44-7.40 (t, 2H), 4.72-4.69 (t, 1H), 4.15-4.11 (t, 2H), 4.07-4.03 (t, 2H), 3.63 (s, 3H), 3.41-3.36 (m, 3H), 2.70-2.64 (dd, 2H), 1.28-1.25 (t, 3H), 0.67-0.64 (m, 2H), 0.57-0.54 (m, 2H); MS: m/z =624.2 (M+1, ESI+).

5.3.18. Synthesis of Compound 70 Hydrochloride


*Step one:*

[0276] To a solution of **compound 132**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidine-3-carboxylic acid (340 mg, 613.06 μmol) and tert-butyl 3-aminoazetidine-1-carboxylate (184.17 mg, 1.07 mmol) in DCM (5 mL) was added HATU (346.93 mg, 919.58 μmol) and DIEA (237.70 mg, 1.84 mmol). The resulting mixture was stirred at 25 °C for 2 h. The reaction mixture was poured into water (50 mL), extracted with DCM (10 mLx3). The combined organic layers were washed with water (30 mLx3) and brine (30 mL), dried over Na_2SO_4 and concentrated under reduce pressure, the residue was purified by column chromatography to afford tert-butyl 3-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidine-3-carboxamido)azetidine-1-carboxylate (300 mg, 69.12% yield) as a yellow solid. MS: $m/z = 709.6(\text{M}+1, \text{ESI}^+)$.

Step two:

[0277] To a solution of tert-butyl 3-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidine-3-carboxamido)azetidine-1-carboxylate (300 mg, 423.25 μmol) in DCM (8 mL) was added TFA (2 g, 17.54 mmol). The reaction mixture was stirred at 25 °C for 1 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by Prep-HPLC to afford **compound 70 hydrochloride**, N-(azetidin-3-yl)-1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidine-3-carboxamide hydrochloride (175 mg, 64.10% yield) as a pale yellow solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.51 (s, 1H), 9.38 (s, 1H), 9.22-9.21 (d, 1H), 9.13 (s, 1H), 8.87 (s, 2H), 8.40-8.37 (d, 1H), 8.14-8.12 (d, 1H), 8.01 (s, 2H), 7.42-7.38 (t, 2H), 4.67-4.61 (m, 1H), 4.28-4.24 (t, 2H), 4.16-4.13 (t, 2H), 4.06-3.93 (m, 4H), 3.67 (s, 3H), 3.57-3.50 (m, 1H), 2.91-2.85 (dd, 2H), 1.36-1.33 (t, 3H); MS: $m/z = 609.1 (\text{M}+1, \text{ESI}^+)$.


5.3.19. Synthesis of Compound 70



[0278] To a mixture of **compound 70 hydrochloride**, N-(azetidin-3-yl)-1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidine-3-carboxamide hydrochloride (130 mg, 0.2 mmol) in H₂O (3 mL) was added 2 M NaHCO₃ (1.05 mL, 2.1 mmol) at 0°C and stirred for 0.5 h. Then extracted with DCM (5 mL × 2). The organic layer was washed with water (5 mL) and brine (5 mL), dried over Na₂SO₄ and concentrated to afford **compound 70**, N-(azetidin-3-yl)-1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidine-3-carboxamide (100 mg, 81.9% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.08 (s, 1H), 8.76 (s, 2H), 8.66 (s, 1H), 8.08 (s, 2H), 7.69 (s, 2H), 7.44-7.40 (t, 2H), 7.22 (s, 1H), 4.63-4.58 (m, 1H), 4.23-4.05 (m, 4H), 3.87-3.69 (m, 2H), 3.63 (s, 3H), 3.50-3.48 (m, 2H), 2.70-2.64 (dd, 2H), 1.28-1.24 (t, 3H); MS: m/z = 609.3 (M+1, ESI+).

[0279]

5.3.20. Synthesis of Compound 71 Hydrochloride



Step one:


[0280] To a solution of **compound 132**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidine-3-carboxylic acid (340 mg, 613.06 μmol) and tert-butyl 4-aminopiperidine-1-carboxylate (184.17 mg, 1.07 mmol) in DCM (6 mL) was added HATU (346.93 mg, 919.58 μmol) and DIEA (237.70 mg, 1.84 mmol). The resulting mixture was stirred at 25°C for 2 h. The reaction mixture was poured into water (50 mL), extracted with DCM (10 mL × 3). The combined organic layers were washed with water (30 mL × 3) and brine (30 mL), dried over Na₂SO₄ and concentrated

under reduce pressure, the residue was purified by column chromatography to afford tert-butyl 4-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidine-3-carboxamido)piperidine-1-carboxylate (300 mg, 69.04% yield) as a yellow solid. MS: $m/z = 737.2$ (M+1, ESI+).

Step two:

[0281] To a solution of tert-butyl 4-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidine-3-carboxamido)piperidine-1-carboxylate (300 mg, 407.13 μmol) in DCM (8 mL) was added TFA (2 g, 17.54 mmol). The reaction mixture was stirred at 25 °C for 1 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by Prep-HPLC to afford **compound 71 hydrochloride**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)-N-(piperidin-4-yl)azetidine-3-carboxamide hydrochloride (120 mg, 43.16% yield) as a pale yellow solid. ^1H NMR (400 MHz, DMSO- d_6) δ 9.25 (s, 2H), 9.14 (s, 1H), 8.90 (s, 2H), 8.49-8.48 (d, 1H), 8.41-8.39 (d, 1H), 8.15-8.12 (d, 1H), 8.01 (s, 2H), 7.42-7.38 (t, 2H), 4.28-4.24 (t, 2H), 4.15-4.12 (t, 2H), 3.86 (s, 1H), 3.68 (s, 3H), 3.60-3.53 (m, 1H), 3.25-3.22 (d, 2H), 2.95-2.86 (m, 4H), 1.92-1.89 (d, 2H), 1.73-1.65 (m, 2H), 1.37-1.33 (t, 3H); MS: $m/z = 637.1$ (M+1, ESI+).

5.3.21. Synthesis of Compound 71




[0282] To a mixture of **compound 71 hydrochloride**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)-N-(piperidin-4-yl)azetidine-3-carboxamide hydrochloride (80 mg, 0.12 mmol) in H₂O (3 mL) was added 2 M NaHCO₃ (1.05 mL, 2.1 mmol) at 0°C and stirred for 0.5 h. Then extracted with DCM (5 mL $\times$ 2). The organic layer was washed with water (5 mL) and brine (5 mL), dried over Na₂SO₄ and concentrated to afford **compound 71**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)-N-(piperidin-4-yl)azetidine-3-carboxamide (25 mg, 33% yield) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 8.75 (s, 2H), 8.65 (s, 1H), 8.24-8.22 (d, 1H), 8.10-8.07 (t, 2H), 7.69

(s, 2H), 7.44-7.40 (t, 2H), 4.19-4.15 (t, 2H), 4.07-4.04 (t, 2H), 3.80 (s, 1H), 3.63 (s, 3H), 3.50-3.42 (m, 1H), 3.16-3.13 (d, 2H), 2.84-2.79 (t, 2H), 2.70-2.64 (dd, 2H), 1.84-1.82 (m, 2H), 1.55-1.52 (m, 2H), 1.28-1.24 (t, 3H); MS: m/z = 637.3 (M+1, ESI+).


[0283]

5.3.22. Synthesis of Compound 80 Hydrochloride



[0284] To a solution of **compound 131**, 2-((2-ethyl-6-(2-(3-oxoazetidin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methylamino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (1 g, 1.91 mmol) and 1-methylazetidin-3-amine 2HCl (454.82 mg, 2.86 mmol) in DCE (10 mL) was added DIEA (385.80 mg, 3.81 mmol) and stirred at 25 °C for 0.5 h, then Ti(i-PrO)₄ (1.08 g, 3.81 mmol) was added in portions. The reaction mixture was stirred at 25 °C for 16 h and NaBH₃CN (359.392 mg, 5.72 mmol) was added to the above solution, the reaction mixture was stirred at 40 °C for another 3 h. Filtered and the filtrate was evaporated under reduce pressure, the residue was purified by Prep-HPLC to afford **compound 80 hydrochloride**, 2-(((2-ethyl-6-(2-(3-((1-methylazetidin-3-yl)amino)azetidin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methylamino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (40 mg, 3.53% yield) as an off-white solid. ¹H NMR (400 MHz, MeOD) δ 9.02 (s, 1H), 8.94 (s, 2H), 8.37-8.34 (d, 1H), 8.12-8.09 (d, 1H), 8.02-7.98 (t, 2H), 7.21-7.17 (t, 2H), 4.75-4.36 (m, 10H), 3.75 (s, 3H), 3.13 (s, 2H), 3.08 (s, 1H), 2.99-2.94 (dd, 2H), 1.44-1.40 (t, 3H); MS: m/z = 595.3 (M+1, ESI+).


5.3.23. Synthesis of Compound 80



[0285] To a mixture of **compound 80 hydrochloride**, 2-(((2-ethyl-6-(2-(3-((1-methylazetidin-3-yl)amino)azetidin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-


yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (34 mg, 0.054 mmol) in H₂O (3 mL) was added 2 M NaHCO₃ (1.05 mL, 2.1 mmol) at 0°C and stirred for 0.5 h. Then extracted with DCM (5 mL × 2). The organic layer was washed with water (5 mL) and brine (5 mL), dried over Na₂SO₄ and concentrated to afford **compound 80**, 2-((2-ethyl-6-(2-(3-((1-methylazetidin-3-yl)amino)azetidin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl) (methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (15 mg, 46.87% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.81 (s, 2H), 8.67 (s, 1H), 8.10-8.07 (t, 2H), 7.71 (s, 2H), 7.44-7.40 (t, 2H), 3.77-3.74 (m, 4H), 3.63 (s, 3H), 3.54-3.48 (m, 5H), 3.16 (s, 2H), 2.70-2.64 (m, 2H), 2.20 (s, 3H), 1.28-1.25 (t, 3H); MS: m/z = 596.0 (M+1, ESI+).

5.3.24. Synthesis of Compound 81 Hydrochloride




[0286] To a solution of **compound 3**, 2-((6-(2-(3-aminoazetidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl) (methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (120 mg, 228.31 μmol) and (2S,4R)-4-hydroxy-1-methylpyrrolidine-2-carboxylic acid (33.14 mg, 228.31 μmol) in DCM (3 mL) was added HATU (129.20 mg, 342.46 μmol) and DIEA (88.52 mg, 684.93 μmol). The resulting mixture was stirred at 25°C for 2 h. The reaction mixture was poured into water (20 mL) and extracted with DCM (10 mL × 3). The combined organic layers were dried over Na₂SO₄ and concentrated under reduced pressure and purified by Prep-HPLC to afford **compound 81 hydrochloride**, (2S,4R)-N-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidin-3-yl)-4-hydroxy-1-methyl pyrrolidine-2-carboxamide hydrochloride (55 mg, 35.03% yield) as a pale yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 10.02 (s, 1H), 9.96-9.95 (d, 1H), 9.16 (s, 1H), 8.91 (s, 2H), 8.42-8.40 (d, 1H), 8.15-8.12 (d, 1H), 8.01 (s, 2H), 7.42-7.38 (t, 2H), 4.68-4.66 (m, 1H), 4.42-4.40 (d, 4H), 4.17-4.12 (m, 2H), 3.82-3.79 (m, 1H), 3.68 (s, 3H), 3.08-3.05 (d, 1H), 2.91-2.86 (m, 5H), 2.48-2.43 (m, 1H), 2.10-2.02 (m, 1H), 1.37-1.34 (t, 3H); MS: m/z = 653.1 (M+1, ESI+).

5.3.25. Synthesis of Compound 81



[0287] To a mixture of **compound 81 hydrochloride**, (2S,4R)-N-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidin-3-yl)-4-hydroxy-1-methylpyrrolidine-2-carboxamide hydrochloride (19 mg, 0.027 mmol) in H₂O (3 mL) was added 2 M NaHCO₃ (1.05 mL, 2.1 mmol) at 0°C and stirred for 0.5 h. Then extracted with DCM (5 mL × 2). The organic layer was washed with water (5 mL) and brine (5 mL), dried over Na₂SO₄ and concentrated to afford **compound 81**, (2S,4R)-N-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidin-3-yl)-4-hydroxy-1-methylpyrrolidine-2-carboxamide (5 mg, 27.78% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.73 (s, 2H), 8.65 (s, 1H), 8.43-8.41 (d, 1H), 8.10-8.07 (t, 2H), 7.69 (s, 2H), 7.44-7.40 (t, 2H), 4.85-4.841 (d, 1H), 4.66-4.60 (m, 1H), 4.30-4.25 (m, 2H), 4.20-4.16 (m, 1H), 3.99-3.96 (m, 2H), 3.63 (s, 3H), 3.26-3.22 (m, 1H), 2.96-2.92 (t, 1H), 2.70-2.64 (m, 2H), 2.24 (s, 3H), 2.19-2.15 (m, 1H), 1.87-1.85 (m, 2H), 1.28-1.24 (t, 3H); MS: m/z = 653.0 (M+1, ESI+).


5.3.26. Synthesis of Compound 105



[0288] To a solution of **compound 131**, 2-((2-ethyl-6-(2-(3-oxoazetidin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl) (methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (250 mg, 476.58 μmol) and cyclopropanamine (43.43 mg, 498.52 μmol) in DCM (8 mL) was added NaBH(OAc)₃ (202.01 mg, 953.16 μmol), the reaction mixture was stirred at 25 °C for 16 h. The mixture was poured into water (30 mL), extracted with DCM (10 mL × 3). The organic was washed by brine (30 mL), then dried over Na₂SO₄ and concentrated. The residue


was purified by Prep-HPLC to afford **compound 105**, 2-((6-(2-(3-(cyclopropylamino)azetidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (86 mg, 31.90% yield) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 8.73 (s, 2H), 8.64 (s, 1H), 8.10-8.05 (m, 2H), 7.68 (s, 2H), 7.44-7.40 (t, 2H), 4.22-4.18 (t, 2H), 3.81-3.70 (m, 3H), 3.63 (s, 3H), 2.98 (bs, 1H), 2.69-2.63 (dd, 2H), 2.09-2.05 (m, 1H), 1.28-1.23 (t, 3H), 0.39-0.34 (m, 2H), 0.25-0.20 (m, 2H); MS: m/z = 566.1 (M+1, ESI+); HRMS: 566.2247.

5.3.27. Synthesis of Compound 106



[0289] To a solution of **compound 131**, 2-((2-ethyl-6-(2-(3-oxoazetidin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (250 mg, 476.58 μmol) and cyclobutanamine (50.84 mg, 714.87 μmol) in DCM (8 mL) was added $\text{NaBH}(\text{OAc})_3$ (303.02 mg, 1.43 mmol), the reaction mixture was stirred at 25 °C for 16 h. The mixture was poured into water (30 mL), extracted with DCM (10 mL x 3). The organic was washed by brine (30 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by Prep-HPLC to afford **compound 106**, 2-((6-(2-(3-(cyclobutylamino)azetidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (92 mg, 33.30% yield) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 8.72 (s, 2H), 8.64 (s, 1H), 8.09-8.07 (t, 2H), 7.68 (s, 2H), 7.43-7.39 (t, 2H), 4.18-4.14 (t, 2H), 3.74-3.63 (m, 6H), 3.18-3.14 (m, 1H), 2.70-2.64 (dd, 3H), 2.07-2.03 (m, 2H), 1.71-1.51 (m, 4H), 1.28-1.25 (t, 3H); MS: m/z = 580.2 (M+1, ESI+); HRMS: 580.2404.

5.3.28. Synthesis of Compound 125




[0290] To a solution of **compound 132**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)azetidine-3-carboxylic acid (380 mg, 685.18 μmol) and azetidine hydrochloride (76.92 mg, 822.22 μmol) in DMF (10 mL) was added HATU (387.75 mg, 1.03 mmol) and DIEA (265.66 mg, 2.06 mmol), the reaction mixture was stirred at 25 °C for 2 h. The mixture was poured into water (100 mL) and extracted with EA (30 mL x 2), the organic layer was washed with brine (100 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by Prep-HPLC to afford **compound 125**, 2-((6-(2-(3-(azetidine-1-carbonyl)azetidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (255 mg, 62.69% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6) δ 8.76 (s, 2H), 8.67 (s, 1H), 8.09 (s, 2H), 7.70 (s, 2H), 7.44-7.40 (t, 2H), 4.20-4.16 (m, 2H), 4.11-4.05 (m, 4H), 3.89-3.86 (t, 2H), 3.64 (s, 3H), 3.54-3.40 (m, 1H), 2.70-2.65 (dd, 2H), 2.22-2.18 (m, 2H), 1.29-1.25 (t, 3H); MS: m/z = 594.1 ($M+1$, ESI+); HRMS: 594.2195.


5.4. Example 3 – Synthesis of Azetidine-linked Pyridine Compounds

General Scheme 3

Scheme 3




5.4.1. Synthesis of Compound 133



[0291] To a solution of 2-((6-bromo-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (12 g, 26.30 mmol) and B_2pin_2 (8.68 g, 34.19 mmol) in dioxane (200 mL) was added KOAc (7.74 g, 78.89 mmol) and Pd(dppf)Cl_2 (962.06 mg, 1.31 mmol), the reaction mixture was stirred at 90 °C for 6 h under N_2 . The reaction mixture was


cooled to room temperature and quenched by saturated NH_4Cl (200 mL), extracted with EA (100 mL x 3) and the combined organic layers were washed with water (100 mL x 3) and brine (100 mL), dried over Na_2SO_4 and concentrated. The residue was purified by reversed-phase column chromatography to afford **compound 133**, (3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridine-6-yl)boronic acid (7.5 g, 67.70% yield) as a light-yellow solid. MS: $m/z = 422.1$ ($M+1$, ESI+).

5.4.2. Synthesis of methyl 1-(5-bromopyridin-2-yl)azetidine-3-carboxylate



[0292] To a solution of 5-bromo-2-chloropyridine (1.3 g, 6.76 mmol) and methyl azetidine-3-carboxylate hydrochloride (1.54 g, 10.13 mmol) in DMF (20 mL) was added Cs_2CO_3 (6.60 g, 20.27 mmol), the reaction mixture was stirred at 140°C for 5 h. The mixture was poured into water (200 mL) and extracted with EA (40 mL x 3), the organic layer was washed with brine (200 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by column chromatography to afford methyl 1-(5-bromopyridin-2-yl)azetidine-3-carboxylate (300 mg, 16.38% yield) as yellow oil. MS: $m/z = 271.0$ ($M+1$, ESI+).

5.4.3. Synthesis of Compound 134



Step one:


[0293] To a mixture of methyl 1-(5-bromopyridin-2-yl)azetidine-3-carboxylate (300 mg, 1.11 mmol) and **compound 133**, (3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridine-6-yl) boronic acid (466.14 mg, 1.11 mmol) in dioxane (20 mL) and water (4 mL) was added Na_2CO_3 (351.85 mg, 3.32 mmol) and $\text{Pd}(\text{PPh}_3)_4$ (127.87 mg, 110.66 μmol), the reaction mixture was stirred at 100°C for 2 h under N_2 . The mixture was poured into water (60 mL) and extracted with EA (20 mL x 2). The organic layer was washed by brine (100 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by

column chromatography to afford methyl 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl) azetidine-3-carboxylate (210 mg, 33.43% yield) as a yellow solid. MS: m/z = 568.2 ($M+1$, ESI+).

Step two:


[0294] To a solution of methyl 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)azetidine-3-carboxylate (210 mg, 369.96 μ mol) in MeOH (9 mL) and H₂O (1 mL) was added LiOH (88.60 mg, 3.70 mmol), the reaction mixture was stirred at 25°C for 5 h. The reaction mixture was concentrated under reduced pressure and the residue was poured into 2N HCl (20mL) and extracted with EA (10mLx2), the organic layer was washed by brine (20 mL), then dried over Na₂SO₄ and concentrated to afford **compound 134**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl) azetidine-3-carboxylic acid (195 mg, 95.21% yield) as a white solid. MS: m/z = 554.1 ($M+1$, ESI+).

5.4.4. Synthesis of 1-(5-bromopyridin-2-yl)azetidin-3-ol



[0295] To a mixture of azetidin-3-ol hydrochloride (3.3 g, 45.15 mmol) and 5-bromo-2-chloro-pyridine (8.69 g, 45.15 mmol) in DMF (50 mL) was added K₂CO₃ (18.72 g, 135.44 mmol), the reaction mixture was stirred at 120 °C for 3 h. The mixture was poured into water (500 mL), extracted with EA (100 mL x 3). The organic was washed by brine (300 mL), then dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography to afford 1-(5-bromopyridin-2-yl)azetidin-3-ol (600 mg, 5.80% yield) as a yellow solid. MS: m/z = 229.0 ($M+1$, ESI+).

5.4.5. Synthesis of Compound 148




Step one:

[0296] To a mixture of 1-(5-bromopyridin-2-yl)azetidin-3-ol (600 mg, 2.62 mmol) and **compound 133**, 3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl boronic acid (1.10 g, 2.62 mmol) in dioxane (20 mL) and water (4 mL) was added Na₂CO₃ (832.83 mg, 7.86 mmol) and Pd(PPh₃)₄ (302.67 mg, 261.92 μmol), the reaction mixture was stirred at 100 °C for 2 h under N₂. The mixture was poured into water (60 mL) and extracted with EA (20 mL x 2). The organic layer was washed by brine (100 mL), then dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography to afford 2-((2-ethyl-6-(6-(3-hydroxyazetidin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (660 mg, 47.94% yield) as a yellow solid. MS: m/z = 526.1 (M+1, ESI+).

Step two:


[0297] To a solution of 2-((2-ethyl-6-(6-(3-hydroxyazetidin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (660 mg, 1.26 mmol) in DCM (10 mL) was added Dess-Martin (1.07 g, 2.51 mmol), the reaction mixture was stirred at 25 °C for 3 h. The mixture was evaporate and purified by column chromatography to afford **compound 148**, 2-((2-ethyl-6-(6-(3-oxoazetidin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl) thiazole-5-carbonitrile (450 mg, 68.44% yield) as a yellow solid. MS: m/z = 524.0 (M+1, ESI+).

5.4.6. Synthesis of Compound 97

[0298] To a solution of **compound 134**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)azetidine-3-carboxylic acid (195 mg, 352.23 μmol) and (1-amino cyclopropyl)methanol (36.82 mg, 422.68 μmol) in DMF (5 mL) was added HATU (199.33 mg, 528.35 μmol) and DIEA (136.57 mg, 1.06 mmol), the reaction mixture was stirred at 25 °C for 2 h. The mixture was poured into water (50 mL) and extracted with EA (20 mL x 2). The organic layer was washed with water (50 mL x 2) and brine (50 mL), then dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC to afford **compound 97**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-


2-yl)(methylamino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)-N-(1-(hydroxymethyl)cyclopropyl)azetidine-3-carboxamide (95 mg, 43.31% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.55 (s, 1H), 8.47-8.46 (d, 1H), 8.27 (s, 1H), 8.10-8.07 (t, 2H), 7.94-7.91 (dd, 1H), 7.67 (s, 2H), 7.44-7.39 (t, 2H), 6.47-6.45 (d, 1H), 4.71-4.68 (t, 1H), 4.06-4.02 (t, 2H), 3.96-3.93 (t, 2H), 3.63 (s, 3H), 3.42-3.38 (m, 3H), 2.69-2.63 (dd, 2H), 1.28-1.24 (t, 3H), 0.67-0.53 (m, 4H); MS: m/z = 623.2 (M+1, ESI+); HRMS: 623.2351.

5.4.7. Synthesis of Compound 124




[0299] To a solution of **compound 134**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methylamino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)azetidine-3-carboxylic acid (510 mg, 921.23 μmol) and azetidine hydrochloride (57.86 mg, 1.01 mmol) in DMF (10 mL) was added HATU (525.42 mg, 1.38 mmol) and DIEA (357.18 mg, 2.76 mmol), the reaction mixture was stirred at 25 °C for 2 h. The mixture was poured into water (100 mL) and extracted with EA (30 mL×2). The organic layer was washed with water (100 mL×2) and brine (100 mL), then dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC to afford **compound 124**, 2-((6-(3-(azetidine-1-carbonyl)azetidin-1-yl)pyridin-3-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methylamino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (277 mg, 50.73% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.56 (s, 1H), 8.48-8.47 (d, 1H), 8.11-8.07 (t, 2H), 7.95-7.92 (dd, 1H), 7.67 (s, 2H), 7.44-7.40 (t, 2H), 6.48-6.44 (d, 1H), 4.11-4.07 (t, 4H), 3.99-3.95 (t, 2H), 3.89-3.85 (t, 2H), 3.64 (s, 3H), 3.57-3.52 (m, 1H), 2.69-2.64 (dd, 2H), 2.24-2.16 (m, 2H), 1.29-1.25 (t, 3H); MS: m/z = 593.3 (M+1, ESI+); HRMS: 593.2245.


5.4.8. Synthesis of Compound 109



[0300] To a solution of **compound 148**, 2-((2-ethyl-6-(6-(3-oxoazetidin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (450 mg, 859.46 μmol) and (1-amino cyclopropyl)methanol hydrochloride (159.32 mg, 1.29 mmol) in DCM (20 mL) was added $\text{NaBH}(\text{OAc})_3$ (364.31 mg, 1.72 mmol), the reaction mixture was stirred at 25 °C for 16 h. The mixture was poured into water (50 mL), extracted with DCM (10 mL $\times$ 3). The organic was washed by brine (30 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by Prep-HPLC to afford **compound 109**, 2-((2-ethyl-6-(6-(3-((1-(hydroxymethyl)cyclopropyl)amino)azetidin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (155 mg, 30.33% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6) δ 8.53 (s, 1H), 8.45-8.44 (d, 1H), 8.11-8.07 (t, 2H), 7.91-7.89 (dd, 1H), 7.64 (s, 2H), 7.44-7.40 (t, 2H), 6.43-6.41 (d, 1H), 4.54-4.51 (t, 1H), 4.17-4.13 (t, 2H), 3.83-3.78 (m, 1H), 3.65-3.63 (m, 5H), 3.27-3.26 (d, 2H), 2.86 (bs, 1H), 2.69-2.63 (dd, 2H), 1.28-1.24 (t, 3H), 0.45-0.39 (m, 4H); MS: m/z = 595.2 (M+1, ESI+); HRMS: 595.2396.

5.5. Example 4 – Synthesis of CH_2 -Carbonyl-linked Pyrimidine-type CompoundsGeneral Scheme 4


5.5.1. Synthesis of Compound 135



[0301] To a solution of **compound 133**, 3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methylamino)-2-ethylimidazo[1,2-a]pyridin-6-yl)boronic acid (4 g, 9.50 mmol) and methyl 2-(5-bromopyrimidin-2-yl)acetate (2.19 g, 9.50 mmol) in dioxane (40 mL) and H₂O (8 mL) was added Pd(PPh₃)₄ (109.73 mg, 94.95 μmol) and Na₂CO₃ (2.01 g, 18.99 mmol), the reaction mixture was stirred at 100 °C for 5 h under N₂. The reaction mixture was cooled to room temperature and quenched by saturated NH₄Cl (200 mL), extracted with EA (100 mL x 3) and the combined organic layers were washed with water (100 mL x 3) and brine (100 mL), dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography to afford methyl 2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methylamino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetate (3 g, 59.89% yield) as a white solid. MS: m/z = 528.1 (M+1, ESI+).


[0302] To a solution of methyl 2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methylamino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetate (3 g, 5.69 mmol) in THF (20 mL) and H₂O (20 mL) was added LiOH (900 mg, 37.58 mmol), the resulting mixture was stirred at 40 °C for 1 h. Cooled to room temperature and the reaction mixture was acidified with 2N HCl to pH to 2, extracted with EA (20 mL x 3) and the combined organic layers were washed with water (50 mL x 3) and brine (50 mL), dried over Na₂SO₄ and concentrated to afford **compound 135**, 2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methylamino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetic acid (2.5 g, 77.89% yield) as a white solid. MS: m/z = 514.0 (M+1, ESI+).

5.5.2. Synthesis of Compound 52



[0303] To a solution of **compound 135**, 2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetic acid (100 mg, 194.72 μmol) and azetidin-3-ol hydrochloride (21.35 mg, 292.09 μmol) in DCM (6 mL) was added HATU (111.06 mg, 292.09 μmol) and DIEA (75.50 mg, 584.17 μmol), the reaction mixture was stirred at 25 °C for 16 h. The reaction mixture was poured into water (20 mL) and extracted with DCM (10 mLx3). The combined organic layers were dried over Na_2SO_4 and concentrated under reduced pressure and the residue purified by Prep-HPLC to afford **compound 52**, 2-((2-ethyl-6-(2-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl) pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (89 mg, 80.1% yield) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.15 (s, 2H), 8.89 (s, 1H), 8.10-8.07 (t, 2H), 7.85-7.82 (dd, 1H), 7.78-7.76 (dd, 1H), 7.44-7.40 (t, 2H), 5.73-5.72 (d, 1H), 4.48-4.36 (m, 2H), 4.06-4.02 (dd, 1H), 3.96-3.92 (dd, 1H), 3.79 (s, 2H), 3.64 (s, 3H), 3.61-3.57 (dd, 1H), 2.71-2.66 (dd, 2H), 1.29-1.26 (t, 3H); MS: m/z = 569.1 ($M+1$, ESI+).

5.5.3. Synthesis of Compound 53 Formate



Step one:

[0304] To a solution of **compound 135**, 2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetic acid (800 mg, 1.56 mmol) and azetidin-3-one hydrochloride (132.87 mg, 1.87 mmol) in DMF (20 mL) was added DIEA (603.99 mg, 4.67 mmol) and T_3P (1.49 g, 2.34 mmol, 50% purity), the reaction mixture was stirred at 25 °C for 3 h. The resulting solution was quenched by saturated NH_4Cl (50 mL), extracted with EA (50 mL x 2), washed with water (50 mL x 2) and brine (50 mL), dried over Na_2SO_4 and concentrated. The residue was purified by column chromatography to afford 2-((2-ethyl-6-(2-(2-oxo-2-(3-oxoazetidin-1-yl)ethyl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (400 mg, 45.32% yield) as a yellow solid. MS: m/z = 567.3 ($M+1$, ESI+).

Step two:


[0305] To a solution of 2-((2-ethyl-6-(2-(2-oxo-2-(3-oxoazetidin-1-yl)ethyl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl) (methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (400

mg, 705.96 μmol) and tert-butyl 3-aminoazetidine-1-carboxylate (121.58 mg, 705.96 μmol) in DCM (10 mL) was added $\text{NaBH}(\text{OAc})_3$ (448.86 mg, 2.12 mmol) in portions, the reaction mixture was stirred at 25 °C for 24 h. The resulting solution was quenched by saturated NH_4Cl (50 mL), extracted with DCM (50 mL x 3), washed with water (50 mL x 2) and brine (50 mL), dried over Na_2SO_4 and concentrated. The residue was purified by column chromatography to afford tert-butyl 3-((1-(2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetyl)azetidin-3-yl)amino)azetidine-1-carboxylate (180 mg, 35.27% yield) as a yellow solid. MS: $m/z = 723.6$ ($M+1$, ESI+).

Step three:


[0306] To a suspension of tert-butyl 3-((1-(2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetyl)azetidin-3-yl)amino)azetidine-1-carboxylate (170 mg, 235.19 μmol) in DCM (10 mL) was added TFA (26.82 mg, 235.19 μmol). The reaction mixture was stirred at 25 °C for 3 h. The resulting solution was evaporated and the residue was purified by Prep-HPLC to afford **compound 53 formate**, 2-((6-(2-(2-(3-(azetidin-3-ylamino)azetidin-1-yl)-2-oxoethyl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile formate (59 mg, 40.29% yield) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.15 (s, 2H), 8.91 (s, 1H), 8.73 (s, 1H), 8.62 (s, 1H), 8.10-8.07 (t, 2H), 7.89-7.80 (m, 2H), 7.44-7.40 (t, 2H), 4.35-4.32 (t, 1H), 4.01-3.75 (m, 10H), 3.65-3.55 (m, 6H), 2.73-2.68 (dd, 2H), 1.30-1.26 (t, 3H); MS: $m/z = 623.2$ ($M+1$, ESI+).

5.5.4. Synthesis of Compound 53



[0307] **Compound 53 formate**, 2-((6-(2-(2-(3-(azetidin-3-ylamino)azetidin-1-yl)-2-oxoethyl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile formate (85 mg, 0.127 mmol) was purified by Prep-HPLC to afford **compound 53**, 2-((6-(2-(2-(3-(azetidin-3-ylamino)azetidin-1-yl)-2-oxoethyl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (6 mg, 7.59% yield) as a white solid. ^1H NMR (400 MHz,

5.5.5. Synthesis of benzyl azetidin-3-yl(methyl)carbamate



Step two:


5.5.6. Synthesis of Compound 54



ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetic acid (1 g, 1.95 mmol) in DCM (20 mL) was added HATU (1.11 g, 2.92 mmol) and DIEA (754.99 mg, 5.84 mmol), the reaction mixture was stirred at 25 °C for 16 h. The reaction mixture was poured into water (200 mL) and extracted with DCM (50 mLx3). The combined organic layers were washed with water (100 mLx3) and brine (100 mL), dried over Na₂SO₄ and concentrated under reduce pressure and the residue was purified by column chromatography to afford benzyl (1-(2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetyl)azetidin-3-yl)(methyl)carbamate (1.1 g, 79.13% yield) as a yellow solid. MS: m/z =716.3(M+1, ESI+)

[0311] To a solution of benzyl (1-(2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetyl)azetidin-3-yl)(methyl)carbamate (300.00 mg, 419.11 μmol) in MeOH (10 mL) was added Pd/C (300 mg, 10% purity), the reaction mixture was stirred at 25 °C for 16 h under H_2 . Filtered and the filtrate was evaporated under reduce pressure, the residue was purified by Prep-HPLC to afford **compound 54**, 2-((2-ethyl-6-(2-(2-(3-(methylamino)azetidin-1-yl)-2-oxoethyl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (26 mg, 10.67% yield) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 9.14 (s, 2H), 8.89 (s, 1H), 8.10-8.07 (t, 2H), 7.85-7.82 (dd, 1H), 7.78-7.76 (dd, 1H), 7.44-7.40 (t, 2H), 4.30-4.26 (t, 1H), 3.97-3.92 (m, 1H), 3.88-3.85 (dd, 1H), 3.79-3.77 (d, 2H), 3.64 (s, 3H), 3.55-3.51 (dd, 1H), 3.46-3.32 (m, 1H), 2.71-2.66 (dd, 2H), 2.28 (s, 1H), 2.19 (s, 3H), 1.29-1.26 (t, 3H); MS: m/z = 582.2(M+1, ESI+).


5.5.7. Synthesis of Compound 55



[01312] To a solution of **compound 135**, 2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo [1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetic acid (150 mg, 292.09 μmol) and (S)-pyrrolidin-3-ol (27.99 mg, 321.30 μmol) in DMF (3 mL) was added T₃P (139.40 mg, 438.13 μmol) and DIEA (113.25 mg, 876.26 μmol), the reaction mixture was stirred at 25°C for 16 h. The reaction mixture was poured into water (200 mL) and extracted with DCM (50 mLx3). The combined organic layers were washed with water (100


mLx3) and brine (100 mL), dried over Na₂SO₄ and concentrated under reduce pressure and the residue was purified by Prep-HPLC to afford **compound 55**, (S)-2-((2-ethyl-6-(2-(2-(3-hydroxypyrrolidin-1-yl)-2-oxoethyl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (40 mg, 22.96% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.15 (s, 2H), 8.90 (s, 1H), 8.10-8.07 (t, 2H), 7.85-7.82 (dd, 1H), 7.78-7.76 (d, 1H), 7.44-7.39 (t, 2H), 5.02-4.93 (dd, 1H), 4.32-4.25 (d, 1H), 4.00-3.94 (m, 2H), 3.64-3.59 (m, 4H), 3.43-3.39 (m, 2H), 3.30-3.23 (m, 1H), 2.71-2.66 (dd, 2H), 2.02-1.72 (m, 2H), 1.29-1.26 (t, 3H); MS: m/z = 583.1 (M+1, ESI+).

5.5.8. Synthesis of Compound 56




[0313] To a solution of **compound 135**, 2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo [1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetic acid (150 mg, 292.09 umol) and (R)-pyrrolidin-3-ol (27.99 mg, 321.30 umol) in DMF (3 mL) was added T₃P (139.40 mg, 438.13 umol) and DIEA (113.25 mg, 876.26 umol), the reaction mixture was stirred at 25°C for 16 h. The reaction mixture was poured into water (200 mL) and extracted with DCM (50 mLx3). The combined organic layers were washed with water (100 mLx3) and brine (100 mL), dried over Na₂SO₄ and concentrated under reduce pressure and the residue was purified by Prep-HPLC to afford **compound 56**, (R)-2-((2-ethyl-6-(2-(2-(3-hydroxypyrrolidin-1-yl)-2-oxoethyl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (80 mg, 45.92% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.15 (s, 2H), 8.90 (s, 1H), 8.10-8.07 (t, 2H), 7.85-7.82 (dd, 1H), 7.78-7.76 (d, 1H), 7.44-7.39 (t, 2H), 5.02-4.93 (dd, 1H), 4.32-4.25 (d, 1H), 4.00-3.94 (m, 2H), 3.65-3.59 (m, 4H), 3.41-3.34 (m, 2H), 3.30-3.23 (m, 1H), 2.72-2.66 (dd, 2H), 2.01-1.72 (m, 2H), 1.30-1.26 (t, 3H); MS: m/z = 583.1 (M+1, ESI+).

5.5.9. Synthesis of Compound 57



[0314] To a solution of **compound 135**, 2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetic acid (150 mg, 292.09 μmol) and piperidin-4-ol (32.50 mg, 321.30 μmol) in DMF (3 mL) was added T₃P (139.40 mg, 438.13 μmol) and DIEA (113.25 mg, 876.26 μmol), the reaction mixture was stirred at 25°C for 16 h. The reaction mixture was poured into water (200 mL) and extracted with DCM (50 mLx3). The combined organic layers were washed with water (100 mLx3) and brine (100 mL), dried over Na₂SO₄ and concentrated under reduce pressure and the residue was purified by Prep-HPLC to afford **compound 57**, 2-((2-ethyl-6-(2-(2-(4-hydroxypiperidin-1-yl)-2-oxoethyl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (70 mg, 40.04% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.16 (s, 2H), 8.90 (s, 1H), 8.10-8.07 (t, 2H), 7.85-7.83 (dd, 1H), 7.78-7.76 (d, 1H), 7.44-7.40 (t, 2H), 4.73-4.72 (d, 1H), 4.05 (s, 2H), 3.91-3.88 (m, 1H), 3.77-3.65 (m, 5H), 3.23-3.18 (t, 1H), 3.05-2.99 (t, 1H), 2.71-2.66 (dd, 2H), 1.70 (s, 2H), 1.29-1.26 (t, 3H); MS: m/z = 597.1 (M+1, ESI+).

5.5.10. Synthesis of Compound 58

*Step one:*


[0315] To a solution of **compound 135**, 2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetic acid (250 mg, 486.81 μmol) and tert-butyl piperazine-1-carboxylate (90.67 mg, 486.81 μmol) in DCM (5 mL) was added HATU (185.18 mg, 486.81 μmol) and DIEA (62.92 mg, 486.81 μmol), the reaction mixture was stirred at 25°C for 1 h. The reaction mixture was poured into water (50

mL) and extracted with DCM (10 mLx3). The combined organic layers were washed with water (20 mLx3) and brine (20 mL), dried over Na₂SO₄ and concentrated under reduce pressure and the residue was purified by column chromatography to afford tert-butyl 4-(2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetyl)piperazine-1-carboxylate (300 mg, 90.39% yield) as a yellow solid. MS: m/z = 682.2 (M+1, ESI+).

Step two:

[0316] To a suspension of tert-butyl 4-(2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetyl)piperazine-1-carboxylate (250 mg, 366.69 μ mol) in DCM (10 mL) was added 3M HCl in EA (2 mL). The reaction mixture was stirred at 25 °C for 1 h. The resulting solution was evaporated and the residue was purified by Prep-HPLC to afford **compound 58**, 2-((2-ethyl-6-(2-(2-oxo-2-(piperazin-1-yl)ethyl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (96 mg, 45.01% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.16 (s, 2H), 8.90 (s, 1H), 8.10-8.07 (t, 2H), 7.85-7.83 (dd, 1H), 7.78-7.76 (d, 1H), 7.44-7.40 (t, 2H), 4.04 (s, 2H), 3.65 (s, 3H), 3.43-3.37 (m, 4H), 2.71-2.61 (m, 7H), 1.29-1.26 (t, 3H); MS: m/z = 582.2 (M+1, ESI+).


5.5.11. Synthesis of Compound 59



[0317] To a solution of **compound 135**, 2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetic acid (140 mg, 272.61 μ mol) and morpholine (35.62 mg, 408.92 μ mol) in DCM (5 mL) was added HATU (155.48 mg, 408.92 μ mol) and DIEA (105.70 mg, 817.84 μ mol), the reaction mixture was stirred at 25°C for 16 h. The reaction mixture was poured into water (50 mL) and extracted with DCM (10 mLx3). The combined organic layers were washed with water (20 mLx3) and brine (20 mL), dried over Na₂SO₄ and concentrated under reduce pressure and the residue was purified by Prep-HPLC to afford **compound 59**, 2-((2-ethyl-6-(2-(2-morpholino-2-oxoethyl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (62 mg, 39.11% yield) as a white solid. ¹H NMR (400


MHz, DMSO- d_6) δ 9.16 (s, 2H), 8.90 (s, 1H), 8.09 (s, 2H), 7.85-7.83 (d, 1H), 7.78-7.76 (d, 1H), 7.44-7.40 (t, 2H), 4.08 (s, 2H), 3.65 (s, 3H), 3.57-3.46 (m, 8H), 2.71-2.67 (m, 2H), 1.29-1.26 (t, 3H); MS: m/z = 583.1 (M+1, ESI+).

5.5.12. Synthesis of Compound 60



[0318] To a solution of **compound 135**, 2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetic acid (150 mg, 292.09 μ mol) and NH_4Cl (31.25 mg, 584.17 μ mol) in DCM (5 mL) was added HATU (166.59 mg, 438.13 μ mol) and DIEA (113.25 mg, 876.26 μ mol), the reaction mixture was stirred at 25°C for 1 h. The reaction mixture was poured into water (50 mL) and extracted with DCM (10 mL $\times$ 3). The combined organic layers were washed with water (20 mL $\times$ 3) and brine (20 mL), dried over Na_2SO_4 and concentrated under reduce pressure and the residue was purified by Prep-HPLC to afford **compound 60**, 2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetamide (50 mg, 33.40% yield) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 9.14 (s, 2H), 8.88 (s, 1H), 8.10-8.07 (t, 2H), 7.84-7.76 (dd, 2H), 7.53 (s, 1H), 7.44-7.39 (t, 2H), 7.04 (s, 1H), 3.78 (s, 2H), 3.65 (s, 3H), 2.72-2.66 (dd, 2H), 1.30-1.26 (t, 3H); MS: m/z = 513.1 (M+1, ESI+).


5.5.13. Synthesis of Compound 61



[0319] To a solution of **compound 135**, 2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetic acid (150 mg, 292.09 μ mol) and methanamine hydrochloride (23.5 mg, 350.87 μ mol) in DMF (5 mL) was


added HATU (165.29 mg, 438.13 μ mol) and DIEA (151 mg, 1.17 mmol), the reaction mixture was stirred at 25°C for 16 h. The reaction mixture was poured into water (50 mL) and extracted with DCM (10 mLx3). The combined organic layers were washed with water (20 mLx3) and brine (20 mL), dried over Na₂SO₄ and concentrated under reduce pressure and the residue was purified by Prep-HPLC to afford **compound 61**, 2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)-N-methyl acetamide (35 mg, 22.76% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.13 (s, 2H), 8.87 (s, 1H), 8.08-8.02 (m, 3H), 7.84-7.76 (m, 2H), 7.44-7.39 (t, 2H), 3.78 (s, 2H), 3.64 (s, 3H), 2.71-2.66 (dd, 2H), 2.61-2.59 (d, 3H), 1.29-1.26 (t, 3H); MS: m/z = 527.3 (M+1, ESI+).

5.5.14. Synthesis of Compound 62



[0320] To a solution of **compound 135**, 2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetic acid (150 mg, 292.09 μ mol) and cyclopropanamine (20.01 mg, 350.50 μ mol) in DMF (5 mL) was added HATU (165.29 mg, 438.13 μ mol) and DIEA (151 mg, 1.17 mmol), the reaction mixture was stirred at 25°C for 16 h. The reaction mixture was poured into water (50 mL) and extracted with DCM (10 mLx3). The combined organic layers were washed with water (20 mLx3) and brine (20 mL), dried over Na₂SO₄ and concentrated under reduce pressure and the residue was purified by Prep-HPLC to afford **compound 62**, 2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)-N-cyclopropyl acetamide (30 mg, 18.59% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.13 (s, 2H), 8.88 (s, 1H), 8.21 (s, 1H), 8.10-8.07 (t, 2H), 7.84-7.76 (m, 2H), 7.44-7.39 (t, 2H), 3.73 (s, 2H), 3.64 (s, 3H), 2.71-2.61 (m, 3H), 1.29-1.26 (t, 3H), 0.63-0.59 (m, 2H), 0.43-0.39 (m, 2H); MS: m/z = 553.3 (M+1, ESI+).

5.5.15. Synthesis of Compound 63


*Step one:*

[0321] To a solution of **compound 135**, 2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetic acid (250 mg, 486.81 μ mol) and tert-butyl 3-amino azetidine-1-carboxylate (83.84 mg, 486.81 μ mol) in DCM (5 mL) was added HATU (277.48 mg, 729.78 μ mol) and DIEA (188.75 mg, 1.46 mmol), the reaction mixture was stirred at 25°C for 1 h. The reaction mixture was poured into water (50 mL) and extracted with DCM (10 mLx3). The combined organic layers were washed with water (20 mLx3) and brine (20 mL), dried over Na₂SO₄ and concentrated under reduce pressure and the residue was purified by column chromatography to afford tert-butyl 3-(2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethyl imidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetamido)azetidine-1-carboxylate (270 mg, 80.07% yield) as a yellow solid. MS: m/z = 668.4 (M+1, ESI+).

Step two:


[0322] To a suspension of tert-butyl 3-(2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetamido)azetidine-1-carboxylate (250 mg, 374.39 μ mol) in DCM (10 mL) was added 3M HCl in EA (2 mL). The reaction mixture was stirred at 25 °C for 1 h. The resulting solution was evaporated and the residue was purified by Prep-HPLC to afford **compound 63**, N-(azetidin-3-yl)-2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetamide (47 mg, 22.12% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.13 (s, 2H), 8.88 (s, 1H), 8.67-8.65 (d, 1H), 8.10-8.07 (t, 2H), 7.84-7.76 (m, 2H), 7.44-7.39 (t, 2H), 4.51-4.45 (m, 1H), 3.79 (s, 2H), 3.64 (s, 3H), 3.58-3.54 (t, 2H), 3.45-3.41 (t, 2H), 2.71-2.66 (dd, 2H), 1.29-1.26 (t, 3H); MS: m/z = 568.4 (M+1, ESI+).

5.5.16. Synthesis of Compound 64



[0323] To a solution of **compound 135**, 2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetic acid (150 mg, 292.09 μmol) and 1-aminocyclopropane-1-carbonitrile hydrochloride (69 mg, 584.17 μmol) in DCM (5 mL) was added HATU (166.59 mg, 438.13 μmol) and DIEA (113.25 mg, 876.26 μmol), the reaction mixture was stirred at 25°C for 1 h. The reaction mixture was poured into water (50 mL) and extracted with DCM (10 mLx3). The combined organic layers were washed with water (20 mLx3) and brine (20 mL), dried over Na_2SO_4 and concentrated under reduce pressure and the residue was purified by Prep-HPLC to afford **compound 64**, 2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)-N-(1-cyanocyclopropyl)acetamide (42 mg, 24.89% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6) δ 9.16 (s, 2H), 9.08 (s, 1H), 8.90 (s, 1H), 8.10-8.07 (t, 2H), 7.86-7.76 (m, 2H), 7.44-7.39 (t, 2H), 3.81 (s, 2H), 3.64 (s, 3H), 2.72-2.66 (dd, 2H), 1.50-1.46 (dd, 2H), 1.29-1.26 (t, 3H), 1.16-1.12 (dd, 2H); MS: m/z = 578.1 ($\text{M}+1$, ESI^+).

5.5.17. Synthesis of Compound 65



Step one:

[0324] To a solution of **compound 135**, 2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetic acid (150 mg, 292.09 μmol) and tert-butyl 4-aminopiperidine-1-carboxylate (87.75 mg, 438.13 μmol) in DMF (5 mL) was added HATU (165.29 mg, 438.13 μmol) and DIEA (151.00 mg, 1.17 mmol), the reaction mixture was stirred at 25°C for 16 h. The reaction mixture was poured into water (50 mL) and extracted with DCM (10 mLx3). The combined organic layers were


washed with water (20 mLx3) and brine (20 mL), dried over Na₂SO₄ and concentrated under reduce pressure and the residue was purified by column chromatography to afford tert-butyl 4-(2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetamido)piperidine-1-carboxylate (100 mg, 49.20% yield) as a yellow solid. MS: m/z = 696.3 (M+1, ESI+).

Step two:


[0325] To a suspension of tert-butyl 4-(2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)acetamido)piperidine-1-carboxylate (100 mg, 143.88 μ mol) in DCM (10 mL) was added 3M HCl in EA (2 mL). The reaction mixture was stirred at 25 °C for 3 h. The resulting solution was evaporated and the residue was purified by Prep-HPLC to afford **compound 65**, 2-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)-N-(piperidin-4-yl)acetamide (67 mg, 78.27% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.13 (s, 2H), 8.88 (s, 1H), 8.10-8.07 (m, 3H), 7.84-7.75 (m, 2H), 7.44-7.39 (t, 2H), 3.77 (s, 2H), 3.64 (s, 3H), 3.58 (s, 1H), 3.32-3.20 (m, 3H), 2.90-2.87 (d, 2H), 2.71-2.66 (dd, 2H), 2.46-2.40 (t, 2H), 1.69-1.66 (d, 2H), 1.29-1.25 (t, 3H); MS: m/z = 596.3 (M+1, ESI+).

5.6. Example 5 – Synthesis of Carbonyl-linked Pyrimidine-type Compounds

General Scheme 5




5.6.1. Synthesis of Compound 136




[0326] To a solution of **compound 133**, 3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-ylboronic acid (3.1 g, 7.36 mmol) and methyl 5-bromopyrimidine-2-carboxylate (1.60 g, 7.36 mmol) in dioxane/H₂O (60 mL/10 mL) was added Na₂CO₃ (2.34 g, 22.08 mmol) and Pd(PPh₃)₄ (425.19 mg, 367.95 μmol). The reaction mixture was stirred at 100 °C for 3 h under Ar. The resulting solution was poured into water (200 mL) and extracted with EA (50 mLx3). The aqueous layer was acidified with 2N HCl (100 mL) and extracted with EA (50 mLx3). The organic layers were dried over Na₂SO₄ and concentrated under reduced pressure to afford **compound 136**, 5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidine-2-carboxylic acid (2.3 g, 62.57% yield) as a yellow solid. MS: m/z = 500.0 (M+1, ESI+).

5.6.2. Synthesis of azetidin-3-one Hydrochloride




[0327] To a solution of tert-butyl 3-oxoazetidine-1-carboxylate (10.00 g, 58.41 mmol) in EA (50 mL) was added 3M HCl in EA (3 M, 58.41 mL). The reaction mixture was stirred at 25 °C for 5 h. The resulting solution was evaporated to afford azetidin-3-one hydrochloride (4.57 g, 72.75% yield) as a light-yellow solid.

5.6.3. Synthesis of Compound 137




[0328] To a solution of **compound 136**, 5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl) pyrimidine-2-carboxylic acid (750.00 mg, 1.50 mmol) and azetidin-3-one hydrochloride (177.61 mg, 1.65 mmol) in DMF (15 mL) was added DIEA (582.15 mg, 4.50 mmol) and T₃P (1.43 g, 2.25 mmol, 50% purity). The reaction mixture was stirred at 25 °C for 2 h. The resulting solution was quenched by saturated NH₄Cl (80 mL) and extracted with EA (80 mL x 2), the combined organic layers were washed with water (50 mL x 2) and brine (50 mL), dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography to afford **compound 137**, 2-((2-ethyl-6-(2-(3-oxoazetidine-1-carbonyl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl) (methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (610 mg, 73.52% yield) as a yellow solid. MS: m/z = 553.1 (M+1, ESI+).

5.6.4. Synthesis of Compound 11




[0329] To a solution of **compound 136**, 5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl) pyrimidine-2-carboxylic acid (1 g, 2.00 mmol) and azetidin-3-ol (146.33 mg, 2.00 mmol) in DMF (20 mL) was added DIEA (776.19 mg, 6.01 mmol) and T₃P (1.91 g, 3.00 mmol, 50% purity). The reaction mixture was stirred at 25 °C for 3 h. The resulting solution was quenched by saturated NH₄Cl (50 mL) and extracted with EA (50 mL x 3), the organic layers were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by Prep-HPLC to afford **compound 11**, 2-((2-ethyl-6-(2-(3-hydroxyazetidine-1-carbonyl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (400 mg, 36.03% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.36 (s, 2H), 9.00 (s, 1H), 8.11-8.08 (t, 2H), 7.92-7.90 (dd, 1H), 7.80-7.78 (dd, 1H), 7.44-7.40 (t, 2H), 5.79-5.78 (d, 1H), 4.59-4.50 (m, 2H), 4.32-4.27 (m, 1H), 4.17-4.14 (dd, 1H), 3.84-3.80 (dd, 1H), 3.66 (s, 3H), 2.72-2.67 (dd, 2H), 1.30-1.26 (m, 3H); MS: m/z = 555.1 (M+1, ESI+).

5.6.5. Synthesis of Compound 12



[0330] To a solution of **compound 137**, 2-((2-ethyl-6-(2-(3-oxoazetidine-1-carbonyl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (280 mg, 506.71 μmol) and cyclopropanamine (37.61 mg, 658.73 μmol) in DCM (10 mL) was added $\text{NaBH}(\text{OAc})_3$ (214.79 mg, 1.01 mmol). The reaction mixture was stirred at 25 °C for 24 h. The resulting solution was quenched by saturated NH_4Cl (50 mL) and extracted with EA (50 mL x 2), the combined organic layers were washed with water (50 mL x 2) and brine (50 mL), dried over Na_2SO_4 and concentrated under reduced pressure. The residue was purified by Prep-HPLC to afford **compound 12**, 2-(((6-(2-(3-(cyclopropylamino)azetidine-1-carbonyl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (52.6 mg, 17.49% yield) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.35 (s, 2H), 9.00 (s, 1H), 8.09 (s, 2H), 7.91-7.89 (d, 1H), 7.80-7.77 (d, 1H), 7.43-7.39 (t, 2H), 4.53-4.49 (t, 1H), 4.24-4.14 (m, 2H), 3.81-3.79 (t, 1H), 3.65 (s, 4H), 3.01 (s, 1H), 2.70-2.60 (d, 2H), 2.02 (s, 1H), 1.29-1.26 (t, 3H), 0.35-0.33 (d, 2H), 0.21 (s, 2H); MS: m/z = 594.1 ($M+1$, ESI+).


5.6.6. Synthesis of Compound 13



[0331] To a solution of **compound 137**, 2-((2-ethyl-6-(2-(3-oxoazetidine-1-carbonyl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (290 mg, 538.44 μmol) and cyclobutanamine (49.78 mg, 699.97 μmol) in DCM (10 mL) was added $\text{NaBH}(\text{OAc})_3$ (228.23 mg, 1.08 mmol). The reaction mixture was stirred at 25 °C for 24 h. The resulting solution was quenched by saturated NH_4Cl (50 mL) and extracted with EA (50 mL x 2), the combined organic layers


were washed with water (50 mL x2) and brine (50 mL), dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by Prep-HPLC to afford **compound 13**, 2-((6-(2-(3-(cyclobutylamino)azetidine-1-carbonyl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (50.4 mg, 15.40% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.35 (s, 2H), 9.00 (s, 1H), 8.11-8.08 (t, 2H), 7.92-7.89 (dd, 1H), 7.80-7.78 (d, 1H), 7.44-7.40 (t, 2H), 4.49-4.45 (t, 1H), 4.21-4.17 (t, 1H), 4.09-4.05 (m, 1H), 3.76-3.73 (m, 1H), 3.65 (s, 3H), 3.63-3.57 (m, 1H), 3.15-3.09 (m, 1H), 2.72-2.67 (dd, 3H), 2.05-1.98 (m, 2H), 1.70-1.49 (m, 4H), 1.30-1.26 (t, 3H); MS: m/z = 608.1 (M+1, ESI+).

5.6.7. Synthesis of Compound 14




[0332] To a solution of **compound 137**, 2-((2-ethyl-6-(2-(3-oxoazetidine-1-carbonyl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (500.00 mg, 904.84 μmol) and azetidine hydrochloride (101.58 mg, 1.09 mmol) in DCM (10 mL) was added NaBH(OAc)₃ (287.66 mg, 1.36 mmol). The mixture was stirred at 25 °C for 24 h. The resulting solution was quenched by saturated NH₄Cl (50 mL) and extracted with EA (50 mL x 2), the combined organic layers were washed with water (50 mL x2) and brine (50 mL), dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by Prep-HPLC to afford **compound 14**, 2-((6-(2-([1,3'-biazetidine]-1'-carbonyl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (53 mg, 9.87% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.35 (s, 2H), 8.99 (s, 1H), 8.11-8.07 (t, 2H), 7.92-7.89 (dd, 1H), 7.81-7.78 (d, 1H), 7.44-7.40 (t, 2H), 4.39-4.35 (t, 1H), 4.13-4.04 (m, 2H), 3.80-3.76 (dd, 1H), 3.65 (s, 3H), 3.41-3.35 (m, 1H), 3.16-3.12 (t, 4H), 2.72-2.67 (dd, 2H), 2.00-1.93 (m, 2H), 1.30-1.26 (t, 3H); MS: m/z = 594.1 (M+1, ESI+).

5.6.8. Synthesis of Compound 15



[0333] To a solution of **compound 136**, 5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidine-2-carboxylic acid (260 mg, 520.50 μmol) and piperidin-4-ol (52.65 mg, 520.50 μmol) in DMF (10 mL) was added T_3P (496.84 mg, 780.75 μmol , 50% purity) and DIEA (201.81 mg, 1.56 mmol). The reaction mixture was stirred at 25 °C for 3 h. The resulting solution was quenched by saturated NH_4Cl (50 mL) and extracted with EA (50 mL x 3), the combined organic layers were washed with water (50 mL x 3) and brine (50 mL), dried over Na_2SO_4 and concentrated under reduced pressure. The residue was purified by Prep-HPLC to afford **compound 15**, 2-((2-ethyl-6-(2-(4-hydroxypiperidine-1-carbonyl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (83 mg, 27.37% yield) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.29 (s, 2H), 8.96 (s, 1H), 8.11-8.07 (t, 2H), 7.90-7.87 (dd, 1H), 7.80-7.78 (dd, 1H), 7.44-7.40 (t, 2H), 4.81-4.80 (d, 1H), 4.05-4.00 (m, 1H), 3.77-3.72 (m, 1H), 3.65 (s, 3H), 3.30-3.27 (m, 2H), 3.06-2.99 (m, 1H), 2.72-2.67 (dd, 2H), 1.83-1.81 (m, 1H), 1.69-1.66 (m, 1H), 1.45-1.26 (m, 5H); MS: m/z = 583.1 ($\text{M}+1$, ESI+).


5.6.9. Synthesis of Compound 16



[0334] To a solution of **compound 136**, 5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidine-2-carboxylic acid (130 mg, 260.25 μmol) and 1-aminocyclopropane-1-carbonitrile hydrochloride (46.28 mg, 390.38 μmol) in DMF (5 mL) was added DIEA (134.54 mg, 1.04 mmol) and T_3P (331.23 mg, 520.50 μmol , 50% purity). The reaction mixture was stirred at 25 °C for 3 h. The resulting solution was quenched by saturated NH_4Cl (50 mL) and extracted with EA (50 mL x 3), the combined


organic layers were washed with water (50 mL x3) and brine (50 mL), dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by Prep-HPLC to afford **compound 16**, 5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)-N-(1-cyanocyclopropyl)pyrimidine-2-carboxamide (50.7 mg, 34.57% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.85 (s, 1H), 9.38 (s, 2H), 9.00 (s, 1H), 8.09 (s, 2H), 7.93-7.90 (d, 1H), 7.82-7.80 (d, 1H), 7.44-7.40 (t, 2H), 3.66 (s, 3H), 2.72-2.67 (dd, 2H), 1.58 (s, 2H), 1.34-1.26 (m, 5H); MS: m/z = 564.1 (M+1, ESI+).

5.6.10. Synthesis of Compound 47




[0335] To a solution of **compound 136**, 5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidine-2-carboxylic acid (200 mg, 400.39 μmol) and pyrrolidine (34.17 mg, 480.46 μmol) in DMF (10 mL) was added DIEA (155.24 mg, 1.20 mmol) and T₃P (382.18 mg, 600.58 μmol, 50% purity). The reaction mixture was stirred at 25 °C for 2 h. The resulting solution was quenched by saturated NH₄Cl (50 mL) and extracted with EA (50 mL x 2), the combined organic layer was washed by water (50 mL x 2) and brine (50 mL), dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC (Waters Xbridge C18 10μm OBD 19*250mm, A: 10 mmol NH₄HCO₃ in water; B: CH₃CN, 5% to 95%) in NH₄HCO₃ condition to afford **compound 47**, 2-((2-ethyl-6-(2-(pyrrolidine-1-carbonyl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (70.0 mg, 31.64% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.32 (s, 2H), 8.97 (s, 1H), 8.10-8.07 (t, 2H), 7.91-7.88 (dd, 1H), 7.81-7.78 (dd, 1H), 7.44-7.40 (t, 2H), 3.66 (s, 3H), 3.52-3.49 (t, 2H), 3.34-3.31 (m, 2H), 2.72-2.67 (dd, 2H), 1.90-1.82 (m, 4H), 1.30-1.26 (t, 3H); MS: m/z = 553.3 (M+1, ESI+).

5.6.11. Synthesis of (5-bromopyrimidin-2-yl)(pyrrolidin-1-yl)methanone




[0336] To a solution of 5-bromopyrimidine-2-carboxylic acid (1 g, 4.93 mmol) and pyrrolidine (419 mg, 5.91 mmol) in DMF (15 mL) was added DIEA (1.9 g, 14.79 mmol) and T₃P (592 mg, 7.4 mmol, 50% purity). The reaction mixture was stirred at 25 °C for 2 h. The resulting solution was quenched by saturated NH₄Cl (150 mL) and extracted with EA (50 mL x 2), the combined organic layer was washed by water (50 mL x 2) and brine (50 mL), dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC to afford (5-bromopyrimidin-2-yl)(pyrrolidin-1-yl)methanone (630 mg, 50% yield) as a colorless oil.

5.6.12. Synthesis of Compound 47 Hydrochloride




[0337] A mixture of **compound 133**, (5-bromopyrimidin-2-yl)(pyrrolidin-1-yl)methanone (400 mg, 1.56 mmol), 3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-ylboronic acid (985 mg, 2.34 mmol), Pd(PPh₃)₄ (180 mg, 156 μmol) and Na₂CO₃ (496 mg, 4.68 mmol) was dissolved in dioxane (40 mL) and water (10 mL) and stirred at 80 °C under N₂ for 2 h. The mixture was cooled to room temperature, then diluted with water (100 mL), extracted with EA (50 mL x 2). The organic layer was dried over Na₂SO₄ and evaporated, the residue was purified by Prep-HPLC (Waters Xbridge C18 10μm OBD 19*250mm, A: 0.05% HCl in water; B: CH₃CN, 5% to 95%) in HCl condition to afford **compound 47 hydrochloride**, 2-((2-ethyl-6-(2-(pyrrolidine-1-carbonyl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (250 mg, 29% yield) as a brown solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.38 (s, 2H), 9.31 (s, 1H), 8.46-8.44 (d, 1H), 8.19-8.17 (d, 1H), 8.04-8.01 (t, 2H), 7.42-7.38 (t, 2H), 3.68 (s, 3H), 3.53-3.50 (t, 2H), 3.34-3.31 (t, 2H), 2.90-2.85 (dd, 2H), 1.91-1.83 (m, 4H), 1.37-1.33 (t, 3H); MS: m/z = 553.2 (M+1, ESI+).

5.6.13. Synthesis of Compound 48



[0338] To a solution of **compound 136**, 5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl) pyrimidine-2-carboxylic acid (200 mg, 400.39 μmol) and (S)-pyrrolidin-3-ol (41.86 mg, 480.46 μmol) in DMF (10 mL) was added DIEA (155.24 mg, 1.20 mmol) and T₃P (382.18 mg, 600.58 μmol , 50% purity). The reaction mixture was stirred at 25 °C for 2 h. The resulting solution was quenched by saturated NH₄Cl (50 mL) and extracted with EA (50 mL x 2), the combined organic layer was washed by water (50 mL x 2) and brine (50 mL), dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC to afford **compound 48**, (S)-2-((2-ethyl-6-(2-(3-hydroxypyrrolidine-1-carbonyl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (71 mg, 31.19% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.33 (s, 2H), 8.97 (s, 1H), 8.09 (s, 2H), 7.91-7.89 (d, 1H), 7.81-7.78 (d, 1H), 7.44-7.40 (t, 2H), 5.05-4.99 (dd, 1H), 4.35-4.26 (d, 1H), 3.66 (s, 3H), 3.62-3.38 (m, 4H), 2.72-2.67 (dd, 2H), 2.00-1.76 (m, 2H), 1.30-1.26 (t, 3H); MS: m/z = 569.3 (M+1, ESI+).


5.6.14. Synthesis of Compound 49



[0339] To a solution of **compound 136**, 5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl) pyrimidine-2-carboxylic acid (200 mg, 400.39 μmol) and (R)-pyrrolidin-3-ol (41.86 mg, 480.46 μmol) in DMF (10 mL) was added DIEA (155.24 mg, 1.20 mmol) and T₃P (382.18 mg, 600.58 μmol , 50% purity). The reaction mixture was stirred at 25 °C for 2 h. The resulting solution was quenched by saturated NH₄Cl (50 mL) and extracted with EA (50 mL x 2), the combined organic layer was washed by water (50 mL x 2) and brine (50 mL), dried over Na₂SO₄ and concentrated. The residue was

purified by Prep-HPLC to afford **compound 49**, (R)-2-((2-ethyl-6-(2-(3-hydroxypyrrolidine-1-carbonyl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (62 mg, 27.31% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.33 (s, 2H), 8.98 (s, 1H), 8.11-8.08 (t, 2H), 7.91-7.89 (dd, 1H), 7.81-7.78 (d, 1H), 7.44-7.40 (t, 2H), 5.05-4.99 (dd, 1H), 4.35-4.26 (d, 1H), 3.66 (s, 3H), 3.62-3.38 (m, 4H), 2.73-2.67 (dd, 2H), 1.99-1.77 (m, 2H), 1.30-1.27 (t, 3H); MS: m/z = 569.3 (M+1, ESI+).

5.6.15. Synthesis of Compound 50



Step one:


[0340] To a solution of **compound 136**, 5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidine-2-carboxylic acid (200 mg, 400.39 μmol) and tert-butyl 3-aminoazetidine-1-carboxylate hydrochloride (91.91 mg, 440.43 μmol) in DMF (8 mL) was added DIEA (155.24 mg, 1.20 mmol) and T₃P (382.18 mg, 600.58 μmol, 50% purity). The reaction mixture was stirred at 25 °C for 3 h. The resulting solution was quenched by saturated NH₄Cl (50 mL) and extracted with EA (50 mL x 2), the combined organic layer was washed by water (50 mL x 2) and brine (50 mL), dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography to afford tert-butyl 3-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidine-2-carboxamido)azetidine-1-carboxylate (200 mg, 76.41% yield) as a yellow solid. MS: m/z = 654.2 (M+1, ESI+).

Step two:

[0341] To a solution of tert-butyl 3-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidine-2-carboxamido)azetidine-1-carboxylate (190.00 mg, 290.64 μmol) in DCM (10 mL) was added TFA (165.69 mg, 1.45 mmol). The mixture was stirred at 25 °C for 2 h. The resulting solution was evaporated and purified by Prep-HPLC to afford **compound 50**, N-(azetidin-3-yl)-5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidine-2-carboxamide (85 mg, 52.83% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.35 (s, 2H), 9.26-9.24 (d, 1H), 8.99 (s, 1H), 8.10-8.07 (t, 2H), 7.91-7.89 (d, 1H), 7.82-7.80 (d,

1H), 7.44-7.39 (t, 2H), 4.75-4.69 (m, 1H), 3.66-3.55 (m, 7H), 2.73-2.67 (dd, 2H), 1.30-1.27 (t, 3H); MS: $m/z = 554.1$ (M+1, ESI+).

5.6.16. Synthesis of Compound 51



Step one:


[0342] To a solution of **compound 136**, 5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidine-2-carboxylic acid (200 mg, 400.39 μmol) and tert-butyl 4-amino piperidine-1-carboxylate hydrochloride (113.74 mg, 480.46 μmol) in DMF (8 mL) was added DIEA (155.24 mg, 1.20 mmol) and T₃P (382.18 mg, 600.58 μmol , 50% purity). The reaction mixture was stirred at 25 °C for 3 h. The resulting solution was quenched by saturated NH₄Cl (50 mL) and extracted with EA (50 mL x 2), the combined organic layer was washed by water (50 mL x 2) and brine (50 mL), dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography to afford tert-butyl 4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidine-2-carboxamido)piperidine-1-carboxylate (215 mg, 78.76% yield) as a yellow solid. MS: $m/z = 682.3$ (M+1, ESI+).

Step two:


[0343] To a solution of tert-butyl 4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidine-2-carboxamido)piperidine-1-carboxylate (215 mg, 315.35 μmol) in dioxane (5 mL) was added 3M HCl in dioxane (525.58 μL , 1.57 mmol). The mixture was stirred at 25 °C for 5 h. The resulting solution was evaporated and purified by Prep-HPLC to afford **compound 51**, 5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)-N-(piperidin-4-yl)pyrimidine-2-carboxamide (65 mg, 35.52% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.34 (s, 2H), 8.97 (s, 1H), 8.63-8.61 (d, 1H), 8.10-8.07 (t, 2H), 7.91-7.88 (dd, 1H), 7.82-7.80 (d, 1H), 7.44-7.40 (t, 2H), 3.86-3.84 (m, 1H), 3.66 (s, 3H), 2.96-2.93 (d, 2H), 2.73-2.67 (dd, 2H), 2.55-2.51 (t, 3H), 1.75-1.72 (d, 2H), 1.53-1.44 (m, 2H), 1.30-1.26 (t, 3H); MS: $m/z = 582.3$ (M+1, ESI+).

5.7. Example 6 – Synthesis of Carbonyl-linked Pyridine-type Compounds

General Scheme 6




5.7.1. Synthesis of (5-bromopyridin-2-yl)(pyrrolidin-1-yl)methanone



[0344] To a solution of 5-bromopyridine-2-carboxylic acid (1.5 g, 7.43 mmol) and pyrrolidine (633.74 mg, 8.91 mmol) in DMF (30 mL) was added HATU (4.24 g, 11.14 mmol) and DIEA (2.88 g, 22.28 mmol, 3.88 mL), the reaction mixture was stirred at 25 °C for 2 h. The reaction mixture was quenched by saturated NH_4Cl (300 mL) and extracted with EA (50 mL x 3), the organic layer was washed by water (200 mL) and brine (200 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by column chromatography to afford (5-bromopyridin-2-yl)(pyrrolidin-1-yl)methanone (760 mg 40.12% yield) as a yellow oil. MS: $m/z = 255.0$ ($M+1$, ESI+).

5.7.2. Synthesis of Compound 87




[0345] To a mixture of **compound 133**, (5-bromopyridin-2-yl)(pyrrolidin-1-yl)methanone (200 mg, 783.97 μmol) and 3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-ylboronic acid (297.23 mg, 705.58 μmol) in dioxane (10 mL) and water (2 mL) was added Na_2CO_3 (249.28 mg, 2.35 mmol) and $\text{Pd}(\text{PPh}_3)_4$ (45.30 mg, 39.20 μmol), the reaction mixture was stirred at 100 °C for 2 h. The reaction mixture was poured into water (100 mL) and extracted with EA (40 mL x 3), the organic layer was


washed by water (100 mLx2) and brine (100 mL), then dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC to afford **compound 87**, 2-((2-ethyl-6-(pyrrolidine-1-carbonyl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methylamino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (110 mg, 25.44% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.04-9.03 (d, 1H), 8.88 (s, 1H), 8.34-8.32 (dd, 1H), 8.11-8.08 (t, 2H), 7.86-7.75 (m, 3H), 7.44-7.40 (t, 2H), 3.65-3.64 (m, 5H), 3.53-3.50 (t, 2H), 2.72-2.66 (dd, 2H), 1.85-1.83 (m, 4H), 1.30-1.26 (t, 3H); MS: m/z = 552.1 (M+1, ESI+); HRMS: 552.1976.

5.8. Example 7 – Synthesis of Piperazine-linked Pyrimidine-type Compounds

General Scheme 7



5.8.1. Synthesis of tert-butyl 4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl) piperazine-1-carboxylate



Step one:


[0346] To a solution of 5-bromo-2-chloropyrimidine (20 g, 103.40 mmol) and tert-butyl piperazine-1-carboxylate (28.89 g, 155.10 mmol) in dioxane (200 mL) was added K₂CO₃

(28.58 g, 206.79 mmol). The mixture was stirred at 110 °C for 4 h. The mixture was poured into water (600 mL) and extracted with EA (600 mL×2). The organic layer was washed with water (300 mL×2) and brine (300 mL×1), then dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography to afford tert-butyl 4-(5-bromopyrimidin-2-yl)piperazine-1-carboxylate (27 g, 76.08% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.47 (s, 2H), 3.70-3.67 (m, 4H), 3.40-3.38 (m, 4H), 1.42 (s, 9H); MS: m/z = 343.1 (M+1, ESI+).

Step two

[0347] To a solution of tert-butyl 4-(5-bromopyrimidin-2-yl)piperazine-1-carboxylate (10 g, 29.14 mmol) and B₂pin₂ (8.14 g, 32.05 mmol) in dioxane (300 mL) was added Pd(dppf)Cl₂ (2.13 g, 2.91 mmol) and KOAc (11.44 g, 116.54 mmol). The mixture was stirred at 90 °C under N₂ for 16 h. The mixture was poured into water (600 mL) and extracted with EA (200 mL×2). The organic layer was washed with water (600 mL×2) and brine (600 mL×1), then dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography to afford tert-butyl 4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)piperazine-1-carboxylate (3.7 g, 32.54% yield) as a yellow solid. MS: m/z = 391.1 (M+1, ESI+).

5.8.2. Synthesis of Compound 4 Hydrochloride



Step one:


[0348] To a mixture of 2-((6-bromo-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (800 mg, 1.75 mmol) and tert-butyl 4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)piperazine-1-carboxylate (821.05 mg, 2.10 mmol) in DME/H₂O (16mL/4mL) was added Na₂CO₃ (371.62 mg, 3.51 mmol) and Pd(PPh₃)₄ (101.29 mg, 87.66 μmol). The reaction mixture was stirred at 90 °C under N₂ for 1.5 h. The mixture was poured into water (40 mL) and extracted with EA (40 mL×2). The organic layer was washed with water (40 mL×2) and brine (40 mL), then dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography to afford tert-butyl 4-

(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazine-1-carboxylate (1 g, 89.16% yield) as a yellow solid. MS: m/z = 640.2 ($M+1$, ESI+).

Step two:


[0349] To a mixture of tert-butyl 4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazine-1-carboxylate (1.2 g, 1.88 mmol) in EA (10 mL) was added 3M HCl in EA (3 M, 20 mL) and stirred at 25 °C for 3 h. The mixture was filtered and the solid cake was washed with EA, then dried under reduce pressure to afford **compound 4 hydrochloride**, 2-((2-ethyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (1 g, 98.79% yield) as a yellow solid. MS: m/z = 540.3 ($M+1$, ESI+).

5.8.3. Synthesis of Compound 4



[0350] To a solution of **compound 128**, 2-((6-(2-chloropyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (300 mg, 612.3 umol) and piperazine (791.13 mg, 918.5 umol) in MeCN (20 mL) was added K_2CO_3 (254 mg, 183.7 umol), the reaction mixture was stirred at 80 °C for 2 h. Filtered and concentrated, the residue was purified by Prep-HPLC to afford **compound 4**, 2-((2-ethyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (120 mg, 36.32% yield) as a white solid. 1H NMR (400 MHz, DMSO- d_6) δ 8.75 (s, 2H), 8.65 (s, 1H), 8.11-8.08 (t, 2H), 7.69 (s, 2H), 7.44-7.39 (t, 2H), 3.71-3.68 (t, 4H), 3.64 (s, 3H), 2.74-2.70 (m, 4H), 2.68-2.64 (q, 2H), 1.29-1.25 (t, 3H); MS: m/z = 540.2 ($M+1$, ESI+).

5.8.4. Synthesis of Compound 5


*Step one:*

[0351] To a mixture of **compound 4 hydrochloride**, 2-((2-ethyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (100 mg, 185.31 μmol), (2S,4R)-1-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (51.42 mg, 222.38 μmol), HOBT (37.56 mg, 277.97 μmol) and EDCI (53.29 mg, 277.97 μmol) in DMF (8 mL) was added DIEA (95.80 mg, 741.25 μmol), the reaction mixture was stirred at 25 °C for 6 h. The mixture was poured into water (40 mL) and extracted with EA (40 mL $\times$ 2). The organic layer was washed with water (40 mL $\times$ 2) and brine (40 mL), then dried over Na_2SO_4 and concentrated to afford tert-butyl (2S,4R)-2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazine-1-carbonyl)-4-hydroxypyrrolidine-1-carboxylate (105 mg, 75.26% yield) which was used for next step without further purification. MS: m/z = 753.4 (M+1, ESI+).

Step two:

[0352] To a mixture of tert-butyl (2S,4R)-2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazine-1-carbonyl)-4-hydroxypyrrolidine-1-carboxylate (130 mg, 172.68 μmol) in EA (5 mL) was added 3M HCl in EA (3 M, 5 mL) and stirred at 25 °C for 1 h. The reaction mixture was concentrated and purified by Prep-HPLC (Waters Xbridge C18 10 μm OBD 19 $\times$ 250mm, A: 10 mmol NH_4HCO_3 in water; B: CH_3CN , 5% to 95%) in NH_4HCO_3 condition to afford **compound 5**, 2-((2-ethyl-6-(2-(4-((2S,4R)-4-hydroxypyrrolidine-2-carbonyl)piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (51 mg, 45.53% yield) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.81 (s, 2H), 8.67 (s, 1H), 8.09 (s, 2H), 7.71 (s, 2H), 7.44-7.40 (t, 2H), 4.70-4.69 (d, 1H), 4.17 (s, 1H), 4.05-4.01 (t, 1H), 3.81-3.45 (m, 13H), 3.07-3.02 (dd, 1H), 2.70-2.64 (q, 2H), 1.86-1.75 (m, 2H), 1.28-1.25 (t, 3H); MS: m/z = 653.2 (M+1, ESI+).

5.8.5. Synthesis of Compound 5 Hydrochloride


*Step one:*

[0353] To a mixture of **compound 4 hydrochloride**, 2-((2-ethyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl) amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (700 mg, 1.30 mmol), (2S,4R)-1-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (360 mg, 1.56 mmol), HOBt (263 mg, 1.95 mmol) and EDCI (373 mg, 1.95 mmol) in DMF (15 mL) was added DIEA (670 mg, 5.19 mmol), the reaction mixture was stirred at 25 °C for 6 h. The mixture was poured into water (150 mL) and extracted with EA (40 mL×2). The organic layer was washed with water (40 mL×2) and brine (40 mL), then dried over Na₂SO₄ and concentrated to afford tert-butyl (2S,4R)-2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazine-1-carbonyl)-4-hydroxypyrrolidine-1-carboxylate (850 mg, 87% yield) which was used for next step without further purification. MS: m/z = 753.4 (M+1, ESI+).

Step two:

[0354] To a mixture of tert-butyl (2S,4R)-2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl) amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazine-1-carbonyl)-4-hydroxy pyrrolidine-1-carboxylate (850 mg, 1.13 mmol) in EA (10 mL) was added 3M HCl in EA (3 M, 5 mL) and stirred at 25 °C for 1 h. The reaction mixture was concentrated and purified by Prep-HPLC (Waters Xbridge C18 10um OBD 19*250mm, A: 0.05% HCl in water; B: CH₃CN, 5% to 95%) in HCl condition to afford **compound 5 hydrochloride**, 2-((2-ethyl-6-(2-(4-((2S,4R)-4-hydroxypyrrolidine-2-carbonyl)piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (485 mg, 62.3% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 10.53 (s, 1H), 9.15 (s, 1H), 8.93 (s, 2H), 8.69 (s, 1H), 8.44-8.42 (d, 1H), 8.15-8.13 (d, 1H), 8.01 (s, 2H), 7.42-7.38 (t, 2H), 4.77 (s, 1H), 4.44 (s, 1H), 3.90-3.83 (m, 4H), 3.69-3.61 (m, 7H), 3.37-3.34 (m, 1H), 3.13 (s, 1H), 2.92-2.87 (dd, 2H), 2.46-2.41 (m, 1H), 2.01-1.94 (m, 1H), 1.38-1.34 (t, 3H); MS: m/z = 653.3 (M+1, ESI+).

5.8.6. Synthesis of Compound 6



Step one:


[0355] To a solution of (2R,4R)-1-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (72.25 mg, 312.45 μ mol) in DMF (10 mL) was added DIEA (107.68 mg, 833.20 μ mol), HOBT (42.22 mg, 312.45 μ mol) and EDCI (59.83 mg, 312.45 μ mol). The reaction mixture was stirred at 25 °C for 1 h. Then **compound 4 hydrochloride**, 2-((2-ethyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (120 mg, 208.30 μ mol) was added to the reaction mixture. The resulting mixture was stirred at 25 °C for 16 h. The reaction mixture was poured into water (50 mL) and extracted with EA (30 mL $\times$ 3). The combined organic layers were dried over Na₂SO₄ and concentrated under reduced pressure and purified by silica gel column (PE:EA=1:1) to afford tert-butyl (2R,4R)-2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazine-1-carbonyl)-4-hydroxy pyrrolidine-1-carboxylate (150 mg, crude) as a brown oil. MS: m/z = 753.2 (M+1, ESI+).

Step two:

[0356] To a solution of tert-butyl (2R,4R)-2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazine-1-carbonyl)-4-hydroxy pyrrolidine-1-carboxylate (150 mg, 199.24 μ mol) in DCM (5 mL) was added 3M HCl in EA (3 M, 5 mL). The reaction mixture was stirred at 25 °C for 1 h. The excess of solvent was removed under reduced pressure. The residue was purified by Prep-HPLC (Waters Xbridge C18 10 μ m OBD 19 $\times$ 250mm, A: 10 mmol NH₄HCO₃ in water; B: CH₃CN, 5% to 95%) in NH₄HCO₃ condition to afford **compound 6**, 2-((2-ethyl-6-(2-(4-((2R,4R)-4-hydroxypyrrolidine-2-carbonyl)piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (15 mg, 11.53% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.80 (s, 2H), 8.65 (s, 1H), 8.08 (s, 2H), 7.70 (s, 2H),

7.43-7.39 (t, 2H), 4.55 (s, 1H), 4.41 (s, 1H), 3.81-3.49 (m, 13H), 2.83-2.80 (d, 1H), 2.68-2.56 (m, 3H), 2.24 (s, 1H), 1.47 (s, 1H), 1.28-1.24 (t, 3H); MS: m/z = 653.2 ($M+1$, ESI+).

5.8.7. Synthesis of Compound 6 Hydrochloride



Step one:


[0357] To a solution of (2R,4R)-1-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (360 mg, 1.56 mmol) in DMF (15 mL) was added DIEA (670 mg, 5.19 mmol), HOBT (263 mg, 1.95 mmol) and EDCI (373 mg, 1.95 mmol). The reaction mixture was stirred at 25 °C for 1 h. Then **compound 4 hydrochloride**, 2-((2-ethyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (700 mg, 1.30 mmol) was added to the reaction mixture. The resulting mixture was stirred at 25 °C for 16 h. The reaction mixture was poured into water (150 mL) and extracted with EA (40 mLx3). The combined organic layers were dried over Na_2SO_4 and concentrated under reduced pressure and purified by silica gel column (PE:EA=1:1) to afford tert-butyl (2R,4R)-2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazine-1-carbonyl)-4-hydroxy pyrrolidine-1-carboxylate (400 mg, 39.1% yield) which was used for next step without further purification. MS: m/z = 753.2 ($M+1$, ESI+).

Step two:

[0358] To a solution of tert-butyl (2R,4R)-2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazine-1-carbonyl)-4-hydroxy pyrrolidine-1-carboxylate (400 mg, 0.53 mmol) in DCM (5 mL) was added 3M HCl in EA (3 M, 5 mL). The reaction mixture was stirred at 25 °C for 1 h. The excess of solvent was removed under reduced pressure. The residue was purified by Prep-HPLC (Waters Xbridge C18 10um OBD 19*250mm, A: 0.05% HCl in water; B: CH_3CN , 5% to 95%) in HCl condition to afford **compound 6 hydrochloride**, 2-((2-ethyl-6-(2-(4-((2R,4R)-4-hydroxypyrrolidine-2-carbonyl)piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (212 mg, 57.9%

yield) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 10.29 (s, 1H), 9.54 (s, 1H), 9.09 (s, 1H), 8.90 (s, 2H), 8.53 (s, 1H), 8.37-8.35 (d, 1H), 8.12-8.10 (d, 1H), 8.03-8.00 (t, 2H), 7.42-7.38 (t, 2H), 4.64-4.60 (m, 1H), 4.39 (s, 1H), 4.05-4.03 (t, 1H), 3.95-3.92 (m, 2H), 3.81-3.80 (m, 2H), 3.70-3.53 (m, 6H), 3.19-3.16 (m, 3H), 2.90-2.84 (dd, 2H), 2.66-2.60 (m, 1H), 1.83-1.79 (m, 1H), 1.35-1.31 (t, 3H); MS: m/z = 653.3 (M+1, ESI+).

5.8.8. Synthesis of Compound 7



Step one:


[0359] To a mixture of **compound 4 hydrochloride**, 2-((2-ethyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (150 mg, 260.38 μmol) and (2S,4S)-1-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (60.22 mg, 260.42 μmol) in DCM (6 mL) was added DIEA (134.61 mg, 1.04 mmol) and HATU (148.50 mg, 390.56 μmol). The resulting mixture was stirred for 1 h at 25°C. The reaction mixture was poured into water (50 mL) and extracted with DCM (10 mLx3). The combined organic layers were dried over Na_2SO_4 and concentrated under reduced pressure to afford tert-butyl (2S,4S)-2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazine-1-carbonyl)-4-hydroxypyrrolidine-1-carboxylate (150 mg, crude) as a yellow oil. MS: m/z = 753.2 (M+1, ESI+).

Step two:

[0360] To a solution of tert-butyl (2S,4S)-2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazine-1-carbonyl)-4-hydroxypyrrolidine-1-carboxylate (150 mg, 199.24 μmol) in EA (5 mL) was added 3M HCl in EA (3 M, 5 mL). The reaction mixture was stirred at 25 °C for 1 h. The excess of solvent was removed under reduced pressure. The residue was purified by Prep-HPLC to afford **compound 7**, 2-((2-ethyl-6-(2-(4-((2S,4S)-4-hydroxypyrrolidine-2-carbonyl)piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (24 mg, 18.46% yield) as a white solid. ^1H NMR (400

MHz, DMSO- d_6) δ 8.81 (s, 2H), 8.66 (s, 1H), 8.09 (s, 2H), 7.70 (s, 2H), 7.43-7.39 (t, 2H), 4.51 (s, 1H), 4.14 (s, 1H), 3.82-3.50 (m, 13H), 2.83-2.80 (d, 1H), 2.70-2.56 (m, 3H), 2.24 (s, 1H), 1.47 (s, 1H), 1.28-1.25 (t, 3H); MS: m/z = 653.2 (M+1, ESI+).

5.8.9. Synthesis of Compound 8



Step one:


[0361] To a solution of **compound 4 hydrochloride**, 2-((2-ethyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (0.12 g, 208.30 μ mol) and DIEA (107.69 mg, 833.20 μ mol) in DCM (5 mL) was added (2R,4S)-1-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (57.80 mg, 249.96 μ mol), EDCI (59.90 mg, 312.45 μ mol) and HOBT (42.22 mg, 312.45 μ mol). The resulting mixture was stirred at room temperature for 2 h. The reaction mixture was poured into water (50 mL) and extracted with DCM (10 mL $\times$ 3). The combined organic layers were dried over Na_2SO_4 and concentrated under reduced pressure to afford tert-butyl (2R,4S)-2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazine-1-carbonyl)-4-hydroxypyrrolidine-1-carboxylate (156 mg, 99.48% yield) as a yellow oil. MS: m/z = 753.2 (M+1, ESI+).

Step two:

[0362] To a solution of tert-butyl (2R,4S)-2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazine-1-carbonyl)-4-hydroxypyrrolidine-1-carboxylate (120 mg, 159.39 μ mol) in DCM (5 mL) was added 3M HCl in EA (3 M, 5 mL). The reaction mixture was stirred at 25 $^\circ\text{C}$ for 1 h. The excess of solvent was removed under reduced pressure. The residue was purified by Prep-HPLC to afford **compound 8**, 2-((2-ethyl-6-(2-(4-((2R,4S)-4-hydroxypyrrolidine-2-carbonyl)piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (31 mg, 29.80% yield) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 8.81 (s, 2H), 8.67 (s, 1H), 8.11-8.07 (m, 2H), 7.71 (s, 2H), 7.44-7.40 (t, 2H), 4.71-4.70 (d, 1H), 4.18 (s, 1H), 4.06-4.02 (t, 1H), 3.82-3.68 (m, 4H), 3.63-3.49 (m, 8H),

3.07-3.03 (dd, 1H), 2.70-2.64 (q, 2H), 2.56-2.52 (dd, 1H), 1.88-1.75 (m, 2H), 1.28-1.25 (t, 3H); MS: $m/z = 653.2$ (M+1, ESI+).

5.8.10. Synthesis of Compound 9




Step one:

[0363] To a solution of **compound 4 hydrochloride**, 2-((2-ethyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (100 mg, 185.31 μmol), 1-(tert-butoxycarbonyl)azetidine-3-carboxylic acid (44.75 mg, 222.38 μmol) in DMF (8 mL) was added HOBT (37.56 mg, 277.97 μmol), EDCI (53.29 mg, 277.97 μmol) and DIEA (95.80 mg, 741.2 μmol). The reaction mixture was stirred at 25 °C for 6 h. The reaction mixture was poured into water (40 mL) and extracted with EA (20 mL $\times 2$). The organic layers were washed with water (40 mL $\times 2$) and brine (40 mL), then dried over Na_2SO_4 and concentrated to afford tert-butyl 3-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazine-1-carbonyl)azetidine-1-carboxylate (100 mg, 74.65% yield) which was used to next step without further purification. MS: $m/z = 723.3$ (M+1, ESI+).

Step two


[0364] To a solution of tert-butyl 3-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazine-1-carbonyl)azetidine-1-carboxylate (110.00 mg, 152.18 μmol) in EA (5 mL) was added 3M HCl in EA (3 M, 5 mL). The reaction mixture was stirred at 25 °C for 1 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by Prep-HPLC to afford **compound 9**, 2-((6-(2-(4-(azetidine-3-carbonyl)piperazin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (20 mg, 21.10% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6) δ 8.80 (s, 2H), 8.66 (s, 1H), 8.09 (s, 2H), 7.70 (s, 2H), 7.44-7.39 (t, 2H), 3.76-3.63 (m, 11H), 3.52-3.49 (m, 5H), 2.70-2.63 (m, 3H), 1.28-1.25 (t, 3H); MS: $m/z = 623.2$ (M+1, ESI+).

5.8.11. Synthesis of Compound 10



[0365] To a solution of **compound 4 hydrochloride**, 2-((2-ethyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (100 mg, 173.58 μmol) and 1-(hydroxymethyl)cyclopropane-1-carboxylic acid (24.19 mg, 208.30 μmol) in DCM (5 mL) was added DIEA (89.74 mg, 694.34 μmol), EDCI (49.91 mg, 260.38 μmol) and HOBT (35.44 mg, 260.38 μmol). The reaction mixture was stirred at 25 °C for 1 h. The reaction mixture was poured into water (40 mL) and extracted with DCM (10 mL $\times$ 2). The organic layers were washed with water (20 mL $\times$ 2) and brine (40 mL), then dried over Na_2SO_4 and concentrated under reduce pressure. The residue was purified by Prep-HPLC to afford **compound 10**, 2-((2-ethyl-6-(2-(4-(1-(hydroxymethyl) cyclopropane-1-carbonyl)piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (31 mg, 28.18% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6) δ 8.81 (s, 2H), 8.66 (s, 1H), 8.08 (s, 2H), 7.70 (s, 2H), 7.42 (s, 2H), 4.86 (s, 1H), 3.78 (s, 4H), 3.63 (s, 7H), 3.47 (s, 2H), 2.66 (s, 2H), 1.28-1.24 (t, 3H), 0.75-0.70 (d, 4H); MS: m/z = 638.1 ($\text{M}+1$, ESI+).


5.8.12. Synthesis of Compound 42



[0366] To a mixture of **compound 4**, 2-((2-ethyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (200 mg, 370.63 μmol) in DCM (10 mL) was added triphosgene (54.99 mg, 185.31 μmol) and stirred at 0 °C for 0.5 h, then TEA (112.51 mg, 1.11 mmol) was added and stirred at 0 °C for another 0.5 h. After that, pyrrolidine (52.72 mg, 741.25 μmol) was added to the above reaction mixture and stirred at 25 °C for 0.5 h. Added water (50 mL) to the reaction mixture,


then extracted with DCM (50 mL $\times$ 2). The organic layer was washed with water (50 mL) and brine (50 mL), dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC to afford **compound 42**, 2-((2-ethyl-6-(2-(4-(pyrrolidine-1-carbonyl)piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (35 mg, 14.89% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.80 (s, 2H), 8.67 (s, 1H), 8.10-8.07 (t, 2H), 7.71 (s, 2H), 7.44-7.40 (t, 2H), 3.80-3.77 (t, 4H), 3.63 (s, 3H), 3.31-3.28 (m, 4H), 3.25-3.23 (m, 4H), 2.70-2.64 (dd, 2H), 1.77-1.74 (t, 4H), 1.28-1.25 (t, 3H); MS: m/z = 637.4(M+1, ESI+).

5.8.13. Synthesis of Compound 43




[0367] To a mixture of **compound 4**, 2-((2-ethyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (200 mg, 370.63 μ mol) in DCM (10 mL) was added triphosgene (54.99 mg, 185.31 μ mol) and stirred at 0 °C for 0.5 h, then TEA (112.51 mg, 1.11 mmol) was added and stirred at 0 °C for another 0.5 h. After that, (R)-pyrrolidin-3-ol (64.58 mg, 741.25 μ mol) was added to the above reaction mixture and stirred at 25 °C for 0.5 h. Added water (50 mL) to the reaction mixture, then extracted with DCM (50 mL $\times$ 2). The organic layer was washed with water (50 mL) and brine (50 mL), dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC (Waters Xbridge C18 10 μ m OBD 19 $\times$ 250mm, A: 10 mmol NH₄HCO₃ in water; B: CH₃CN, 5% to 95%) in NH₄HCO₃ condition to afford **compound 43**, (R)-2-((2-ethyl-6-(2-(4-(3-hydroxypyrrolidine-1-carbonyl) piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (100 mg, 41.34% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.80 (s, 2H), 8.67 (s, 1H), 8.09-8.07 (t, 2H), 7.71 (s, 2H), 7.44-7.40 (t, 2H), 4.92 (s, 1H), 4.22 (s, 1H), 3.83-3.74 (m, 4H), 3.63 (s, 3H), 3.52-3.45 (m, 2H), 3.28-3.18 (m, 5H), 3.13-3.10 (d, 1H), 2.70-2.64 (dd, 2H), 1.82-1.71 (m, 2H), 1.29-1.25 (t, 3H); MS: m/z = 653.6 (M+1, ESI+); HRMS: 653.2564.

5.8.14. Synthesis of Compound 43 Hydrochloride




[0368] To a mixture of **compound 4**, 2-((2-ethyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (600 mg, 1.11 mmol) in DCM (15 mL) was added triphosgene (165 mg, 556 μ mol) and stirred at 0 °C for 0.5 h, then TEA (338 mg, 3.33 mmol) was added and stirred at 0 °C for another 0.5 h. After that, (R)-pyrrolidin-3-ol (194 mg, 2.22 mmol) was added to the above reaction mixture and stirred at 25 °C for 0.5 h. Added water (50 mL) to the reaction mixture, then extracted with DCM (50 mL $\times$ 2). The organic layer was washed with water (50 mL) and brine (50 mL), dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC (Waters Xbridge C18 10 μ m OBD 19 $\times$ 250mm, A: 0.05% HCl in water; B: CH₃CN, 5% to 95%) in HCl condition to afford **compound 43 hydrochloride**, (R)-2-((2-ethyl-6-(2-(4-(3-hydroxypyrrolidine-1-carbonyl)piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (290 mg, 34.27% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.10 (s, 1H), 8.87 (s, 2H), 8.39-8.36 (dd, 2H), 8.13-8.11 (d, 1H), 8.03-7.99 (t, 2H), 7.42-7.38 (t, 2H), 4.22 (s, 1H), 3.87-3.76 (m, 4H), 3.66 (s, 3H), 3.52-3.45 (m, 2H), 3.31-3.18 (m, 5H), 3.13-3.10 (d, 1H), 2.90-2.85 (dd, *J*₁=7.6 Hz, 2H), 1.84-1.71 (m, 2H), 1.35-1.31 (t, 3H); MS: *m/z* = 653.3 (*M*+1, ESI⁺).

5.8.15. Synthesis of Compound 44



[0369] To a mixture of **compound 4**, 2-((2-ethyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (200 mg, 370.63 μmol) in DCM (10 mL) was added triphosgene (54.99 mg, 185.31 μmol) and stirred at 0 °C for 0.5 h, then TEA (112.51 mg, 1.11 mmol) was added and stirred at 0 °C for another 0.5 h. After that, (3S)-pyrrolidin-3-ol (64 mg, 734.62 μmol) was added to the above reaction mixture and stirred at 25 °C for 0.5 h. Added water (50 mL) to the reaction mixture, then extracted with DCM (50 mL $\times$ 2). The organic layer was washed with water (50 mL) and brine (50 mL), dried over Na_2SO_4 and concentrated. The residue was purified by Prep-HPLC to **compound 44**, (S)-2-((2-ethyl-6-(2-(4-(3-hydroxypyrrolidine-1-carbonyl)piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (39 mg, 16.59% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6) δ 8.80 (s, 2H), 8.67 (s, 1H), 8.10-8.07 (t, 2H), 7.71 (s, 2H), 7.44-7.40 (t, 2H), 4.89-4.88 (d, 1H), 4.22 (s, 1H), 3.84-3.74 (m, 4H), 3.63 (s, 3H), 3.52-3.45 (m, 2H), 3.29-3.18 (m, 5H), 3.12-3.09 (d, 1H), 2.70-2.64 (dd, 2H), 1.80-1.73 (m, 2H), 1.28-1.25 (t, 3H); MS: m/z = 653.2 ($M+1$, ESI+).

5.8.16. Synthesis of Compound 138




Step one:

[0370] To a solution of **compound 4**, 2-((2-ethyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (500 mg, 926.56 μmol) in DMF (20 mL) was added NaH (111.18 mg, 2.78 mmol, 60% purity), the reaction mixture was stirred for 30min at room temperature. Then ethyl 2-bromoacetate (232.11 mg, 1.39 mmol) was added and stirred for 3 h at room temperature. The reaction mixture was quenched with water (200 mL) and extracted with EA (20 mL $\times$ 3). The combined organic layers were dried over Na_2SO_4 and concentrated. The residue was purified by column chromatography to afford ethyl 2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl) piperazin-1-yl)acetate (344 mg, 59.33% yield) as a yellow solid. MS: m/z = 626.1 ($M+1$, ESI+).


Step two:

[0371] To a solution of ethyl 2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethyl imidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazin-1-yl)acetate (344 mg, 549.77 μmol) in THF (5 mL) and H₂O (10 mL) was added LiOH (19.75 mg, 824.65 μmol). The reaction mixture was stirred for 2 h at room temperature. The reaction mixture was quenched with water (50 mL) and extracted with EA (20 mLx3). The aqueous layer was adjusted to PH 5-6 with 2N HCl and extracted with DCM (20 mLx3), the combined organic layers were dried over Na₂SO₄ and concentrated to afford **compound 138**, 2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazin-1-yl)acetic acid (300 mg, 91.46% yield). MS: m/z = 598.3(M+1, ESI+).

5.8.17. Synthesis of Compound 45


[0372] To a solution of **compound 138** 2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazin-1-yl)acetic acid (150 mg, 250.98 μmol) and (R)-pyrrolidin-3-ol hydrochloride (31.02 mg, 250.98 μmol) in DCM(5 mL) was added HATU (286.29 mg, 752.93 μmol) and DIEA (162.18 mg, 1.25 mmol), the reaction mixture was stirred at 25 °C for 16 h. The reaction mixture was quenched with water (20 mL) and extracted with DCM (10 mLx3). The combined organic layers were washed with water (20 mL) and brine (20 mL), dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC (Waters Xbridge C18 10 μm OBD 19*250mm, A: 10 mmol NH₄HCO₃ in water; B: CH₃CN, 5% to 95%) in NH₄HCO₃ condition to afford **compound 45**, (R)-2-((2-ethyl-6-(2-(4-(2-(3-hydroxypyrrolidin-1-yl)-2-oxoethyl)piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (95 mg, 58.53% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 8.77 (s, 2H), 8.65 (s, 1H), 8.10-8.07 (t, 2H), 7.70 (s, 2H), 7.44-7.40 (t, 2H), 4.97-4.88 (dd, 1H), 4.30-4.29 (d, 1H), 3.78 (s, 4H), 3.63 (s, 3H), 3.58-3.52 (m, 2H), 3.28-3.23 (m, 1H), 3.16-3.09 (m, 2H), 2.70-2.64 (dd, 2H), 2.50-2.49 (m, 3H), 1.95-1.68 (m, 2H), 1.28-1.25 (t, 3H); MS: m/z = 667.2(M+1, ESI+).

5.8.18. Synthesis of Compound 45 Hydrochloride



[0373] To a solution of **compound 138**, 2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo [1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazin-1-yl)acetic acid (1.2 g, 2 mmol) and (R)-pyrrolidin-3-ol hydrochloride (248 mg, 2 mmol) in DCM (20 mL) was added HATU (2.29 g, 6.02 mmol) and DIEA (1.3 g, 10 mmol), the reaction mixture was stirred at 25 °C for 16 h. The reaction mixture was quenched with water (80 mL) and extracted with DCM (10 mLx3). The combined organic layers were washed with water (20 mL) and brine (20 mL), dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC (Waters Xbridge C18 10um OBD 19*250mm, A: 0.05% HCl in water; B: CH₃CN, 5% to 95%) in HCl condition to afford **compound 45 hydrochloride**, (R)-2-((2-ethyl-6-(2-(4-(2-(3-hydroxypyrrolidin-1-yl)-2-oxoethyl)piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (270 mg, 17.3% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 10.69 (s, 1H), 9.15 (s, 1H), 8.95 (s, 2H), 8.43-8.41 (d, 1H), 8.14-8.12 (d, 1H), 7.99 (s, 2H), 7.41-7.36 (t, 2H), 4.71-4.68 (m, 2H), 4.38-4.25 (m, 3H), 3.67-3.38 (m, 9H), 3.35-3.25 (m, 5H), 2.90-2.85 (dd, 2H), 1.95-1.81 (m, 2H), 1.36-1.32 (t, 3H); MS: m/z = 667.2(M+1, ESI+).


5.8.19. Synthesis of Compound 46



[0374] To a solution of **compound 138**, 2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo [1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazin-1-yl)acetic acid (150 mg, 250.98 μmol) and (S)-pyrrolidin-3-ol hydrochloride (46.52 mg, 376.47 μmol) in DCM(5 mL) was added HATU (286.29 mg, 752.93 μmol) and DIEA (162.18 mg, 1.25

mmol), the reaction mixture was stirred at 25 °C for 16 h. The reaction mixture was quenched with water (20 mL) and extracted with DCM (10 mLx3). The combined organic layers were washed with water (20 mL) and brine (20 mL), dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC (Waters Xbridge C18 10um OBD 19*250mm, A: 10 mmol NH₄HCO₃ in water; B: CH₃CN, 5% to 95%) in NH₄HCO₃ condition to afford **compound 46**, (S)-2-((2-ethyl-6-(2-(4-(2-(3-hydroxypyrrolidin-1-yl)-2-oxoethyl)piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (105 mg, 62.87% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 8.76 (s, 2H), 8.65 (s, 1H), 8.10-8.07 (t, 2H), 7.70 (s, 2H), 7.44-7.40 (t, 2H), 4.99-4.90 (dd, 1H), 4.30-4.29 (d, 1H), 3.78 (s, 4H), 3.63 (s, 3H), 3.60-3.52 (m, 2H), 3.40-3.36 (m, 2H), 3.29-3.23 (m, 1H), 3.16-3.11 (m, 2H), 2.70-2.64 (dd, 2H), 2.55-2.51 (m, 3H), 1.91-1.71 (m, 2H), 1.28-1.25 (t, 3H); MS: m/z = 667.2(M+1, ESI+).


5.8.20. Synthesis of Compound 46 Hydrochloride



[0375] To a solution of **compound 138**, 2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazin-1-yl)acetic acid (1.2 g, 2 mmol) and (S)-pyrrolidin-3-ol hydrochloride (248 mg, 2 mmol) in DCM (20 mL) was added HATU (2.29 g, 6.02 mmol) and DIEA (1.3 g, 10 mmol), the reaction mixture was stirred at 25 °C for 16 h. The reaction mixture was quenched with water (20 mL) and extracted with DCM (10 mLx3). The combined organic layers were washed with water (20 mL) and brine (20 mL), dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC (Waters Xbridge C18 10um OBD 19*250mm, A: 0.05% HCl in water; B: CH₃CN, 5% to 95%) in HCl condition to afford **compound 46 hydrochloride**, (S)-2-((2-ethyl-6-(2-(4-(2-(3-hydroxypyrrolidin-1-yl)-2-oxoethyl)piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (201 mg, 12.9% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 10.75 (s, 1H), 9.18 (s, 1H), 8.97 (s, 2H), 8.46-8.43 (d, 1H), 8.16-8.14 (d, 1H), 8.01 (s, 2H), 7.42-7.38 (t, 2H), 4.73-4.70 (m,

2H), 4.41-4.30 (m, 3H), 3.69-3.39 (m, 9H), 3.37-3.27 (m, 5H), 2.92-2.87 (dd, 2H), 1.94-1.81 (m, 2H), 1.38-1.34 (t, 3H); MS: m/z = 667.1 (M+1, ESI+).

5.8.21. Synthesis of Compound 66 Hydrochloride



Step one:


[0376] To a mixture of **compound 4**, 2-((2-ethyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (550 mg, 1.02 mmol) in DCM (6 mL) was added triphosgene (120.98 mg, 407.69 μ mol) at 0°C and stirred for 0.5 h. then DIEA (395.18 mg, 3.06 mmol) was added and stirred at 0 °C for another 0.5 h. After that, tert-butyl 3-aminoazetidine-1-carboxylate (175.53 mg, 1.02 mmol) was added to the above reaction mixture and stirred at 25 °C for 1 h. Added water (50 mL) to the reaction mixture, then extracted with DCM (50 mL $\times$ 2). The organic layer was washed with water (50 mL) and brine (50 mL), dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography to afford tert-butyl 3-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazine-1-carboxamido)azetidine-1-carboxylate (600 mg, 79.78% yield) as a yellow solid. MS: m/z = 738.2 (M+1, ESI+).

Step two:

[0377] To a solution of tert-butyl 3-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazine-1-carboxamido)azetidine-1-carboxylate (600 mg, 813.18 μ mol) in DCM (8 mL) was added TFA (2 g, 17.54 mmol) and stirred at 25 °C for 1 h. The resulting mixture was evaporated under reduce pressure, then the residue was purified by Prep-HPLC (Waters Xbridge C18 10 μ m OBD 19*250mm, A: 0.05% HCl in water; B: CH₃CN, 5% to 95%) in HCl condition to afford **compound 66 hydrochloride**, N-(azetidin-3-yl)-4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazine-1-carboxamide hydrochloride (220 mg, 42.42% yield) as a pale yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.35 (s, 1H), 9.24 (s, 1H), 9.11 (s, 1H), 8.89 (s, 2H), 8.41-8.39 (d, 1H), 8.14-8.12 (d, 1H), 8.01 (s, 2H), 7.64 (s, 1H), 7.42-7.38 (t, 2H), 4.59-4.55 (t,

1H), 4.03-3.98 (m, 4H), 3.80 (s, 4H), 3.67 (s, 3H), 3.46 (s, 4H), 2.91-2.85 (dd, 2H), 1.36-1.32 (t, 3H); MS: m/z = 638.2 (M+1, ESI+).

5.8.22. Synthesis of Compound 66 Formate



Step one:


[0378] To a mixture of **compound 4**, 2-((2-ethyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (230 mg, 0.427 mmol) in DCM (6 mL) was added triphosgene (38 mg, 0.128 mmol) at 0 °C and stirred for 0.5 h. then DIEA (165 mg, 1.28 mmol) was added and stirred at 0 °C for another 0.5 h. After that, tert-butyl 3-aminoazetidine-1-carboxylate (73 mg, 0.427 mmol) was added to the above reaction mixture and stirred at 25 °C for 1 h. Added water (50 mL) to the reaction mixture, then extracted with DCM (50 mL × 2). The organic layer was washed with water (50 mL) and brine (50 mL), dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography to afford tert-butyl 3-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazine-1-carboxamido)azetidine-1-carboxylate (200 mg, 63.7% yield) as a yellow solid. MS: m/z = 738.2 (M+1, ESI+).

Step two:

[0379] To a solution of tert-butyl 3-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazine-1-carboxamido)azetidine-1-carboxylate (200 mg, 271 μmol) in DCM (8 mL) was added TFA (666 mg, 90 μmol) and stirred at 25 °C for 1 h. The resulting mixture was evaporated under reduce pressure, then the residue was purified by Prep-HPLC (Waters Xbridge C18 10μm OBD 19*250mm, A: 0.1% FA in water; B: CH₃CN, 5% to 95%) in FA condition to afford **compound 66 Formate**, N-(azetidin-3-yl)-4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazine-1-carboxamide formate (150 mg, 81.1% yield) as a pale yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.80 (s, 2H), 8.66 (s, 1H), 8.42 (s, 1H), 8.11-8.07 (t, 2H), 7.70 (s, 2H), 7.44-


7.40 (t, 2H), 4.54-4.48 (m, 1H), 3.93-3.88 (t, 2H), 3.77-3.70 (m, 8H), 3.63 (s, 3H), 3.43-3.40 (m, 4H), 2.70-2.64 (dd, 2H), 1.28-1.25 (t, 3H); MS: m/z = 638.2 (M+1, ESI+).

5.8.23. Synthesis of Compound 66



[0380] To a mixture of **compound 66 formate**, N-(azetidin-3-yl)-4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo [1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazine-1-carboxamide formate (120 mg, 0.175 mmol) in H₂O (3 mL) was added 2 M NaHCO₃ (1.05 mL, 2.1 mmol) at 0°C and stirred for 0.5 h. Then extracted with DCM (5 mL × 2). The organic layer was washed with water (5 mL) and brine (5 mL), dried over Na₂SO₄ and concentrated to afford **compound 66**, N-(azetidin-3-yl)-4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl) amino)-2-ethylimidazo [1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazine-1-carboxamide (75 mg, 66.96% yield) as a yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.79 (s, 2H), 8.65 (s, 1H), 8.10-8.07 (t, 2H), 7.70 (s, 2H), 7.44-7.39 (t, 2H), 7.08-7.06 (d, J=6.8 Hz, 1H), 3.74-3.51 (m, 13H), 2.70-2.64 (dd, 2H), 1.28-1.25 (t, 3H); MS: m/z = 638.3 (M+1, ESI+).

5.8.24. Synthesis of Compound 67 Hydrochloride



Step one:


[0381] To a mixture of **compound 4**, 2-((2-ethyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (550 mg, 1.02 mmol) in DCM (6 mL) was added triphosgene (120.98 mg, 407.69 μmol) at 0°C and stirred for 0.5 h. then DIEA (395.18 mg, 3.06 mmol) was added and stirred at 0 °C for another 0.5 h. After that, tert-butyl 4-aminopiperidine-1-carboxylate (204.13 mg, 1.02 mmol) was added to the above reaction mixture and stirred at 25 °C for 2 h. Added water (50 mL) to the reaction mixture, then extracted with DCM (50 mL × 2). The organic layer was washed

with water (50 mL) and brine (50 mL), dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography to afford tert-butyl 4-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazine-1-carboxamido)piperidine-1-carboxylate (540 mg, 69.18% yield) as a yellow solid. MS: m/z = 766.5 (M+1, ESI+).

Step two:

[0382] To a solution of tert-butyl 4-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazine-1-carboxamido)piperidine-1-carboxylate (540 mg, 705.05 μ mol) in DCM (8 mL) was added TFA (2 g, 17.54 mmol) and stirred at 25 °C for 1 h. The resulting mixture was evaporated under reduce pressure, then the residue was purified by Prep-HPLC (Waters Xbridge C18 10 μ m OBD 19*250mm, A: 0.05% HCl in water; B: CH₃CN, 5% to 95%) in HCl condition to afford **compound 67 hydrochloride**, 4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)-N-(piperidin-4-yl)piperazine-1-carboxamide hydrochloride (240 mg, 51.13% yield) as a pale yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.11 (s, 3H), 8.88 (s, 2H), 8.41-8.39 (d, 1H), 8.14-8.12 (d, 1H), 8.01 (s, 2H), 7.42-7.38 (t, 2H), 6.67 (s, 2H), 3.78-3.67 (m, 8H), 3.43 (s, 4H), 3.25-3.22 (d, 2H), 2.91-2.85 (dd, 2H), 1.89-1.86 (m, 2H), 1.74-1.66 (m, 2H), 1.36-1.33 (t, 3H); MS: m/z = 666.4 (M+1, ESI+).


5.8.25. Preparation of Compound 67



[0383] **Compound 67 hydrochloride**, 4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)-N-(piperidin-4-yl)piperazine-1-carboxamide hydrochloride (180 mg, 0.253 mmol) was purified by Prep-HPLC to afford **compound 67**, 4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)-N-(piperidin-4-yl)piperazine-1-carboxamide (122 mg, 72.62% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.79 (s, 2H), 8.66 (s, 1H), 8.10-8.07 (m, 2H), 7.70 (s, 2H), 7.44-7.40 (t, 2H),

6.30 (d, 2H), 3.75-3.73 (m, 4H), 3.63 (s, 3H), 3.51-3.46 (m, 8H), 2.93-2.90 (d, 2H), 2.70-2.64 (dd, 2H), 2.49-2.42 (m, 2H), 1.68-1.65 (d, 2H), 1.25 (t, 3H); MS: m/z = 666.1 (M+1, ESI+).

5.8.26. Synthesis of Compound 67 Formate



Step one:


[0384] To a mixture of **compound 4**, 2-((2-ethyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (230 mg, 0.427 mmol) in DCM (6 mL) was added triphosgene (51 mg, 170.5 μ mol) at 0 °C and stirred for 0.5 h. then DIEA (165 mg, 1.28 mmol) was added and stirred at 0 °C for another 0.5 h. After that, tert-butyl 4-aminopiperidine-1-carboxylate (85 mg, 0.427 mmol) was added to the above reaction mixture and stirred at 25 °C for 1 h. Added water (50 mL) to the reaction mixture, then extracted with DCM (50 mL $\times$ 2). The organic layer was washed with water (50 mL) and brine (50 mL), dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography to afford tert-butyl 4-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazine-1-carboxamido)piperidine-1-carboxylate (250 mg, 76.7% yield) as a yellow solid. MS: m/z = 766.2 (M+1, ESI+).

Step two:

[0385] To a solution of tert-butyl 4-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperazine-1-carboxamido)piperidine-1-carboxylate (250 mg, 326 μ mol) in DCM (8 mL) was added TFA (95 mg, 978 μ mol) and stirred at 25 °C for 1 h. The resulting mixture was evaporated under reduce pressure, then the residue was purified by Prep-HPLC (Waters Xbridge C18 10 μ m OBD 19*250mm, A: 0.1% FA in water; B: CH₃CN, 5% to 95%) in FA condition to afford **compound 67 formate**, 4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)-N-(piperidin-4-yl)piperazine-1-carboxamide formate (155 mg, 66.8% yield) as a pale yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.79 (s, 2H), 8.66 (s, 1H), 8.39 (s, 1H), 8.10-8.07 (t, 2H), 7.70 (s, 2H), 7.44-7.40 (t, 2H), 6.50 (s,


1H), 3.74-3.63 (m, 9H), 3.40-3.38 (m, 5H), 3.16 (s, 2H), 2.79-2.64 (m, 4H), 1.83-1.81 (m, 2H), 1.54 (s, 2H), 1.28-1.25 (t, 3H); MS: m/z = 666.3 (M+1, ESI+).

5.8.27. Synthesis of Compound 1



[0386] To a solution of **compound 4**, 2-((2-ethyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (300 mg, 520.75 μ mol) and 1-cyanocyclopropane-1-carboxylic acid (57.85 mg, 520.75 μ mol) in DMF (10 mL) was added HATU (294.70 mg, 781.13 μ mol) and DIPEA (269.21 mg, 2.08 mmol), the reaction mixture was stirred at 25 °C for 16 h. Added water (50 mL) to the reaction mixture, then extracted with EA (50 mL $\times$ 2). The organic layer was washed with water (50 mL) and brine (50 mL), dried over Na_2SO_4 and concentrated. The residue was purified by Prep-HPLC to afford **compound 1**, 2-((6-(2-(4-(1-cyanocyclopropane-1-carbonyl)piperazin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (65 mg, 18.51% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6) δ 8.84 (s, 2H), 8.69 (s, 1H), 8.11-8.07 (t, 2H), 7.72-7.71 (dd, 2H), 7.44-7.40 (t, 2H), 3.87-3.63 (m, 10H), 2.95-2.90 (d, 1H), 2.70-2.64 (dd, 2H), 1.64-1.60 (m, 2H), 1.54-1.51 (m, 2H), 1.29-1.25 (t, 3H); MS: m/z = 633.5 (M+1, ESI+).


5.8.28. Synthesis of Compound 2



[0387] To a solution of **compound 4**, 2-((2-ethyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (200 mg, 370.62 μ mol) and 1-hydroxycyclopropane-1-carboxylic acid (45.40 mg, 444.74 μ mol) in DMF (10 mL) was added HATU (211.39 mg, 555.93 μ mol) and DIEA (143.70 mg, 1.11 mmol), the reaction mixture was stirred at 25 °C for 2. The reaction mixture was poured


into water (100mL), extracted with EA (20mLx3), washed by brine (100mL) and dried over Na₂SO₄. The combined organic layers were concentrated under reduced pressure, the residue was purified by Prep-HPLC to afford **compound 2**, 2-((2-ethyl-6-(2-(4-(1-hydroxycyclopropane-1-carbonyl)piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (90 mg, 38.93% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.81(s, 2H), 8.68 (s, 1H), 8.11-8.10 (t, 2H), 7.71 (s, 2H), 7.44-7.40 (t, 2H), 6.40 (s, 1H), 3.81-3.64 (m, 11H), 2.71-2.64 (dd, 2H), 1.29-1.25 (t, 3H), 0.97-0.94 (m, 2H), 0.81-0.78 (m, 2H); MS: m/z = 624.2 (M+1, ESI+).

5.8.29. Synthesis of Compound 78 Hydrochloride




[0388] To a solution of **compound 4**, 2-((2-ethyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (300 mg, 520.75 umol) and (2S,4R)-4-hydroxy-1-methylpyrrolidine-2-carboxylic acid (104.91 mg, 722.72 umol) in DMF (10 mL) was added HATU (314.61 mg, 833.91 umol) and DIPEA (215.55 mg, 1.67 mmol), the reaction mixture was stirred at 25 °C for 16 h. Added water (50 mL) to the reaction mixture, then extracted with EA (50 mL × 2). The organic layer was washed with water (50 mL) and brine (50 mL), dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC to afford **compound 78 hydrochloride**, 2-((2-ethyl-6-(2-(4-((2S,4R)-4-hydroxy-1-methylpyrrolidine-2-carbonyl)piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (100 mg, 25.57% yield) as a pale yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.75 (s, 1H), 9.12 (s, 1H), 8.92 (s, 2H), 8.42-8.39 (d, 1H), 8.15-8.12 (d, 1H), 8.01 (s, 2H), 7.42-7.38 (t, 2H), 5.04-4.98 (m, 1H), 4.40 (s, 1H), 3.88-3.77 (m, 5H), 3.67-3.56 (m, 7H), 3.08-3.05 (m, 1H), 2.90-2.85 (m, 5H), 2.50-2.45 (m, 1H), 2.09-2.02 (m, 1H), 1.36-1.33 (t, 3H); MS: m/z = 667.1 (M+1, ESI+).

5.8.30. Synthesis of Compound 78



[0389] **Compound 78 hydrochloride**, 2-((2-ethyl-6-(2-(4-((2S,4R)-4-hydroxy-1-methylpyrrolidine-2-carbonyl)piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (60 mg, 0.077 mmol) was purified by Prep-HPLC to afford **compound 78**, 2-((2-ethyl-6-(2-(4-((2S,4R)-4-hydroxy-1-methylpyrrolidine-2-carbonyl)piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (25 mg, 49.02% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.81 (s, 2H), 8.67 (s, 1H), 8.10-8.07 (m, 2H), 7.71 (s, 2H), 7.44-7.40 (t, 2H), 4.89-4.88 (m, 1H), 4.22 (s, 1H), 3.85-3.82 (m, 2H), 3.70-3.60 (m, 8H), 3.48-3.42 (m, 2H), 3.25-3.21 (m, 1H), 2.70-2.64 (dd, 2H), 2.22 (s, 3H), 2.15-2.11 (m, 1H), 2.00-1.95 (m, 1H), 1.89-1.84 (m, 1H), 1.26-1.23 (t, 3H); MS: m/z = 667.1 (M+1, ESI+).


5.8.31. Synthesis of Compound 79 Hydrochloride



[0390] To a solution of **compound 4**, 2-((2-ethyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (300 mg, 520.75 μmol) and 1-methylazetidine-3-carboxylic acid (83.21 mg, 722.72 μmol) in DMF (10 mL) was added HOBT (112.68 mg, 833.91 μmol), EDCI (159.86 mg, 833.91 μmol) and DIPEA (215.55 mg, 1.67 mmol), the reaction mixture was stirred at 25 °C for 16 h. Added water (50 mL) to the reaction mixture, then extracted with EA (50 mL × 2). The organic layer was washed with water (50 mL) and brine (50 mL), dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC to afford **compound 79 hydrochloride**, 2-((2-ethyl-6-(2-(4-(1-methylazetidine-3-carbonyl)piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (210 mg, 56.14%


yield) as a pale yellow solid. ^1H NMR (400 MHz, $\text{D}_2\text{O}+\text{DMSO}-d_6$) δ 9.03(s, 1H), 8.86 (s, 2H), 8.40-8.37 (d, 1H), 8.14-8.12 (d, 1H), 7.97 (s, 2H), 7.39-7.35 (t, 2H), 4.48-4.41 (m, 2H), 4.07-3.95 (m, 3H), 3.85 (s, 4H), 3.68 (s, 3H), 3.62 (s, 2H), 3.41 (s, 2H), 2.91-2.83 (m, 5H), 1.36-1.32 (t, 3H); MS: m/z = 637.3 (M+1, ESI+).

5.8.32. Synthesis of Compound 79



[0391] To a mixture of **compound 79 hydrochloride**, 2-((2-ethyl-6-(2-(4-(1-methylazetidine-3-carbonyl)piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (130 mg, 0.193 mmol) in H_2O (3 mL) was added 2 M NaHCO_3 (1.05 mL, 2.1 mmol) at 0°C and stirred for 0.5 h. Then extracted with DCM (5 mL $\times$ 2). The organic layer was washed with water (5 mL) and brine (5 mL), dried over Na_2SO_4 and concentrated to afford **compound 79**, 2-((2-ethyl-6-(2-(4-(1-methylazetidine-3-carbonyl)piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (70 mg, 57% yield) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.73 (s, 2H), 8.64 (s, 1H), 8.10-8.07 (t, 2H), 7.69 (s, 1H), 7.44-7.40 (t, 2H), 4.18-4.14 (t, 2H), 3.72-3.33 (m, 9H), 2.77-2.64 (m, 4H), 2.26 (s, 3H), 1.28-1.24 (t, 3H); MS: m/z = 637.0 (M+1, ESI+).


5.8.33. Synthesis of Compound 82 Hydrochloride



[0392] To a solution of 1-methylazetidine-3-amine 2HCl (176.85 mg, 1.11 mmol) in DMF (10 mL) was added CDI (90.14 mg, 555.94 μmol) and DIEA (112.51 mg, 1.11 mmol) and stirred at 25°C for 3 h. Then **compound 4**, 2-((2-ethyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (300 mg, 555.94 μmol) was added to the above reaction solution and the reaction mixture was


stirred at 25 °C for 16 h. Added water (100 mL) to the reaction mixture, then extracted with EA (30 mL × 3). The organic layer was washed with water (100 mL) and brine (100 mL), dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC to afford **compound 82 hydrochloride**, 4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)-N-(1-methylazetidin-3-yl)piperazine-1-carboxamide hydrochloride (220 mg, 57.50% yield) as a pale yellow solid. ¹H NMR (400 MHz, D₂O+DMSO-d₆) δ 9.04 (s, 1H), 8.86 (s, 2H), 8.40-8.38 (dd, 1H), 8.15-8.12 (d, 1H), 7.99-7.96 (t, 2H), 7.40-7.35 (t, 2H), 4.61-4.48 (m, 1H), 4.42-4.28 (m, 2H), 4.11-4.04 (m, 2H), 3.82 (s, 4H), 3.68 (s, 3H), 3.47 (s, 4H), 2.93-2.87 (m, 5H), 1.36-1.32 (t, 3H); MS: m/z = 652.2(M+1, ESI+).

5.8.34. Synthesis of Compound 82



[0393] To a mixture of **compound 82 hydrochloride**, 4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)-N-(1-methylazetidin-3-yl)piperazine-1-carboxamide hydrochloride (60 mg, 0.078 mmol) in H₂O (3 mL) was added 2 M NaHCO₃ (1.05 mL, 2.1 mmol) at 0°C and stirred for 0.5 h. Then extracted with DCM (5 mL × 2). The organic layer was washed with water (5 mL) and brine (5 mL), dried over Na₂SO₄ and concentrated to afford **compound 82**, 4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)-N-(1-methylazetidin-3-yl)piperazine-1-carboxamide (8 mg, 15.68% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.80 (s, 2H), 8.66 (s, 1H), 8.10-8.07 (t, 2H), 7.70 (s, 2H), 7.44-7.40 (t, 2H), 6.91-6.89 (d, 1H), 4.22-4.17 (m, 1H), 3.76-3.70 (m, 4H), 3.63-3.56 (m, 5H), 3.40-3.38 (m, 4H), 2.97 (s, 2H), 2.70-2.64 (m, 2H), 2.31 (s, 2H), 1.28-1.25 (t, 3H); MS: m/z = 652.0 (M+1, ESI+).

5.8.35. Synthesis of (4-(5-bromopyrimidin-2-yl)piperazin-1-yl)(cyclopropyl)methanone




Step one:

[0394] To a solution of piperazine (2.67 g, 31.02 mmol) and 5-bromo-2-chloropyrimidine (3 g, 15.51 mmol) in MeCN (30 mL) was added Cs_2CO_3 (15.16 g, 46.53 mmol), the reaction mixture was stirred at 80 °C for 2 h. The mixture was filtered and concentrated. The residue was purified by column chromatography to afford 5-bromo-2-(piperazin-1-yl)pyrimidine (1.4 g, 37.13% yield) as a yellow solid. MS: $m/z = 243.1$ ($M+1$, ESI+).

Step two:

[0395] To a solution of cyclopropanecarboxylic acid (389.54 mg, 4.52 mmol) and 5-bromo-2-(piperazin-1-yl)pyrimidine (1 g, 4.11 mmol) in DMF (15 mL) was added HATU (2.35 g, 6.17 mmol) and DIEA (1.59 g, 12.34 mmol), the reaction mixture was stirred at 25 °C for 2 h. The mixture was poured into water (150 mL) and extracted with EA (50 mL x 3). The organic layer was washed with water (100 mL x 2) and brine (100 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by column chromatography to afford (4-(5-bromopyrimidin-2-yl)piperazin-1-yl)(cyclopropyl)methanone (530 mg, 41.41% yield) as a yellow solid. MS: $m/z = 311.1$ ($M+1$, ESI+).


5.8.36. Synthesis of Compound 110



[0396] To a mixture of 3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl boronic acid (406.12 mg, 964.08 μmol) and (4-(5-bromopyrimidin-2-yl)piperazin-1-yl)(cyclopropyl)methanone (300 mg, 964.08 μmol) in dioxane (10 mL) and water (2 mL) was added Na_2CO_3 (306.55 mg, 2.89 mmol) and $\text{Pd}(\text{PPh}_3)_4$ (557.03 mg, 482.04 μmol), the reaction mixture was stirred at 100 °C for 2 h under

N₂. The mixture was poured into water (60 mL) and extracted with EA (20 mL x 2). The organic layer was washed by brine (100 mL), then dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography to afford **compound 110**, 2-((6-(2-(4-(cyclopropanecarbonyl) piperazin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl) thiazole-5-carbonitrile (154 mg, 26.29% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.81 (s, 2H), 8.68 (s, 1H), 8.11-8.08 (t, 2H), 7.71 (s, 2H), 7.44-7.39 (t, 2H), , 3.85-3.77 (m, 6H), 3.64 (s, 3H), 3.61-3.56 (m, 2H), 2.71-2.65 (dd, 2H), 2.03-1.99 (m, 1H), 1.29-1.25 (t, 3H), 0.79-0.70 (m, 4H); MS: m/z = 608.1 (M+1, ESI+); HRMS: 608.2351.

5.8.37. Synthesis of 1-cyclopropylazetidine-3-carboxylic acid




Step one:

[0397] To a solution of ethyl azetidine-3-carboxylate (4 g, 30.97 mmol) in MeOH (20 mL) and EtOH (20 mL) was added (1-ethoxycyclopropoxy)trimethylsilane (10.80 g, 61.94 mmol), acetic acid (371.96 mg, 6.19 mmol) and NaBH₃CN (3.89 g, 61.94 mmol), the reaction mixture was stirred at 75 °C for 16 h. The mixture was concentrated, then poured into water (100 mL) and extracted with EA (50 mL x 2). The organic layer was washed with water (100 mL) and brine (50 mL), then dried over Na₂SO₄ and concentrated. The residue purified by column chromatography to afford ethyl 1-cyclopropylazetidine-3-carboxylate (1.4 g, 26.71% yield) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 4.18 (d, 2H), 3.68-3.56 (m, 2H), 3.53-3.42 (m, 2H), 3.29 (d, 1H), 1.96-1.86 (m, 1H), 1.29 (t, 3H), 0.40 (m, 4H); MS: m/z = 169.9 (M+1, ESI+).

Step two:


[0398] To a solution of ethyl 1-cyclopropylazetidine-3-carboxylate (800 mg, 4.73 mmol) in MeOH (10 mL) and water (5 mL) was added LiOH (566.09 mg, 23.64 mmol), the reaction mixture was stirred at 25 °C for 16 h. The mixture was adjusted PH to 5-6 by 2 M HCl and concentrated. The residue was washed with MeOH (5 mL x 4). The organic layer was concentrated to afford 1-cyclopropylazetidine-3-carboxylic acid (330 mg, 49.45% yield) as a yellow oil. MS: m/z = 142.1 (M+1, ESI+).

5.8.38. Synthesis of Compound 111




[0399] To a solution of 1-cyclopropylazetidine-3-carboxylic acid (156.96 mg, 1.11 mmol) and **compound 4**, 2-((2-ethyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (400 mg, 741.25 μ mol) in DMF (8 mL) was added HATU (422.77 mg, 1.11 mmol) and DIEA (287.40 mg, 2.22 mmol), the reaction mixture was stirred at 25 °C for 2 h. The mixture was poured into water (80 mL) and extracted with EA (30 mL $\times$ 3). The organic layer was washed with brine (80 mL), then dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC to afford **compound 111**, 2-((6-(2-(4-(1-cyclopropylazetidine-3-carbonyl)piperazin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (197 mg, 40.10% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.80 (s, 2H), 8.67 (s, 1H), 8.11-8.07 (t, 2H), 7.70 (s, 2H), 7.44-7.40 (t, 2H), 3.77-3.74 (t, 4H), 3.63 (s, 3H), 3.54-3.52 (t, 2H), 3.46-3.43 (m, 3H), 3.40-3.32 (m, 2H), 3.27-3.26 (m, 2H), 2.70-2.64 (dd, 2H), 1.81-1.79 (m, 1H), 1.28-1.25 (t, 3H), 0.32-0.28 (m, 2H), 0.19-0.15 (m, 2H); MS: m/z = 663.2 (M+1, ESI⁺); HRMS: 663.2775.

5.9. Example 8 – Synthesis of Piperazine-linked Pyridine-type Compounds


General Scheme 8

5.9.1. Synthesis of 1-(5-bromopyridin-2-yl)piperazine




[0400] To a mixture of 5-bromo-2-chloropyridine (10 g, 51.96 mmol) and piperazine (89.52 mg, 103.93 mmol) in DMF (10 mL) was added Cs_2CO_3 (50.7.9 mg, 155.89 mmol), the reaction mixture was stirred at 120 °C for 3 h. The mixture was quenched by saturated NH_4Cl (100 mL) and extracted with EA (50 mL x 3), The organic layer was washed by water (100 mL x 2) and brine (100 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by column chromatography to afford 1-(5-bromopyridin-2-yl)piperazine (6.4 g, 50.87% yield) as a yellow oil. MS: m/z = 243.8 ($M+1+2$, ESI+).

5.9.2. Synthesis of Compound 139



[0401] To a mixture of **compound 133**, 3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methylamino)-2-ethylimidazo[1,2-a]pyridin-6-yl)boronic acid (2 g, 4.75 mmol) and 1-(5-bromopyridin-2-yl)piperazine (1.15 g, 4.75 mmol) in dioxane (20 mL) and water (4 mL) was added Na_2CO_3 (1.51 g, 14.24 mmol) and $\text{Pd}(\text{PPh}_3)_4$ (548.63 mg, 474.77 μmol), the reaction mixture was stirred at 100 °C for 2 h. The mixture was diluted by DCM (100 mL). The organic layer was washed by water (100 mL x 2) and brine (100 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by column chromatography to afford **compound 139**, 2-((2-ethyl-6-(6-(piperazin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methylamino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (1.8 g, 70.39% yield) as a yellow solid. MS: m/z = 539.2 ($M+1$, ESI+).


5.9.3. Synthesis of Compound 149

*Step one:*

[0402] To a solution of **compound 139**, 2-((2-ethyl-6-(6-(piperazin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methylamino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (250 mg, 464.13 μmol) and ethyl 2-bromoacetate (93.01 mg, 556.96 μmol) in MeCN (10 mL) was added K_2CO_3 (192.44 mg, 1.39 mmol), the reaction mixture was stirred at 70 °C for 2 h. The mixture was filtered and concentrated, the residue was purified by column chromatography to afford ethyl 2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methylamino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperazin-1-yl)acetate (220 mg, 75.87% yield) as a white solid. MS: m/z = 625.1 ($M+1$, ESI+).


Step two:

[0403] To a solution of ethyl 2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethyl imidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperazin-1-yl)acetate (220 mg, 352.15 μmol) in MeOH (9 mL) and H₂O (1 mL) was added LiOH (84.34 mg, 3.52 mmol), the reaction mixture was stirred at 25°C for 3 h. The reaction mixture was concentrated under reduced pressure and the residue was poured into 2N HCl (20mL) and extracted with EA (10mLx2), the organic layer was washed by brine (20 mL), then dried over Na₂SO₄ and concentrated to afford the crude product **compound 149**, 2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperazin-1-yl)acetic acid (185 mg, 88.04% yield) as a white solid. MS: m/z = 597.2 (M+1, ESI+).

5.9.4. Synthesis of Compound 85


[0404] To a solution of **compound 139**, 2-((2-ethyl-6-(6-(piperazin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (250 mg, 464.13 μmol) in DCM (10 mL) at 0 °C was added triphosgene (55.09 mg, 185.65 μmol), the mixture was stirred at 0 °C for 30 min. Then TEA (234.83 mg, 2.32 mmol) and pyrrolidine (33.01 mg, 464.13 μmol) was added. The reaction mixture was stirred at 25 °C for 5 h. The mixture was quenched by water (50 mL) and extracted with DCM (20 mL x 3). The organic layer was washed with brine (50 mL), dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC to afford **compound 85**, 2-((2-ethyl-6-(6-(4-(pyrrolidine-1-carbonyl)piperazin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (150 mg, 50.83% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.59 (s, 1H), 8.55-8.54 (d, 1H), 8.11-8.08 (t, 2H), 7.99-7.96 (m, 1H), 7.72-7.66 (dd, 2H), 7.44-7.40 (t, 2H), 6.93-6.90 (d, 1H), 3.64 (s, 3H), 3.56-3.53 (t, 4H), 3.31-3.25 (m, 8H), 2.69-2.64 (dd, 2H), 1.77-1.74 (t, 4H), 1.29-1.25 (t, 3H); MS: m/z = 636.3 (M+1, ESI+); HRMS: 636.2663.

5.9.5. Synthesis of Compound 86 Hydrochloride



[0405] To a solution of **compound 139**, 2-((2-ethyl-6-(6-(piperazin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (200 mg, 371.31 μmol) and 1-methylazetidine-3-carboxylic acid (51.30 mg, 445.57 μmol) in DMF (10 mL) was added T₃P (354.43 mg, 556.96 μmol , 50% purity) and DIEA (143.97 mg, 1.11 mmol), the reaction mixture was stirred at 25 °C for 2 h. The reaction mixture was poured into water (100mL) and extracted with EA (40 mL x 3). The organic layer was washed with brine (100 mLX2), dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC to afford **compound 86 hydrochloride**, 2-((2-ethyl-6-(6-(4-(1-methylazetidine-3-carbonyl) piperazin-1-yl)pyridin-3-yl)imidazo[1,2-a] pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (62 mg, 24.84% yield) as a pale yellow solid. ¹H NMR (400 MHz, MeOD) δ 8.95 (s, 1H), 8.45 (s, 1H), 8.37-8.31 (t, 2H), 8.09-8.00 (m, 3H), 7.39-7.37 (d, 1H), 7.22-7.18 (t, 2H), 4.59-4.51 (m, 2H), 4.22-4.18 (m, 3H), 3.84-3.79 (m, 6H), 3.75 (s, 3H), 3.68 (s, 2H), 2.99-2.94 (m, 5H), 1.44-1.40 (t, 3H); MS: m/z = 636.2 (M+1, ESI+); HRMS: 636.2669.


5.9.6. Synthesis of Compound 86



[0406] To a mixture of **compound 86 hydrochloride**, 2-((2-ethyl-6-(6-(4-(1-methylazetidine-3-carbonyl)piperazin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (14 mg, 0.018 mmol) in H₂O (3 mL) was added 2 M NaHCO₃ (1.05 mL, 2.1 mmol) at 0°C and stirred for 0.5 h. Then extracted with DCM (5 mL x 2). The organic layer was washed with water (5 mL) and brine (5 mL), dried over Na₂SO₄ and concentrated to afford **compound 86**, 2-((2-


ethyl-6-(6-(4-(1-methylazetidine-3-carbonyl)piperazin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (5 mg, 41.67% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.59 (s, 1H), 8.55-8.54 (d, 1H), 8.10-8.07 (t, 2H), 8.00-7.97 (m, 1H), 7.72-7.65 (m, 2H), 7.44-7.40 (t, 2H), 6.94-6.92 (d, 1H), 3.63 (s, 3H), 3.53-3.36 (m, 11H), 3.10-3.07 (m, 2H), 2.69-2.63 (m, 2H), 2.16 (s, 3H), 1.28-1.25 (t, 3H); MS: m/z = 636.0 (M+1, ESI+).

5.9.7. Synthesis of Compound 91




[0407] To a solution of **compound 149**, 2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperazin-1-yl)acetic acid (185 mg, 310.05 μmol) and (S)-pyrrolidin-3-ol (185.87 mg, 1.86 mmol) in DMF (10 mL) was added HATU (175.46 mg, 465.08 μmol) and DIEA (120.21 mg, 930.15 μmol), the reaction mixture was stirred at 25 °C for 16 h. The mixture was poured into water (100 mL) and extracted with EA (40 mL×2). The organic layer was washed with water (100 mL×2) and brine (100 mL), then dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC to afford **compound 91**, (S)-2-((2-ethyl-6-(6-(4-(2-(3-hydroxypyrrolidin-1-yl)-2-oxoethyl)piperazin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (100 mg, 48.44% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.58 (s, 1H) 8.53-8.52 (d, 1H), 8.11-8.08 (t, 2H), 7.96-7.93 (dd, 1H), 7.72-7.66 (m, 2H), 7.44-7.39 (t, 2H), 6.91-6.89 (d, 1H), 5.00-4.92 (dd, 1H), 4.31-4.24 (d, 1H), 3.65 (s, 3H), 3.61-3.54 (m, 6H), 3.44-3.34 (m, 1H), 3.31-3.20 (m, 1H), 3.16-3.12 (m, 2H), 2.70-2.65 (dd, 2H), 2.57-2.55 (m, 4H), 1.83-1.73 (m, 2H), 1.29-1.25 (t, 3H); MS: m/z = 666.2 (M+1, ESI+); HRMS: 666.2771.

5.9.8. Synthesis of Compound 92



[0408] To a suspension of **compound 139**, 2-((2-ethyl-6-(6-(piperazin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (250 mg, 464.13 μmol) in DCM (10 mL) at 0 °C was added triphosgene (55.09 mg, 185.65 μmol), the reaction mixture was stirred at 0 °C for 30 min. Then TEA (234.83 mg, 2.32 mmol) and (R)-pyrrolidin-3-ol (40.44 mg, 464.13 μmol) was added, the reaction mixture was stirred at 25 °C for 5 h. The mixture was quenched by water (50 mL) and extracted with DCM (20 mL x 3), the organic layer was washed with brine (50 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by Prep-HPLC (Waters Xbridge C18 10 μm OBD 19*250mm, A: 10 mmol NH_4HCO_3 in water; B: CH_3CN , 5% to 95%) in NH_4HCO_3 condition to afford **compound 92**, (R)-2-((2-ethyl-6-(6-(4-(3-hydroxypyrrolidine-1-carbonyl)piperazin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (145 mg, 47.93% yield) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.59 (s, 1H), 8.55-8.54 (d, 1H), 8.11-8.07 (t, 2H), 7.99-7.96 (dd, 1H), 7.73-7.65 (m, 2H), 7.44-7.40 (t, 2H), 6.93-6.91 (d, 1H), 4.89 (s, 1H), 4.22 (s, 1H), 3.64 (s, 3H), 3.60-3.45 (m, 6H), 3.30-3.20 (m, 5H), 3.12-3.10 (d, 1H), 2.69-2.64 (dd, 2H), 1.83-1.71 (m, 2H), 1.29-1.25 (t, 3H); MS: m/z = 652.2 ($\text{M}+1$, ESI $^+$); HRMS: 652.2617.

5.9.9. Synthesis of Compound 92 Hydrochloride




[0409] To a suspension of **compound 139**, 2-((2-ethyl-6-(6-(piperazin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (500 mg, 928 μmol) in DCM (10 mL) at 0 °C was added triphosgene (110 mg, 370 μmol), the

reaction mixture was stirred at 0 °C for 30 min. Then TEA (470 mg, 4.64 mmol) and (R)-pyrrolidin-3-ol (81 mg, 928 μmol) was added, the reaction mixture was stirred at 25 °C for 5 h. The mixture was quenched by water (50 mL) and extracted with DCM (20 mL x 3), the organic layer was washed with brine (50 mL), then dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC (Waters Xbridge C18 10μm OBD 19*250mm, A: 0.05% HCl in water; B: CH₃CN, 5% to 95%) in HCl condition to afford **compound 92**


hydrochloride, (R)-2-((2-ethyl-6-(6-(4-(3-hydroxypyrrolidine-1-carbonyl)piperazin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (205 mg, 29% yield) as a pale yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.18 (s, 1H), 8.50 (s, 1H), 8.41-8.35 (m, 2H), 8.14-8.12 (dd, J=9.2 Hz, 1H), 8.04-8.00 (t, 2H), 7.42-7.35 (m, 3H), 4.23 (s, 1H), 3.83-3.72 (m, 4H), 3.68 (s, 3H), 3.52-3.45 (m, 2H), 3.41-3.27 (m, 5H), 3.13-3.11 (d, J=10.8 Hz, 1H), 2.91-2.85 (dd, J₁=7.2 Hz, J₂=14.4 Hz, 2H), 1.85-1.72 (m, 2H), 1.36-1.33 (t, 3H); MS: m/z = 652.1 (M+1, ESI+).

5.9.10. Synthesis of Compound 93



[0410] To a solution of **compound 139**, 2-((2-ethyl-6-(6-(piperazin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (250 mg, 464.13 μmol) and 1-(hydroxymethyl) cyclopropane-1-carboxylic acid (64.67 mg, 556.96 μmol) in DMF (10 mL) was added HATU (262.65 mg, 696.20 μmol) and DIEA (179.95 mg, 1.39 mmol), the reaction mixture was stirred at 25 °C for 2 h. The mixture was poured into water (100 mL) and extracted with EA (40 mL×2). The organic layer was washed with water (100 mL×2) and brine (100 mL), then dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC to afford **compound 93**, 2-((2-ethyl-6-(6-(1-(hydroxymethyl)cyclopropane-1-carbonyl)piperazin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl) (methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (105 mg, 35.53% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.59 (s, 1H), 8.56-8.55 (d, 1H), 8.11-8.07 (t, 2H), 8.00-7.97 (dd, 1H), 7.73-7.66 (m, 2H), 7.44-7.40 (t, 2H), 6.96-6.94 (d, 1H), 4.89-4.86 (t, 1H), 3.64-3.56 (m, 11H), 3.48-3.47 (d, 2H), 2.69-2.64 (dd, 2H), 1.29-1.25 (t, 3H), 0.77-0.69 (m, 4H); MS: m/z = 637.2 (M+1, ESI+); HRMS: 637.2510.

5.9.11. Synthesis of Compound 94


*Step one:*

[0411] To a solution of tert-butyl 4-aminopiperidine-1-carboxylate (102.25 mg, 510.54 μmol) in DCM (10 mL) at 0 °C was added triphosgene (55.09 mg, 185.65 μmol), the reaction mixture was stirred at 0 °C for 30 min. Then, **compound 139**, 2-((2-ethyl-6-(6-(piperazin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (250 mg, 464.13 μmol) and TEA (234.83 mg, 2.32 mmol) was added, the reaction mixture was stirred at 25 °C for 3 h. The mixture was poured into water (100 mL) and extracted with DCM (30 mL x 3), the organic layer was washed with brine (100 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by column chromatography to afford tert-butyl 4-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperazine-1-carboxamido)piperidine-1-carboxylate (195 mg, 70.42% yield) as a yellow solid. MS: m/z = 765.4 ($M+1$, ESI+).

Step two:

[0412] To a solution of tert-butyl 4-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperazine-1-carboxamido)piperidine-1-carboxylate (195.00 mg, 254.93 μmol) in DCM (10 mL) was added TFA (290.67 mg, 2.55 mmol), the reaction mixture was stirred at 25 °C for 5 h. The mixture was concentrated under reduce pressure and the residue was purified by Prep-HPLC to afford **compound 94**, 4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)-N-(piperidin-4-yl)piperazine-1-carboxamide (123 mg, 72.58% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6) δ 8.58 (s, 1H), 8.55-8.54 (d, 1H), 8.11-8.07 (t, 2H), 7.98-7.95 (dd, 1H), 7.73-7.66 (m, 2H), 7.44-7.40 (t, 2H), 6.95-6.93 (d, 1H), 6.30-6.29 (d, 1H), 3.64 (s, 3H), 3.52-3.38 (m, 10H), 2.92-2.89 (d, 2H), 2.69-2.64 (dd, 2H), 2.47-2.41 (m, 2H), 1.68-1.65 (d, 2H), 1.32-1.23 (t, 5H); MS: m/z = 665.3 ($M+1$, ESI+); HRMS: 665.2931.

5.9.12. Synthesis of Compound 95


*Step one:*

[0413] To a solution of **compound 139**, 2-((2-ethyl-6-(6-(piperazin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (250 mg, 464.13 μmol) and (2S,4R)-1-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (128.79 mg, 556.96 μmol) in DMF (10 mL) was added HATU (262.65 mg, 696.20 μmol) and DIEA (179.95 mg, 1.39 mmol), the reaction mixture was stirred at 25 °C for 2 h. The mixture was poured into water (100 mL) and extracted with EA (40 mL $\times$ 2). The organic layer was washed with water (100 mL $\times$ 2) and brine (100 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by Prep-HPLC to afford tert-butyl (2S,4R)-2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperazine-1-carbonyl)-4-hydroxypyrrolidine-1-carboxylate (200 mg, 57.31% yield) as a yellow solid. MS: m/z = 752.2 ($M+1$, ESI+).

Step two:

[0414] To a solution of tert-butyl (2S,4R)-2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperazine-1-carbonyl)-4-hydroxypyrrolidine-1-carboxylate (200 mg, 266.00 μmol) in DCM (5 mL) was added TFA (303.30 mg, 2.66 mmol), the reaction mixture was stirred at 25 °C for 3 h. The mixture was concentrated under reduce pressure and the residue was purified by Prep-HPLC to afford **compound 95**, 2-((2-ethyl-6-(6-(4-((2S,4R)-4-hydroxypyrrolidine-2-carbonyl)piperazin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (115 mg, 66.33% yield) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.60 (s, 1H), 8.56-8.55 (d, 1H), 8.11-8.08 (t, 2H), 8.00-7.97 (dd, 1H), 7.73-7.66 (m, 2H), 7.44-7.39 (t, 2H), 6.96-6.93 (d, 1H), 4.20-4.19 (t, 1H), 4.08-4.04 (t, 1H), 3.65-3.40 (m, 13H), 3.09-3.05 (dd, 1H), 2.70-2.55 (dd, 3H), 1.89-1.77 (m, 2H), 1.29-1.25 (t, 3H); MS: m/z = 652.1 ($M+1$, ESI+); HRMS: 652.2610.

5.9.13. Synthesis of Compound 96 Hydrochloride


*Step one:*

[0415] To a suspension of **compound 139**, 2-((2-ethyl-6-(6-(piperazin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (250 mg, 464.13 μmol) in DCM (10 mL) at 0 °C was added triphosgene (55.09 mg, 185.65 μmol), the reaction mixture was stirred at 0 °C for 30 min. Then TEA (234.83 mg, 2.32 mmol) and tert-butyl 3-aminoazetidine-1-carboxylate (87.93 mg, 510.54 μmol) was added, the reaction mixture was stirred at 25 °C for 3 h. The mixture was poured into water (50 mL) and extracted with DCM (20 mL x 3), the organic layer was washed with brine (50 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by Prep-HPLC to afford tert-butyl 3-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperazine-1-carboxamido)azetidine-1-carboxylate (190 mg, 55.56% yield) as a yellow solid. MS: m/z = 737.4 ($M+1$, ESI+).

Step two:


[0416] To a solution of tert-butyl 3-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperazine-1-carboxamido)azetidine-1-carboxylate (190.00 mg, 257.85 μmol) in DCM (5 mL) was added TFA (294.00 mg, 2.58 mmol), the reaction mixture was stirred at 25 °C for 5 h. The mixture was concentrated under reduce pressure and the residue was purified by Prep-HPLC to afford **compound 96 hydrochloride**, N-(azetidin-3-yl)-4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperazine-1-carboxamide hydrochloride (125 mg, 72.01% yield) as a yellow solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.32-9.22 (m, 2H), 9.10 (s, 1H), 8.56-8.55 (d, 1H), 8.37-8.35 (d, 1H), 8.24-8.22 (d, 1H), 8.11-8.08 (d, 1H), 8.04-8.00 (t, 2H), 7.66-7.65 (d, 1H), 7.42-7.38 (t, 2H), 7.23-7.21 (d, 1H), 4.60-4.55 (m, 1H), 4.04-3.99 (dd, 4H), 3.94-3.82 (m, 7H), 3.60-3.51 (m, 4H), 2.90-2.84 (dd, 2H), 1.36-1.32 (t, 3H); MS: m/z = 637.3 ($M+1$, ESI+); HRMS: 637.2620.

5.9.14. Synthesis of Compound 96




[0417] To a mixture of **compound 96 hydrochloride**, N-(azetidin-3-yl)-4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperazine-1-carboxamide hydrochloride (90 mg, 0.120 mmol) in H₂O (3 mL) was added 2 M NaHCO₃ (1.05 mL, 2.1 mmol) at 0°C and stirred for 0.5 h. Then extracted with DCM (5 mL × 2). The organic layer was washed with water (5 mL) and brine (5 mL), dried over Na₂SO₄ and concentrated to afford **compound 96**, N-(azetidin-3-yl)-4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperazine-1-carboxamide (60 mg, 78.22% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.56-8.52 (m, 2H), 8.10-8.07 (t, 2H), 7.98-7.95 (m, 1H), 7.73-7.65 (m, 2H), 7.44-7.39 (t, 2H), 6.96-6.93 (d, 1H), 3.72-3.43 (m, 12H), 2.69-2.64 (m, 3H), 1.28-1.24 (t, 3H); MS: m/z = 637.0 (M+1, ESI+).

5.9.15. Synthesis of (4-(5-bromopyridin-2-yl)piperazin-1-yl)(cyclopentyl)methanone




[0418] To a solution of cyclopentanecarboxylic acid (450 mg, 3.94 mmol) and 5-bromo-2-(piperazin-1-yl)pyrimidine (954.53 mg, 3.94 mmol) in DMF (10 mL) was added T₃P (3.76 g, 5.91 mmol, 50% purity) and DIEA (1.53 g, 11.83 mmol), the reaction mixture was stirred at 25 °C for 2 h. The mixture was poured into water (100 mL) and extracted with EA (40 mL × 3). The organic layer was washed with water (100 mL × 2) and brine (100 mL), then dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography to afford (4-(5-bromopyridin-2-yl)piperazin-1-yl)(cyclopentyl)methanone (630 mg, 47.24% yield) as a yellow solid. MS: m/z = 338.1 (M+1, ESI+).

5.9.16. Synthesis of Compound 112




[0419] To a mixture of **compound 133**, 3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl boronic acid (498.17 mg, 1.18 mmol) and (4-(5-bromopyridin-2-yl)piperazin-1-yl)(cyclopentyl)methanone (400 mg, 1.18 mmol) in dioxane (8 mL) and water (2 mL) was added Na_2CO_3 (376.02 mg, 3.55 mmol) and $\text{Pd}(\text{PPh}_3)_4$ (136.65 mg, 118.26 μmol), the reaction mixture was stirred at 100 °C for 2 h under N_2 . The mixture was poured into water (60 mL) and extracted with EA (20 mL x 2). The organic layer was washed by brine (100 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by column chromatography to afford **compound 112**, 2-((6-(4-(cyclopentanecarbonyl)piperazin-1-yl)pyridin-3-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (160 mg, 21.33% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6) δ 8.60-8.55 (m, 2H), 8.10 (s, 2H), 8.00-7.97 (m, 1H), 7.72-7.66 (dd, 2H), 7.44-7.39 (t, 2H), 6.94-6.92 (d, 1H), 3.65-3.53 (m, 11H), 3.03-2.99 (m, 1H), 2.70-2.64 (dd, 2H), 1.78-1.52 (m, 8H), 1.29-1.25 (t, 3H); MS: m/z = 635.2 ($\text{M}+1$, ESI+); HRMS: 635.2710.

5.10. Example 9 – Synthesis of Piperidine-linked Pyrimidine-type Compounds

General Scheme 9

5.10.1. Synthesis of Compound 140 – Method 1


Method 1



[0420] To a solution of **compound 128**, 2-((6-(2-chloropyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (1 g, 2.04 mmol)

and piperidin-4-one hydrochloride (415.12 mg, 3.06 mmol) in MeCN (20 mL) was added Cs_2CO_3 (2.66 mg, 8.16 mmol), the reaction mixture was stirred at 80 °C for 16 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by column chromatography to afford **compound 140**, 2-((2-ethyl-6-(2-(4-oxopiperidin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (440 mg, 39.01% yield) as a yellow solid. MS: $m/z = 553.1(\text{M}+1, \text{ESI}^+)$.

5.10.2. Synthesis of Compound 140 – Method 2




Step one:

[0421] To a solution of **compound 128**, 2-((6-(2-chloropyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (500mg, 1.02mmol) and piperidin-4-ol (150 mg, 1.48 mmol) in MeCN (50mL) was added Cs_2CO_3 (980 mg, 3.01 mmol), the resulting mixture was stirred 70 °C for 16 h. The mixture was concentrated under reduced pressure and the residue was purified by column chromatography to afford 2-((2-ethyl-6-(2-(4-hydroxypiperidin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (440 mg, 77.74% yield) as a yellow solid. MS: $m/z = 555.2(\text{M}+1, \text{ESI}^+)$.

Step two:

[0422] To a solution of 2-((2-ethyl-6-(2-(4-hydroxypiperidin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (470 mg, 847.40 μmol) in DCM (20 mL) was added Dess-Martin (940 mg, 2.22 mmol) and stirred at 25 °C for 3 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by column chromatography to afford **compound 140**, 2-((2-ethyl-6-(2-(4-oxopiperidin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridine-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (463 mg, 98.93% yield) as a yellow solid. MS: $m/z = 553.4(\text{M}+1, \text{ESI}^+)$.

5.10.3. Synthesis of Compound 141 Hydrochloride


*Step one:*

[0423] To a solution of **compound 128**, 2-((6-(2-chloropyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (500 mg, 1.02 mmol) and tert-butyl piperidin-4-ylcarbamate (613.15 mg, 3.06 mmol) in MeCN (30 mL) was added Cs₂CO₃ (997.50 mg, 3.06 mmol). The reaction mixture was stirred at 80°C for 24 h. The reaction mixture was filtered, the filtrate was concentrated under reduced pressure and the residue was purified by Prep-HPLC to afford tert-butyl (1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridine-6-yl)pyrimidin-2-yl)piperidin-4-yl)carbamate (572.1 mg, 85.73% yield) as a yellow solid. MS: m/z = 654.2 (M+1, ESI+).

Step two:

[0424] To a solution of tert-butyl (1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridine-6-yl)pyrimidin-2-yl)piperidin-4-yl)carbamate (572.1 mg, 855.43 μmol) in EA (5 mL) was added 3M HCl in EA (3 M, 5 mL), the reaction mixture was stirred at 25°C for 1 h. The excess of solvent was removed under reduced pressure to afford **compound 141 hydrochloride**, 2-((6-(2-(4-aminopiperidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (501.2 mg, 96.82% yield) as a yellow solid. MS: m/z = 554.3 (M+1, ESI+).

5.10.4. Synthesis of Compound 142




Step one:

[0425] To a solution of **compound 128**, 2-((6-(2-chloropyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (700 mg, 1.43 mmol) and methyl piperidine-4-carboxylate hydrochloride (384.99 mg, 2.14 mmol) in MeCN (10 mL) was added Cs₂CO₃ (1.40 g, 4.29 mmol), the reaction mixture was stirred at 25°C for 3 h. The reaction mixture was evaporated under reduce pressure and the residue was purified by column chromatography to afford methyl 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidine-4-carboxylate (750 mg, 87.98% yield) as a yellow solid. MS: m/z = 597.1(M+1, ESI+).

Step two:

[0426] To a solution of methyl 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidine-4-carboxylate (750 mg, 1.26 mmol) in THF (10 mL) and H₂O (10 mL) was added LiOH (90.31 mg, 3.77 mmol). The reaction mixture was stirred at 40°C for 3 h. The reaction mixture was adjusted to pH 5-6 with 2M HCl and extracted with DCM (20mLx3), the combined organic layers were washed with brine (100mL), dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography to afford **compound 142** 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidine-4-carboxylic acid(600 mg, 81.93% yield) as a yellow solid. MS: m/z = 583.3(M+1, ESI+).

5.10.5. Synthesis of 1-(piperidin-4-ylamino)cyclopropane-1-carbonitrile*Step one:*


[0427] To a solution of 1-benzylpiperidin-4-one (1 g, 5.28mmol) and 1-aminocyclopropane-1-carbonitrile hydrochloride (939.73 mg, 7.93 mmol) in DCM (10 mL) was added AcOH (two drops), the reaction mixture was stirred at 25°C for 16 h. Then NaBH₄ (2.00 g, 52.84 mmol) was added and stirred at 25°C for 3 h. The reaction mixture was poured into water (50 mL) and extracted with DCM (10 mLx3). The combined organic layers were dried over Na₂SO₄ and concentrated under reduced pressure and purified by silica gel column to afford

1-((1-benzylpiperidin-4-yl)amino)cyclopropane-1-carbonitrile (1.05 g, 77.74% yield) as a yellow oil. MS: $m/z = 256.2$ (M+1, ESI+).

Step two:


[0428] To a solution of 1-((1-benzylpiperidin-4-yl)amino)cyclopropane-1-carbonitrile (500 mg, 1.96 mmol) in MeOH (5 mL) was added Pd/C (231.89 mg, 1.96 mmol), the reaction mixture was stirred at 25°C for 5 h under H₂. The reaction mixture was filtered and the filtrate was evaporated under reduce pressure to afford 1-(piperidin-4-ylamino)cyclopropane-1-carbonitrile (600 mg, crude) as a yellow oil which was used for next step without further purification. MS: $m/z = 166.2$ (M+1, ESI+).

5.10.6. Synthesis of Compound 17




[0429] To a solution of **compound 128**, 2-((6-(2-chloropyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (150 mg, 306.15 umol) and 1-(piperidin-4-ylamino) cyclopropane-1-carbonitrile (101.17mg, 612.3 umol) in MeCN (10 mL) was added Cs₂CO₃ (299.25 mg, 918.45 umol), the reaction mixture was stirred at 25°C for 3 h. The reaction mixture was filtered, the filtrate was concentrated under reduced pressure and the residue was purified by Prep-HPLC to afford **compound 17**, 2-((6-(2-(4-((1-cyanocyclopropyl)amino)piperidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (42 mg, 22.17% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.75 (s, 2H), 8.64 (s, 1H), 8.10-8.07 (t, 2H), 7.69 (s, 2H), 7.44-7.40 (t, 2H), 4.51-4.47 (d, 2H), 3.63 (s, 3H), 3.45 (d, 1H), 3.18-3.12 (t, 2H), 3.04 (s, 1H), 2.70-2.64 (dd, 2H), 1.93-1.89 (dd, 2H), 1.28-1.17 (m, 7H), 0.95-0.92 (m, 2H); MS: $m/z = 619.4$ (M+1, ESI+).

5.10.7. Synthesis of Compound 18



[0430] To a solution of **compound 140**, 2-((2-ethyl-6-(2-(4-oxopiperidin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (150 mg, 271.43 μmol) and (1-amino cyclopropyl)methanol hydrochloride (50.32 mg, 407.15 μmol) in DCM (5 mL) was added $\text{NaBH}(\text{OAc})_3$ (115.05 mg, 542.86 μmol). The mixture was stirred at 25 °C for 24 h. The resulting solution was quenched by saturated NH_4Cl (30 mL) and extracted with DCM (30 mL x 3), the combined organic layers were washed with water (30 mL x 2) and brine (30 mL), dried over Na_2SO_4 and concentrated under reduced pressure. The residue was purified by Prep-HPLC to afford **compound 18**, 2-(((2-ethyl-6-(2-(4-((1-(hydroxymethyl)cyclopropyl)amino)piperidin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (81 mg, 47.84% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6) δ 8.74 (s, 2H), 8.64 (s, 1H), 8.11-8.07 (t, 2H), 7.69 (s, 2H), 7.44-7.39 (t, 2H), 4.51-4.48 (t, 3H), 3.63 (s, 3H), 3.36-3.34 (d, 2H), 3.11-3.05 (m, 3H), 2.70-2.64 (dd, 2H), 2.20 (bs, 1H), 1.85-1.82 (d, 2H), 1.29-1.11 (m, 5H), 0.40 (s, 4H); MS: m/z = 624.3 ($\text{M}+1$, ESI+).


5.10.8. Synthesis of Compound 19



[0431] To a solution of **compound 141 hydrochloride**, 2-((6-(2-(4-aminopiperidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (250 mg, 423.65 μmol) and 1-hydroxycyclopropane-1-carboxylic acid (64.87 mg, 635.47 μmol) in DCM (20 mL) was added HATU (241.62 mg, 635.47 μmol) and DIEA (164.26 mg, 1.27 mmol), the reaction mixture was stirred at 25°C for 16 h. The reaction mixture was poured into water (50 mL)


and extracted with DCM (10 mLx3). The combined organic layers were dried over Na₂SO₄ and concentrated under reduced pressure and purified by Prep-HPLC to afford **compound 19**, N-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)-1-hydroxycyclopropane-1-carboxamide (120 mg, 44.46% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.77 (s, 2H), 8.65 (s, 1H), 8.11-8.07 (t, 2H), 7.73-7.70 (m, 3H), 7.44-7.40 (t, 2H), 6.17 (s, 1H), 4.68-4.64 (d, 2H), 3.93 (s, 1H), 3.63 (s, 3H), 3.04-2.99 (t, 2H), 2.70-2.64 (dd, 2H), 1.78-1.74 (dd, 2H), 1.53-1.44 (m, 2H), 1.28-1.25 (t, 3H), 1.02-0.99 (dd, 2H), 0.82-0.79 (dd, 2H); MS: m/z = 638.3 (M+1, ESI+).

5.10.9. Synthesis of Compound 20



[0432] To a solution of **compound 141 hydrochloride**, 2-((6-(2-(4-aminopiperidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl) (methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (250 mg, 423.65 μmol), and 1-cyanocyclopropane-1-carboxylic acid (63.54 mg, 571.92 μmol) in DCM (20 mL) was added HATU (217.46 mg, 571.92 μmol) and DIEA (147.83 mg, 1.14 mmol), the reaction mixture was stirred at 25 °C for 16 h. The reaction mixture was poured into water (50 mL) and extracted with DCM (10 mLx3). The combined organic layers were dried over Na₂SO₄ and concentrated under reduced pressure and purified by Prep-HPLC to afford **compound 20**, 1-cyano-N-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl) cyclopropane-1-carboxamide (130 mg, 23.38% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.78 (s, 2H), 8.66 (s, 1H), 8.11-8.07 (t, 2H), 7.97-7.95 (d, 1H), 7.70 (s, 2H), 7.44-7.40 (t, 2H), 4.68-4.64 (d, 2H), 3.92-3.90 (m, 1H), 3.63 (s, 3H), 3.01-2.95 (t, 2H), 2.70-2.64 (dd, 2H), 1.75-1.73 (d, 2H), 1.55-1.46 (m, 6H), 1.28-1.25 (t, 3H); MS: m/z = 647.2 (M+1, ESI+).

5.10.10. Synthesis of Compound 68 Formate


*Step one:*

[0433] A mixture of **compound 140**, 2-((2-ethyl-6-(2-(4-oxopiperidin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (200 mg, 361.91 μmol) and tert-butyl 3-aminoazetidine-1-carboxylate (74.80 mg, 434.29 μmol) in DCM (5 mL) was stirred at 25 °C for 16 h. Then $\text{NaBH}(\text{OAc})_3$ (153.41 mg, 723.82 μmol) was added to the above solution and stirred at 25 °C for another 3 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by column chromatography to afford tert-butyl 3-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)amino)azetidine-1-carboxylate (145 mg, 56.52% yield) as a yellow solid. MS: m/z = 709.3($M+1$, ESI+).

Step two:

[0434] To a solution of tert-butyl 3-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)amino)azetidine-1-carboxylate (140mg, 197.50 μmol) in DCM (5 mL) was added TFA (5 mL). The reaction mixture was stirred at 25 °C for 2 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by Prep-HPLC (Waters Xbridge C18 10 μm OBD 19*250mm, A: 0.1% FA in water; B: CH_3CN , 5% to 95%) in FA condition to afford **compound 68 formate**, 2-((6-(2-(4-(azetidin-3-ylamino)piperidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile formate (75 mg, 58.14% yield) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.75 (s, 2H), 8.64 (s, 1H), 8.20 (s, 1H), 8.11-8.07 (t, 2H), 7.69 (s, 2H), 7.44-7.40 (t, 2H), 4.54-4.51 (d, 2H), 4.00 (s, 2H), 3.78-3.63 (m, 7H), 3.06-3.00 (t, 2H), 2.70-2.64 (dd, 3H), 1.77-1.74 (d, 2H), 1.28-1.25 (t, 3H), 1.15-1.13 (d, 2H); MS: m/z = 609.2($M+1$, ESI+).

5.10.11. Synthesis of Compound 68 Hydrochloride


*Step one*

[0435] A mixture of **compound 140**, 2-((2-ethyl-6-(2-(4-oxopiperidin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (800 mg, 1.45 mmol) and tert-butyl 3-aminoazetidine-1-carboxylate (74.80 mg, 434.29 μ mol) in DCM (5 mL) was stirred at 25 °C for 16 h. Then NaBH(OAc)₃ (612 mg, 1.74 mmol) was added to the above solution and stirred at 25 °C for another 3 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by column chromatography to afford tert-butyl 3-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)amino)azetidine-1-carboxylate (800 mg, 78.4% yield) as a yellow solid. MS: m/z = 709.3(M+1, ESI+).

Step two

[0436] To a solution of tert-butyl 3-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)amino)azetidine-1-carboxylate (800 mg, 1.13 mmol) in DCM (5 mL) was added TFA (5 mL). The reaction mixture was stirred at 25 °C for 2 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by Prep-HPLC (Waters Xbridge C18 10 μ m OBD 19*250mm, A: 0.05% HCl in water; B: CH₃CN, 5% to 95%) in HCl condition to afford compound 68 HCl, 2-((6-(2-(4-(azetidin-3-ylamino)piperidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (125 mg, 15.41% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.98 (s, 1H), 8.87 (s, 2H), 8.36-8.34 (d, 1H), 8.11-8.08 (d, 1H), 8.02-7.99 (m, 2H), 7.21-7.17 (t, 2H), 4.90 (s, 2H), 4.64-4.54 (m, 3H), 4.46-4.41 (m, 2H), 3.75 (s, 3H), 3.66-3.60 (m, 1H), 3.23-3.16 (t, 2H), 2.99-2.94 (dd, 2H), 2.24-2.21 (d, 2H), 1.81-1.73 (m, 2H), 1.44-1.40 (t, 3H); MS: m/z = 609.2(M+1, ESI+).

5.10.12. Synthesis of Compound 69 Formate


*Step one:*

[0437] A mixture of **compound 140**, 2-((2-ethyl-6-(2-(4-oxopiperidin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (200 mg, 361.91 μmol) and tert-butyl 4-amino piperidine-1-carboxylate (86.98 mg, 434.29 μmol) in DCM (5 mL) was stirred at 25 °C for 16 h. Then $\text{NaBH}(\text{OAc})_3$ (153.41 mg, 723.82 μmol) was added to the above solution and stirred at 25 °C for another 3 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by column chromatography to afford tert-butyl 4-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)amino)piperidine-1-carboxylate (150 mg, 56.17% yield) as a yellow solid. MS: m/z = 737.3($M+1$, ESI+).

Step two:

[0438] To a solution of tert-butyl 4-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)amino)piperidine-1-carboxylate (135 mg, 183.20 μmol) in DCM (5 mL) was added TFA (5 mL). The reaction mixture was stirred at 25 °C for 2 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by Prep-HPLC (Waters Xbridge C18 10 μm OBD 19*250mm, A: 0.1% FA in water; B: CH_3CN , 5% to 95%) in FA condition to afford **compound 69 formate**, 2-((2-ethyl-6-(2-(4-(piperidin-4-ylamino)piperidin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile formate (75 mg, 60% yield) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.80 (s, 2H), 8.66 (s, 1H), 8.11-8.07 (t, 2H), 7.71 (s, 2H), 7.44-7.40 (t, 2H), 4.75-4.72 (d, 2H), 3.63 (s, 3H), 3.46-3.32 (m, 5H), 3.02-2.89 (m, 5H), 2.70-2.65 (dd, 2H), 2.14-2.05 (m, 4H), 1.69-1.66 (d, 2H), 1.43-1.40 (d, 2H), 1.29-1.25 (t, 3H); MS: m/z = 637.3($M+1$, ESI+).

5.10.13. Synthesis of Compound 69 Hydrochloride




Step one:

[0439] A mixture of 2-((2-ethyl-6-(2-(4-oxopiperidin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methylamino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (360 mg, 652 μmol) and tert-butyl 4-aminopiperidine-1-carboxylate (156 mg, 782 μmol) in DCM (5 mL) was stirred at 25 °C for 16 h. Then $\text{NaBH}(\text{OAc})_3$ (207 mg, 978 μmol) was added to the above solution and stirred at 25 °C for another 3 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by column chromatography to afford tert-butyl 4-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methylamino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)amino)piperidine-1-carboxylate (320 mg, 66.7% yield) as a yellow solid. MS: $m/z = 737.3(\text{M}+1, \text{ESI}^+)$.

Step two:

[0440] To a solution of tert-butyl 4-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl) piperidin-4-yl)amino)piperidine-1-carboxylate (320 mg, 435 μmol) in DCM (5 mL) was added TFA (5 mL). The reaction mixture was stirred at 25 °C for 2 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by Prep-HPLC (Waters Xbridge C18 10 μm OBD 19*250mm, A: 0.05% HCl in water; B: CH₃CN, 5% to 95%) in HCl condition to afford 2-((2-ethyl-6-(2-(4-(piperidin-4-ylamino) piperidin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl) thiazole-5-carbonitrile hydrochloride (250 mg, 77.1% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.75 (s, 2H), 9.44 (s, 1H), 9.10-9.05 (m, 2H), 8.87 (s, 2H), 8.40-8.37 (d, 1H), 8.13-8.11 (d, 1H), 8.03-7.99 (t, 2H), 7.42-7.38 (t, 2H), 4.83-4.80 (d, 2H), 3.67 (s, 3H), 3.51 (s, 2H), 3.37-3.34 (d, 2H), 3.03-2.85 (m, 6H), 2.27-2.24 (d, 2H), 2.18-2.15 (d, 2H), 1.97-1.89 (dd, 2H), 1.69-1.61 (dd, 2H), 1.36-1.32 (t, 3H); MS: m/z = 637.4(M+1, ESI+).

5.10.14. Synthesis of Compound 72 Hydrochloride


*Step one:*

[0441] To a solution of **compound 142** 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidine-4-carboxylic acid (300 mg, 514.89 μmol) and tert-butyl 3-aminoazetidine-1-carboxylate (88.68 mg, 514.89 μmol) in DMF (10 mL) was added HATU (587.33 mg, 1.54 mmol) and DIEA (332.72 mg, 2.57 mmol), the reaction mixture was stirred at 25°C for 16 h. The reaction mixture was poured into H₂O (100 mL) and extracted with EA (30mLx3), the combined organic layers were washed with brine (100mL), dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography to afford tert-butyl 3-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidine-4-carboxamido)azetidine-1-carboxylate (350 mg, 92.25% yield). MS: m/z = 737.4 (M+1, ESI+).

Step two:


[0442] To a solution of tert-butyl 3-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidine-4-carboxamido)azetidine-1-carboxylate (350 mg, 474.99 μmol) in DCM (10 mL) was added TFA (2 mL) and stirred at 25 °C for 3 h. The reaction mixture was evaporated under reduce pressure and the residue was purified by Prep-HPLC to afford **compound 72 hydrochloride**, N-(azetidin-3-yl)-1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidine-4-carboxamide hydrochloride (160 mg, 52.90% yield) as a pale yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.55 (s, 1H), 9.42 (s, 1H), 9.12 (s, 1H), 8.98-8.97 (d, 1H), 8.87 (s, 2H), 8.42-8.39 (d, 1H), 8.14-8.12 (d, 1H), 8.01 (s, 2H), 7.42-7.38 (t, 2H), 4.71-4.58 (m, 3H), 4.04-3.91 (m, 4H), 3.68 (s, 3H), 3.08-3.02 (t, 2H), 2.91-2.86 (m, 2H), 1.83-1.80 (m, 2H), 1.53-1.45 (m, 2H), 1.37-1.33 (t, 3H); MS: m/z = 637.3(M+1, ESI+).

5.10.15. Synthesis Compound 72



[0443] To a mixture of **compound 72 hydrochloride**, N-(azetidin-3-yl)-1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidine-4-carboxamide hydrochloride (120 mg, 0.178 mmol) in H₂O (3 mL) was added 2 M NaHCO₃ (1.05 mL, 2.1 mmol) at 0°C and stirred for 0.5 h. Then extracted with DCM (5 mL × 2). The organic layer was washed with water (5 mL) and brine (5 mL), dried over Na₂SO₄ and concentrated to afford **compound 72**, N-(azetidin-3-yl)-1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidine-4-carboxamide (100 mg, 88.5% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.76 (s, 2H), 8.64 (s, 1H), 8.55-8.53 (m, 1H), 8.08-8.06 (t, 2H), 7.70 (s, 1H), 7.44-7.40 (t, 2H), 4.70-4.52 (m, 3H), 4.08-4.04 (m, 2H), 3.94-3.88 (m, 2H), 3.63 (s, 3H), 3.03-2.97 (m, 2H), 2.70-2.64 (m, 2H), 1.79-1.76 (m, 2H), 1.51-1.43 (m, 2H), 1.28-1.25 (t, 3H); MS: m/z = 609.3 (M+1, ESI+).

5.10.16. Synthesis of Compound 73 Hydrochloride

*Step one:*


[0444] To a solution of **compound 142**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidine-4-carboxylic acid (300 mg, 514.89 μmol) and tert-butyl 4-aminopiperidine-1-carboxylate (154.68 mg, 772.33 μmol) in DMF (10 mL) was added HATU (587.33 mg, 1.54 mmol) and DIEA (332.72 mg, 2.57 mmol), the reaction mixture was stirred at 25 °C for 16 h. The reaction mixture was poured into H₂O (100 mL) and extracted with EA (30 mL × 3), the combined organic layers were washed with brine (100 mL), dried over Na₂SO₄ and concentrated. The residue was

purified by column chromatography to afford tert-butyl 4-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidine-4-carboxamido)piperidine-1-carboxylate (300 mg, 76.14% yield). MS: m/z = 765.4(M+1, ESI+).

Step two:


[0445] To a solution of tert-butyl 4-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidine-4-carboxamido)piperidine-1-carboxylate (300 mg, 392.20 μ mol) in DCM (10 mL) was added TFA (2 mL) and stirred at 25 °C for 3 h. The reaction mixture was evaporated under reduce pressure and the residue was purified by Prep-HPLC to afford **compound 73 hydrochloride**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)-N-(piperidin-4-yl)piperidine-4-carboxamide hydrochloride (160 mg, 61.37% yield) as a pale yellow solid. ^1H NMR (400 MHz, DMSO- d_6) δ 9.29 (s, 2H), 9.12 (s, 1H), 8.87 (s, 2H), 8.42-8.39 (d, 1H), 8.21-8.19 (d, 1H), 8.14-8.12 (d, 1H), 8.01 (s, 2H), 7.42-7.38 (t, 2H), 4.73-4.70 (d, 2H), 3.80-3.78 (d, 1H), 3.68 (s, 3H), 3.23-2.86 (m, 8H), 1.88-1.45 (m, 9H), 1.37-1.33 (t, 3H); MS: m/z = 665.3(M+1, ESI+)

5.10.17. Preparation of Compound 73



[0446] **Compound 73 hydrochloride**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)-N-(piperidin-4-yl)piperidine-4-carboxamide hydrochloride (120 mg, 0.171 mmol) was purified by Prep-HPLC to afford **compound 73**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)-N-(piperidin-4-yl)piperidine-4-carboxamide (70 mg, 61.40% yield) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 8.76 (s, 2H), 8.65 (s, 1H), 8.10-8.07 (t, 2H), 7.73-7.69 (m, 3H), 7.44-7.40 (t, 2H), 4.70-4.67 (d, 2H), 3.63 (s, 3H), 3.58-3.52 (m, 1H), 2.96-2.89 (m, 4H), 2.70-2.64 (dd, 2H), 2.47-2.41 (m, 2H), 1.72-1.69 (d, 2H), 1.64-1.62 (d, 2H), 1.49-1.45 (m, 2H), 1.28-1.18 (m, 7H); MS: m/z = 665.1 (M+1, ESI+).

5.10.18. Synthesis of Compound 74 Formate


*Step one:*

[0447] To a solution of **compound 141 hydrochloride**, 2-((6-(2-(4-aminopiperidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (200 mg, 361.24 μmol) and (2R,4S)-1-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (108.59 mg, 469.61 μmol) in DMF (10 mL) was added HOBT (73.22 mg, 541.85 μmol), EDCI (103.87 mg, 541.85 μmol) and TEA (109.66 mg, 1.08 mmol), the reaction mixture was stirred at 25 °C for 16 h. The reaction mixture was poured into H₂O (100 mL) and extracted with EA (30 mL x 3), the combined organic layers were washed with brine (100 mL x 3), dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography to afford tert-butyl (2R,4S)-2-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylate (220 mg, 79.41% yield) as a yellow solid. MS: m/z = 767.3 (M+1, ESI+).

Step two:


[0448] To a solution of tert-butyl (2R,4S)-2-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylate (220 mg, 286.87 μmol) in DCM (15 mL) was added 3M HCl in EA (956.25 μL) and stirred at 25 °C for 16 h. The reaction mixture was concentrated and purified by Prep-HPLC to afford **compound 73 formate**, (2R,4S)-N-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)-4-hydroxypyrrolidine-2-carboxamide formate (103 mg, 53.85% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.77 (s, 2H), 8.65 (s, 1H), 8.25 (s, 1H), 8.09 (s, 2H), 7.94 (s, 1H), 7.70 (s, 2H), 7.44-7.40 (t, 2H), 4.57-4.54 (d, 2H), 4.17 (s, 1H), 3.85-3.84 (d, 1H), 3.72-3.68 (t, 1H), 3.63 (s, 3H), 3.13-3.07 (t, 2H), 2.84-2.62 (m, 4H), 1.93 (s, 1H), 1.78-1.75 (d, 2H), 1.67-1.66 (d, 1H), 1.37-1.35 (d, 2H), 1.28-1.24 (t, 3H); MS: m/z = 667.5 (M+1, ESI+).

5.10.19. Synthesis of Compound 74



[0449] Compound 74 formate, (2R,4S)-N-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethyl imidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)-4-hydroxypyrrolidine-2-carboxamide formate (99 mg, 0.139 mmol) was purified by Prep-HPLC to afford **compound 74**, (2R,4S)-N-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl) piperidin-4-yl)-4-hydroxypyrrolidine-2-carboxamide (56 mg, 60.47% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.77 (s, 2H), 8.65 (s, 1H), 8.10-8.01 (m, 3H), 7.70 (s, 2H), 7.44-7.40 (t, 2H), 4.56-4.53 (d, 2H), 4.21 (s, 1H), 3.85-3.74 (m, 2H), 3.63 (s, 3H), 3.15-3.08 (t, 2H), 2.91-2.64 (m, 4H), 1.98-1.77 (m, 4H), 1.38-1.22 (m, 5H); MS: m/z= 667.1 (M+1, ESI+).

5.10.20. Synthesis of Compound 75 Formate

*Step one:*


[0450] To a solution of **compound 141 hydrochloride**, 2-((6-(2-(4-aminopiperidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl) (methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (200 mg, 361.24 μmol) and (2S,4S)-1-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (108.59 mg, 469.61 μmol) in DMF (10 mL) was added HOBT (73.22 mg, 541.85 μmol), EDCI (103.87 mg, 541.85 μmol) and TEA (109.66 mg, 1.08 mmol), the reaction mixture was stirred at 25 °C for 16 h. The reaction mixture was poured into H₂O (100 mL) and extracted with EA (30 mL x 3), the combined organic layers were washed with brine (100 mL x 3), dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography to afford tert-butyl (2S,4S)-2-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl) piperidin-4-yl)carbamoyl)-4-

hydroxypyrrolidine-1-carboxylate (210 mg, 75.81% yield) as a yellow solid. MS: $m/z = 767.3$ (M+1, ESI+).

Step two:


[0451] To a solution of tert-butyl (2S,4S)-2-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethyl imidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)carbamoyl)-4-hydroxy pyrrolidine-1-carboxylate (210 mg, 273.84 μmol) in DCM (15 mL) was added 3M HCl in EA (912.78 μL) and stirred at 25 °C for 16 h. The reaction mixture was concentrated and purified by Prep-HPLC to afford **compound 75 formate**, (2S,4S)-N-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)-4-hydroxypyrrolidine-2-carboxamide formate (57 mg, 29.23% yield) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 8.77 (s, 2H), 8.65 (s, 1H), 8.24 (s, 1H), 8.11-8.07 (t, 2H), 7.94 (s, 1H), 7.70 (s, 2H), 7.44-7.40 (t, 2H), 4.55-4.52 (d, 2H), 4.11 (s, 1H), 3.87-3.86 (d, 1H), 3.63 (s, 3H), 3.53-3.52 (d, 1H), 3.17-3.11 (t, 2H), 2.89-2.87 (t, 1H), 2.70-2.64 (m, 3H), 2.15-2.13 (m, 1H), 1.80-1.77 (d, 2H), 1.60 (s, 1H), 1.41-1.32 (m, 2H), 1.28-1.25 (t, 3H); MS: $m/z = 667.5$ (M+1, ESI+).

5.10.21. Synthesis of Compound 75



[0452] **Compound 75 formate**, (2S,4S)-N-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethyl imidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)-4-hydroxypyrrolidine-2-carboxamide formate (49 mg, 0.069 mmol) was purified by Prep-HPLC to afford **compound 75**, (2S,4S)-N-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)-4-hydroxypyrrolidine-2-carboxamide (29 mg, 63.31% yield) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 8.77 (s, 2H), 8.65 (s, 1H), 8.10-8.09 (t, 2H), 7.91-7.89 (m, 1H), 7.70 (s, 2H), 7.44-7.40 (t, 2H), 4.67-4.51 (m, 2H), 4.11-4.09 (m, 1H), 3.85-3.74 (m, 1H), 3.63 (s, 3H), 3.50-3.49 (m, 1H), 3.16-3.10 (m, 2H), 2.86-2.63 (m, 4H), 2.14 (s, 1H), 1.80-1.77 (m, 3H), 1.39-1.22 (m, 5H); MS: $m/z = 667.1$ (M+1, ESI+).

5.10.22. Synthesis of Compound 76 Formate


*Step one:*

[0453] To a solution of **compound 141 hydrochloride**, 2-((6-(2-(4-aminopiperidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (200 mg, 361.24 μmol) and (2R,4R)-1-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (108.59 mg, 469.61 μmol) in DMF (10 mL) was added HOBT (73.22 mg, 541.85 μmol), EDCI (103.87 mg, 541.85 μmol) and TEA (109.66 mg, 1.08 mmol), the reaction mixture was stirred at 25 °C for 16 h. The reaction mixture was poured into H₂O (100 mL) and extracted with EA (30 mL x 3), the combined organic layers were washed with brine (100 mL x 3), dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography to afford tert-butyl (2R,4R)-2-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylate (210 mg, 75.81% yield) as a yellow solid. MS: m/z = 767.3 (M+1, ESI+).

Step two:


[0454] To a solution of tert-butyl (2R,4R)-2-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylate (210 mg, 273.84 μmol) in DCM (15 mL) was added 3M HCl in EA (912.78 μL) and stirred at 25 °C for 16 h. The reaction mixture was concentrated and purified by Prep-HPLC to afford **compound 76 formate**, (2R,4R)-N-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)-4-hydroxypyrrolidine-2-carboxamide formate (58 mg, 31.77% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.77 (s, 2H), 8.66 (s, 1H), 8.32 (s, 1H), 8.11-8.07 (m, 3H), 7.70 (s, 2H), 7.44-7.40 (t, 2H), 4.55-4.52 (d, 2H), 4.16-4.15 (t, 1H), 3.91-3.84 (m, 1H), 3.65-3.64 (m, 4H), 3.18-3.12 (m, 2H), 2.95-2.91 (m, 1H), 2.78-2.74 (m, 1H), 2.70-2.65 (dd, 2H), 2.23-2.16 (m, 1H), 1.81-1.78 (d, 2H), 1.68-1.63 (m, 1H), 1.42-1.32 (m, 2H), 1.29-1.25 (t, 3H); MS: m/z = 667.5 (M+1, ESI+).

5.10.23. Synthesis of Compound 76



[0455] Compound 76 formate (2R,4R)-N-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)-4-hydroxypyrrolidine-2-carboxamide formate (51 mg, 0.072 mmol) was purified by Prep-HPLC to afford **compound 76**, (2R,4R)-N-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)-4-hydroxypyrrolidine-2-carboxamide (45 mg, 94.34% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.77 (s, 2H), 8.65 (s, 1H), 8.10-8.07 (t, 2H), 7.86-7.84 (d, 1H), 7.70 (s, 2H), 7.44-7.40 (t, 2H), 4.61-4.51 (m, 3H), 4.09-4.07 (m, 1H), 3.85-3.74 (m, 1H), 3.63 (s, 3H), 3.13-3.09 (m, 2H), 2.85-2.81 (m, 1H), 2.70-2.60 (m, 3H), 2.14-2.07 (m, 1H), 1.81-1.77 (m, 2H), 1.60-1.54 (m, 1H), 1.40-1.31 (m, 2H), 1.28-1.25 (t, 3H); MS: m/z= 667.1 (M+1, ESI+).

5.10.24. Synthesis of Compound 77 Formate



Step one:


[0456] To a solution of **compound 141 hydrochloride**, 2-((6-(2-(4-aminopiperidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (200 mg, 361.24 μmol) and (2R,4R)-1-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (108.59 mg, 469.61 μmol) in DMF (10 mL) was added HOBT (73.22 mg, 541.85 μmol), EDCI (103.87 mg, 541.85 μmol) and TEA (109.66 mg, 1.08 mmol), the reaction mixture was stirred at 25 °C for 16 h. The reaction mixture was poured into H₂O (100 mL) and extracted with EA (30 mL x 3), the combined organic layers were washed with brine (100 mL x 3), dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography to afford tert-butyl (2S,4R)-2-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-

ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl) piperidin-4-yl)carbamoyl)-4-hydroxypyrrolidine-1-carboxylate (200 mg, 72.20% yield) as a yellow solid. MS: $m/z = 767.3$ (M+1, ESI+).

Step two:


[0457] To a solution of tert-butyl (2S,4R)-2-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethyl imidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)carbamoyl)-4-hydroxy pyrrolidine-1-carboxylate (180 mg, 234.72 μmol) in DCM (15 mL) was added 3M HCl in EA (912.78 μL) and stirred at 25 °C for 16 h. The reaction mixture was concentrated and purified by Prep-HPLC to afford **compound 77 formate**, (2S,4R)-N-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)-4-hydroxypyrrolidine-2-carboxamide formate (92 mg, 58.79% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6) δ 8.77 (s, 2H), 8.66 (s, 1H), 8.29 (s, 1H), 8.11-8.07 (m, 3H), 7.70 (s, 2H), 7.44-7.40 (t, 2H), 4.56-4.53 (d, 2H), 4.22 (s, 1H), 3.87-3.81 (m, 2H), 3.63 (s, 3H), 3.15-3.09 (t, 2H), 2.96-2.93 (m, 1H), 2.82-2.79 (m, 1H), 2.70-2.65 (dd, 2H), 2.02-1.97 (m, 1H), 1.80-1.67 (m, 3H), 1.41-1.33 (m, 2H), 1.29-1.25 (t, 3H); MS: $m/z = 667.2$ (M+1, ESI+).

5.10.25. Synthesis of Compound 77



[0458] **Compound 77 formate**, (2S,4R)-N-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethyl imidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)-4-hydroxypyrrolidine-2-carboxamide formate (84 mg, 0.118 mmol) was purified by Prep-HPLC to afford **compound 77**, (2S,4R)-N-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl) piperidin-4-yl)-4-hydroxypyrrolidine-2-carboxamide (75 mg, 95.42% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6) δ 8.77 (s, 2H), 8.65 (s, 1H), 8.11-8.07 (t, 2H), 7.88-7.86 (d, 1H), 7.70 (s, 2H), 7.44-7.40 (t, 2H), 4.67-4.54 (m, 3H), 4.15 (s, 1H), 3.85-3.82 (m, 1H), 3.63 (s, 3H), 3.12-3.06 (t, 2H), 2.81-2.64 (m, 4H), 1.90-1.64 (m, 4H), 1.39-1.32 (m, 2H), 1.28-1.25 (t, 3H); MS: $m/z = 667.2$ (M+1, ESI+).

5.10.26. Synthesis of Compound 83 Hydrochloride

*Step one:*

[0459] To a solution of **compound 141 hydrochloride**, 2-((6-(2-(4-aminopiperidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methylamino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (300 mg, 508.47 μmol) and 1-(tert-butoxycarbonyl)azetidine-3-carboxylic acid (109.03 mg, 541.85 μmol) in DCM (10 mL) was added HATU (618.09 mg, 1.63 mmol) and DIEA (350.15 mg, 2.71 mmol), the reaction mixture was stirred at 25 °C for 16 h. The reaction mixture was poured into H₂O (50 mL) and extracted with DCM (20 mL x 3), the combined organic layers were washed with brine (50 mL x 3), dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography to afford tert-butyl 3-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methylamino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)carbamoyl)azetidine-1-carboxylate (350 mg, 87.66% yield). MS: m/z = 737.4 (M+1, ESI+).

Step two:


[0460] To a solution of tert-butyl 3-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methylamino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)carbamoyl)azetidine-1-carboxylate (350 mg, 474.99 μmol) in DCM (10 mL) was added TFA (3.08 g, 2.00 mL) and stirred at 25 °C for 3 h. The reaction mixture was concentrated and purified by Prep-HPLC to afford **compound 83 hydrochloride**, N-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methylamino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)azetidine-3-carboxamide hydrochloride (160 mg, 50.04% yield) as a pale yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.76 (s, 1H), 9.20 (s, 1H), 9.13 (s, 1H), 8.87 (s, 2H), 8.50-8.48 (d, 1H), 8.42-8.40 (d, 1H), 8.14-8.12 (d, 1H), 8.01 (s, 2H), 7.42-7.38 (t, 2H), 4.55-4.52 (d, 2H), 3.98-3.94 (m, 5H), 3.69-3.61 (m, 4H), 3.28-3.23 (t, 2H), 2.92-2.86 (dd, 2H), 1.84-1.82 (d, 2H), 1.38-1.34 (m, 5H); MS: m/z = 637.3 (M+1, ESI+).

chromatography to afford tert-butyl 4-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)carbamoyl)piperidine-1-carboxylate (300 mg, 72.38% yield). MS: m/z = 765.3(M+1, ESI+).

Step two:


[0463] To a solution of tert-butyl 4-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)carbamoyl)piperidine-1-carboxylate (300 mg, 392.20 μ mol) in DCM (10 mL) was added TFA (2.54 g, 1.65 mL) and stirred at 25 °C for 3 h. The reaction mixture was concentrated and purified by Prep-HPLC to afford **compound 84 hydrochloride**, N-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)piperidine-4-carboxamide hydrochloride (200 mg, 72.72% yield) as a pale yellow solid. ^1H NMR (400 MHz, DMSO- d_6) δ 9.40 (s, 1H), 9.12 (s, 1H), 9.04 (s, 1H), 8.86 (s, 2H), 8.41-8.39 (d, 1H), 8.14-8.09 (m, 2H), 8.01 (s, 2H), 7.42-7.38 (t, 2H), 4.57-4.54 (d, 2H), 3.87 (s, 1H), 3.68 (s, 3H), 3.22-3.16 (m, 4H), 2.91-2.80 (m, 4H), 2.43 (s, 1H), 1.81-1.72 (m, 6H), 1.37-1.33 (m, 5H); MS: m/z = 665.4(M+1, ESI+).

5.10.29. Synthesis of Compound 84




[0464] **Compound 84 hydrochloride**, N-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)piperidine-4-carboxamide hydrochloride (140 mg, 0.181 mmol) was purified by Prep-HPLC to afford **compound 84**, N-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-4-yl)piperidine-4-carboxamide (110 mg, 91.66% yield) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 8.76 (s, 2H), 8.65 (s, 1H), 8.11-8.07 (t, 2H), 7.70-7.66 (m, 3H), 7.44-7.40 (t, 2H), 4.55-4.52 (d, 2H), 3.84-3.80 (m, 1H), 3.63 (s, 3H), 3.13-3.08 (t, 2H), 2.98-2.95 (d, 2H), 2.70-2.64 (dd, 2H), 2.50-2.45 (m, 2H), 2.19-2.13 (m, 1H), 1.78-1.75 (d, 2H), 1.58-1.41 (m, 4H), 1.33-1.16 (m, 6H); MS: m/z = 666.1 (M+1, ESI+).

5.10.30. Synthesis of Compound 107



[0465] To a solution of **compound 140**, 2-((2-ethyl-6-(2-(4-oxopiperidin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (250 mg, 452.39 μmol) and cyclopropanamine (38.74 mg, 678.58 μmol) in DCM (10 mL) was added $\text{NaBH}(\text{OAc})_3$ (191.76 mg, 904.77 μmol), the reaction mixture was stirred at 25 °C for 16 h. The mixture was poured into water (30 mL), extracted with DCM (10 mL $\times$ 3). The organic was washed by brine (30 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by Prep-HPLC to afford **compound 107**, 2-((6-(2-(4-(cyclopropylamino)piperidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (62 mg, 23.08% yield) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.69 (s, 2H), 8.60 (s, 1H), 8.06-8.03 (t, 2H), 7.64 (s, 2H), 7.39-7.34 (t, 2H), 4.47-4.43 (m, 2H), 3.59 (s, 3H), 3.06-3.01 (t, 2H), 2.73-2.60 (m, 3H), 2.09-2.02 (m, 2H), 1.84-1.81 (d, 2H), 1.24-1.13 (m, 5H), 0.33-0.29 (m, 2H), 0.16-0.13 (m, 2H); MS: m/z = 594.1 ($\text{M}+1$, ESI $^+$); HRMS: 594.2558.


5.10.31. Synthesis of Compound 108



[0466] To a solution of **compound 140**, 2-((2-ethyl-6-(2-(4-oxopiperidin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (250 mg, 452.39 μmol) and cyclobutanamine (48.26 mg, 678.58 μmol) in DCM (10 mL) was added $\text{NaBH}(\text{OAc})_3$ (191.76 mg, 904.77 μmol), the reaction mixture was stirred at 25 °C for 16 h. The mixture was poured into water (30 mL), extracted with DCM (10 mL $\times$ 3). The organic was washed by brine (30 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by Prep-HPLC to afford **compound 108**, 2-((6-(2-(4-(cyclobutylamino)piperidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile.


(cyclobutylamino)piperidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (86 mg, , 31.28% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.74 (s, 2H), 8.64 (s, 1H), 8.10-8.08 (t, 2H), 7.69 (s, 2H), 7.44-7.39 (t, 2H), 4.50-4.46 (m, 2H), 3.64 (s, 3H), 3.26-3.22 (m, 1H), 3.08-3.03 (t, 2H), 2.70-2.65 (m, 3H), 2.10-2.06 (m, 2H), 1.77-1.50 (m, 6H), 1.29-1.25 (t, 3H), 1.18-1.10 (m, 2H); MS: m/z = 608.2 (M+1, ESI+); HRMS: 608.2716.

5.10.32. Synthesis of Compound 115




[0467] To a solution of **compound 142**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidine-4-carboxylic acid (400 mg, 686.52 μmol) and pyrrolidine (48.83 mg, 686.52 μmol) in DMF (8 mL) was added HATU (391.55 mg, 1.03 mmol) and DIEA (266.18 mg, 2.06 mmol), the reaction mixture was stirred at 25 °C for 2 h. The mixture was poured into water (80 mL) and extracted with EA (30 mL x 2), the organic layer was washed with brine (50 mL), then dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC to afford **compound 115**, 2-((2-ethyl-6-(2-(4-(pyrrolidine-1-carbonyl)piperidin-1-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (205 mg, 46.97% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.76 (s, 2H), 8.65 (s, 1H), 8.11-8.07 (t, 2H), 7.69 (s, 2H), 7.44-7.39 (t, 2H), 4.72-4.69 (d, 2H), 3.63 (s, 3H), 3.53-3.49 (t, 2H), 3.27-3.24 (t, 2H), 3.02-2.96 (m, 2H), 2.78-2.64 (m, 3H), 1.91-1.85 (m, 2H), 1.79-1.70 (m, 4H), 1.52-1.42 (m, 2H), 1.29-1.25 (t, 3H); MS: m/z = 636.2 (M+1, ESI+); HRMS: 636.2655.

5.10.33. Synthesis of Compound 115 Hydrochloride




[0468] To a solution of **compound 142**, 2-((2-ethyl-6-(6-(4-(pyrrolidine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (125 mg, 0.2 mmol) in MeOH (8 mL) was added 2 M HCl (0.6 mL, 1.2 mmol) and stirred at 25 °C for 2 h. The mixture was evaporated under reduced pressure to afford **compound 115 hydrochloride**, 2-((2-ethyl-6-(6-(4-(pyrrolidine-1-carbonyl) piperidin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (140 mg, 95.9% yield) as a pale yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.06 (s, 1H), 8.83 (s, 2H), 8.35-8.33 (m, 1H), 8.11-8.00 (m, 3H), 7.42-7.38 (t, 2H), 4.74-4.71 (d, 2H), 3.66 (s, 3H), 3.53-3.50 (t, 2H), 3.27-3.23 (t, 2H), 3.06-2.99 (m, 2H), 2.89-2.75 (m, 3H), 1.92-1.72 (m, 6H), 1.52-1.41 (m, 2H), 1.34-1.30 (t, 3H); MS: m/z = 636.2 (M+1, ESI+).

5.10.34. Synthesis of Compound 123




[0469] To a solution of **compound 142**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidine-4-carboxylic acid (670 mg, 1.15 mmol) and azetidine hydrochloride (129.10 mg, 1.38 mmol) in DMF (10 mL) was added HATU (650.74 mg, 1.72 mmol) and DIEA (445.85 mg, 3.45 mmol), the reaction mixture was stirred at 25 °C for 2 h. The mixture was poured into water (100 mL) and extracted with EA (40 mL x 2), the organic layer was washed with brine (100 mL), then dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC to afford **compound 123**, 2-((6-(2-(4-(azetidine-1-carbonyl)piperidin-1-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (350 mg, 48.96% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.75 (s, 2H), 8.65 (s, 1H), 8.11-8.08 (t, 2H), 7.70 (s, 2H), 7.44-7.39 (t, 2H), 4.69-4.66 (d, 2H), 4.21-4.17 (t, 2H), 3.84-3.80 (t, 2H), 3.64 (s, 3H), 3.02-2.95 (m, 2H), 2.70-2.65 (dd, 2H), 2.54-2.49 (m, 1H), 2.22-2.15 (m, 2H), 1.68-1.65 (m, 2H), 1.48-1.37 (m, 2H), 1.29-1.25 (t, 3H); MS: m/z = 622.2 (M+1, ESI+); HRMS: 622.2509.

5.10.35. Synthesis of Compound 127




[0470] To a solution of **compound 142**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo [1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidine-4-carboxylic acid (570 mg, 978.29 μmol) and morpholine (102.27 mg, 1.17 mmol) in DMF (10 mL) was added HATU (553.62 mg, 1.47 mmol) and DIEA (379.30 mg, 2.93 mmol), the reaction mixture was stirred at 25 °C for 2 h. The mixture was poured into water (100 mL) and extracted with EA (30 mL x 2), the organic layer was washed with brine (100 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by Prep-HPLC to afford **compound 127**, 2-((2-ethyl-6-(2-(4-(morpholine-4-carbonyl)piperidin-1-yl)pyrimidin-5-yl)imidazo [1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (260 mg, 40.78% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6) δ 8.76 (s, 2H), 8.65 (s, 1H), 8.11-8.08 (t, 2H), 7.70 (s, 2H), 7.44-7.39 (t, 2H), 4.71-4.68 (d, 2H), 3.64 (s, 3H), 3.58-3.54 (m, 6H), 3.44-3.43 (m, 2H), 3.04-2.93 (m, 3H), 2.71-2.65 (dd, 2H), 1.71-1.68 (m, 2H), 1.54-1.45 (m, 2H), 1.29-1.25 (t, 3H); MS: m/z = 652.2 ($\text{M}+1$, ESI+); HRMS: 652.2616.

5.11. Example 10 – Synthesis of Piperidine-linked Pyridine-type Compounds


General Scheme 10

5.11.1. Synthesis of 1-(5-bromopyridin-2-yl)piperidin-4-ol



[0471] To a solution of 5-bromo-2-chloropyridine (3 g, 15.59 mmol) and piperidin-4-ol (1.73 g, 17.15 mmol) in DMF (30 mL) was added Cs_2CO_3 (15.24 g, 46.77 mmol), the reaction mixture was stirred at 130 °C for 5 h. The mixture was poured into water (300 mL) and extracted with EA (100 mL x 2), the organic layer was washed by water (100 mL x 2) and brine (100 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by column chromatography to afford 1-(5-bromo pyridin-2-yl)piperidin-4-ol (2.1 g, 52.39% yield) as a yellow solid. MS: $m/z = 257.0$ ($M+1$, ESI+).

5.11.2. Synthesis of Compound 143


*Step one:*

[0472] To a mixture of 1-(5-bromopyridin-2-yl)piperidin-4-ol (915.57 mg, 3.56 mmol) and **compound 133**, 3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-ylboronic acid (1.5 g, 3.56 mmol) in dioxane (20 mL) and water (4 mL) was added Na₂CO₃ (1.13 g, 10.68 mmol) and Pd(PPh₃)₄ (205.74 mg, 178.04 μmol), the reaction mixture was stirred at 100 °C for 2 h under N₂. The mixture was poured into water (60 mL) and extracted with EA (20 mL x 2). The organic layer was washed by brine (100 mL), then dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography to afford 2-((2-ethyl-6-(6-(4-hydroxypiperidin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (1.2 g, 60.87% yield) as a yellow solid. MS: m/z = 554.1 (M+1, ESI+).

Step two:


[0473] To a solution of 2-((2-ethyl-6-(6-(4-hydroxypiperidin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (1.2 g, 2.17 mmol) in DCM (25 mL) was added Dess-Martin (919.30 mg, 2.17 mmol), the reaction mixture was stirred at 25 °C for 2 h. The mixture was evaporated and purified by column chromatography to afford **compound 143**, 2-((2-ethyl-6-(6-(4-oxopiperidin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (960 mg, 80.29% yield) as a yellow solid. MS: m/z = 552.2 (M+1, ESI+).

5.11.3. Synthesis of tert-butyl (1-(5-bromopyridin-2-yl)piperidin-4-yl)carbamate



[0474] To a mixture of tert-butyl piperidin-4-ylcarbamate (1.77 g, 8.83 mmol) and 5-bromo-2-chloropyridine (1.7 g, 8.83 mmol) in DMF (30 mL) was added K₂CO₃ (3.66 g, 26.50 mmol), the reaction mixture was stirred at 120 °C for 5 h. The mixture was poured into water (300 mL) and extracted with EA (100 mL x 2), the organic layer was washed with water (200 mL x 2) and brine (200 mL), then dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography to afford tert-butyl (1-(5-bromopyridin-2-yl)piperidin-4-yl)carbamate (570 mg, 18.11% yield) as a yellow solid. MS: m/z = 356.1 (M+1, ESI+).

5.11.4. Synthesis of Compound 144



Step one:


[0475] To a mixture of **compound 133**, (3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)boronic acid (378.38 mg, 898.23 μmol) and tert-butyl (1-(5-bromopyridin-2-yl)piperidin-4-yl)carbamate (320 mg, 898.23 μmol) in dioxane (10 mL) and water (2 mL) was added Na_2CO_3 (285.61 mg, 2.69 mmol) and $\text{Pd}(\text{PPh}_3)_4$ (51.90 mg, 44.91 μmol), the reaction mixture was stirred at 100 °C for 2 h under N_2 . The mixture was poured into water (50 mL) and extracted with EA (20 mL x 2), the organic layer was washed by brine (30 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by column chromatography to afford tert-butyl (1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperidin-4-yl)carbamate (295 mg, 50.31% yield) as a yellow solid. MS: m/z = 653.3 ($\text{M}+1$, ESI+).

Step two:

[0476] To a solution of tert-butyl (1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperidin-4-yl)carbamate (295 mg, 451.91 μmol) in DCM (5 mL) was added TFA (257.63 mg, 2.26 mmol), the reaction mixture was stirred at 25 °C for 3 h. The mixture was poured into aq. NaHCO_3 (50 mL) and extracted with DCM (20 mL $\times$ 2). The organic layer was washed with water (50


mL×2) and brine (50 mL), then dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography to afford **compound 144**, 2-((6-(6-(4-aminopiperidin-1-yl)pyridin-3-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methylamino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (230 mg, 76.46% yield) as a white solid. MS: m/z = 553.3 (M+1, ESI+).

5.11.5. Synthesis of methyl 1-(5-bromopyridin-2-yl)piperidine-4-carboxylate



[0477] To a solution of methyl piperidine-4-carboxylate (7.44 g, 51.96 mmol) and 5-bromo-2-chloro pyridine (5 g, 25.98 mmol) in DMF (50 mL) was added K₂CO₃ (10.77 g, 77.95 mmol), the reaction mixture was stirred at 120 °C for 5 h. The mixture was poured into water (500 mL) and extracted with EA (100 mL x 3), the organic layer was washed with water (300 mL x 2) and brine (300 mL), then dried over Na₂SO₄ and concentrated. The residue was purified by silica gel column to afford methyl 1-(5-bromopyridin-2-yl)piperidine-4-carboxylate (2.6 g, 33.45% yield) as a yellow solid. MS: m/z = 299.1 (M+1, ESI+).

5.11.6. Synthesis of Compound 145



Step one:


[0478] To a mixture of **compound 133**, 3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methylamino)-2-ethylimidazo[1,2-a]pyridin-6-yl)boronic acid (3 g, 7.12 mmol) and methyl 1-(5-bromopyridin-2-yl)piperidine-4-carboxylate (2.34 g, 7.83 mmol) in dioxane (50 mL) and water (10 mL) was added Na₂CO₃ (2.26 g, 21.36 mmol) and Pd(PPh₃)₄ (411.47 mg, 356.08 μmol), the reaction mixture was stirred at 100 °C for 2 h under N₂. The mixture was poured into water (100 mL) and extracted with EA (40 mL x 2). The organic layer was washed by brine (100 mL), then dried over Na₂SO₄ and concentrated. The residue was

purified by column chromatography to afford methyl 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperidine-4-carboxylate (2.7 g, 63.65% yield) as a yellow solid. MS: m/z = 596.2 (M+1, ESI+).

Step two:


[0479] To a solution of methyl 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperidine-4-carboxylate (2.7 g, 4.53 mmol) in MeOH (30 mL) and water (10 mL) was added LiOH (542.74 mg, 22.66 mmol), the reaction mixture was stirred at 25 °C for 16 h. The mixture was concentrated and adjusted to pH to 5-6, then poured into water (100 mL) and extracted with EA (40 mL x 3). The organic layer was washed with brine (100 mL), then dried over Na₂SO₄ and concentrated to afford **compound 145**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperidine-4-carboxylic acid (1.8 g, 68.27% yield) as a yellow solid. MS: m/z = 582.1 (M+1, ESI+).

5.11.7. Synthesis of Compound 88



[0480] To a solution of **compound 143**, 2-((2-ethyl-6-(6-(4-oxopiperidin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (250 mg, 453.20 μmol) and (1-amino)cyclopropylmethanol (43.43 mg, 498.52 μmol) in DCM (10 mL) was added NaBH(OAc)₃ (115.26 mg, 543.84 μmol), the reaction mixture was stirred at 25 °C for 16 h. The mixture was evaporated and purified by Prep-HPLC to afford **compound 88** 2-((2-ethyl-6-(6-(4-((1-(hydroxymethyl)cyclopropyl)amino)piperidin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (139 mg, 49.25% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.55 (s, 1H), 8.50 (d, 1H), 8.11-8.08 (t, 2H), 7.92-7.89 (dd, 1H), 7.71-7.65 (m, 2H), 7.44-7.39 (t, 2H), 6.90-6.88 (d, 1H), 4.51-4.48 (t, 1H), 4.21-4.18 (d, 2H), 3.64 (s, 3H), 3.35-3.34 (m, 2H), 3.04-2.91 (m, 3H), 2.69-2.64 (dd, 2H), 2.23 (s, 1H), 1.83-1.81 (d, 2H), 1.29-1.14 (m, 4H), 0.39 (s, 4H); MS: m/z = 623.3 (M+1, ESI+); HRMS: 623.2717.

5.11.8. Synthesis of Compound 89 Hydrochloride


*Step one:*

[0481] To a suspension of **compound 143**, 2-((2-ethyl-6-(6-(4-oxopiperidin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (250 mg, 453.20 μmol) and tert-butyl 3-aminoazetidine-1-carboxylate (78.05 mg, 453.20 μmol) in DCM (8 mL) was added $\text{NaBH}(\text{OAc})_3$ (115.26 mg, 543.84 μmol), the reaction mixture was stirred at 25 °C for 16 h. The mixture was filtered and concentrated. The residue was purified by column chromatography to afford tert-butyl 3-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperidin-4-yl)amino)azetidine-1-carboxylate (210 mg, 65.46% yield) as a yellow solid. MS: $m/z = 708.3$ ($M+1$, ESI+).

Step two:


[0482] To a solution of tert-butyl 3-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperidin-4-yl)amino)azetidine-1-carboxylate (210.00 mg, 296.67 μmol) in DCM (5 mL) was added TFA (169.13 mg, 1.48 mmol), the reaction mixture was stirred at 25 °C for 3 h. The mixture was concentrated under reduced pressure and the residue was purified by Prep-HPLC to afford **compound 89 hydrochloride**, 2-((6-(6-(4-(azetidin-3-ylamino)piperidin-1-yl)pyridin-3-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (160 mg, 83.72% yield) as a yellow solid. ^1H NMR (400 MHz, DMSO-d_6) δ 11.02 (s, 2H), 10.11-10.10 (d, 1H), 9.31 (s, 1H), 9.22 (s, 1H), 8.48-8.41 (m, 3H), 8.15-8.13 (d, 1H), 8.02 (s, 2H), 7.51-7.49 (d, 1H), 7.43-7.39 (t, 2H), 4.63-4.60 (d, 2H), 4.43-4.35 (m, 3H), 4.17 (s, 2H), 3.70 (s, 3H), 3.50 (s, 1H), 3.27-3.21 (t, 2H), 2.92-2.86 (dd, 2H), 2.17-2.14 (m, 2H), 1.75-1.72 (m, 2H), 1.38-1.34 (t, 3H); MS: $m/z = 608.3$ ($M+1$, ESI+); HRMS: 608.2712.

5.11.9. Synthesis of Compound 89



[0483] To a mixture of **compound 89 hydrochloride**, 2-((6-(6-(4-(azetidin-3-ylamino)piperidin-1-yl)pyridin-3-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methylamino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (90 mg, 0.125 mmol) in H₂O (3 mL) was added 2 M NaHCO₃ (1.05 mL, 2.1 mmol) at 0°C and stirred for 0.5 h. Then extracted with DCM (5 mL × 2). The organic layer was washed with water (5 mL) and brine (5 mL), dried over Na₂SO₄ and concentrated to afford **compound 89**, 2-((6-(6-(4-(azetidin-3-ylamino)piperidin-1-yl)pyridin-3-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methylamino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (80 mg, 81.63% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.54-8.49 (m, 2H), 8.10-8.07 (t, 2H), 7.92-7.89 (m, 1H), 7.71-7.65 (m, 2H), 7.44-7.39 (t, 2H), 6.91-6.89 (d, 1H), 4.23-4.20 (m, 2H), 3.76-3.63 (m, 8H), 2.94-2.88 (t, 2H), 2.69-2.63 (m, 4H), 1.74-1.72 (t, 2H), 1.28-1.25 (t, 3H); MS: m/z = 609.1 (M+1, ESI+).

5.11.10. Synthesis of Compound 90

*Step one:*


[0484] To a suspension of **compound 143**, 2-((2-ethyl-6-(6-(4-oxopiperidin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methylamino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (250 mg, 453.20 μmol) and tert-butyl 4-aminopiperidine-1-carboxylate (90.77 mg, 453.20 μmol) in DCM (8 mL) was added NaBH(OAc)₃ (115.26 mg, 543.84 μmol), the reaction mixture was stirred at 25 °C for 16 h. The mixture was filtered and concentrated, the residue was purified by column chromatography to afford tert-butyl 4-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methylamino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-

yl)piperidin-4-yl)amino)piperidine-1-carboxylate (215 mg, 64.47% yield) as a yellow solid. MS: $m/z = 736.3$ ($M+1$, ESI+).

Step two:

[0485] To a solution of tert-butyl 4-((1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperidin-4-yl)amino)piperidine-1-carboxylate (215.00 mg, 292.15 μmol) in DCM (5 mL) was added TFA (166.56 mg, 1.46 mmol), the reaction mixture was stirred at 25 °C for 3 h. The mixture was concentrated under reduce pressure and the residue was purified by Prep-HPLC to afford **compound 90**, 2-((2-ethyl-6-(6-(4-(piperidin-4-ylamino)piperidin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (135 mg, 72.68% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6) δ 8.55-8.49 (m, 2H), 8.11-8.07 (t, 2H), 7.92-7.89 (dd, 1H), 7.71-7.64 (m, 2H), 7.44-7.39 (t, 2H), 6.90-6.88 (d, 1H), 4.23-4.20 (d, 2H), 3.63 (s, 3H), 2.95-2.78 (m, 4H), 2.69-2.64 (dd, 2H), 2.60-2.54 (m, 1H), 2.45-2.39 (t, 2H), 1.82-1.79 (d, 2H), 1.72-1.70 (d, 2H), 1.29-1.16 (t, 3H), 1.24-1.03 (m, 4H); MS: $m/z = 636.4$ ($M+1$, ESI+); HRMS: 636.3033.


5.11.11. Synthesis of Compound 98



[0486] To a solution of **compound 144**, 2-((6-(6-(4-aminopiperidin-1-yl)pyridin-3-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (235 mg, 353.02 μmol) and 1-hydroxycyclopropane-1-carboxylic acid (36.04 mg, 353.02 μmol) in DMF (5 mL) was added HATU (174.50 mg, 458.93 μmol) and DIEA (136.88 mg, 1.06 mmol), the reaction mixture was stirred at 25 °C for 3 h. The mixture was poured into water (50 mL) and extracted with EA (20 mL $\times$ 2). The organic layer was washed with water (50 mL $\times$ 2) and brine (50 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by Prep-HPLC to afford **compound 98**, N-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperidin-4-yl)-1-hydroxycyclopropane-1-carboxamide (85 mg, 37.81% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6) δ 8.57-8.52 (m, 2H), 8.11-8.07 (t, 2H), 7.95-7.92 (dd, 1H), 7.72-7.65 (m, 3H), 7.44-7.40 (t, 2H), 6.94-6.92 (d, 1H), 6.16 (s, 1H), 4.34-4.31 (d, 2H),


3.92-3.86 (m, 1H), 3.64 (s, 3H), 2.95-2.89 (t, 2H), 2.69-2.64 (dd, 2H), 1.76-1.73 (d, 2H), 1.58-1.49 (m, 2H), 1.28-1.25 (t, 3H), 1.02-0.99 (m, 2H), 0.82-0.79 (m, 2H); MS: m/z = 637.2 (M+1, ESI+); HRMS: 637.2509.

5.11.12. Synthesis of Compound 113




[0487] To a solution of pyrrolidine (47.07 mg, 661.90 μ mol) and **compound 145**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperidine-4-carboxylic acid (350 mg, 601.72 μ mol) in DMF (8 mL) was added HATU (343.19 mg, 902.59 μ mol) and DIEA (233.30 mg, 1.81 mmol), the reaction mixture was stirred at 25 °C for 2 h. The mixture was poured into water (80 mL) and extracted with EA (30 mL $\times$ 3). The organic layer was washed with brine (80 mL), then dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC (Waters Xbridge C18 10 μ m OBD 19 $\times$ 250mm, A: 10 mmol NH₄HCO₃ in water; B: CH₃CN, 5% to 95%) in NH₄HCO₃ condition to afford **compound 113**, 2-((2-ethyl-6-(6-(4-(pyrrolidine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (193 mg, 50.53% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.57 (s, 1H), 8.51 (d, 1H), 8.11-8.08 (t, 2H), 7.94-7.91 (dd, 1H), 7.72-7.65 (m, 2H), 7.44-7.40 (t, 2H), 6.93-6.90 (d, 1H), 4.39-4.36 (d, 2H), 3.64 (s, 3H), 3.52-3.49 (t, 2H), 3.27-3.24 (t, 2H), 2.94-2.88 (m, 2H), 2.75-2.64 (m, 3H), 1.91-1.84 (m, 2H), 1.79-1.68 (m, 4H), 1.57-1.47 (m, 2H), 1.29-1.25 (t, 3H); MS: m/z = 635.3 (M+1, ESI+); HRMS: 635.2703.

5.11.13. Synthesis of Compound 113 Hydrochloride



[0488] To a solution of **compound 145**, pyrrolidine (67 mg, 945 μmol) and 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperidine-4-carboxylic acid (500 mg, 860 μmol) in DMF (8 mL) was added HATU (490 mg, 1.29 mmol) and DIEA (333 mg, 2.58 mmol), the reaction mixture was stirred at 25 °C for 2 h. The mixture was poured into water (80 mL) and extracted with EA (30 mLx3). The organic layer was washed with brine (80 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by Prep-HPLC (Waters Xbridge C18 10 μm OBD 19*250mm, A: 0.05% HCl in water; B: CH_3CN , 5% to 95%) in HCl condition to afford **compound 113 hydrochloride**, 2-((2-ethyl-6-(6-(4-(pyrrolidine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl) amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (230 mg, 35.93% yield) as a pale yellow solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.18 (s, 1H), 8.42-8.37 (m, 3H), 8.14-8.12 (d, 1H), 8.04-8.00 (t, 2H), 7.49-7.38 (m, 3H), 4.50-4.47 (d, 2H), 3.68 (s, 3H), 3.54-3.51 (t, 2H), 3.30-3.25 (m, 4H), 2.90-2.83 (m, 3H), 1.91-1.60 (m, 8H), 1.36-1.33 (t, 3H); MS: m/z = 635.3 (M+1, ESI+).


5.11.14. Synthesis of Compound 114



[0489] To a solution of **compound 145**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperidine-4-carboxylic acid (400 mg, 687.68 μmol) and (R)-pyrrolidin-3-ol (65.90 mg, 756.45 μmol) in DMF (8 mL) was added HATU (392.22 mg, 1.03 mmol) and DIEA (266.63 mg, 2.06 mmol), the reaction mixture was stirred at 25 °C for 2 h. The mixture was poured into water (80 mL) and extracted with EA (30 mLx3). The organic layer was washed with brine (80 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by Prep-HPLC (Waters Xbridge C18 10 μm OBD 19*250mm, A: 10 mmol NH_4HCO_3 in water; B: CH_3CN , 5% to 95%) in NH_4HCO_3 condition to afford **compound 114**, (R)-2-((2-ethyl-6-(6-(4-(3-hydroxypyrrolidine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (223 mg, 49.83% yield) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.48-8.47 (m, 2H), 8.10-8.07 (m, 2H), 7.89-7.86 (dd, 1H), 7.67-7.62 (m, 2H), 7.39-7.35 (t, 2H), 6.89-6.86 (d, 1H), 4.86-4.76 (dd, 1H),


4.36-4.24 (m, 3H), 3.64 (s, 3H), 3.61-3.58 (m, 1H), 3.38-3.22 (m, 3H), 2.97-2.91 (m, 2H), 2.76-2.63 (m, 3H), 1.98-1.69 (m, 4H), 1.61-1.51 (m, 2H) 1.29-1.25 (t, 3H); MS: m/z = 651.2 (M+1, ESI+); HRMS: 651.2653.

5.11.15. Synthesis of Compound 114 Hydrochloride



[0490] To a solution of **compound 145**, (R)-pyrrolidin-3-ol (82 mg, 945 μ mol) and 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperidine-4-carboxylic acid (500 mg, 860 μ mol) in DMF (8 mL) was added HATU (490 mg, 1.29 mmol) and DIEA (333 mg, 2.58 mmol), the reaction mixture was stirred at 25 °C for 2 h. The mixture was poured into water (80 mL) and extracted with EA (30 mLx3). The organic layer was washed with brine (80 mL), then dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC (Waters Xbridge C18 10 μ m OBD 19*250mm, A: 0.05% HCl in water; B: CH₃CN, 5% to 95%) in HCl condition to afford **compound 114 hydrochloride**, (R)-2-((2-ethyl-6-(6-(4-(3-hydroxypyrrolidine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (205 mg, 31.34% yield) as a pale yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.10 (s, 1H), 8.46 (s, 1H), 8.35-8.24 (m, 2H), 8.10-8.07 (d, 1H), 8.04-8.01 (t, 2H), 7.42-7.31 (m, 3H), 4.46-4.16 (m, 4H), 3.67-3.58 (m, 5H), 3.41-3.16 (m, 5H), 2.89-2.76 (m, 3H), 1.97-1.54 (m, 6H), 1.35-1.33 (t, 3H); MS: m/z = 651.2 (M+1, ESI+).

5.11.16. Synthesis of Compound 118




Step one:

[0491] To a solution of **compound 145**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperidine-4-carboxylic acid (300 mg, 515.76 μ mol) and tert-butyl piperazine-1-carboxylate (105.67 mg, 567.34 μ mol) in DMF (5 mL) was added HATU (294.16 mg, 773.65 μ mol) and DIEA (199.98 mg, 1.55 mmol), the reaction mixture was stirred at 25 °C for 2 h. The mixture was poured into water (50 mL) and extracted with EA (20 mL x 3). The organic layer was washed with water (50 mLx2) and brine (50 mL), then dried over Na₂SO₄ and concentrated. The residue was purified by silica gel column to afford tert-butyl 4-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperidine-4-carbonyl)piperazine-1-carboxylate (280 mg, 72.39% yield) as a yellow solid. MS: m/z = 750.1 (M+1, ESI+).

Step two:


[0492] To a solution of tert-butyl 4-(1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperidine-4-carbonyl)piperazine-1-carboxylate (280 mg, 373.38 μ mol) in DCM (5 mL) was added TFA (212.87 mg, 1.87 mmol), the reaction mixture was stirred at 25 °C for 5 h. The mixture was concentrated and purified by Prep-HPLC to afford **compound 118**, 2-((2-ethyl-6-(6-(4-(piperazine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (172 mg, 70.89% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.57 (s, 1H), 8.51 (d, 1H), 8.11-8.08 (t, 2H), 7.94-7.91 (dd, 1H), 7.71-7.65 (m, 2H), 7.44-7.39 (t, 2H), 6.92-6.90 (d, 1H), 4.37-4.33 (d, 2H), 3.64 (s, 3H), 3.45-3.44 (m, 2H), 3.36-3.34 (m, 2H), 2.95-2.87 (m, 3H), 2.70-2.60 (m, 6H), 1.66-1.52 (m, 4H), 1.29-1.25 (t, 3H); MS: m/z = 650.3 (M+1, ESI+); HRMS: 650.2822.

5.11.17. Synthesis of Compound 119

[0493] To a solution of **compound 145**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperidine-4-carboxylic acid (300 mg, 515.76 μ mol) and piperidin-4-ol (62.60 mg, 618.92 μ mol) in DMF (5 mL) was


added HATU (291.87 mg, 773.65 μmol) and DIEA (199.98 mg, 1.55 mmol), the reaction mixture was stirred at 25 °C for 2 h. The mixture was poured into water (50 mL) and extracted with EA (20 mL x 3). The organic layer was washed with water (50 mLx2) and brine (50 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by silica gel column to afford **compound 119**, 2-((2-ethyl-6-(6-(4-(4-hydroxypiperidine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (90 mg, 26.25% yield) as a yellow solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.56 (s, 1H), 8.51 (d, 1H), 8.11-8.07 (t, 2H), 7.94-7.91 (dd, 1H), 7.71-7.65 (m, 2H), 7.44-7.39 (t, 2H), 6.92-6.90 (d, 1H), 4.74-4.73 (d, 1H), 4.36-4.33 (d, 2H), 3.91-3.78 (m, 2H), 3.71-3.64 (m, 1H), 3.63 (s, 3H), 3.24-3.19 (m, 1H), 2.99-2.90 (m, 4H), 2.69-2.64 (dd, 2H), 1.77-1.75 (m, 1H), 1.65-1.62 (m, 3H), 1.56-1.50 (m, 2H), 1.35-1.20 (m, 6H); MS: m/z = 665.2 ($M+1$, ESI+); HRMS: 665.2819.

5.11.18. Synthesis of Compound 120




[0494] To a solution of **compound 145**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperidine-4-carboxylic acid (300 mg, 515.76 μmol) and azetidin-3-ol hydrochloride (45.24 mg, 618.92 μmol) in DMF (10 mL) was added HATU (291.87 mg, 773.65 μmol) and DIEA (199.98 mg, 1.55 mmol), the reaction mixture was stirred at 25 °C for 2 h. The mixture was poured into water (100 mL) and extracted with EA (30 mL x 3). The organic layer was washed with water (100 mLx2) and brine (100 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by silica gel column to afford **compound 120**, 2-((2-ethyl-6-(6-(4-(3-hydroxyazetidine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (120 mg, 36.54% yield) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.56 (s, 1H), 8.51 (d, 1H), 8.11-8.07 (t, 2H), 7.93-7.91 (dd, 1H), 7.71-7.64 (m, 2H), 7.44-7.39 (t, 2H), 6.92-6.90 (d, 1H), 5.71-5.69 (d, 1H), 4.46-4.33 (m, 4H), 4.01-3.99 (m, 1H), 3.97-3.88 (m, 1H), 3.63 (s, 3H), 3.56-3.52 (m, 1H), 2.93-2.87 (m, 2H), 2.69-2.63 (dd, 2H), 1.65-1.62 (m, 2H), 1.51-1.45 (m, 2H), 1.28-1.24 (t, 3H); MS: m/z = 637.2 ($M+1$, ESI+); HRMS: 637.2505.

5.11.19. Synthesis of Compound 121



[0495] To a solution of **compound 145**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo [1,2-a]pyridin-6-yl)pyridin-2-yl)piperidine-4-carboxylic acid (500 mg, 859.61 μmol) and piperidine (87.83 mg, 1.03 mmol) in DMF (10 mL) was added HATU (486.46 mg, 1.29 mmol) and DIEA (333.29 mg, 2.58 mmol), the reaction mixture was stirred at 25 °C for 2 h. The mixture was poured into water (100 mL) and extracted with EA (30 mL x 3). The organic layer was washed with water (100 mLx2) and brine (100 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by Prep-HPLC (Waters Xbridge C18 10 μm OBD 19*250mm, A: 10 mmol NH_4HCO_3 in water; B: CH_3CN , 5% to 95%) in NH_4HCO_3 condition to afford **compound 121**, 2-((2-ethyl-6-(6-(4-(piperidine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (200 mg, 35.86% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6) δ 8.57 (s, 1H), 8.52-8.51 (d, 1H), 8.11-8.08 (t, 2H), 7.94-7.91 (dd, 1H), 7.69-7.65 (m, 2H), 7.44-7.39 (t, 2H), 6.92-6.89 (d, 1H), 4.37-4.33 (d, 2H), 3.64 (s, 3H), 3.48-3.41 (m, 4H), 2.96-2.90 (m, 3H), 2.70-2.64 (dd, 2H), 1.65-1.50 (m, 8H), 1.41-1.40 (m, 2H), 1.29-1.25 (t, 3H); MS: m/z = 649.2 ($M+1$, ESI+); HRMS: 649.2870.


5.11.20. Synthesis of Compound 121 Hydrochloride



[0496] To a solution of **compound 145**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo [1,2-a]pyridin-6-yl)pyridin-2-yl)piperidine-4-carboxylic acid (500 mg, 859.61 μmol) and piperidine (87.83 mg, 1.03 mmol) in DMF (10 mL) was added HATU (486.46 mg, 1.29 mmol) and DIEA (333.29 mg, 2.58 mmol), the reaction


mixture was stirred at 25 °C for 2 h. The mixture was poured into water (100 mL) and extracted with EA (30 mL x 3). The organic layer was washed with water (100 mLx2) and brine (100 mL), then dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC (Waters Xbridge C18 10um OBD 19*250mm, A: 0.05% HCl in water; B: CH₃CN, 5% to 95%) in HCl condition to afford **compound 121 hydrochloride**, 2-((2-ethyl-6-(6-(4-(piperidine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile hydrochloride (170 mg, 26.07% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.11 (s, 1H), 8.45 (s, 1H), 8.35-8.25 (m, 2H), 8.10-8.00 (m, 3H), 7.42-7.32 (m, 3H), 4.44-4.41 (d, 2H), 3.67 (s, 3H), 3.50-3.40 (m, 4H), 3.25-3.19 (t, 2H), 3.06-3.01 (m, 1H), 2.89-2.83 (m, 2H), 1.76-1.40 (m, 10H), 1.35-1.31 (t, 3H); MS: m/z = 649.4 (M+1, ESI+).

5.11.21. Synthesis of Compound 122



[0497] To a solution of **compound 145**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyridin-2-yl)piperidine-4-carboxylic acid (500 mg, 859.61 μmol) and azetidine hydrochloride (96.50 mg, 1.03 mmol) in DMF (10 mL) was added HATU (486.46 mg, 1.29 mmol) and DIEA (333.29 mg, 2.58 mmol), the reaction mixture was stirred at 25 °C for 2 h. The mixture was poured into water (100 mL) and extracted with EA (30 mL x 3). The organic layer was washed with water (100 mLx2) and brine (100 mL), then dried over Na₂SO₄ and concentrated. The residue was purified by silica gel column to afford **compound 122**, 2-((6-(6-(4-(azetidine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (110 mg, 20.61% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.58 (s, 1H), 8.52-8.51 (d, 1H), 8.12-8.08 (t, 2H), 7.93-7.91 (dd, 1H), 7.72-7.66 (m, 2H), 7.44-7.39 (t, 2H), 6.92-6.89 (d, 1H), 4.37-4.34 (d, 2H), 4.20-4.16 (t, 2H), 3.84-3.80 (t, 2H), 3.65 (s, 3H), 2.93-2.87 (t, 2H), 2.70-2.65 (dd, 2H), 2.49-2.45 (m, 1H), 2.22-2.15 (m, 2H), 1.65-1.63 (m, 2H), 1.53-1.43 (m, 2H), 1.30-1.26 (t, 3H); MS: m/z = 621.2 (M+1, ESI+); HRMS: 621.2560.


5.11.22. Synthesis of Compound 126




[0498] To a solution of **compound 145**, 1-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo [1,2-a]pyridin-6-yl)pyridin-2-yl)piperidine-4-carboxylic acid (500 mg, 859.61 μmol) and morpholine (82.38 mg, 945.57 μmol) in DMF (10 mL) was added HATU (490.27 mg, 1.29 mmol) and DIEA (333.29 mg, 2.58 mmol), the reaction mixture was stirred at 25 °C for 2 h. The mixture was poured into water (100 mL) and extracted with EA (30 mL x 2), the organic layer was washed with brine (100 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by Prep-HPLC to afford **compound 126**, 2-((2-ethyl-6-(6-(4-(morpholine-4-carbonyl)piperidin-1-yl)pyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (272 mg, 48.62% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6) δ 8.58 (s, 1H), 8.52-8.51 (d, 1H), 8.11-8.08 (t, 2H), 7.94-7.91 (dd, 1H), 7.72-7.66 (m, 2H), 7.44-7.40 (t, 2H), 6.93-6.91 (d, 1H), 4.37-4.34 (d, 2H), 3.64 (s, 3H), 3.58-3.53 (m, 6H), 3.44-3.43 (m, 2H), 2.95-2.89 (m, 3H), 2.70-2.64 (dd, 2H), 1.68-1.65 (m, 2H), 1.59-1.49 (m, 2H), 1.29-1.25 (t, 3H); MS: m/z = 651.2 ($\text{M}+1$, ESI+); HRMS: 651.2662.

5.12. Example 11 – Synthesis of Reverse Piperidine-linked Pyrimidine-type Compounds

General Scheme 11



5.12.1. Synthesis of tert-butyl 4-(5-bromopyrimidin-2-yl)piperidine-1-carboxylate



Step one:


[0499] To a solution of tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (20 g, 64.68 mmol) and 5-bromo-2-iodopyrimidine (27.64 g, 97.02 mmol) in dioxane (100 mL) and H₂O (20 mL) was added Na₂CO₃ (20.57 g, 194.04 mmol) and Pd(PPh₃)₄ (3.74 g, 3.23 mmol), the reaction mixture was stirred at 80 °C for 16 h. The mixture was poured into water (300 mL) and extracted with EA (100 mL×2). The organic layer was washed with water (300 mL×2) and brine (300 mL×1), then dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography to afford tert-

butyl 4-(5-bromopyrimidin-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (10 g, 45.44% yield) as a white solid. MS: $m/z = 340.2$ (M+1, ESI+).

Step two:

[0500] To a solution of tert-butyl 4-(5-bromopyrimidin-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (8 g, 23.51 mmol) in MeOH (80 mL) was added Raney Ni (1.38 g, 23.51 mmol). The reaction mixture was stirred at 25 °C for 16 h under H₂. Filtered and the filtrate was concentrated under reduce pressure. The residue was purified by column chromatography to afford tert-butyl 4-(5-bromopyrimidin-2-yl)piperidine-1-carboxylate (1.6 g, 19.88% yield) as a colorless oil. MS: $m/z = 342.3$ (M+1, ESI+).

5.12.2. Synthesis of Compound 146



Step one:


[0501] To a solution of **compound 133**, (3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)boronic acid (2.26 g, 5.36 mmol) and tert-butyl 4-(5-bromopyrimidin-2-yl)piperidine-1-carboxylate (2.2 g, 6.43 mmol) in dioxane (20 mL) and H₂O (5 mL) was added Na₂CO₃ (1.70 g, 16.07 mmol) and Pd(PPh₃)₄ (309.52 mg, 267.85 μmol), the reaction mixture was stirred at 80 °C for 16 h. The mixture was poured into water (200 mL) and extracted with EA (80 mL×2). The organic layer was washed with water (200 mL×2) and brine (200 mL×1), then dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography to afford tert-butyl 4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidine-1-carboxylate (2.3 g, 67.22% yield) as a white solid. MS: $m/z = 639.2$ (M+1, ESI+).

Step two:

[0502] To a solution of tert-butyl 4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidine-1-carboxylate (1 g, 1.57 mmol) in MeOH (10 mL) was added 3M HCl in EA (5.2 mL, 15.7 mmol) and the mixture was stirred at 25 °C for 16 h. The solution was adjusted to pH 8 with

aq. NaHCO₃ and extracted with EA(20 mL×2). The organic layer was washed with water (40 mL×2) and brine (40 mL×1), then dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography to **compound 146**, afford 2-((2-ethyl-6-(2-(piperidin-4-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (810 mg, 96.06% yield) as a yellow solid. MS: m/z = 539.2(M+1, ESI+).

5.12.3. Synthesis of Compound 147




Step one:

[0503] To a solution of **compound 146**, 2-((2-ethyl-6-(2-(piperidin-4-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (800 mg, 1.49 mmol) and ethyl 2-bromoacetate (744.10 mg, 4.46 mmol) in MeCN (10 mL) was added K₂CO₃ (153.95 mg, 1.11 mmol), the reaction mixture was stirred at 60 °C for 2 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by column chromatography to afford ethyl 2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-1-yl)acetate (920 mg, crude) as yellow solid. MS: m/z = 625.2 (M+1, ESI+).

Step two:


[0504] To a solution of ethyl 2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-1-yl)acetate (920 mg, 1.47 mmol) in THF (5 mL) and H₂O (5 mL) was added LiOH (176.34 mg, 7.36 mmol), the reaction mixture was stirred at 25 °C for 16 h. The mixture was concentrated under reduce pressure and the residue was purified by Prep-HPLC to afford **compound 147**, 2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-1-yl)acetic acid (750 mg, 85.35% yield) as a yellow solid. m/z = 597.0(M+1, ESI+).

5.12.4. Synthesis of Compound 99



[0505] To a solution of **compound 146**, 2-((2-ethyl-6-(2-(piperidin-4-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (500 mg, 928 μmol) and cyclopropanecarboxylic acid (159.83 mg, 1.86 mmol) in DMF (10 mL) was added HATU (420.25 mg, 1.11 mmol) and DIEA (360 mg, 2.79 mmol). The reaction mixture was stirred at 25 °C for 16 h. The mixture was poured into water (100 mL) and extracted with EA (40 mL $\times$ 2). The organic layer was washed with water (100 mL $\times$ 2) and brine (100 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by Prep-HPLC to afford **compound 99**, 2-((6-(2-(1-(cyclopropanecarbonyl)piperidin-4-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (170 mg, 30.19% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6) δ 9.15 (s, 2H), 8.87 (s, 1H), 8.11-8.07 (t, 2H), 7.84-7.75 (m, 2H), 7.44-7.39 (t, 2H), 4.44-4.32 (m, 2H), 3.65 (s, 3H), 3.21-3.13 (m, 2H), 2.77-2.66 (m, 3H), 2.04-1.95 (m, 3H), 1.77-1.59 (m, 2H), 1.30-1.26 (t, 3H), 0.75-0.67 (m, 4H); MS: m/z = 607.3 ($\text{M}+1$, ESI^+); HRMS: 607.2404.


5.12.5. Synthesis of Compound 100



[0506] To a solution of **compound 146**, 2-((2-ethyl-6-(2-(piperidin-4-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (500 mg, 928 μmol) and cyclobutanecarboxylic acid (185.87 mg, 1.86 mmol) in DMF (10 mL) was added HATU (420.25 mg, 1.11 mmol) and DIEA (360 mg, 2.79 mmol). The reaction mixture was stirred at 25 °C for 16 h. The mixture was poured into water (100 mL) and extracted with EA (40 mL $\times$ 2). The organic layer was washed with water (100 mL $\times$ 2) and brine (100 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by Prep-


HPLC to afford **compound 100**, 2-((6-(2-(1-(cyclobutanecarbonyl)piperidin-4-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (180 mg, 31.24% yield) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 9.14 (s, 2H), 8.87 (s, 1H), 8.10-8.07 (t, 2H), 7.83-7.75 (m, 2H), 7.44-7.39 (t, 2H), 4.44-4.41 (d, 1H), 3.79-3.75 (d, 1H), 3.65 (s, 3H), 3.38-3.34 (m, 1H), 3.15-3.06 (m, 2H), 2.76-2.66 (m, 3H), 2.19-2.04 (m, 4H), 1.98-1.85 (m, 3H), 1.76-1.56 (m, 3H), 1.30-1.26 (t, 3H); MS: m/z = 621.3 (M+1, ESI+); HRMS: 621.2561.

5.12.6. Synthesis of Compound 101




[0507] To a solution of **compound 146**, 2-((2-ethyl-6-(2-(piperidin-4-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (300 mg, 557 μmol) in DMF (5 mL) was added CDI (135.46 mg, 835.44 μmol), the reaction was stirred at room temperature for 1 h and azetidine hydrochloride (156.32 mg, 1.67 mmol) was added into the above solution. The reaction mixture was stirred at 65 $^{\circ}\text{C}$ for 16 h. The mixture was poured into water (50 mL) and extracted with EA (20 mL $\times$ 2). The organic layer was washed with water (50 mL $\times$ 2) and brine (50 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by Prep-HPLC to afford **compound 101**, 2-((6-(2-(1-(azetidine-1-carbonyl)piperidin-4-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (62 mg, 17.90% yield) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 9.14 (s, 2H), 8.86 (s, 1H), 8.10-8.07 (t, 2H), 7.83-7.75 (m, 2H), 7.44-7.39 (t, 2H), 3.90-3.79 (m, 3H), 3.64-3.61 (m, 4H), 3.08-3.01 (m, 1H), 2.90-2.82 (m, 2H), 2.74-2.66 (m, 5H), 2.17-2.09 (m, 1H), 1.94-1.91 (d, 2H), 1.80-1.64 (m, 2H), 1.29-1.25 (t, 3H); MS: m/z = 622.3 (M+1, ESI+); HRMS: 622.2509.

5.12.7. Synthesis of Compound 102



[0508] To a solution of **compound 146**, 2-((2-ethyl-6-(2-(piperidin-4-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (300 mg, 557 μmol) in DMF (10 mL) was added CDI (135.46 mg, 835.44 μmol), the reaction was stirred at room temperature for 1 h and pyrrolidine (118.83 mg, 1.67 mmol) was added into the above solution. The reaction mixture was stirred at 80 °C for 16 h. The mixture was poured into water (100 mL) and extracted with EA (30 mL $\times$ 2). The organic layer was washed with water (100 mL $\times$ 2) and brine (100 mL), then dried over Na_2SO_4 and concentrated. The residue was purified by Prep-HPLC to afford **compound 102**, 2-((2-ethyl-6-(2-(pyrrolidine-1-carbonyl)piperidin-4-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (68 mg, 19.20% yield) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.14 (s, 2H), 8.86 (s, 1H), 8.10-8.07 (t, 2H), 7.83-7.75 (m, 2H), 7.44-7.39 (t, 2H), 3.75-3.72 (d, 2H), 3.64 (s, 3H), 3.28-3.25 (t, 4H), 3.08-3.02 (m, 1H), 2.87-2.82 (t, 2H), 2.71-2.66 (dd, 2H), 1.95-1.92 (d, 2H), 1.79-1.70 (m, 6H), 1.29-1.25 (t, 3H); MS: m/z = 636.4 ($M+1$, ESI $^+$); HRMS: 636.2662.


5.12.8. Synthesis of Compound 103



[0509] To a solution of **compound 147**, 2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-1-yl)acetic acid (150 mg, 251.39 μmol) and azetidine hydrochloride (28.71 mg, 306.84 μmol) in DMF (5 mL) was added HATU (189.69 mg, 502.78 μmol) and DIEA (98 mg, 755 μmol). The reaction mixture was stirred at 25 °C for 16 h. The mixture was poured into water (50 mL) and extracted with EA (20 mL $\times$ 2). The organic layer was washed with water (50 mL $\times$ 2) and

brine (50 mL), then dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC to afford **compound 103**, 2-((6-(2-(1-(2-(azetidin-1-yl)-2-oxoethyl)piperidin-4-yl)pyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (62 mg, 38.75% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.13 (s, 2H), 8.86 (s, 1H), 8.10-8.07 (t, 2H), 7.83-7.75 (m, 2H), 7.44-7.39 (t, 2H), 4.21-4.17 (t, 2H), 3.86-3.83 (t, 2H), 3.64 (s, 3H), 2.96-2.79 (m, 5H), 2.72-2.66 (dd, 2H), 2.22-2.14 (m, 4H), 1.93-1.81 (m, 4H), 1.29-1.25 (t, 3H); MS: m/z = 636.1 (M+1, ESI+); HRMS: 636.2666.

5.12.9. Synthesis of Compound 104




[0510] To a solution of **compound 147**, 2-(4-(5-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2-yl)piperidin-1-yl)acetic acid (300 mg, 502.78 μmol) and pyrrolidine (107.28 mg, 1.51 mmol) in DMF (5 mL) was added HATU (379.37 mg, 1.01 mmol) and DIEA (196 mg, 1.51 mmol). The reaction mixture was stirred at 25 °C for 16 h. The mixture was poured into water (50 mL) and extracted with EA (20 mL×2). The organic layer was washed with water (50 mL×2) and brine (50 mL), then dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC to afford **compound 104**, 2-((2-ethyl-6-(2-(1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)piperidin-4-yl)pyrimidin-5-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (90 mg, 27.55% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.13 (s, 2H), 8.86 (s, 1H), 8.10-8.07 (t, 2H), 7.83-7.75 (m, 2H), 7.44-7.39 (t, 2H), 3.64 (s, 3H), 3.50-3.46 (t, 2H), 3.29-3.26 (t, 2H), 3.11 (s, 2H), 2.96-2.86 (m, 3H), 2.70-2.66 (dd, 2H), 2.22 (s, 2H), 1.93-1.71 (m, 8H), 1.29-1.26 (t, 3H); MS: m/z = 650.2 (M+1, ESI+); HRMS: 650.2820.

5.13. Example 12 – Activity of exemplary compounds in hATX/ENPP2 biochemical assays

[0511] This example describes the biochemical data (IC₅₀ value ranges) of the compounds described in the present disclosure from hATX/ENPP2 assays using 16:0-LPC as the

substrate. The subject compounds were compared to compound GPLG-1690 as a reference compound. GPLG-1690 (Ziritaxestat) is a known compound of the following structure:



GPLG-1690.

Experimental Procedures

[0512] 20 nL of a dilution series (a total of 12 concentrations) of compound, starting from 10 mM highest concentration, 1/3 dilution, is transferred to the wells by Echo[®]550 Liquid Handler.

[0513] hENPP2 is used at a final concentration of 2.5 nM. The enzyme is diluted in 50 mM Tris-HCl pH 8.0, 140 mM NaCl, 5 mM CaCl₂, 0.01% Triton X-100 in a total volume of 5 μ L. The aqueous solution of enzyme is added to the wells and incubated with different concentrations of the compounds at room temperature for 15 min. The reaction is started by the addition of 5 μ L of 80 μ M LPC (16:0) and 10 μ L of the detection mixture containing 200 μ M Amplex Red, 10 U/mL choline oxidase and 4 U/mL HRP.

[0514] Fluorescence at 590 nm was measured kinetically with excitation at 530 nm. The slope of the curve (from 60 to 70 min of the reaction time) was used to calculate the compounds' IC₅₀ values.

Data

[0515] The IC₅₀ values of reference compound GPLG-1690; and exemplary compounds 1-115 and 118-127 from hATX/ENPP2 assays are listed in Table 2 below. hATX/ENPP2 IC₅₀ (nM) ranges: (A) refers to IC₅₀ $\leq$ 20 nM; (B) refers to 20 < IC₅₀ $\leq$ 200 nM; and (C) refers to IC₅₀ > 200 nM.

Table 2: Activity of exemplary compounds in hATX/ENPP2 assays					
Cmpd No.	hATX/ENPP2 IC ₅₀ (nM)	Cmpd No.	hATX/ENPP2 IC ₅₀ (nM)	Cmpd No.	hATX/ENPP2 IC ₅₀ (nM)
GPLG-1690 (reference)	B				
1	A	2	A	3	B
4	B	5	A	6	A
7	A	8	A	9	A
10	A	11	B	12	B
13	C	14	B	15	B
16	B	17	B	18	A
19	A	20	B	21	B
22	C	23	B	24	B
25	B	26	B	27	B
28	B	29	B	30	B
31	B	32	A	33	A
34	C	35	B	36	B
37	B	38 (formate salt)	C	39	B
40	C	41	B	42	A
43	A	44	A	45	A
46	A	47	B	48	B
49	B	50	B	51	B
52	B	53	B	54	B
55	B	56	B	57	B
58	B	59	B	60	B
61	B	62	B	63	C
64	B	65	B	66	A

Table 2: Activity of exemplary compounds in hATX/ENPP2 assays					
Cmpd No.	hATX/ENPP2 IC ₅₀ (nM)	Cmpd No.	hATX/ENPP2 IC ₅₀ (nM)	Cmpd No.	hATX/ENPP2 IC ₅₀ (nM)
GPLG-1690 (reference)	B				
				(hydrochloride salt)	
67	B	68 (formate salt)	A	69 (formate salt)	A
70 (hydrochloride salt)	B	71 (hydrochloride salt)	B	72 (hydrochloride salt)	A
73	A	74	A	75	A
76	A	77	A	78	A
79 (hydrochloride salt)	A	80 (hydrochloride salt)	B	81 (hydrochloride salt)	B
82 (hydrochloride salt)	A	83 (hydrochloride salt)	A	84	A
85	B	86	B	87	B
88	A	89 (hydrochloride salt)	A	90	A
91	A	92	A	93	A
94	B	95	A	96 (hydrochloride salt)	B
97	B	98	A	99	B
100	B	101	B	102	B
103	B	104	B	105	B
106	B	107	B	108	B
109	B	110	B	111	B
112	B	113	A	114	A
115	A	118	A	119	A
120	A	121	B	122	A

Table 2: Activity of exemplary compounds in hATX/ENPP2 assays					
Cmpd No.	hATX/ENPP2 IC ₅₀ (nM)	Cmpd No.	hATX/ENPP2 IC ₅₀ (nM)	Cmpd No.	hATX/ENPP2 IC ₅₀ (nM)
GPLG-1690 (reference)	B				
123	A	124	B	125	B
126	A	127	A		

[0516] As seen above, the majority of the subject compounds show better or comparative activity to the reference compound GPLG-1690 in hATX/ENPP2 assays.

5.14. Example 13 – Inhibitory activity of exemplary compounds in LPA Assays

[0517] Autotaxin (ATX) plays an important role in lysophosphatidic acid (LPA) signaling. An *in vitro* LPA assay was conducted to determine IC₅₀ values of the test compounds on reduction of LPA 18:2 level in rat or mouse plasma. This example describes the assay data (IC₅₀ value ranges) of exemplary compounds from LPA assays using mouse and rat plasma. Compound GPLG-1690 was assayed as a reference compound.

Experimental Procedures

[0518] The 10mM DMSO stock solutions of test compounds and 4-fold serial dilutions of the test compounds were prepared at various concentrations. The diluted solutions of the compounds were diluted with 1X PBS (pH 7.5) buffer. 38 µL of rat or mouse plasma samples were mixed with 2 µL of the diluted solutions of the compounds or 2% DMSO solutions in 96-well plate (final 0.1% DMSO). After incubating for 2hr at 37°C, 120 µL MeOH containing IS (250 ng/mL of LPA 17:0) was added to each well. Mixture was vortexed for 1 min, and then centrifuged for 30 min (4000 rpm, 4°C). 100 µL supernatant was transferred to a 96-well plate containing 100 µL pure water and the plate was shaken for 10 min. 5 µL supernatant was injected into LC-MS/MS system. No calibration curve will be prepared for LPA 18:2 and all quantifications were performed based on peak area ratios (LPA 18:2/LPA 17:0). For each concentration of compound LPA data were expressed as percentage of reduction (% reduction) using the formula:

100 - [(LPA ratio-LPA ratio in control sample after 0 hr incubation)/(LPA ratio in control sample after 2 hr incubation- LPA ratio in control sample after 0 hr incubation))*100].

Data

[0519] The IC₅₀ values of reference compound GPLG-1690 and various subject compounds from LPA assays in mouse and rat plasma are listed in Table 3 below. IC₅₀ (nM) ranges: (A) refers to IC₅₀ ≤ 200 nM; (B) refers to 200 < IC₅₀ ≤ 800 nM; and (C) refers to IC₅₀ > 800 nM.

Table 3: Inhibitory Activity of exemplary compounds in LPA Assays		
Cmpd No.	Mouse plasma, LPA IC₅₀	Rat plasma, LPA IC₅₀
GPLG-1690 (reference)	C	C
10	B	A
30	B	B
42	B	B
43	A	A
44	B	B
45 (hydrochloride salt)	B	A
46 (hydrochloride salt)	B	B
79 (hydrochloride salt)	B	A
85	B	A
86 (hydrochloride salt)	C	B
87	B	B
92	A	B
93	B	A
109	B	A
113	C	A
114	B	B
115	B	A

Table 3: Inhibitory Activity of exemplary compounds in LPA Assays		
Cmpd No.	Mouse plasma, LPA IC₅₀	Rat plasma, LPA IC₅₀
GPLG-1690 (reference)	C	C
118	B	A
119	B	B
120	B	B
121	B	A
122	B	A
123	B	B
124	B	B
125	B	A
126	B	A
127	B	A

[0520] As seen above, the majority of the subject compounds show better inhibitory activity as compared to the reference compound GPLG-1690 in LPA assays.

5.15. Example 14 – Pharmacokinetic Data

[0521] This example describes the pharmacokinetic (PK) data obtained for various compounds of the present disclosure, from studies using mice. The following PK parameters were calculated:

- Bioavailability (F%) were calculated using the linear/log trapezoidal rule
- Peak plasma concentrations (C_{max} (ng/mL)) were taken directly from the plasma concentration vs. time profiles for the PO group
- Area under the curve e.g., the area under the concentration curve from time 0 to infinity (AUC_{0-inf} (ng*h/mL)).

Experimental Procedures

[0522] After intravenous (IV) and oral (PO) administration at 2 mg/kg and 10 mg/kg to male C57BL/6 mice, respectively, the blood samples were collected at the designed sampling time points. All blood samples were transferred into pre-chilled commercial polyethylene microcentrifuge tubes containing K₂-EDTA as an anticoagulant. Samples were processed for plasma by centrifugation. Plasma samples were transferred into polypropylene tubes pre-chilled on dry ice and then quickly frozen over dry ice and kept at -70 ± 10 °C until LC-MS/MS analysis. Mice plasma samples were analyzed using qualified bioanalytical methods based on protein precipitation followed by LC-MS/MS analysis. Individual plasma concentration data of each compound was subjected to noncompartmental pharmacokinetic analysis using Phoenix WinNonlin™. Nominal doses were used for pharmacokinetic parameters calculation.

Data

[0523] The PK parameters of various subject compounds are listed in Table 4 below.

Table 4: Mouse PK study of exemplary compounds			
Cmpd No.	F% C_{max} (ng/mL) AUC_{0-inf} (ng*h/mL)	Cmpd No.	F% C_{max} (ng/mL) AUC_{0-inf} (ng*h/mL)
1	F% : 56.5 C _{max} : 3034 AUC _{0-inf} : 27236	2	F% : 61.0 C _{max} : 4070 AUC _{0-inf} : 35115
10	F% : 28.0 C _{max} : 4951 AUC _{0-inf} : 26691	30	F% : 42 C _{max} : 4312 AUC _{0-inf} : 21714
43	F% : 39.5 C _{max} : 5166 AUC _{0-inf} : 31028	44	F% : 33.4 C _{max} : 4727 AUC _{0-inf} : 25035
47	F% : 62.3 C _{max} : 4763 AUC _{0-inf} : 42329	92	F% : 25 C _{max} : 4264 AUC _{0-inf} : 22842
113	F% : 44.7 C _{max} : 6528 AUC _{0-inf} : 40493	114	F% : 28.4 C _{max} : 7042 AUC _{0-inf} : 37962
115	F% : 48.5 C _{max} : 3985 AUC _{0-inf} : 37146	119	F% : 33.06 C _{max} : 7682 AUC _{0-inf} : 57122
120	F% : 40.82 C _{max} : 8468 AUC _{0-inf} : 50455	122	F% : 57.8 C _{max} : 7000 AUC _{0-inf} : 47658

Table 4: Mouse PK study of exemplary compounds			
Cmpd No.	F% C_{max} (ng/mL) AUC_{0-inf} (ng*h/mL)	Cmpd No.	F% C_{max} (ng/mL) AUC_{0-inf} (ng*h/mL)
123	F% : 55.7 C _{max} : 7253 AUC _{0-inf} : 60965	124	F% : 40.0 C _{max} : 3823 AUC _{0-inf} : 13126
125	F% : 38.8 C _{max} : 10233 AUC _{0-inf} : 34069	126	F% : 59.2 C _{max} : 5582 AUC _{0-inf} : 38287


EQUIVALENTS AND INCORPORATION BY REFERENCE

[0524] While the invention has been particularly shown and described with reference to a preferred embodiment and various alternate embodiments, it will be understood by persons skilled in the relevant art that various changes in form and details can be made therein without departing from the spirit and scope of the invention.

[0525] All references, issued patents and patent applications cited within the body of the instant specification are herein incorporated by reference in their entirety, for all purposes.

CLAIMS

1. A compound of formula (I):



or a pharmaceutically acceptable salt or isomer thereof,

wherein:

X^1 , X^2 , and X^3 are independently selected from C- R^1 and N;

Z^1 , Z^2 , and Z^3 are independently selected from C- R^1 and N;

each R^1 is independently selected from -H, -halogen, optionally substituted -(C₁-C₆)alkyl and optionally substituted -(C₁-C₆)alkoxy;

Y is selected from S, O, and N- R^2 , wherein R^2 is selected from -H, and optionally substituted -(C₁-C₆)alkyl;

R^3 is selected from optionally substituted R^4 -C(O)-(C₁-C₃)alkyl-, R^4 C(O)-, optionally substituted monocyclic or bicyclic carbocycle, optionally substituted monocyclic or bicyclic heterocycle, R^5R^6 HC-, and R^5R^6 N-;

R^4 is selected from H₂N-, HO-, R^5R^6 N-, optionally substituted (C₁-C₁₀)alkyl-, optionally substituted (C₁-C₁₀)alkoxy-, optionally substituted monocyclic or bicyclic carbocycle, optionally substituted monocyclic or bicyclic heterocycle, optionally substituted cycloalkyl-(C₁-C₆)alkylene-, and optionally substituted heterocycle-(C₁-C₆)alkylene-;

R^5 and R^6 are independently selected from H-, H₂N-, HO-, optionally substituted (C₁-C₁₀)alkyl-, optionally substituted monocyclic or bicyclic carbocycle, optionally substituted monocyclic or bicyclic heterocycle, optionally substituted R^4 C(O)-(C₁-C₁₀)alkyl-, R^4 C(O)-, R^4 -, and substituted amino; or R^5 and R^6 together with the nitrogen or carbon atom to which they are attached are cyclically linked to form an optionally substituted carbocycle or an optionally substituted heterocycle;


R^7 is selected from H-, and optionally substituted (C₁-C₆)alkyl-;

R^8 is selected from -H, -halogen, and optionally substituted -(C₁-C₆)alkyl-;

R^9 and each R^{10} are independently selected from -H, -halogen, -CN, -OH, optionally substituted $-(C_1-C_6)$ alkoxy, $-NH_2$, substituted amino, optionally substituted $-(C_1-C_6)$ alkyl- NH_2 and optionally substituted $-(C_1-C_6)$ alkyl; and

n is 0, 1, 2, 3, 4, or 5.

2. The compound of claim 1, wherein X^1 is N, X^2 is C-H, and X^3 is C-H.
3. The compound of claim 1, wherein X^1 is C-H, X^2 is C-H, and X^3 is C-H.
4. The compound of any one of claims 1 to 3, wherein Y is S.
5. The compound of any one of claims 1 to 4, wherein Z^1 is C-H, Z^2 is C-H, and Z^3 is C-H.
6. The compound of any one of claims 1 to 5, wherein the compound is of formula (Ia):



(Ia)

wherein:

R^1 is selected from -H, -halogen, optionally substituted $-(C_1-C_6)$ alkyl and optionally substituted $-(C_1-C_6)$ alkoxy;


R^3 is selected from $R^4C(O)-$, $R^4C(O)CH_2-$, R^5R^6N- , and R^5R^6HC- ;

R^{11} is -H, -halogen, -CN, -OH, optionally substituted $-(C_1-C_6)$ alkoxy, $-NH_2$, $-NR^5R^6$, $-CH_2NH_2$ and optionally substituted $-(C_1-C_6)$ alkyl; and

n is 0, 1, 2, or 3.

7. The compound of claim 6, wherein X^1 is N.
8. The compound of claim 6, wherein X^1 is C-H.
9. The compound of any one of claims 1 to 8, wherein R^7 is optionally substituted (C_1-C_6) alkyl-.
10. The compound of claim 9, wherein R^7 is H_3C- .
11. The compound of any one of claims 1 to 10, wherein R^8 is optionally substituted $-(C_1-C_6)$ alkyl.
12. The compound of claim 11, wherein R^8 is $-CH_2CH_3$.
13. The compound of any one of claims 1 to 12, wherein R^9 is -CN.

14. The compound of any one of claims 1 to 13, wherein R^{11} is -halogen.
15. The compound of claim 14, wherein R^{11} is -F.
16. The compound of any one of claims 1 to 15, wherein the compound is of formula (Ib):






wherein:

X^1 is C-H or N; and

R^1 is -H, -halogen, or optionally substituted -(C₁-C₆)alkyl and optionally substituted -(C₁-C₆)alkoxy.

17. The compound of any one of claims 1 to 16, wherein:



d) R^3 is that is an optionally substituted monocyclic or bicyclic (C₂-C₉)heterocycle-; or

e) R^3 is that is an optionally substituted monocyclic or bicyclic (C₃-C₈)carbocycle-, or an optionally substituted monocyclic or bicyclic (C₂-C₉)heterocycle-; wherein:


R^4 is selected from HO-, H₂N-, R¹⁵R¹⁶N-, optionally substituted (C₁-C₅)alkyl-, optionally substituted monocyclic or bicyclic carbocycle, and optionally substituted monocyclic or bicyclic heterocycle;

R^{12} is selected from -H, -NH₂, -OH, -CH₂C(O)R⁴, -C(O)R⁴, -CHR¹⁵R¹⁶, -NR¹⁵R¹⁶, optionally substituted -(C₁-C₅)alkyl, optionally substituted monocyclic or bicyclic -(C₃-C₈)carbocycle, and an optionally substituted monocyclic or bicyclic -(C₂-C₉)heterocycle; and

R^{13} and R^{14} are independently selected from -H, -CH₂C(O)R¹⁷, -CH₂R¹⁷, -C(O)R¹⁷, -R¹⁸C(O)R¹⁷, -CH₂R¹⁸C(O)R¹⁷, optionally substituted -(C₁-C₅)alkyl, optionally substituted monocyclic or bicyclic -(C₃-C₈)carbocycle, and an optionally substituted monocyclic or bicyclic -(C₂-C₉)heterocycle, wherein R^{17} and R^{18} are independently selected from optionally substituted -(C₁-C₅)alkyl, optionally substituted monocyclic or bicyclic -(C₃-C₈)carbocycle, and an optionally substituted monocyclic or bicyclic -(C₂-C₉)heterocycle; and

R^{15} and R^{16} are independently selected from H-, optionally substituted (C₂-C₅)heterocycloalkyl-C(O)-, optionally substituted (C₃-C₆) cycloalkyl-C(O)-, optionally substituted (C₁-C₅)alkyl-, optionally substituted 3- to 10-membered saturated monocyclic heterocycle or carbocycle, and optionally substituted 3- to 10-membered saturated bicyclic heterocycle or carbocycle, wherein the optional substituents are selected from hydroxy, HOCH₂-, cyano, halogen, substituted amino, and (C₁-C₅)alkyl; or R^{15} and R^{16} are cyclically linked to form a 3- to 6-membered monocyclic saturated heterocycle, optionally substituted with hydroxy, HOCH₂-, cyano, halogen, substituted amino, or (C₁-C₅)alkyl.

18. The compound of any one of claims 1 to 17, wherein:




R^4 is selected from R^{32} , R^{32} HN-, R^{32} N(R^{33})-, and R^{32} HN- R^{36} -;

R^{32} and R^{33} are independently selected from H-, optionally substituted (C₁-C₃)alkyl, optionally substituted cycloalkyl, and optionally substituted saturated heterocycle;


R^{36} is selected from optionally substituted (C₁-C₃)alkyl, optionally substituted cycloalkyl, and optionally substituted saturated heterocycle; and

the optional substituents of the R^{32} , R^{33} and R^{36} groups are independently selected from -CN, -OH, -CH₂OH, -(C₁-C₃)alkyl, -(C₁-C₃)alkoxy, -(C₃-C₆)cycloalkyl, (C₂-C₅)heterocycloalkyl, and -N(R^{37}) R^{38} , wherein R^{37} and R^{38} are independently selected from H, (C₁-C₃)alkyl, (C₃-C₆)cycloalkyl, and (C₂-C₅)heterocycloalkyl.

19. The compound of claim 18, wherein R⁴ is selected from:




20. The compound of claim 19, wherein the compound is selected from:




Compound 11

Compound 12




Compound 13


Compound 14




Compound 15




Compound 16




Compound 47




Compound 48




Compound 49




Compound 50




Compound 51




Compound 52




Compound 53




Compound 54




Compound 55




Compound 56




Compound 57




Compound 58




Compound 59




Compound 60




Compound 61




Compound 62




Compound 63



Compound 64




Compound 65



Compound 87

and

21. The compound of any one of claims 1 to 17, wherein:



R^3 is


R^{14} is selected from R^{34} -, $R^{34}CH_2$ -, $R^{34}C(O)R^{35}$ -, and $R^{34}C(O)R^{35}CH_2$ -;

each R^{34} and R^{35} are independently selected from optionally substituted $-(C_1-C_3)$ alkyl, optionally substituted cycloalkyl, and optionally substituted saturated heterocycle;


the optional substituents of the R^{34} and R^{35} groups are independently selected from -CN, -OH, $-CH_2OH$, $-(C_1-C_3)$ alkyl, $-(C_1-C_3)$ alkoxy, and $-(C_1-C_3)$ alkyl; and


R^{13} is -H.

22. The compound of claim 21, wherein R¹⁴ is selected from:




23. The compound of claim 22, wherein the compound is selected from:






Compound 38




Compound 39




Compound 40

and




Compound 41

24. The compound of any one of claims 1 to 17, wherein R^3 is



25. The compound of claim 24, wherein R^3 is selected from:




26. The compound of claim 24 or 25, wherein:

R^{12} is selected from H-, H_2N -, $R^{31}-C(O)$ -, $R^{31}-C(O)CH_2$ -, $R^{31}-NHC(O)$ -, $R^{31}-C(O)NH$ -, $R^{31}-NH$ -, $R^{31}-N(CH_3)C(O)$ -, $R^{31}-C(O)N(CH_3)$ -, $R^{31}-N(CH_3)$ -, and $R^{31}-O$ -;


R^{31} is selected from optionally substituted cycloalkyl, and optionally substituted saturated heterocycle; and

the optional substituents of the R^{31} group are selected from NC-, HO-, $HOCH_2$ -, (C_1-C_3) alkyl-, (C_1-C_3) alkoxy-, substituted (C_1-C_3) alkyl-, (C_3-C_6) cycloalkyl-, and (C_2-C_5) heterocycloalkyl-.


27. The compound of any one of claims 24 to 26, wherein R¹² is selected from:




28. The compound of any one of claims 24 to 27, wherein the compound is selected from:




Compound 1




Compound 2




Compound 3




Compound 4




Compound 5




Compound 6




Compound 7




Compound 8




Compound 9




Compound 10




Compound 17




Compound 18




Compound 19




Compound 20




Compound 23




Compound 24




Compound 25




Compound 26




Compound 27




Compound 28




Compound 29




Compound 30




Compound 31




Compound 32




Compound 33




Compound 42




Compound 43




Compound 44




Compound 45




Compound 46




Compound 66




Compound 67




Compound 68




Compound 69




Compound 70




Compound 71




Compound 72




Compound 73




Compound 74




Compound 75




Compound 76




Compound 77




Compound 78



Compound 79




Compound 80




Compound 81

Compound 82




Compound 83

Compound 84




Compound 85

Compound 86




Compound 88

Compound 89




Compound 90

Compound 91




Compound 92


Compound 93




Compound 94




Compound 95




Compound 96




Compound 97




Compound 98




Compound 105




Compound 106




Compound 107




Compound 108




Compound 109




Compound 110




Compound 111




Compound 112




Compound 113




Compound 114




Compound 115




Compound 118




Compound 119




Compound 120




Compound 121




Compound 122




Compound 123




Compound 124



Compound 125




Compound 126



Compound 127

and

29. The compound of any one of claims 1 to 5, wherein the compound is of formula (Ie):



wherein:

X^1 and X^4 are independently N or C- R^1 ;


R^1 is selected from H, halogen, optionally substituted $-(C_1-C_6)alkyl$, and optionally substituted $-(C_1-C_6)alkoxy$; and

R^{31} is selected from optionally substituted $(C_2-C_5)heterocycloalkyl$, and optionally substituted $(C_3-C_7)cycloalkyl$;

R^{11} is -H, -halogen, -CN, -OH, optionally substituted $-(C_1-C_6)$ alkoxy, -
 NH_2 , $-NR^5R^6$, $-CH_2NH_2$ and optionally substituted $-(C_1-C_6)$ alkyl; and
 n is 0, 1, 2, or 3.

30. The compound of claim 29, wherein the optional substituents of the R^{31} group are selected from NC-, HO-, $HOCH_2$ -, (C_1-C_3) alkyl- (e.g., H_3C -), (C_1-C_3) alkoxy-, substituted (C_1-C_3) alkyl-, and (C_3-C_6) cycloalkyl- (e.g., cyclopropyl).

31. The compound of claim 29 or 30, wherein the compound is of formula (If):



wherein:

X^1 and X^4 are independently N or CH;

R^{41} is H-, or HO-; and

q is 0, 1 or 2; wherein

when q is 0 or 1, X^5 is CH_2 ; and

when q is 2, X^5 is NH, O, or CH(OH).

32. The compound of any one of claims 29 to 31, wherein R^7 is optionally substituted (C_1-C_6) alkyl-.

33. The compound of claim 32, wherein R^7 is H_3C -.

34. The compound of any one of claims 29 to 33, wherein R^8 is optionally substituted $-(C_1-C_6)$ alkyl-.


35. The compound of claim 34, wherein R^8 is $-CH_2CH_3$.

36. The compound of any one of claims 29 to 35, wherein R^9 is -CN.

37. The compound of any one of claims 29 to 36, wherein R^{11} is -halogen.

38. The compound of claim 37, wherein R^{11} is -F.

39. The compound of claim 24 or 29, wherein the compound is of formula (Ic):



wherein:


X^1 and X^4 are independently N or C- R^1 ;

R^1 is selected from H, halogen, optionally substituted $-(C_1-C_6)alkyl$, and optionally substituted $-(C_1-C_6)alkoxy$; and

R^{31} is selected from optionally substituted $(C_2-C_5)heterocycloalkyl$, and optionally substituted $(C_3-C_7)cycloalkyl$.

40. The compound of claim 39, wherein the optional substituents of the R^{31} group are selected from NC-, HO-, HOCH₂-, $(C_1-C_3)alkyl$ - (e.g., H₃C-), $(C_1-C_3)alkoxy$ -, substituted $(C_1-C_3)alkyl$ -, and $(C_3-C_6)cycloalkyl$ - (e.g., cyclopropyl).

41. The compound of claim 39 or 40, wherein the compound is of formula (Id):



wherein:

X^1 and X^4 are independently N or CH;

R^{41} is H-, or HO-; and

q is 0, 1 or 2; wherein


when q is 0 or 1, X^5 is CH₂; and


when q is 2, X^5 is NH, O, or CH(OH).

42. The compound of any one of claims 29 to 41, wherein X^1 is N.


43. The compound of any one of claims 29 to 41, wherein X^1 is C-H.

44. The compound of any one of claims 41 to 43, wherein the compound is selected from:






45. The compound of any one of claims 1 to 17, wherein R^3 is



46. The compound of claim 45, wherein R^3 is




47. The compound of claim 45 or 46, wherein:

R^{12} is selected from H-, R^{31} -C(O)-, R^{31} -C(O)CH₂-, R^{31} -NHC(O)-, R^{31} -C(O)NH-, R^{31} -N(CH₃)C(O)-, and R^{31} -C(O)N(CH₃) -;


R^{31} is selected from optionally substituted (C₁-C₃)alkyl-, optionally substituted cycloalkyl-, and optionally substituted saturated heterocycle; and

the optional substituents of the R^{31} group are selected from NC-, HO-, HOCH₂-, (C₁-C₃)alkyl-, (C₁-C₃)alkoxy- and substituted (C₁-C₃)alkyl-.


48. The compound of any one of claims 46 to 47, wherein R^{12} is selected from:




49. The compound of any one of claims 45 to 48, wherein the compound is selected from:




Compound 99




Compound 100




Compound 101



Compound 102



Compound 103




Compound 104

and

50. A pharmaceutical composition comprising:
 a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 49; and
 a pharmaceutically acceptable excipient.
51. A compound for use in inhibiting autotaxin (ATX), wherein the compound is a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 49.
52. A pharmaceutical composition for use in inhibiting autotaxin (ATX), wherein the pharmaceutical composition is according to claim 50.
53. Use of a compound for the manufacture of a medicament for inhibiting autotaxin (ATX), wherein the compound is a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 49.
54. Use of a pharmaceutical composition for the manufacture of a medicament for inhibiting autotaxin (ATX), wherein the pharmaceutical composition is according to claim 50.

55. A method of inhibiting autotaxin, the method comprising contacting a biological system comprising autotaxin with an effective amount of a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 49 to inhibit autotaxin.
56. The method of claim 55, wherein the biological system is comprised in an *in vitro* sample.
57. The method of claim 55, wherein the biological system is *in vivo*.
58. A method of inhibiting autotaxin in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 49, or a pharmaceutical composition according to claim 50.
59. A method of treating an ATX-related indication in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 49, or a pharmaceutical composition according to claim 50.
60. The method of claim 59, wherein the ATX-related indication is selected from an inflammatory disease, autoimmune disease, proliferative disease, cancer, and fibrosis.
61. The method of claim 60, wherein the fibrosis occurs in the liver.
62. A compound for use in inhibiting autotaxin (ATX), wherein the compound is a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 49.
63. A pharmaceutical composition for use in inhibiting autotaxin (ATX), wherein the pharmaceutical composition is according to claim 50.
64. Use of a compound for the manufacture of a medicament for treating an ATX-related indication, wherein the compound is a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 49.
65. Use of a pharmaceutical composition for the manufacture of a medicament treating an ATX-related indication, wherein the pharmaceutical composition is according to claim 50.
66. The use of claim 64 or 65, wherein the ATX-related indication is selected from an inflammatory disease, autoimmune disease, proliferative disease, cancer, and fibrosis.
67. The use of claim 66, wherein the fibrosis occurs in the liver.

68. A compound of formula (II):



or a pharmaceutically acceptable salt or isomer thereof,

wherein:

Z^1 , Z^2 , and Z^3 are independently selected from C- R^1 and N;

R^{20} and R^{21} are each independently selected from H, and optionally substituted -(C₁-C₆)alkyl; or R^{20} and R^{21} together with the boron atom to which they are attached from an optionally substituted heterocycle;

each R^1 is independently selected from -H, -halogen, optionally substituted -(C₁-C₆)alkyl and optionally substituted -(C₁-C₆)alkoxy;

Y is selected from S, O, and N- R^2 , wherein R^2 is selected from -H, and optionally substituted -(C₁-C₆)alkyl;


R^7 is selected from H-, and optionally substituted (C₁-C₆)alkyl-;

R^8 is selected from -H, -halogen, and optionally substituted -(C₁-C₆)alkyl;


R^9 and each R^{10} are independently selected from -H, -halogen, -CN, -OH, optionally substituted -(C₁-C₆)alkoxy, -NH₂, substituted amino, optionally substituted -(C₁-C₆)alkyl-NH₂ and optionally substituted -(C₁-C₆)alkyl; and

n is 0, 1, 2, 3, 4, or 5.

69. The compound of claim 68, wherein the compound is:



70. A compound of formula (III):



or a pharmaceutically acceptable salt or isomer thereof,

wherein:

X^1 , X^2 , and X^3 are independently selected from $C-R^1$ and N ;

Z^1, Z^2 , and Z^3 are independently selected from C-R¹ and N;

each R¹ is independently selected from -H, -halogen, optionally substituted -(C₁-C₆)alkyl and optionally substituted -(C₁-C₆)alkoxy;

Y is selected from S, O, and N-R², wherein R² is selected from -H, and optionally substituted -(C₁-C₆)alkyl;

R^{3a} is selected from optionally substituted R⁴-C(O)-(C₁-C₃)alkyl-, R⁴C(O)-, halogen, optionally substituted monocyclic or bicyclic carbocycle, optionally substituted monocyclic or bicyclic heterocycle, R⁵R⁶HC-, and R⁵R⁶N-;

R⁴ is selected from H₂N-, HO-, R⁵R⁶N-, optionally substituted (C₁-C₁₀)alkyl-, optionally substituted (C₁-C₁₀)alkoxy-, optionally substituted monocyclic or bicyclic carbocycle, optionally substituted monocyclic or bicyclic heterocycle, optionally substituted cycloalkyl-(C₁-C₆)alkylene-, and optionally substituted heterocycle-(C₁-C₆)alkylene-;

R⁵ and R⁶ are independently selected from H-, H₂N-, HO-, optionally substituted (C₁-C₁₀)alkyl-, optionally substituted monocyclic or bicyclic carbocycle, optionally substituted monocyclic or bicyclic heterocycle, optionally substituted R⁴C(O)-(C₁-C₁₀)alkyl-, R⁴C(O)-, R⁴-, and substituted amino;

or R⁵ and R⁶ together with the nitrogen or carbon atom to which they are attached are cyclically linked to form an optionally substituted carbocycle or an optionally substituted heterocycle;

R⁷ is selected from H-, and optionally substituted (C₁-C₆)alkyl-;

R⁸ is selected from -H, -halogen, and optionally substituted -(C₁-C₆)alkyl;

R^9 and each R^{10} are independently selected from -H, -halogen, -CN, -OH, optionally substituted $-(C_1-C_6)$ alkoxy, $-NH_2$, substituted amino, optionally substituted $-(C_1-C_6)$ alkyl- NH_2 and optionally substituted $-(C_1-C_6)$ alkyl; and

n is 0, 1, 2, 3, 4, or 5.

71. The compound of claim 70, wherein the compound is:

